bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
inguinal herniorrhaphy . is a Intervention_Surgical, recurrence is a Outcome_Physical, satisfaction is a Outcome_Other, hematoma / seroma is a Outcome_Physical, orchitis is a Outcome_Physical, neuralgia is a Outcome_Physical, patient - reported pain is a Outcome_Pain, activity is a Outcome_Physical, less activity is a Outcome_Physical	27502_task0	Sentence: Patient-reported outcomes after inguinal herniorrhaphy . BACKGROUND Patient-reported outcomes ( PRO ) reflect the functional outcomes of inguinal herniorrhaphy . We studied the effect of hernia recurrence and complications on PRO for participants in the Veterans Affairs trial of Open or Laparoscopic Repair of Inguinal Hernia . METHODS Analyzed PRO included ( 1 ) the Medical Outcomes Study Short Form 36 , version 2 , ( 2 ) the Surgical Pain Scale , ( 3 ) the Activities Assessment Scale , and ( 4 ) patient satisfaction . Recurrences and complications were recorded at follow-up visits . Complications were categorized by ( 1 ) hematoma/seroma , ( 2 ) orchitis , ( 3 ) neuralgia , and ( 4 ) other . Univariate and multivariable regression analyses identified variables significantly associated with postoperative PRO . RESULTS Of the 1603 patients with PRO data , 105 had a recurrence and 342 had a complication at 2 years . Multivariable analyses showed neuralgia ( P < .0005 ) adversely affected all PRO , and recurrence ( P < .05 ) affected patient-reported pain , activity , and satisfaction , but not the score for the Medical Outcomes Study Short Form 3 . Patients with a recurrence after open repair had more pain than those with a recurrence after laparoscopic repair ( P = .0001 ) . Patients with other complications after laparoscopic repair reported more pain and less activity than those with other complications after open repair ( P = .003 and P = .009 , respectively ) . CONCLUSIONS The effectiveness of inguinal herniorrhaphy should be measured by the rate of recurrence and neuralgia . Postoperative neuralgias have a deleterious effect on all patient-reported outcomes . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Outcome_Physical, Intervention_Surgical, Outcome_Pain	[ "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Patient-reported outcomes after inguinal herniorrhaphy . BACKGROUND Patient-reported outcomes ( PRO ) reflect the functional outcomes of inguinal herniorrhaphy . We studied the effect of hernia recurrence and complications on PRO for participants in the Veterans Affairs trial of Open or Laparoscopic Repair of Inguinal Hernia . METHODS Analyzed PRO included ( 1 ) the Medical Outcomes Study Short Form 36 , version 2 , ( 2 ) the Surgical Pain Scale , ( 3 ) the Activities Assessment Scale , and ( 4 ) patient satisfaction . Recurrences and complications were recorded at follow-up visits . Complications were categorized by ( 1 ) hematoma/seroma , ( 2 ) orchitis , ( 3 ) neuralgia , and ( 4 ) other . Univariate and multivariable regression analyses identified variables significantly associated with postoperative PRO . RESULTS Of the 1603 patients with PRO data , 105 had a recurrence and 342 had a complication at 2 years . Multivariable analyses showed neuralgia ( P < .0005 ) adversely affected all PRO , and recurrence ( P < .05 ) affected patient-reported pain , activity , and satisfaction , but not the score for the Medical Outcomes Study Short Form 3 . Patients with a recurrence after open repair had more pain than those with a recurrence after laparoscopic repair ( P = .0001 ) . Patients with other complications after laparoscopic repair reported more pain and less activity than those with other complications after open repair ( P = .003 and P = .009 , respectively ) . CONCLUSIONS The effectiveness of inguinal herniorrhaphy should be measured by the rate of recurrence and neuralgia . Postoperative neuralgias have a deleterious effect on all patient-reported outcomes .	[ "Patient", "-", "reported", "outcomes", "after", "inguinal", "herniorrhaphy", ".", "BACKGROUND", "Patient", "-", "reported", "outcomes", "(", "PRO", ")", "reflect", "the", "functional", "outcomes", "of", "inguinal", "herniorrhaphy", ".", "We", "studied", "the", "effect", "of", "hernia", "recurrence", "and", "complications", "on", "PRO", "for", "participants", "in", "the", "Veterans", "Affairs", "trial", "of", "Open", "or", "Laparoscopic", "Repair", "of", "Inguinal", "Hernia", ".", "METHODS", "Analyzed", "PRO", "included", "(", "1", ")", "the", "Medical", "Outcomes", "Study", "Short", "Form", "36", ",", "version", "2", ",", "(", "2", ")", "the", "Surgical", "Pain", "Scale", ",", "(", "3", ")", "the", "Activities", "Assessment", "Scale", ",", "and", "(", "4", ")", "patient", "satisfaction", ".", "Recurrences", "and", "complications", "were", "recorded", "at", "follow", "-", "up", "visits", ".", "Complications", "were", "categorized", "by", "(", "1", ")", "hematoma", "/", "seroma", ",", "(", "2", ")", "orchitis", ",", "(", "3", ")", "neuralgia", ",", "and", "(", "4", ")", "other", ".", "Univariate", "and", "multivariable", "regression", "analyses", "identified", "variables", "significantly", "associated", "with", "postoperative", "PRO", ".", "RESULTS", "Of", "the", "1603", "patients", "with", "PRO", "data", ",", "105", "had", "a", "recurrence", "and", "342", "had", "a", "complication", "at", "2", "years", ".", "Multivariable", "analyses", "showed", "neuralgia", "(", "P", "<", ".0005", ")", "adversely", "affected", "all", "PRO", ",", "and", "recurrence", "(", "P", "<", ".05", ")", "affected", "patient", "-", "reported", "pain", ",", "activity", ",", "and", "satisfaction", ",", "but", "not", "the", "score", "for", "the", "Medical", "Outcomes", "Study", "Short", "Form", "3", ".", "Patients", "with", "a", "recurrence", "after", "open", "repair", "had", "more", "pain", "than", "those", "with", "a", "recurrence", "after", "laparoscopic", "repair", "(", "P", "=", ".0001", ")", ".", "Patients", "with", "other", "complications", "after", "laparoscopic", "repair", "reported", "more", "pain", "and", "less", "activity", "than", "those", "with", "other", "complications", "after", "open", "repair", "(", "P", "=", ".003", "and", "P", "=", ".009", ",", "respectively", ")", ".", "CONCLUSIONS", "The", "effectiveness", "of", "inguinal", "herniorrhaphy", "should", "be", "measured", "by", "the", "rate", "of", "recurrence", "and", "neuralgia", ".", "Postoperative", "neuralgias", "have", "a", "deleterious", "effect", "on", "all", "patient", "-", "reported", "outcomes", "." ]	[ "Outcome_Other", "Intervention_Surgical", "Outcome_Pain", "Outcome_Physical" ]
inguinal herniorrhaphy . is a Intervention_Surgical, recurrence is a Outcome_Physical, satisfaction is a Outcome_Other, hematoma / seroma is a Outcome_Physical, orchitis is a Outcome_Physical, neuralgia is a Outcome_Physical, patient - reported pain is a Outcome_Pain, activity is a Outcome_Physical, less activity is a Outcome_Physical	27502_task1	Sentence: Patient-reported outcomes after inguinal herniorrhaphy . BACKGROUND Patient-reported outcomes ( PRO ) reflect the functional outcomes of inguinal herniorrhaphy . We studied the effect of hernia recurrence and complications on PRO for participants in the Veterans Affairs trial of Open or Laparoscopic Repair of Inguinal Hernia . METHODS Analyzed PRO included ( 1 ) the Medical Outcomes Study Short Form 36 , version 2 , ( 2 ) the Surgical Pain Scale , ( 3 ) the Activities Assessment Scale , and ( 4 ) patient satisfaction . Recurrences and complications were recorded at follow-up visits . Complications were categorized by ( 1 ) hematoma/seroma , ( 2 ) orchitis , ( 3 ) neuralgia , and ( 4 ) other . Univariate and multivariable regression analyses identified variables significantly associated with postoperative PRO . RESULTS Of the 1603 patients with PRO data , 105 had a recurrence and 342 had a complication at 2 years . Multivariable analyses showed neuralgia ( P < .0005 ) adversely affected all PRO , and recurrence ( P < .05 ) affected patient-reported pain , activity , and satisfaction , but not the score for the Medical Outcomes Study Short Form 3 . Patients with a recurrence after open repair had more pain than those with a recurrence after laparoscopic repair ( P = .0001 ) . Patients with other complications after laparoscopic repair reported more pain and less activity than those with other complications after open repair ( P = .003 and P = .009 , respectively ) . CONCLUSIONS The effectiveness of inguinal herniorrhaphy should be measured by the rate of recurrence and neuralgia . Postoperative neuralgias have a deleterious effect on all patient-reported outcomes . Instructions: please typing these entity words according to sentence: inguinal herniorrhaphy ., recurrence, satisfaction, hematoma / seroma, orchitis, neuralgia, patient - reported pain, activity, less activity Options: Outcome_Other, Outcome_Physical, Intervention_Surgical, Outcome_Pain	[ "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Patient-reported outcomes after inguinal herniorrhaphy . BACKGROUND Patient-reported outcomes ( PRO ) reflect the functional outcomes of inguinal herniorrhaphy . We studied the effect of hernia recurrence and complications on PRO for participants in the Veterans Affairs trial of Open or Laparoscopic Repair of Inguinal Hernia . METHODS Analyzed PRO included ( 1 ) the Medical Outcomes Study Short Form 36 , version 2 , ( 2 ) the Surgical Pain Scale , ( 3 ) the Activities Assessment Scale , and ( 4 ) patient satisfaction . Recurrences and complications were recorded at follow-up visits . Complications were categorized by ( 1 ) hematoma/seroma , ( 2 ) orchitis , ( 3 ) neuralgia , and ( 4 ) other . Univariate and multivariable regression analyses identified variables significantly associated with postoperative PRO . RESULTS Of the 1603 patients with PRO data , 105 had a recurrence and 342 had a complication at 2 years . Multivariable analyses showed neuralgia ( P < .0005 ) adversely affected all PRO , and recurrence ( P < .05 ) affected patient-reported pain , activity , and satisfaction , but not the score for the Medical Outcomes Study Short Form 3 . Patients with a recurrence after open repair had more pain than those with a recurrence after laparoscopic repair ( P = .0001 ) . Patients with other complications after laparoscopic repair reported more pain and less activity than those with other complications after open repair ( P = .003 and P = .009 , respectively ) . CONCLUSIONS The effectiveness of inguinal herniorrhaphy should be measured by the rate of recurrence and neuralgia . Postoperative neuralgias have a deleterious effect on all patient-reported outcomes .	[ "Patient", "-", "reported", "outcomes", "after", "inguinal", "herniorrhaphy", ".", "BACKGROUND", "Patient", "-", "reported", "outcomes", "(", "PRO", ")", "reflect", "the", "functional", "outcomes", "of", "inguinal", "herniorrhaphy", ".", "We", "studied", "the", "effect", "of", "hernia", "recurrence", "and", "complications", "on", "PRO", "for", "participants", "in", "the", "Veterans", "Affairs", "trial", "of", "Open", "or", "Laparoscopic", "Repair", "of", "Inguinal", "Hernia", ".", "METHODS", "Analyzed", "PRO", "included", "(", "1", ")", "the", "Medical", "Outcomes", "Study", "Short", "Form", "36", ",", "version", "2", ",", "(", "2", ")", "the", "Surgical", "Pain", "Scale", ",", "(", "3", ")", "the", "Activities", "Assessment", "Scale", ",", "and", "(", "4", ")", "patient", "satisfaction", ".", "Recurrences", "and", "complications", "were", "recorded", "at", "follow", "-", "up", "visits", ".", "Complications", "were", "categorized", "by", "(", "1", ")", "hematoma", "/", "seroma", ",", "(", "2", ")", "orchitis", ",", "(", "3", ")", "neuralgia", ",", "and", "(", "4", ")", "other", ".", "Univariate", "and", "multivariable", "regression", "analyses", "identified", "variables", "significantly", "associated", "with", "postoperative", "PRO", ".", "RESULTS", "Of", "the", "1603", "patients", "with", "PRO", "data", ",", "105", "had", "a", "recurrence", "and", "342", "had", "a", "complication", "at", "2", "years", ".", "Multivariable", "analyses", "showed", "neuralgia", "(", "P", "<", ".0005", ")", "adversely", "affected", "all", "PRO", ",", "and", "recurrence", "(", "P", "<", ".05", ")", "affected", "patient", "-", "reported", "pain", ",", "activity", ",", "and", "satisfaction", ",", "but", "not", "the", "score", "for", "the", "Medical", "Outcomes", "Study", "Short", "Form", "3", ".", "Patients", "with", "a", "recurrence", "after", "open", "repair", "had", "more", "pain", "than", "those", "with", "a", "recurrence", "after", "laparoscopic", "repair", "(", "P", "=", ".0001", ")", ".", "Patients", "with", "other", "complications", "after", "laparoscopic", "repair", "reported", "more", "pain", "and", "less", "activity", "than", "those", "with", "other", "complications", "after", "open", "repair", "(", "P", "=", ".003", "and", "P", "=", ".009", ",", "respectively", ")", ".", "CONCLUSIONS", "The", "effectiveness", "of", "inguinal", "herniorrhaphy", "should", "be", "measured", "by", "the", "rate", "of", "recurrence", "and", "neuralgia", ".", "Postoperative", "neuralgias", "have", "a", "deleterious", "effect", "on", "all", "patient", "-", "reported", "outcomes", "." ]	[ "Outcome_Other", "Intervention_Surgical", "Outcome_Pain", "Outcome_Physical" ]
inguinal herniorrhaphy ., recurrence, satisfaction, hematoma / seroma, orchitis, neuralgia, patient - reported pain, activity, less activity	27502_task2	Sentence: Patient-reported outcomes after inguinal herniorrhaphy . BACKGROUND Patient-reported outcomes ( PRO ) reflect the functional outcomes of inguinal herniorrhaphy . We studied the effect of hernia recurrence and complications on PRO for participants in the Veterans Affairs trial of Open or Laparoscopic Repair of Inguinal Hernia . METHODS Analyzed PRO included ( 1 ) the Medical Outcomes Study Short Form 36 , version 2 , ( 2 ) the Surgical Pain Scale , ( 3 ) the Activities Assessment Scale , and ( 4 ) patient satisfaction . Recurrences and complications were recorded at follow-up visits . Complications were categorized by ( 1 ) hematoma/seroma , ( 2 ) orchitis , ( 3 ) neuralgia , and ( 4 ) other . Univariate and multivariable regression analyses identified variables significantly associated with postoperative PRO . RESULTS Of the 1603 patients with PRO data , 105 had a recurrence and 342 had a complication at 2 years . Multivariable analyses showed neuralgia ( P < .0005 ) adversely affected all PRO , and recurrence ( P < .05 ) affected patient-reported pain , activity , and satisfaction , but not the score for the Medical Outcomes Study Short Form 3 . Patients with a recurrence after open repair had more pain than those with a recurrence after laparoscopic repair ( P = .0001 ) . Patients with other complications after laparoscopic repair reported more pain and less activity than those with other complications after open repair ( P = .003 and P = .009 , respectively ) . CONCLUSIONS The effectiveness of inguinal herniorrhaphy should be measured by the rate of recurrence and neuralgia . Postoperative neuralgias have a deleterious effect on all patient-reported outcomes . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Patient-reported outcomes after inguinal herniorrhaphy . BACKGROUND Patient-reported outcomes ( PRO ) reflect the functional outcomes of inguinal herniorrhaphy . We studied the effect of hernia recurrence and complications on PRO for participants in the Veterans Affairs trial of Open or Laparoscopic Repair of Inguinal Hernia . METHODS Analyzed PRO included ( 1 ) the Medical Outcomes Study Short Form 36 , version 2 , ( 2 ) the Surgical Pain Scale , ( 3 ) the Activities Assessment Scale , and ( 4 ) patient satisfaction . Recurrences and complications were recorded at follow-up visits . Complications were categorized by ( 1 ) hematoma/seroma , ( 2 ) orchitis , ( 3 ) neuralgia , and ( 4 ) other . Univariate and multivariable regression analyses identified variables significantly associated with postoperative PRO . RESULTS Of the 1603 patients with PRO data , 105 had a recurrence and 342 had a complication at 2 years . Multivariable analyses showed neuralgia ( P < .0005 ) adversely affected all PRO , and recurrence ( P < .05 ) affected patient-reported pain , activity , and satisfaction , but not the score for the Medical Outcomes Study Short Form 3 . Patients with a recurrence after open repair had more pain than those with a recurrence after laparoscopic repair ( P = .0001 ) . Patients with other complications after laparoscopic repair reported more pain and less activity than those with other complications after open repair ( P = .003 and P = .009 , respectively ) . CONCLUSIONS The effectiveness of inguinal herniorrhaphy should be measured by the rate of recurrence and neuralgia . Postoperative neuralgias have a deleterious effect on all patient-reported outcomes .	[ "Patient", "-", "reported", "outcomes", "after", "inguinal", "herniorrhaphy", ".", "BACKGROUND", "Patient", "-", "reported", "outcomes", "(", "PRO", ")", "reflect", "the", "functional", "outcomes", "of", "inguinal", "herniorrhaphy", ".", "We", "studied", "the", "effect", "of", "hernia", "recurrence", "and", "complications", "on", "PRO", "for", "participants", "in", "the", "Veterans", "Affairs", "trial", "of", "Open", "or", "Laparoscopic", "Repair", "of", "Inguinal", "Hernia", ".", "METHODS", "Analyzed", "PRO", "included", "(", "1", ")", "the", "Medical", "Outcomes", "Study", "Short", "Form", "36", ",", "version", "2", ",", "(", "2", ")", "the", "Surgical", "Pain", "Scale", ",", "(", "3", ")", "the", "Activities", "Assessment", "Scale", ",", "and", "(", "4", ")", "patient", "satisfaction", ".", "Recurrences", "and", "complications", "were", "recorded", "at", "follow", "-", "up", "visits", ".", "Complications", "were", "categorized", "by", "(", "1", ")", "hematoma", "/", "seroma", ",", "(", "2", ")", "orchitis", ",", "(", "3", ")", "neuralgia", ",", "and", "(", "4", ")", "other", ".", "Univariate", "and", "multivariable", "regression", "analyses", "identified", "variables", "significantly", "associated", "with", "postoperative", "PRO", ".", "RESULTS", "Of", "the", "1603", "patients", "with", "PRO", "data", ",", "105", "had", "a", "recurrence", "and", "342", "had", "a", "complication", "at", "2", "years", ".", "Multivariable", "analyses", "showed", "neuralgia", "(", "P", "<", ".0005", ")", "adversely", "affected", "all", "PRO", ",", "and", "recurrence", "(", "P", "<", ".05", ")", "affected", "patient", "-", "reported", "pain", ",", "activity", ",", "and", "satisfaction", ",", "but", "not", "the", "score", "for", "the", "Medical", "Outcomes", "Study", "Short", "Form", "3", ".", "Patients", "with", "a", "recurrence", "after", "open", "repair", "had", "more", "pain", "than", "those", "with", "a", "recurrence", "after", "laparoscopic", "repair", "(", "P", "=", ".0001", ")", ".", "Patients", "with", "other", "complications", "after", "laparoscopic", "repair", "reported", "more", "pain", "and", "less", "activity", "than", "those", "with", "other", "complications", "after", "open", "repair", "(", "P", "=", ".003", "and", "P", "=", ".009", ",", "respectively", ")", ".", "CONCLUSIONS", "The", "effectiveness", "of", "inguinal", "herniorrhaphy", "should", "be", "measured", "by", "the", "rate", "of", "recurrence", "and", "neuralgia", ".", "Postoperative", "neuralgias", "have", "a", "deleterious", "effect", "on", "all", "patient", "-", "reported", "outcomes", "." ]	[ "Outcome_Other", "Intervention_Surgical", "Outcome_Pain", "Outcome_Physical" ]
genes is a Entity, p53 is a Protein, Bcl-2 is a Protein	372_task0	Sentence: The effect of Toremifene on the expression of some genes in human mononuclear cells. Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells. After short-term, in vitro exposure to therapeutical levels, distinct changes in P-glycoprotein, steroid receptors, p53 and Bcl-2 expression take place. In view of the increasing use of antiestrogens in cancer therapy and prevention, there is obvious merit in long-term in vivo studies to be conducted. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The effect of Toremifene on the expression of some genes in human mononuclear cells. Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells. After short-term, in vitro exposure to therapeutical levels, distinct changes in P-glycoprotein, steroid receptors, p53 and Bcl-2 expression take place. In view of the increasing use of antiestrogens in cancer therapy and prevention, there is obvious merit in long-term in vivo studies to be conducted.	[ "The", "effect", "of", "Toremifene", "on", "the", "expression", "of", "some", "genes", "in", "human", "mononuclear", "cells", ".", "\n", "Toremifene", "exerts", "multiple", "and", "varied", "effects", "on", "the", "gene", "expression", "of", "human", "peripheral", "mononuclear", "cells", ".", "After", "short", "-", "term", ",", "in", "vitro", "exposure", "to", "therapeutical", "levels", ",", "distinct", "changes", "in", "P", "-", "glycoprotein", ",", "steroid", "receptors", ",", "p53", "and", "Bcl-2", "expression", "take", "place", ".", "In", "view", "of", "the", "increasing", "use", "of", "antiestrogens", "in", "cancer", "therapy", "and", "prevention", ",", "there", "is", "obvious", "merit", "in", "long", "-", "term", "in", "vivo", "studies", "to", "be", "conducted", ".", "\n" ]	[ "Protein", "Entity" ]
genes is a Entity, p53 is a Protein, Bcl-2 is a Protein	372_task1	Sentence: The effect of Toremifene on the expression of some genes in human mononuclear cells. Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells. After short-term, in vitro exposure to therapeutical levels, distinct changes in P-glycoprotein, steroid receptors, p53 and Bcl-2 expression take place. In view of the increasing use of antiestrogens in cancer therapy and prevention, there is obvious merit in long-term in vivo studies to be conducted. Instructions: please typing these entity words according to sentence: genes, p53, Bcl-2 Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The effect of Toremifene on the expression of some genes in human mononuclear cells. Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells. After short-term, in vitro exposure to therapeutical levels, distinct changes in P-glycoprotein, steroid receptors, p53 and Bcl-2 expression take place. In view of the increasing use of antiestrogens in cancer therapy and prevention, there is obvious merit in long-term in vivo studies to be conducted.	[ "The", "effect", "of", "Toremifene", "on", "the", "expression", "of", "some", "genes", "in", "human", "mononuclear", "cells", ".", "\n", "Toremifene", "exerts", "multiple", "and", "varied", "effects", "on", "the", "gene", "expression", "of", "human", "peripheral", "mononuclear", "cells", ".", "After", "short", "-", "term", ",", "in", "vitro", "exposure", "to", "therapeutical", "levels", ",", "distinct", "changes", "in", "P", "-", "glycoprotein", ",", "steroid", "receptors", ",", "p53", "and", "Bcl-2", "expression", "take", "place", ".", "In", "view", "of", "the", "increasing", "use", "of", "antiestrogens", "in", "cancer", "therapy", "and", "prevention", ",", "there", "is", "obvious", "merit", "in", "long", "-", "term", "in", "vivo", "studies", "to", "be", "conducted", ".", "\n" ]	[ "Protein", "Entity" ]
genes, p53, Bcl-2	372_task2	Sentence: The effect of Toremifene on the expression of some genes in human mononuclear cells. Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells. After short-term, in vitro exposure to therapeutical levels, distinct changes in P-glycoprotein, steroid receptors, p53 and Bcl-2 expression take place. In view of the increasing use of antiestrogens in cancer therapy and prevention, there is obvious merit in long-term in vivo studies to be conducted. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The effect of Toremifene on the expression of some genes in human mononuclear cells. Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells. After short-term, in vitro exposure to therapeutical levels, distinct changes in P-glycoprotein, steroid receptors, p53 and Bcl-2 expression take place. In view of the increasing use of antiestrogens in cancer therapy and prevention, there is obvious merit in long-term in vivo studies to be conducted.	[ "The", "effect", "of", "Toremifene", "on", "the", "expression", "of", "some", "genes", "in", "human", "mononuclear", "cells", ".", "\n", "Toremifene", "exerts", "multiple", "and", "varied", "effects", "on", "the", "gene", "expression", "of", "human", "peripheral", "mononuclear", "cells", ".", "After", "short", "-", "term", ",", "in", "vitro", "exposure", "to", "therapeutical", "levels", ",", "distinct", "changes", "in", "P", "-", "glycoprotein", ",", "steroid", "receptors", ",", "p53", "and", "Bcl-2", "expression", "take", "place", ".", "In", "view", "of", "the", "increasing", "use", "of", "antiestrogens", "in", "cancer", "therapy", "and", "prevention", ",", "there", "is", "obvious", "merit", "in", "long", "-", "term", "in", "vivo", "studies", "to", "be", "conducted", ".", "\n" ]	[ "Protein", "Entity" ]
Gastrektomie is an umlsterm, Knochenstoffwechsels is an umlsterm, Parathormon is an umlsterm, Calcium is an umlsterm, Knochen is an umlsterm, Patienten is an umlsterm, Knochenmasse is an umlsterm, Vitamin D is an umlsterm, Calcium is an umlsterm, Knochenstoffwechsels is an umlsterm, Gastrektomie is an umlsterm	DerChirurg.70680784.ger.abstr_task0	Sentence: Zusammenfassung . Nach Magenresektion oder Gastrektomie sind Stoerungen der Calcium- und Knochenstoffwechsels bekannt . Wahrscheinlich kommt es postoperativ aufgrund einer verminderten Calciumabsorption zu einem Abfall des Serumcalciums . Als Gegenregulation wird Parathormon ausgeschuettet und 1,25-(OH)2-Vitamin D neu gebildet , welche beide Calcium aus dem Knochen mobilisieren . Bei einem Teil der Patienten kommt es in der Folge zu einer Abnahme der Knochenmasse mit einem erhoehten Frakturrisiko . Bisher liegen keine anerkannten Behandlungsempfehlungen dieser Stoerungen vor , lediglich die Substitution von Vitamin D und Calcium wurde wiederholt empfohlen . Es wird eine Uebersicht ueber die derzeitigen Vorstellungen zur Regulation des Calcium- und Knochenstoffwechsels nach Gastrektomie gegeben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Zusammenfassung . Nach Magenresektion oder Gastrektomie sind Stoerungen der Calcium- und Knochenstoffwechsels bekannt . Wahrscheinlich kommt es postoperativ aufgrund einer verminderten Calciumabsorption zu einem Abfall des Serumcalciums . Als Gegenregulation wird Parathormon ausgeschuettet und 1,25-(OH)2-Vitamin D neu gebildet , welche beide Calcium aus dem Knochen mobilisieren . Bei einem Teil der Patienten kommt es in der Folge zu einer Abnahme der Knochenmasse mit einem erhoehten Frakturrisiko . Bisher liegen keine anerkannten Behandlungsempfehlungen dieser Stoerungen vor , lediglich die Substitution von Vitamin D und Calcium wurde wiederholt empfohlen . Es wird eine Uebersicht ueber die derzeitigen Vorstellungen zur Regulation des Calcium- und Knochenstoffwechsels nach Gastrektomie gegeben .	[ "Zusammenfassung", ".", "Nach", "Magenresektion", "oder", "Gastrektomie", "sind", "Stoerungen", "der", "Calcium-", "und", "Knochenstoffwechsels", "bekannt", ".", "Wahrscheinlich", "kommt", "es", "postoperativ", "aufgrund", "einer", "verminderten", "Calciumabsorption", "zu", "einem", "Abfall", "des", "Serumcalciums", ".", "Als", "Gegenregulation", "wird", "Parathormon", "ausgeschuettet", "und", "1,25-(OH)2-Vitamin", "D", "neu", "gebildet", ",", "welche", "beide", "Calcium", "aus", "dem", "Knochen", "mobilisieren", ".", "Bei", "einem", "Teil", "der", "Patienten", "kommt", "es", "in", "der", "Folge", "zu", "einer", "Abnahme", "der", "Knochenmasse", "mit", "einem", "erhoehten", "Frakturrisiko", ".", "Bisher", "liegen", "keine", "anerkannten", "Behandlungsempfehlungen", "dieser", "Stoerungen", "vor", ",", "lediglich", "die", "Substitution", "von", "Vitamin", "D", "und", "Calcium", "wurde", "wiederholt", "empfohlen", ".", "Es", "wird", "eine", "Uebersicht", "ueber", "die", "derzeitigen", "Vorstellungen", "zur", "Regulation", "des", "Calcium-", "und", "Knochenstoffwechsels", "nach", "Gastrektomie", "gegeben", "." ]	[ "umlsterm" ]
Gastrektomie is an umlsterm, Knochenstoffwechsels is an umlsterm, Parathormon is an umlsterm, Calcium is an umlsterm, Knochen is an umlsterm, Patienten is an umlsterm, Knochenmasse is an umlsterm, Vitamin D is an umlsterm, Calcium is an umlsterm, Knochenstoffwechsels is an umlsterm, Gastrektomie is an umlsterm	DerChirurg.70680784.ger.abstr_task1	Sentence: Zusammenfassung . Nach Magenresektion oder Gastrektomie sind Stoerungen der Calcium- und Knochenstoffwechsels bekannt . Wahrscheinlich kommt es postoperativ aufgrund einer verminderten Calciumabsorption zu einem Abfall des Serumcalciums . Als Gegenregulation wird Parathormon ausgeschuettet und 1,25-(OH)2-Vitamin D neu gebildet , welche beide Calcium aus dem Knochen mobilisieren . Bei einem Teil der Patienten kommt es in der Folge zu einer Abnahme der Knochenmasse mit einem erhoehten Frakturrisiko . Bisher liegen keine anerkannten Behandlungsempfehlungen dieser Stoerungen vor , lediglich die Substitution von Vitamin D und Calcium wurde wiederholt empfohlen . Es wird eine Uebersicht ueber die derzeitigen Vorstellungen zur Regulation des Calcium- und Knochenstoffwechsels nach Gastrektomie gegeben . Instructions: please typing these entity words according to sentence: Gastrektomie, Knochenstoffwechsels, Parathormon, Calcium, Knochen, Patienten, Knochenmasse, Vitamin D, Calcium, Knochenstoffwechsels, Gastrektomie Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Zusammenfassung . Nach Magenresektion oder Gastrektomie sind Stoerungen der Calcium- und Knochenstoffwechsels bekannt . Wahrscheinlich kommt es postoperativ aufgrund einer verminderten Calciumabsorption zu einem Abfall des Serumcalciums . Als Gegenregulation wird Parathormon ausgeschuettet und 1,25-(OH)2-Vitamin D neu gebildet , welche beide Calcium aus dem Knochen mobilisieren . Bei einem Teil der Patienten kommt es in der Folge zu einer Abnahme der Knochenmasse mit einem erhoehten Frakturrisiko . Bisher liegen keine anerkannten Behandlungsempfehlungen dieser Stoerungen vor , lediglich die Substitution von Vitamin D und Calcium wurde wiederholt empfohlen . Es wird eine Uebersicht ueber die derzeitigen Vorstellungen zur Regulation des Calcium- und Knochenstoffwechsels nach Gastrektomie gegeben .	[ "Zusammenfassung", ".", "Nach", "Magenresektion", "oder", "Gastrektomie", "sind", "Stoerungen", "der", "Calcium-", "und", "Knochenstoffwechsels", "bekannt", ".", "Wahrscheinlich", "kommt", "es", "postoperativ", "aufgrund", "einer", "verminderten", "Calciumabsorption", "zu", "einem", "Abfall", "des", "Serumcalciums", ".", "Als", "Gegenregulation", "wird", "Parathormon", "ausgeschuettet", "und", "1,25-(OH)2-Vitamin", "D", "neu", "gebildet", ",", "welche", "beide", "Calcium", "aus", "dem", "Knochen", "mobilisieren", ".", "Bei", "einem", "Teil", "der", "Patienten", "kommt", "es", "in", "der", "Folge", "zu", "einer", "Abnahme", "der", "Knochenmasse", "mit", "einem", "erhoehten", "Frakturrisiko", ".", "Bisher", "liegen", "keine", "anerkannten", "Behandlungsempfehlungen", "dieser", "Stoerungen", "vor", ",", "lediglich", "die", "Substitution", "von", "Vitamin", "D", "und", "Calcium", "wurde", "wiederholt", "empfohlen", ".", "Es", "wird", "eine", "Uebersicht", "ueber", "die", "derzeitigen", "Vorstellungen", "zur", "Regulation", "des", "Calcium-", "und", "Knochenstoffwechsels", "nach", "Gastrektomie", "gegeben", "." ]	[ "umlsterm" ]
Gastrektomie, Knochenstoffwechsels, Parathormon, Calcium, Knochen, Patienten, Knochenmasse, Vitamin D, Calcium, Knochenstoffwechsels, Gastrektomie	DerChirurg.70680784.ger.abstr_task2	Sentence: Zusammenfassung . Nach Magenresektion oder Gastrektomie sind Stoerungen der Calcium- und Knochenstoffwechsels bekannt . Wahrscheinlich kommt es postoperativ aufgrund einer verminderten Calciumabsorption zu einem Abfall des Serumcalciums . Als Gegenregulation wird Parathormon ausgeschuettet und 1,25-(OH)2-Vitamin D neu gebildet , welche beide Calcium aus dem Knochen mobilisieren . Bei einem Teil der Patienten kommt es in der Folge zu einer Abnahme der Knochenmasse mit einem erhoehten Frakturrisiko . Bisher liegen keine anerkannten Behandlungsempfehlungen dieser Stoerungen vor , lediglich die Substitution von Vitamin D und Calcium wurde wiederholt empfohlen . Es wird eine Uebersicht ueber die derzeitigen Vorstellungen zur Regulation des Calcium- und Knochenstoffwechsels nach Gastrektomie gegeben . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Zusammenfassung . Nach Magenresektion oder Gastrektomie sind Stoerungen der Calcium- und Knochenstoffwechsels bekannt . Wahrscheinlich kommt es postoperativ aufgrund einer verminderten Calciumabsorption zu einem Abfall des Serumcalciums . Als Gegenregulation wird Parathormon ausgeschuettet und 1,25-(OH)2-Vitamin D neu gebildet , welche beide Calcium aus dem Knochen mobilisieren . Bei einem Teil der Patienten kommt es in der Folge zu einer Abnahme der Knochenmasse mit einem erhoehten Frakturrisiko . Bisher liegen keine anerkannten Behandlungsempfehlungen dieser Stoerungen vor , lediglich die Substitution von Vitamin D und Calcium wurde wiederholt empfohlen . Es wird eine Uebersicht ueber die derzeitigen Vorstellungen zur Regulation des Calcium- und Knochenstoffwechsels nach Gastrektomie gegeben .	[ "Zusammenfassung", ".", "Nach", "Magenresektion", "oder", "Gastrektomie", "sind", "Stoerungen", "der", "Calcium-", "und", "Knochenstoffwechsels", "bekannt", ".", "Wahrscheinlich", "kommt", "es", "postoperativ", "aufgrund", "einer", "verminderten", "Calciumabsorption", "zu", "einem", "Abfall", "des", "Serumcalciums", ".", "Als", "Gegenregulation", "wird", "Parathormon", "ausgeschuettet", "und", "1,25-(OH)2-Vitamin", "D", "neu", "gebildet", ",", "welche", "beide", "Calcium", "aus", "dem", "Knochen", "mobilisieren", ".", "Bei", "einem", "Teil", "der", "Patienten", "kommt", "es", "in", "der", "Folge", "zu", "einer", "Abnahme", "der", "Knochenmasse", "mit", "einem", "erhoehten", "Frakturrisiko", ".", "Bisher", "liegen", "keine", "anerkannten", "Behandlungsempfehlungen", "dieser", "Stoerungen", "vor", ",", "lediglich", "die", "Substitution", "von", "Vitamin", "D", "und", "Calcium", "wurde", "wiederholt", "empfohlen", ".", "Es", "wird", "eine", "Uebersicht", "ueber", "die", "derzeitigen", "Vorstellungen", "zur", "Regulation", "des", "Calcium-", "und", "Knochenstoffwechsels", "nach", "Gastrektomie", "gegeben", "." ]	[ "umlsterm" ]
Mycobacterium tuberculosis is a Microorganism, apoptotic cells is a Habitat, DCs is a Habitat, Mycobacterium tuberculosis is a Microorganism, Mtb is a Microorganism, DC is a Habitat, DCs is a Habitat, DC is a Habitat, Annexin1-deficient mice is a Habitat, Mtb is a Microorganism, Mtb is a Microorganism, CD8 + T cell is a Habitat, Mtb - infected human blood monocyte - derived DCs is a Habitat, Mtb is a Microorganism, Mtb is a Microorganism, DC is a Habitat	45_task0	Sentence: Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. The phagocytosis of apoptotic cells and associated vesicles (efferocytosis) by DCs is an important mechanism for both self tolerance and host defense. Although some of the engulfment ligands involved in efferocytosis have been identified and studied in vitro, the contributions of these ligands in vivo remain ill defined. Here, we determined that during Mycobacterium tuberculosis (Mtb) infection, the engulfment ligand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs and intrinsically enhances the capacity of the DC antigen-presenting machinery. Annexin1-deficient mice were highly susceptible to Mtb infection and showed an impaired Mtb antigen-specific CD8+ T cell response. Importantly, annexin1 expression was greatly downregulated in Mtb-infected human blood monocyte-derived DCs, indicating that reduction of annexin1 is a critical mechanism for immune evasion by Mtb. Collectively, these data indicate that annexin1 is essential in immunity to Mtb infection and mediates the power of DC efferocytosis and cross-presentation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Habitat	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O" ]	Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. The phagocytosis of apoptotic cells and associated vesicles (efferocytosis) by DCs is an important mechanism for both self tolerance and host defense. Although some of the engulfment ligands involved in efferocytosis have been identified and studied in vitro, the contributions of these ligands in vivo remain ill defined. Here, we determined that during Mycobacterium tuberculosis (Mtb) infection, the engulfment ligand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs and intrinsically enhances the capacity of the DC antigen-presenting machinery. Annexin1-deficient mice were highly susceptible to Mtb infection and showed an impaired Mtb antigen-specific CD8+ T cell response. Importantly, annexin1 expression was greatly downregulated in Mtb-infected human blood monocyte-derived DCs, indicating that reduction of annexin1 is a critical mechanism for immune evasion by Mtb. Collectively, these data indicate that annexin1 is essential in immunity to Mtb infection and mediates the power of DC efferocytosis and cross-presentation.	[ "Annexin1", "regulates", "DC", "efferocytosis", "and", "cross", "-", "presentation", "during", "Mycobacterium", "tuberculosis", "infection", ".", "The", "phagocytosis", "of", "apoptotic", "cells", "and", "associated", "vesicles", "(", "efferocytosis", ")", "by", "DCs", "is", "an", "important", "mechanism", "for", "both", "self", "tolerance", "and", "host", "defense", ".", "Although", "some", "of", "the", "engulfment", "ligands", "involved", "in", "efferocytosis", "have", "been", "identified", "and", "studied", "in", "vitro", ",", "the", "contributions", "of", "these", "ligands", "in", "vivo", "remain", "ill", "defined", ".", "Here", ",", "we", "determined", "that", "during", "Mycobacterium", "tuberculosis", "(", "Mtb", ")", "infection", ",", "the", "engulfment", "ligand", "annexin1", "is", "an", "important", "mediator", "in", "DC", "cross", "-", "presentation", "that", "increases", "efferocytosis", "in", "DCs", "and", "intrinsically", "enhances", "the", "capacity", "of", "the", "DC", "antigen", "-", "presenting", "machinery", ".", "Annexin1-deficient", "mice", "were", "highly", "susceptible", "to", "Mtb", "infection", "and", "showed", "an", "impaired", "Mtb", "antigen", "-", "specific", "CD8", "+", "T", "cell", "response", ".", "Importantly", ",", "annexin1", "expression", "was", "greatly", "downregulated", "in", "Mtb", "-", "infected", "human", "blood", "monocyte", "-", "derived", "DCs", ",", "indicating", "that", "reduction", "of", "annexin1", "is", "a", "critical", "mechanism", "for", "immune", "evasion", "by", "Mtb", ".", "Collectively", ",", "these", "data", "indicate", "that", "annexin1", "is", "essential", "in", "immunity", "to", "Mtb", "infection", "and", "mediates", "the", "power", "of", "DC", "efferocytosis", "and", "cross", "-", "presentation", ".", " " ]	[ "Habitat", "Microorganism" ]
Mycobacterium tuberculosis is a Microorganism, apoptotic cells is a Habitat, DCs is a Habitat, Mycobacterium tuberculosis is a Microorganism, Mtb is a Microorganism, DC is a Habitat, DCs is a Habitat, DC is a Habitat, Annexin1-deficient mice is a Habitat, Mtb is a Microorganism, Mtb is a Microorganism, CD8 + T cell is a Habitat, Mtb - infected human blood monocyte - derived DCs is a Habitat, Mtb is a Microorganism, Mtb is a Microorganism, DC is a Habitat	45_task1	Sentence: Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. The phagocytosis of apoptotic cells and associated vesicles (efferocytosis) by DCs is an important mechanism for both self tolerance and host defense. Although some of the engulfment ligands involved in efferocytosis have been identified and studied in vitro, the contributions of these ligands in vivo remain ill defined. Here, we determined that during Mycobacterium tuberculosis (Mtb) infection, the engulfment ligand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs and intrinsically enhances the capacity of the DC antigen-presenting machinery. Annexin1-deficient mice were highly susceptible to Mtb infection and showed an impaired Mtb antigen-specific CD8+ T cell response. Importantly, annexin1 expression was greatly downregulated in Mtb-infected human blood monocyte-derived DCs, indicating that reduction of annexin1 is a critical mechanism for immune evasion by Mtb. Collectively, these data indicate that annexin1 is essential in immunity to Mtb infection and mediates the power of DC efferocytosis and cross-presentation. Instructions: please typing these entity words according to sentence: Mycobacterium tuberculosis, apoptotic cells, DCs, Mycobacterium tuberculosis, Mtb, DC, DCs, DC, Annexin1-deficient mice, Mtb, Mtb, CD8 + T cell, Mtb - infected human blood monocyte - derived DCs, Mtb, Mtb, DC Options: Microorganism, Habitat	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O" ]	Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. The phagocytosis of apoptotic cells and associated vesicles (efferocytosis) by DCs is an important mechanism for both self tolerance and host defense. Although some of the engulfment ligands involved in efferocytosis have been identified and studied in vitro, the contributions of these ligands in vivo remain ill defined. Here, we determined that during Mycobacterium tuberculosis (Mtb) infection, the engulfment ligand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs and intrinsically enhances the capacity of the DC antigen-presenting machinery. Annexin1-deficient mice were highly susceptible to Mtb infection and showed an impaired Mtb antigen-specific CD8+ T cell response. Importantly, annexin1 expression was greatly downregulated in Mtb-infected human blood monocyte-derived DCs, indicating that reduction of annexin1 is a critical mechanism for immune evasion by Mtb. Collectively, these data indicate that annexin1 is essential in immunity to Mtb infection and mediates the power of DC efferocytosis and cross-presentation.	[ "Annexin1", "regulates", "DC", "efferocytosis", "and", "cross", "-", "presentation", "during", "Mycobacterium", "tuberculosis", "infection", ".", "The", "phagocytosis", "of", "apoptotic", "cells", "and", "associated", "vesicles", "(", "efferocytosis", ")", "by", "DCs", "is", "an", "important", "mechanism", "for", "both", "self", "tolerance", "and", "host", "defense", ".", "Although", "some", "of", "the", "engulfment", "ligands", "involved", "in", "efferocytosis", "have", "been", "identified", "and", "studied", "in", "vitro", ",", "the", "contributions", "of", "these", "ligands", "in", "vivo", "remain", "ill", "defined", ".", "Here", ",", "we", "determined", "that", "during", "Mycobacterium", "tuberculosis", "(", "Mtb", ")", "infection", ",", "the", "engulfment", "ligand", "annexin1", "is", "an", "important", "mediator", "in", "DC", "cross", "-", "presentation", "that", "increases", "efferocytosis", "in", "DCs", "and", "intrinsically", "enhances", "the", "capacity", "of", "the", "DC", "antigen", "-", "presenting", "machinery", ".", "Annexin1-deficient", "mice", "were", "highly", "susceptible", "to", "Mtb", "infection", "and", "showed", "an", "impaired", "Mtb", "antigen", "-", "specific", "CD8", "+", "T", "cell", "response", ".", "Importantly", ",", "annexin1", "expression", "was", "greatly", "downregulated", "in", "Mtb", "-", "infected", "human", "blood", "monocyte", "-", "derived", "DCs", ",", "indicating", "that", "reduction", "of", "annexin1", "is", "a", "critical", "mechanism", "for", "immune", "evasion", "by", "Mtb", ".", "Collectively", ",", "these", "data", "indicate", "that", "annexin1", "is", "essential", "in", "immunity", "to", "Mtb", "infection", "and", "mediates", "the", "power", "of", "DC", "efferocytosis", "and", "cross", "-", "presentation", ".", " " ]	[ "Habitat", "Microorganism" ]
Mycobacterium tuberculosis, apoptotic cells, DCs, Mycobacterium tuberculosis, Mtb, DC, DCs, DC, Annexin1-deficient mice, Mtb, Mtb, CD8 + T cell, Mtb - infected human blood monocyte - derived DCs, Mtb, Mtb, DC	45_task2	Sentence: Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. The phagocytosis of apoptotic cells and associated vesicles (efferocytosis) by DCs is an important mechanism for both self tolerance and host defense. Although some of the engulfment ligands involved in efferocytosis have been identified and studied in vitro, the contributions of these ligands in vivo remain ill defined. Here, we determined that during Mycobacterium tuberculosis (Mtb) infection, the engulfment ligand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs and intrinsically enhances the capacity of the DC antigen-presenting machinery. Annexin1-deficient mice were highly susceptible to Mtb infection and showed an impaired Mtb antigen-specific CD8+ T cell response. Importantly, annexin1 expression was greatly downregulated in Mtb-infected human blood monocyte-derived DCs, indicating that reduction of annexin1 is a critical mechanism for immune evasion by Mtb. Collectively, these data indicate that annexin1 is essential in immunity to Mtb infection and mediates the power of DC efferocytosis and cross-presentation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O" ]	Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. The phagocytosis of apoptotic cells and associated vesicles (efferocytosis) by DCs is an important mechanism for both self tolerance and host defense. Although some of the engulfment ligands involved in efferocytosis have been identified and studied in vitro, the contributions of these ligands in vivo remain ill defined. Here, we determined that during Mycobacterium tuberculosis (Mtb) infection, the engulfment ligand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs and intrinsically enhances the capacity of the DC antigen-presenting machinery. Annexin1-deficient mice were highly susceptible to Mtb infection and showed an impaired Mtb antigen-specific CD8+ T cell response. Importantly, annexin1 expression was greatly downregulated in Mtb-infected human blood monocyte-derived DCs, indicating that reduction of annexin1 is a critical mechanism for immune evasion by Mtb. Collectively, these data indicate that annexin1 is essential in immunity to Mtb infection and mediates the power of DC efferocytosis and cross-presentation.	[ "Annexin1", "regulates", "DC", "efferocytosis", "and", "cross", "-", "presentation", "during", "Mycobacterium", "tuberculosis", "infection", ".", "The", "phagocytosis", "of", "apoptotic", "cells", "and", "associated", "vesicles", "(", "efferocytosis", ")", "by", "DCs", "is", "an", "important", "mechanism", "for", "both", "self", "tolerance", "and", "host", "defense", ".", "Although", "some", "of", "the", "engulfment", "ligands", "involved", "in", "efferocytosis", "have", "been", "identified", "and", "studied", "in", "vitro", ",", "the", "contributions", "of", "these", "ligands", "in", "vivo", "remain", "ill", "defined", ".", "Here", ",", "we", "determined", "that", "during", "Mycobacterium", "tuberculosis", "(", "Mtb", ")", "infection", ",", "the", "engulfment", "ligand", "annexin1", "is", "an", "important", "mediator", "in", "DC", "cross", "-", "presentation", "that", "increases", "efferocytosis", "in", "DCs", "and", "intrinsically", "enhances", "the", "capacity", "of", "the", "DC", "antigen", "-", "presenting", "machinery", ".", "Annexin1-deficient", "mice", "were", "highly", "susceptible", "to", "Mtb", "infection", "and", "showed", "an", "impaired", "Mtb", "antigen", "-", "specific", "CD8", "+", "T", "cell", "response", ".", "Importantly", ",", "annexin1", "expression", "was", "greatly", "downregulated", "in", "Mtb", "-", "infected", "human", "blood", "monocyte", "-", "derived", "DCs", ",", "indicating", "that", "reduction", "of", "annexin1", "is", "a", "critical", "mechanism", "for", "immune", "evasion", "by", "Mtb", ".", "Collectively", ",", "these", "data", "indicate", "that", "annexin1", "is", "essential", "in", "immunity", "to", "Mtb", "infection", "and", "mediates", "the", "power", "of", "DC", "efferocytosis", "and", "cross", "-", "presentation", ".", " " ]	[ "Habitat", "Microorganism" ]
Diagnose is an umlsterm, Osteoporose is an umlsterm, Beurteilung is an umlsterm, radiologischen is an umlsterm, Methoden is an umlsterm, Skelett is an umlsterm, Computertomographie is an umlsterm, Ultraschall is an umlsterm, geschlechts- is an umlsterm, rassenspezifischen is an umlsterm, Knochenmasse is an umlsterm, Patienten is an umlsterm, radiologische is an umlsterm, Diagnose is an umlsterm, Osteoporose is an umlsterm, Knochenmasse is an umlsterm, Frakturen is an umlsterm, Spitzenknochenmasse is an umlsterm, Normbevoelkerung is an umlsterm, Knochenmasse is an umlsterm, Patienten is an umlsterm, Staerken is an umlsterm, Technik is an umlsterm	DerRadiologe.90390222.ger.abstr_task0	Sentence: Eine fruehe Diagnose der Osteoporose und eine akkurate Beurteilung von Behandlungserfolgen stehen im Mittelpunkt der radiologischen Bestrebungen . Die haeufigsten klinisch angewendeten Methoden , um das periphere Skelett sowie das Achsensekelett zu beurteilen sind die 2-Spektren-Roentgenabsorptimetrie ( DXA , " dual x-ray absorptiometry " ) , die quantitative Computertomographie ( QCT ) and der quantitative Ultraschall ( QUS ) . Generell werden die Messergebnise eines Individuums mit einer alters- , geschlechts- , und rassenspezifischen Kontrollgruppen verglichen . In diesem Zusammenhang ist die Bestimmung der Knochenmasse ein Indikator des kuenftigen Frakturrisikos eines Patienten . Die radiologische Diagnose der Osteoporose kann durch die Bestimmung der Knochenmasse erfolgen , auch wenn keine praevalenten Frakturen vorliegen . Das Frakturrisiko fuer den Messwert eines Individuums steigt um etwa das 1,5- bis 2,5fache fuer jede Standardabweichung ( SD ) unter der Spitzenknochenmasse der Normbevoelkerung ( T-Wert ) . Die Wahl des Messortes und der Untersuchungstechnik zur Bestimmung der Knochenmasse oder des Frakturrisikos muss sich nach individuellen Gegebenheiten am Patienten sowie den Staerken und Limitationen der Technik richten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]	Eine fruehe Diagnose der Osteoporose und eine akkurate Beurteilung von Behandlungserfolgen stehen im Mittelpunkt der radiologischen Bestrebungen . Die haeufigsten klinisch angewendeten Methoden , um das periphere Skelett sowie das Achsensekelett zu beurteilen sind die 2-Spektren-Roentgenabsorptimetrie ( DXA , " dual x-ray absorptiometry " ) , die quantitative Computertomographie ( QCT ) and der quantitative Ultraschall ( QUS ) . Generell werden die Messergebnise eines Individuums mit einer alters- , geschlechts- , und rassenspezifischen Kontrollgruppen verglichen . In diesem Zusammenhang ist die Bestimmung der Knochenmasse ein Indikator des kuenftigen Frakturrisikos eines Patienten . Die radiologische Diagnose der Osteoporose kann durch die Bestimmung der Knochenmasse erfolgen , auch wenn keine praevalenten Frakturen vorliegen . Das Frakturrisiko fuer den Messwert eines Individuums steigt um etwa das 1,5- bis 2,5fache fuer jede Standardabweichung ( SD ) unter der Spitzenknochenmasse der Normbevoelkerung ( T-Wert ) . Die Wahl des Messortes und der Untersuchungstechnik zur Bestimmung der Knochenmasse oder des Frakturrisikos muss sich nach individuellen Gegebenheiten am Patienten sowie den Staerken und Limitationen der Technik richten .	[ "Eine", "fruehe", "Diagnose", "der", "Osteoporose", "und", "eine", "akkurate", "Beurteilung", "von", "Behandlungserfolgen", "stehen", "im", "Mittelpunkt", "der", "radiologischen", "Bestrebungen", ".", "Die", "haeufigsten", "klinisch", "angewendeten", "Methoden", ",", "um", "das", "periphere", "Skelett", "sowie", "das", "Achsensekelett", "zu", "beurteilen", "sind", "die", "2-Spektren", "-", "Roentgenabsorptimetrie", "(", "DXA", ",", "\"", "dual", "x", "-", "ray", "absorptiometry", "\"", ")", ",", "die", "quantitative", "Computertomographie", "(", "QCT", ")", "and", "der", "quantitative", "Ultraschall", "(", "QUS", ")", ".", "Generell", "werden", "die", "Messergebnise", "eines", "Individuums", "mit", "einer", "alters-", ",", "geschlechts-", ",", "und", "rassenspezifischen", "Kontrollgruppen", "verglichen", ".", "In", "diesem", "Zusammenhang", "ist", "die", "Bestimmung", "der", "Knochenmasse", "ein", "Indikator", "des", "kuenftigen", "Frakturrisikos", "eines", "Patienten", ".", "Die", "radiologische", "Diagnose", "der", "Osteoporose", "kann", "durch", "die", "Bestimmung", "der", "Knochenmasse", "erfolgen", ",", "auch", "wenn", "keine", "praevalenten", "Frakturen", "vorliegen", ".", "Das", "Frakturrisiko", "fuer", "den", "Messwert", "eines", "Individuums", "steigt", "um", "etwa", "das", "1,5-", "bis", "2,5fache", "fuer", "jede", "Standardabweichung", "(", "SD", ")", "unter", "der", "Spitzenknochenmasse", "der", "Normbevoelkerung", "(", "T", "-", "Wert", ")", ".", "Die", "Wahl", "des", "Messortes", "und", "der", "Untersuchungstechnik", "zur", "Bestimmung", "der", "Knochenmasse", "oder", "des", "Frakturrisikos", "muss", "sich", "nach", "individuellen", "Gegebenheiten", "am", "Patienten", "sowie", "den", "Staerken", "und", "Limitationen", "der", "Technik", "richten", "." ]	[ "umlsterm" ]
Diagnose is an umlsterm, Osteoporose is an umlsterm, Beurteilung is an umlsterm, radiologischen is an umlsterm, Methoden is an umlsterm, Skelett is an umlsterm, Computertomographie is an umlsterm, Ultraschall is an umlsterm, geschlechts- is an umlsterm, rassenspezifischen is an umlsterm, Knochenmasse is an umlsterm, Patienten is an umlsterm, radiologische is an umlsterm, Diagnose is an umlsterm, Osteoporose is an umlsterm, Knochenmasse is an umlsterm, Frakturen is an umlsterm, Spitzenknochenmasse is an umlsterm, Normbevoelkerung is an umlsterm, Knochenmasse is an umlsterm, Patienten is an umlsterm, Staerken is an umlsterm, Technik is an umlsterm	DerRadiologe.90390222.ger.abstr_task1	Sentence: Eine fruehe Diagnose der Osteoporose und eine akkurate Beurteilung von Behandlungserfolgen stehen im Mittelpunkt der radiologischen Bestrebungen . Die haeufigsten klinisch angewendeten Methoden , um das periphere Skelett sowie das Achsensekelett zu beurteilen sind die 2-Spektren-Roentgenabsorptimetrie ( DXA , " dual x-ray absorptiometry " ) , die quantitative Computertomographie ( QCT ) and der quantitative Ultraschall ( QUS ) . Generell werden die Messergebnise eines Individuums mit einer alters- , geschlechts- , und rassenspezifischen Kontrollgruppen verglichen . In diesem Zusammenhang ist die Bestimmung der Knochenmasse ein Indikator des kuenftigen Frakturrisikos eines Patienten . Die radiologische Diagnose der Osteoporose kann durch die Bestimmung der Knochenmasse erfolgen , auch wenn keine praevalenten Frakturen vorliegen . Das Frakturrisiko fuer den Messwert eines Individuums steigt um etwa das 1,5- bis 2,5fache fuer jede Standardabweichung ( SD ) unter der Spitzenknochenmasse der Normbevoelkerung ( T-Wert ) . Die Wahl des Messortes und der Untersuchungstechnik zur Bestimmung der Knochenmasse oder des Frakturrisikos muss sich nach individuellen Gegebenheiten am Patienten sowie den Staerken und Limitationen der Technik richten . Instructions: please typing these entity words according to sentence: Diagnose, Osteoporose, Beurteilung, radiologischen, Methoden, Skelett, Computertomographie, Ultraschall, geschlechts-, rassenspezifischen, Knochenmasse, Patienten, radiologische, Diagnose, Osteoporose, Knochenmasse, Frakturen, Spitzenknochenmasse, Normbevoelkerung, Knochenmasse, Patienten, Staerken, Technik Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]	Eine fruehe Diagnose der Osteoporose und eine akkurate Beurteilung von Behandlungserfolgen stehen im Mittelpunkt der radiologischen Bestrebungen . Die haeufigsten klinisch angewendeten Methoden , um das periphere Skelett sowie das Achsensekelett zu beurteilen sind die 2-Spektren-Roentgenabsorptimetrie ( DXA , " dual x-ray absorptiometry " ) , die quantitative Computertomographie ( QCT ) and der quantitative Ultraschall ( QUS ) . Generell werden die Messergebnise eines Individuums mit einer alters- , geschlechts- , und rassenspezifischen Kontrollgruppen verglichen . In diesem Zusammenhang ist die Bestimmung der Knochenmasse ein Indikator des kuenftigen Frakturrisikos eines Patienten . Die radiologische Diagnose der Osteoporose kann durch die Bestimmung der Knochenmasse erfolgen , auch wenn keine praevalenten Frakturen vorliegen . Das Frakturrisiko fuer den Messwert eines Individuums steigt um etwa das 1,5- bis 2,5fache fuer jede Standardabweichung ( SD ) unter der Spitzenknochenmasse der Normbevoelkerung ( T-Wert ) . Die Wahl des Messortes und der Untersuchungstechnik zur Bestimmung der Knochenmasse oder des Frakturrisikos muss sich nach individuellen Gegebenheiten am Patienten sowie den Staerken und Limitationen der Technik richten .	[ "Eine", "fruehe", "Diagnose", "der", "Osteoporose", "und", "eine", "akkurate", "Beurteilung", "von", "Behandlungserfolgen", "stehen", "im", "Mittelpunkt", "der", "radiologischen", "Bestrebungen", ".", "Die", "haeufigsten", "klinisch", "angewendeten", "Methoden", ",", "um", "das", "periphere", "Skelett", "sowie", "das", "Achsensekelett", "zu", "beurteilen", "sind", "die", "2-Spektren", "-", "Roentgenabsorptimetrie", "(", "DXA", ",", "\"", "dual", "x", "-", "ray", "absorptiometry", "\"", ")", ",", "die", "quantitative", "Computertomographie", "(", "QCT", ")", "and", "der", "quantitative", "Ultraschall", "(", "QUS", ")", ".", "Generell", "werden", "die", "Messergebnise", "eines", "Individuums", "mit", "einer", "alters-", ",", "geschlechts-", ",", "und", "rassenspezifischen", "Kontrollgruppen", "verglichen", ".", "In", "diesem", "Zusammenhang", "ist", "die", "Bestimmung", "der", "Knochenmasse", "ein", "Indikator", "des", "kuenftigen", "Frakturrisikos", "eines", "Patienten", ".", "Die", "radiologische", "Diagnose", "der", "Osteoporose", "kann", "durch", "die", "Bestimmung", "der", "Knochenmasse", "erfolgen", ",", "auch", "wenn", "keine", "praevalenten", "Frakturen", "vorliegen", ".", "Das", "Frakturrisiko", "fuer", "den", "Messwert", "eines", "Individuums", "steigt", "um", "etwa", "das", "1,5-", "bis", "2,5fache", "fuer", "jede", "Standardabweichung", "(", "SD", ")", "unter", "der", "Spitzenknochenmasse", "der", "Normbevoelkerung", "(", "T", "-", "Wert", ")", ".", "Die", "Wahl", "des", "Messortes", "und", "der", "Untersuchungstechnik", "zur", "Bestimmung", "der", "Knochenmasse", "oder", "des", "Frakturrisikos", "muss", "sich", "nach", "individuellen", "Gegebenheiten", "am", "Patienten", "sowie", "den", "Staerken", "und", "Limitationen", "der", "Technik", "richten", "." ]	[ "umlsterm" ]
Diagnose, Osteoporose, Beurteilung, radiologischen, Methoden, Skelett, Computertomographie, Ultraschall, geschlechts-, rassenspezifischen, Knochenmasse, Patienten, radiologische, Diagnose, Osteoporose, Knochenmasse, Frakturen, Spitzenknochenmasse, Normbevoelkerung, Knochenmasse, Patienten, Staerken, Technik	DerRadiologe.90390222.ger.abstr_task2	Sentence: Eine fruehe Diagnose der Osteoporose und eine akkurate Beurteilung von Behandlungserfolgen stehen im Mittelpunkt der radiologischen Bestrebungen . Die haeufigsten klinisch angewendeten Methoden , um das periphere Skelett sowie das Achsensekelett zu beurteilen sind die 2-Spektren-Roentgenabsorptimetrie ( DXA , " dual x-ray absorptiometry " ) , die quantitative Computertomographie ( QCT ) and der quantitative Ultraschall ( QUS ) . Generell werden die Messergebnise eines Individuums mit einer alters- , geschlechts- , und rassenspezifischen Kontrollgruppen verglichen . In diesem Zusammenhang ist die Bestimmung der Knochenmasse ein Indikator des kuenftigen Frakturrisikos eines Patienten . Die radiologische Diagnose der Osteoporose kann durch die Bestimmung der Knochenmasse erfolgen , auch wenn keine praevalenten Frakturen vorliegen . Das Frakturrisiko fuer den Messwert eines Individuums steigt um etwa das 1,5- bis 2,5fache fuer jede Standardabweichung ( SD ) unter der Spitzenknochenmasse der Normbevoelkerung ( T-Wert ) . Die Wahl des Messortes und der Untersuchungstechnik zur Bestimmung der Knochenmasse oder des Frakturrisikos muss sich nach individuellen Gegebenheiten am Patienten sowie den Staerken und Limitationen der Technik richten . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]	Eine fruehe Diagnose der Osteoporose und eine akkurate Beurteilung von Behandlungserfolgen stehen im Mittelpunkt der radiologischen Bestrebungen . Die haeufigsten klinisch angewendeten Methoden , um das periphere Skelett sowie das Achsensekelett zu beurteilen sind die 2-Spektren-Roentgenabsorptimetrie ( DXA , " dual x-ray absorptiometry " ) , die quantitative Computertomographie ( QCT ) and der quantitative Ultraschall ( QUS ) . Generell werden die Messergebnise eines Individuums mit einer alters- , geschlechts- , und rassenspezifischen Kontrollgruppen verglichen . In diesem Zusammenhang ist die Bestimmung der Knochenmasse ein Indikator des kuenftigen Frakturrisikos eines Patienten . Die radiologische Diagnose der Osteoporose kann durch die Bestimmung der Knochenmasse erfolgen , auch wenn keine praevalenten Frakturen vorliegen . Das Frakturrisiko fuer den Messwert eines Individuums steigt um etwa das 1,5- bis 2,5fache fuer jede Standardabweichung ( SD ) unter der Spitzenknochenmasse der Normbevoelkerung ( T-Wert ) . Die Wahl des Messortes und der Untersuchungstechnik zur Bestimmung der Knochenmasse oder des Frakturrisikos muss sich nach individuellen Gegebenheiten am Patienten sowie den Staerken und Limitationen der Technik richten .	[ "Eine", "fruehe", "Diagnose", "der", "Osteoporose", "und", "eine", "akkurate", "Beurteilung", "von", "Behandlungserfolgen", "stehen", "im", "Mittelpunkt", "der", "radiologischen", "Bestrebungen", ".", "Die", "haeufigsten", "klinisch", "angewendeten", "Methoden", ",", "um", "das", "periphere", "Skelett", "sowie", "das", "Achsensekelett", "zu", "beurteilen", "sind", "die", "2-Spektren", "-", "Roentgenabsorptimetrie", "(", "DXA", ",", "\"", "dual", "x", "-", "ray", "absorptiometry", "\"", ")", ",", "die", "quantitative", "Computertomographie", "(", "QCT", ")", "and", "der", "quantitative", "Ultraschall", "(", "QUS", ")", ".", "Generell", "werden", "die", "Messergebnise", "eines", "Individuums", "mit", "einer", "alters-", ",", "geschlechts-", ",", "und", "rassenspezifischen", "Kontrollgruppen", "verglichen", ".", "In", "diesem", "Zusammenhang", "ist", "die", "Bestimmung", "der", "Knochenmasse", "ein", "Indikator", "des", "kuenftigen", "Frakturrisikos", "eines", "Patienten", ".", "Die", "radiologische", "Diagnose", "der", "Osteoporose", "kann", "durch", "die", "Bestimmung", "der", "Knochenmasse", "erfolgen", ",", "auch", "wenn", "keine", "praevalenten", "Frakturen", "vorliegen", ".", "Das", "Frakturrisiko", "fuer", "den", "Messwert", "eines", "Individuums", "steigt", "um", "etwa", "das", "1,5-", "bis", "2,5fache", "fuer", "jede", "Standardabweichung", "(", "SD", ")", "unter", "der", "Spitzenknochenmasse", "der", "Normbevoelkerung", "(", "T", "-", "Wert", ")", ".", "Die", "Wahl", "des", "Messortes", "und", "der", "Untersuchungstechnik", "zur", "Bestimmung", "der", "Knochenmasse", "oder", "des", "Frakturrisikos", "muss", "sich", "nach", "individuellen", "Gegebenheiten", "am", "Patienten", "sowie", "den", "Staerken", "und", "Limitationen", "der", "Technik", "richten", "." ]	[ "umlsterm" ]
Kindesmisshandlung is an umlsterm, Kind is an umlsterm, erziehungsberechtigte is an umlsterm, Person is an umlsterm, Diagnose is an umlsterm, Kindesmisshandlungen is an umlsterm, Arzt is an umlsterm, Kindesmisshandlung is an umlsterm, Kindes is an umlsterm, Gesundheit is an umlsterm, Eltern is an umlsterm, Erziehungsberechtigten is an umlsterm, Kindesmisshandlung is an umlsterm, Polizei is an umlsterm	Notfall+Rettungsmedizin.80010013.ger.abstr_task0	Sentence: Im Falle einer Kindesmisshandlung steht das Kind , und nicht die erziehungsberechtigte Person im Mittelpunkt jeder diagnostischen und therapeutischen Massnahme . Bei Unsicherheiten kann eine Diagnose durch konsiliarische Beiziehung eines mit Kindesmisshandlungen erfahrenen Kollegen bzw. durch rechtsmedizinische Institute abgesichert werden . Unter bestimmten Voraussetzungen kann der Arzt Tatbestaende im Zusammenhang mit einer Kindesmisshandlung offenbaren . Das Interesse des Kindes auf seine Gesundheit hat dann Vorrang vor der aerztlichen Schweigepflicht und dem Geheimhaltungsinteresse der Eltern oder Erziehungsberechtigten , sollten diese fuer die Misshandlung verantwortlich sein . Beim Bekanntwerden einer Kindesmisshandlung sollte eine Mitteilung an das zustaendige Jugendamt , das in eigener Kompetenz ueber das weitere Vorgehen entscheidet , oder auch an die Polizei erfolgen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Im Falle einer Kindesmisshandlung steht das Kind , und nicht die erziehungsberechtigte Person im Mittelpunkt jeder diagnostischen und therapeutischen Massnahme . Bei Unsicherheiten kann eine Diagnose durch konsiliarische Beiziehung eines mit Kindesmisshandlungen erfahrenen Kollegen bzw. durch rechtsmedizinische Institute abgesichert werden . Unter bestimmten Voraussetzungen kann der Arzt Tatbestaende im Zusammenhang mit einer Kindesmisshandlung offenbaren . Das Interesse des Kindes auf seine Gesundheit hat dann Vorrang vor der aerztlichen Schweigepflicht und dem Geheimhaltungsinteresse der Eltern oder Erziehungsberechtigten , sollten diese fuer die Misshandlung verantwortlich sein . Beim Bekanntwerden einer Kindesmisshandlung sollte eine Mitteilung an das zustaendige Jugendamt , das in eigener Kompetenz ueber das weitere Vorgehen entscheidet , oder auch an die Polizei erfolgen .	[ "Im", "Falle", "einer", "Kindesmisshandlung", "steht", "das", "Kind", ",", "und", "nicht", "die", "erziehungsberechtigte", "Person", "im", "Mittelpunkt", "jeder", "diagnostischen", "und", "therapeutischen", "Massnahme", ".", "Bei", "Unsicherheiten", "kann", "eine", "Diagnose", "durch", "konsiliarische", "Beiziehung", "eines", "mit", "Kindesmisshandlungen", "erfahrenen", "Kollegen", "bzw", ".", "durch", "rechtsmedizinische", "Institute", "abgesichert", "werden", ".", "Unter", "bestimmten", "Voraussetzungen", "kann", "der", "Arzt", "Tatbestaende", "im", "Zusammenhang", "mit", "einer", "Kindesmisshandlung", "offenbaren", ".", "Das", "Interesse", "des", "Kindes", "auf", "seine", "Gesundheit", "hat", "dann", "Vorrang", "vor", "der", "aerztlichen", "Schweigepflicht", "und", "dem", "Geheimhaltungsinteresse", "der", "Eltern", "oder", "Erziehungsberechtigten", ",", "sollten", "diese", "fuer", "die", "Misshandlung", "verantwortlich", "sein", ".", "Beim", "Bekanntwerden", "einer", "Kindesmisshandlung", "sollte", "eine", "Mitteilung", "an", "das", "zustaendige", "Jugendamt", ",", "das", "in", "eigener", "Kompetenz", "ueber", "das", "weitere", "Vorgehen", "entscheidet", ",", "oder", "auch", "an", "die", "Polizei", "erfolgen", "." ]	[ "umlsterm" ]
Kindesmisshandlung is an umlsterm, Kind is an umlsterm, erziehungsberechtigte is an umlsterm, Person is an umlsterm, Diagnose is an umlsterm, Kindesmisshandlungen is an umlsterm, Arzt is an umlsterm, Kindesmisshandlung is an umlsterm, Kindes is an umlsterm, Gesundheit is an umlsterm, Eltern is an umlsterm, Erziehungsberechtigten is an umlsterm, Kindesmisshandlung is an umlsterm, Polizei is an umlsterm	Notfall+Rettungsmedizin.80010013.ger.abstr_task1	Sentence: Im Falle einer Kindesmisshandlung steht das Kind , und nicht die erziehungsberechtigte Person im Mittelpunkt jeder diagnostischen und therapeutischen Massnahme . Bei Unsicherheiten kann eine Diagnose durch konsiliarische Beiziehung eines mit Kindesmisshandlungen erfahrenen Kollegen bzw. durch rechtsmedizinische Institute abgesichert werden . Unter bestimmten Voraussetzungen kann der Arzt Tatbestaende im Zusammenhang mit einer Kindesmisshandlung offenbaren . Das Interesse des Kindes auf seine Gesundheit hat dann Vorrang vor der aerztlichen Schweigepflicht und dem Geheimhaltungsinteresse der Eltern oder Erziehungsberechtigten , sollten diese fuer die Misshandlung verantwortlich sein . Beim Bekanntwerden einer Kindesmisshandlung sollte eine Mitteilung an das zustaendige Jugendamt , das in eigener Kompetenz ueber das weitere Vorgehen entscheidet , oder auch an die Polizei erfolgen . Instructions: please typing these entity words according to sentence: Kindesmisshandlung, Kind, erziehungsberechtigte, Person, Diagnose, Kindesmisshandlungen, Arzt, Kindesmisshandlung, Kindes, Gesundheit, Eltern, Erziehungsberechtigten, Kindesmisshandlung, Polizei Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Im Falle einer Kindesmisshandlung steht das Kind , und nicht die erziehungsberechtigte Person im Mittelpunkt jeder diagnostischen und therapeutischen Massnahme . Bei Unsicherheiten kann eine Diagnose durch konsiliarische Beiziehung eines mit Kindesmisshandlungen erfahrenen Kollegen bzw. durch rechtsmedizinische Institute abgesichert werden . Unter bestimmten Voraussetzungen kann der Arzt Tatbestaende im Zusammenhang mit einer Kindesmisshandlung offenbaren . Das Interesse des Kindes auf seine Gesundheit hat dann Vorrang vor der aerztlichen Schweigepflicht und dem Geheimhaltungsinteresse der Eltern oder Erziehungsberechtigten , sollten diese fuer die Misshandlung verantwortlich sein . Beim Bekanntwerden einer Kindesmisshandlung sollte eine Mitteilung an das zustaendige Jugendamt , das in eigener Kompetenz ueber das weitere Vorgehen entscheidet , oder auch an die Polizei erfolgen .	[ "Im", "Falle", "einer", "Kindesmisshandlung", "steht", "das", "Kind", ",", "und", "nicht", "die", "erziehungsberechtigte", "Person", "im", "Mittelpunkt", "jeder", "diagnostischen", "und", "therapeutischen", "Massnahme", ".", "Bei", "Unsicherheiten", "kann", "eine", "Diagnose", "durch", "konsiliarische", "Beiziehung", "eines", "mit", "Kindesmisshandlungen", "erfahrenen", "Kollegen", "bzw", ".", "durch", "rechtsmedizinische", "Institute", "abgesichert", "werden", ".", "Unter", "bestimmten", "Voraussetzungen", "kann", "der", "Arzt", "Tatbestaende", "im", "Zusammenhang", "mit", "einer", "Kindesmisshandlung", "offenbaren", ".", "Das", "Interesse", "des", "Kindes", "auf", "seine", "Gesundheit", "hat", "dann", "Vorrang", "vor", "der", "aerztlichen", "Schweigepflicht", "und", "dem", "Geheimhaltungsinteresse", "der", "Eltern", "oder", "Erziehungsberechtigten", ",", "sollten", "diese", "fuer", "die", "Misshandlung", "verantwortlich", "sein", ".", "Beim", "Bekanntwerden", "einer", "Kindesmisshandlung", "sollte", "eine", "Mitteilung", "an", "das", "zustaendige", "Jugendamt", ",", "das", "in", "eigener", "Kompetenz", "ueber", "das", "weitere", "Vorgehen", "entscheidet", ",", "oder", "auch", "an", "die", "Polizei", "erfolgen", "." ]	[ "umlsterm" ]
Kindesmisshandlung, Kind, erziehungsberechtigte, Person, Diagnose, Kindesmisshandlungen, Arzt, Kindesmisshandlung, Kindes, Gesundheit, Eltern, Erziehungsberechtigten, Kindesmisshandlung, Polizei	Notfall+Rettungsmedizin.80010013.ger.abstr_task2	Sentence: Im Falle einer Kindesmisshandlung steht das Kind , und nicht die erziehungsberechtigte Person im Mittelpunkt jeder diagnostischen und therapeutischen Massnahme . Bei Unsicherheiten kann eine Diagnose durch konsiliarische Beiziehung eines mit Kindesmisshandlungen erfahrenen Kollegen bzw. durch rechtsmedizinische Institute abgesichert werden . Unter bestimmten Voraussetzungen kann der Arzt Tatbestaende im Zusammenhang mit einer Kindesmisshandlung offenbaren . Das Interesse des Kindes auf seine Gesundheit hat dann Vorrang vor der aerztlichen Schweigepflicht und dem Geheimhaltungsinteresse der Eltern oder Erziehungsberechtigten , sollten diese fuer die Misshandlung verantwortlich sein . Beim Bekanntwerden einer Kindesmisshandlung sollte eine Mitteilung an das zustaendige Jugendamt , das in eigener Kompetenz ueber das weitere Vorgehen entscheidet , oder auch an die Polizei erfolgen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Im Falle einer Kindesmisshandlung steht das Kind , und nicht die erziehungsberechtigte Person im Mittelpunkt jeder diagnostischen und therapeutischen Massnahme . Bei Unsicherheiten kann eine Diagnose durch konsiliarische Beiziehung eines mit Kindesmisshandlungen erfahrenen Kollegen bzw. durch rechtsmedizinische Institute abgesichert werden . Unter bestimmten Voraussetzungen kann der Arzt Tatbestaende im Zusammenhang mit einer Kindesmisshandlung offenbaren . Das Interesse des Kindes auf seine Gesundheit hat dann Vorrang vor der aerztlichen Schweigepflicht und dem Geheimhaltungsinteresse der Eltern oder Erziehungsberechtigten , sollten diese fuer die Misshandlung verantwortlich sein . Beim Bekanntwerden einer Kindesmisshandlung sollte eine Mitteilung an das zustaendige Jugendamt , das in eigener Kompetenz ueber das weitere Vorgehen entscheidet , oder auch an die Polizei erfolgen .	[ "Im", "Falle", "einer", "Kindesmisshandlung", "steht", "das", "Kind", ",", "und", "nicht", "die", "erziehungsberechtigte", "Person", "im", "Mittelpunkt", "jeder", "diagnostischen", "und", "therapeutischen", "Massnahme", ".", "Bei", "Unsicherheiten", "kann", "eine", "Diagnose", "durch", "konsiliarische", "Beiziehung", "eines", "mit", "Kindesmisshandlungen", "erfahrenen", "Kollegen", "bzw", ".", "durch", "rechtsmedizinische", "Institute", "abgesichert", "werden", ".", "Unter", "bestimmten", "Voraussetzungen", "kann", "der", "Arzt", "Tatbestaende", "im", "Zusammenhang", "mit", "einer", "Kindesmisshandlung", "offenbaren", ".", "Das", "Interesse", "des", "Kindes", "auf", "seine", "Gesundheit", "hat", "dann", "Vorrang", "vor", "der", "aerztlichen", "Schweigepflicht", "und", "dem", "Geheimhaltungsinteresse", "der", "Eltern", "oder", "Erziehungsberechtigten", ",", "sollten", "diese", "fuer", "die", "Misshandlung", "verantwortlich", "sein", ".", "Beim", "Bekanntwerden", "einer", "Kindesmisshandlung", "sollte", "eine", "Mitteilung", "an", "das", "zustaendige", "Jugendamt", ",", "das", "in", "eigener", "Kompetenz", "ueber", "das", "weitere", "Vorgehen", "entscheidet", ",", "oder", "auch", "an", "die", "Polizei", "erfolgen", "." ]	[ "umlsterm" ]
Mps1p is a Gene_or_gene_product, spindle pole is a Cellular_component, Spc110p is a Gene_or_gene_product, spindle pole body is a Cellular_component, SPB is a Cellular_component, Spc110p is a Gene_or_gene_product, Nuf1p is a Gene_or_gene_product, serine is a Simple_chemical, threonine is a Simple_chemical, spindle apparatus is a Cellular_component, Mps1p is a Gene_or_gene_product, Spc110p is a Gene_or_gene_product, Mps1p is a Gene_or_gene_product, Spc110p is a Gene_or_gene_product, Ser(60 ) is a Simple_chemical, Thr(64 ) is a Simple_chemical, Thr(68 ) is a Simple_chemical, Spc110p is a Gene_or_gene_product, Mps1p is a Gene_or_gene_product, alanine is a Simple_chemical, SPB is a Cellular_component, Mps1p is a Gene_or_gene_product, Alanine is a Simple_chemical, alanine is a Simple_chemical, Ser(36 ) is a Simple_chemical, SPC97 is a Gene_or_gene_product, Tub4p is a Complex, alanine is a Simple_chemical, serine is a Simple_chemical, threonine is a Simple_chemical, aspartate is a Simple_chemical, Mps1p is a Gene_or_gene_product, Ser(36 ) is a Simple_chemical, Spc110p is a Gene_or_gene_product, inner plaque is a Cellular_component, SPB is a Cellular_component, Tub4p is a Complex	40_task0	Sentence: Yeast Mps1p phosphorylates the spindle pole component Spc110p in the N-terminal domain. The yeast spindle pole body (SPB) component Spc110p (Nuf1p) undergoes specific serine/threonine phosphorylation as the mitotic spindle apparatus forms, and this phosphorylation persists until cells enter anaphase. We demonstrate that the dual-specificity kinase Mps1p is essential for the mitosis-specific phosphorylation of Spc110p in vivo and that Mps1p phosphorylates Spc110p in vitro. Phosphopeptides generated by proteolytic cleavage were identified and sequenced by mass spectrometry. Ser(60), Thr(64), and Thr(68) are the major sites in Spc110p phosphorylated by Mps1p in vitro, and alanine substitution at these sites abolishes the mitosis-specific isoform in vivo. This is the first time that phosphorylation sites of an SPB component have been determined, and these are the first sites of Mps1p phosphorylation identified. Alanine substitution for any one of these phosphorylated residues, in conjunction with an alanine substitution at residue Ser(36), is lethal in combination with alleles of SPC97, which encodes a component of the Tub4p complex. Consistent with a specific dysfunction for the alanine substitution mutations, simultaneous mutation of all four serine/threonine residues to aspartate does not confer any defect. Sites of Mps1p phosphorylation and Ser(36) are located within the N-terminal globular domain of Spc110p, which resides at the inner plaque of the SPB and binds the Tub4p complex. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Simple_chemical, Complex, Gene_or_gene_product, Cellular_component	[ "O", "B-Gene_or_gene_product", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "I-Cellular_component", "O", "B-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Cellular_component", "O", "O", "O", "B-Complex", "O", "O", "O" ]	Yeast Mps1p phosphorylates the spindle pole component Spc110p in the N-terminal domain. The yeast spindle pole body (SPB) component Spc110p (Nuf1p) undergoes specific serine/threonine phosphorylation as the mitotic spindle apparatus forms, and this phosphorylation persists until cells enter anaphase. We demonstrate that the dual-specificity kinase Mps1p is essential for the mitosis-specific phosphorylation of Spc110p in vivo and that Mps1p phosphorylates Spc110p in vitro. Phosphopeptides generated by proteolytic cleavage were identified and sequenced by mass spectrometry. Ser(60), Thr(64), and Thr(68) are the major sites in Spc110p phosphorylated by Mps1p in vitro, and alanine substitution at these sites abolishes the mitosis-specific isoform in vivo. This is the first time that phosphorylation sites of an SPB component have been determined, and these are the first sites of Mps1p phosphorylation identified. Alanine substitution for any one of these phosphorylated residues, in conjunction with an alanine substitution at residue Ser(36), is lethal in combination with alleles of SPC97, which encodes a component of the Tub4p complex. Consistent with a specific dysfunction for the alanine substitution mutations, simultaneous mutation of all four serine/threonine residues to aspartate does not confer any defect. Sites of Mps1p phosphorylation and Ser(36) are located within the N-terminal globular domain of Spc110p, which resides at the inner plaque of the SPB and binds the Tub4p complex.	[ "Yeast", "Mps1p", "phosphorylates", "the", "spindle", "pole", "component", "Spc110p", "in", "the", "N", "-", "terminal", "domain", ".", "\n", "The", "yeast", "spindle", "pole", "body", "(", "SPB", ")", "component", "Spc110p", "(", "Nuf1p", ")", "undergoes", "specific", "serine", "/", "threonine", "phosphorylation", "as", "the", "mitotic", "spindle", "apparatus", "forms", ",", "and", "this", "phosphorylation", "persists", "until", "cells", "enter", "anaphase", ".", "We", "demonstrate", "that", "the", "dual", "-", "specificity", "kinase", "Mps1p", "is", "essential", "for", "the", "mitosis", "-", "specific", "phosphorylation", "of", "Spc110p", "in", "vivo", "and", "that", "Mps1p", "phosphorylates", "Spc110p", "in", "vitro", ".", "Phosphopeptides", "generated", "by", "proteolytic", "cleavage", "were", "identified", "and", "sequenced", "by", "mass", "spectrometry", ".", "Ser(60", ")", ",", "Thr(64", ")", ",", "and", "Thr(68", ")", "are", "the", "major", "sites", "in", "Spc110p", "phosphorylated", "by", "Mps1p", "in", "vitro", ",", "and", "alanine", "substitution", "at", "these", "sites", "abolishes", "the", "mitosis", "-", "specific", "isoform", "in", "vivo", ".", "This", "is", "the", "first", "time", "that", "phosphorylation", "sites", "of", "an", "SPB", "component", "have", "been", "determined", ",", "and", "these", "are", "the", "first", "sites", "of", "Mps1p", "phosphorylation", "identified", ".", "Alanine", "substitution", "for", "any", "one", "of", "these", "phosphorylated", "residues", ",", "in", "conjunction", "with", "an", "alanine", "substitution", "at", "residue", "Ser(36", ")", ",", "is", "lethal", "in", "combination", "with", "alleles", "of", "SPC97", ",", "which", "encodes", "a", "component", "of", "the", "Tub4p", "complex", ".", "Consistent", "with", "a", "specific", "dysfunction", "for", "the", "alanine", "substitution", "mutations", ",", "simultaneous", "mutation", "of", "all", "four", "serine", "/", "threonine", "residues", "to", "aspartate", "does", "not", "confer", "any", "defect", ".", "Sites", "of", "Mps1p", "phosphorylation", "and", "Ser(36", ")", "are", "located", "within", "the", "N", "-", "terminal", "globular", "domain", "of", "Spc110p", ",", "which", "resides", "at", "the", "inner", "plaque", "of", "the", "SPB", "and", "binds", "the", "Tub4p", "complex", ".", "\n" ]	[ "Cellular_component", "Simple_chemical", "Gene_or_gene_product", "Complex" ]
Mps1p is a Gene_or_gene_product, spindle pole is a Cellular_component, Spc110p is a Gene_or_gene_product, spindle pole body is a Cellular_component, SPB is a Cellular_component, Spc110p is a Gene_or_gene_product, Nuf1p is a Gene_or_gene_product, serine is a Simple_chemical, threonine is a Simple_chemical, spindle apparatus is a Cellular_component, Mps1p is a Gene_or_gene_product, Spc110p is a Gene_or_gene_product, Mps1p is a Gene_or_gene_product, Spc110p is a Gene_or_gene_product, Ser(60 ) is a Simple_chemical, Thr(64 ) is a Simple_chemical, Thr(68 ) is a Simple_chemical, Spc110p is a Gene_or_gene_product, Mps1p is a Gene_or_gene_product, alanine is a Simple_chemical, SPB is a Cellular_component, Mps1p is a Gene_or_gene_product, Alanine is a Simple_chemical, alanine is a Simple_chemical, Ser(36 ) is a Simple_chemical, SPC97 is a Gene_or_gene_product, Tub4p is a Complex, alanine is a Simple_chemical, serine is a Simple_chemical, threonine is a Simple_chemical, aspartate is a Simple_chemical, Mps1p is a Gene_or_gene_product, Ser(36 ) is a Simple_chemical, Spc110p is a Gene_or_gene_product, inner plaque is a Cellular_component, SPB is a Cellular_component, Tub4p is a Complex	40_task1	Sentence: Yeast Mps1p phosphorylates the spindle pole component Spc110p in the N-terminal domain. The yeast spindle pole body (SPB) component Spc110p (Nuf1p) undergoes specific serine/threonine phosphorylation as the mitotic spindle apparatus forms, and this phosphorylation persists until cells enter anaphase. We demonstrate that the dual-specificity kinase Mps1p is essential for the mitosis-specific phosphorylation of Spc110p in vivo and that Mps1p phosphorylates Spc110p in vitro. Phosphopeptides generated by proteolytic cleavage were identified and sequenced by mass spectrometry. Ser(60), Thr(64), and Thr(68) are the major sites in Spc110p phosphorylated by Mps1p in vitro, and alanine substitution at these sites abolishes the mitosis-specific isoform in vivo. This is the first time that phosphorylation sites of an SPB component have been determined, and these are the first sites of Mps1p phosphorylation identified. Alanine substitution for any one of these phosphorylated residues, in conjunction with an alanine substitution at residue Ser(36), is lethal in combination with alleles of SPC97, which encodes a component of the Tub4p complex. Consistent with a specific dysfunction for the alanine substitution mutations, simultaneous mutation of all four serine/threonine residues to aspartate does not confer any defect. Sites of Mps1p phosphorylation and Ser(36) are located within the N-terminal globular domain of Spc110p, which resides at the inner plaque of the SPB and binds the Tub4p complex. Instructions: please typing these entity words according to sentence: Mps1p, spindle pole, Spc110p, spindle pole body, SPB, Spc110p, Nuf1p, serine, threonine, spindle apparatus, Mps1p, Spc110p, Mps1p, Spc110p, Ser(60 ), Thr(64 ), Thr(68 ), Spc110p, Mps1p, alanine, SPB, Mps1p, Alanine, alanine, Ser(36 ), SPC97, Tub4p, alanine, serine, threonine, aspartate, Mps1p, Ser(36 ), Spc110p, inner plaque, SPB, Tub4p Options: Simple_chemical, Complex, Gene_or_gene_product, Cellular_component	[ "O", "B-Gene_or_gene_product", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "I-Cellular_component", "O", "B-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Cellular_component", "O", "O", "O", "B-Complex", "O", "O", "O" ]	Yeast Mps1p phosphorylates the spindle pole component Spc110p in the N-terminal domain. The yeast spindle pole body (SPB) component Spc110p (Nuf1p) undergoes specific serine/threonine phosphorylation as the mitotic spindle apparatus forms, and this phosphorylation persists until cells enter anaphase. We demonstrate that the dual-specificity kinase Mps1p is essential for the mitosis-specific phosphorylation of Spc110p in vivo and that Mps1p phosphorylates Spc110p in vitro. Phosphopeptides generated by proteolytic cleavage were identified and sequenced by mass spectrometry. Ser(60), Thr(64), and Thr(68) are the major sites in Spc110p phosphorylated by Mps1p in vitro, and alanine substitution at these sites abolishes the mitosis-specific isoform in vivo. This is the first time that phosphorylation sites of an SPB component have been determined, and these are the first sites of Mps1p phosphorylation identified. Alanine substitution for any one of these phosphorylated residues, in conjunction with an alanine substitution at residue Ser(36), is lethal in combination with alleles of SPC97, which encodes a component of the Tub4p complex. Consistent with a specific dysfunction for the alanine substitution mutations, simultaneous mutation of all four serine/threonine residues to aspartate does not confer any defect. Sites of Mps1p phosphorylation and Ser(36) are located within the N-terminal globular domain of Spc110p, which resides at the inner plaque of the SPB and binds the Tub4p complex.	[ "Yeast", "Mps1p", "phosphorylates", "the", "spindle", "pole", "component", "Spc110p", "in", "the", "N", "-", "terminal", "domain", ".", "\n", "The", "yeast", "spindle", "pole", "body", "(", "SPB", ")", "component", "Spc110p", "(", "Nuf1p", ")", "undergoes", "specific", "serine", "/", "threonine", "phosphorylation", "as", "the", "mitotic", "spindle", "apparatus", "forms", ",", "and", "this", "phosphorylation", "persists", "until", "cells", "enter", "anaphase", ".", "We", "demonstrate", "that", "the", "dual", "-", "specificity", "kinase", "Mps1p", "is", "essential", "for", "the", "mitosis", "-", "specific", "phosphorylation", "of", "Spc110p", "in", "vivo", "and", "that", "Mps1p", "phosphorylates", "Spc110p", "in", "vitro", ".", "Phosphopeptides", "generated", "by", "proteolytic", "cleavage", "were", "identified", "and", "sequenced", "by", "mass", "spectrometry", ".", "Ser(60", ")", ",", "Thr(64", ")", ",", "and", "Thr(68", ")", "are", "the", "major", "sites", "in", "Spc110p", "phosphorylated", "by", "Mps1p", "in", "vitro", ",", "and", "alanine", "substitution", "at", "these", "sites", "abolishes", "the", "mitosis", "-", "specific", "isoform", "in", "vivo", ".", "This", "is", "the", "first", "time", "that", "phosphorylation", "sites", "of", "an", "SPB", "component", "have", "been", "determined", ",", "and", "these", "are", "the", "first", "sites", "of", "Mps1p", "phosphorylation", "identified", ".", "Alanine", "substitution", "for", "any", "one", "of", "these", "phosphorylated", "residues", ",", "in", "conjunction", "with", "an", "alanine", "substitution", "at", "residue", "Ser(36", ")", ",", "is", "lethal", "in", "combination", "with", "alleles", "of", "SPC97", ",", "which", "encodes", "a", "component", "of", "the", "Tub4p", "complex", ".", "Consistent", "with", "a", "specific", "dysfunction", "for", "the", "alanine", "substitution", "mutations", ",", "simultaneous", "mutation", "of", "all", "four", "serine", "/", "threonine", "residues", "to", "aspartate", "does", "not", "confer", "any", "defect", ".", "Sites", "of", "Mps1p", "phosphorylation", "and", "Ser(36", ")", "are", "located", "within", "the", "N", "-", "terminal", "globular", "domain", "of", "Spc110p", ",", "which", "resides", "at", "the", "inner", "plaque", "of", "the", "SPB", "and", "binds", "the", "Tub4p", "complex", ".", "\n" ]	[ "Cellular_component", "Simple_chemical", "Gene_or_gene_product", "Complex" ]
Mps1p, spindle pole, Spc110p, spindle pole body, SPB, Spc110p, Nuf1p, serine, threonine, spindle apparatus, Mps1p, Spc110p, Mps1p, Spc110p, Ser(60 ), Thr(64 ), Thr(68 ), Spc110p, Mps1p, alanine, SPB, Mps1p, Alanine, alanine, Ser(36 ), SPC97, Tub4p, alanine, serine, threonine, aspartate, Mps1p, Ser(36 ), Spc110p, inner plaque, SPB, Tub4p	40_task2	Sentence: Yeast Mps1p phosphorylates the spindle pole component Spc110p in the N-terminal domain. The yeast spindle pole body (SPB) component Spc110p (Nuf1p) undergoes specific serine/threonine phosphorylation as the mitotic spindle apparatus forms, and this phosphorylation persists until cells enter anaphase. We demonstrate that the dual-specificity kinase Mps1p is essential for the mitosis-specific phosphorylation of Spc110p in vivo and that Mps1p phosphorylates Spc110p in vitro. Phosphopeptides generated by proteolytic cleavage were identified and sequenced by mass spectrometry. Ser(60), Thr(64), and Thr(68) are the major sites in Spc110p phosphorylated by Mps1p in vitro, and alanine substitution at these sites abolishes the mitosis-specific isoform in vivo. This is the first time that phosphorylation sites of an SPB component have been determined, and these are the first sites of Mps1p phosphorylation identified. Alanine substitution for any one of these phosphorylated residues, in conjunction with an alanine substitution at residue Ser(36), is lethal in combination with alleles of SPC97, which encodes a component of the Tub4p complex. Consistent with a specific dysfunction for the alanine substitution mutations, simultaneous mutation of all four serine/threonine residues to aspartate does not confer any defect. Sites of Mps1p phosphorylation and Ser(36) are located within the N-terminal globular domain of Spc110p, which resides at the inner plaque of the SPB and binds the Tub4p complex. Instructions: please extract entity words from the input sentence	[ "O", "B-Gene_or_gene_product", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "I-Cellular_component", "O", "B-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Cellular_component", "O", "O", "O", "B-Complex", "O", "O", "O" ]	Yeast Mps1p phosphorylates the spindle pole component Spc110p in the N-terminal domain. The yeast spindle pole body (SPB) component Spc110p (Nuf1p) undergoes specific serine/threonine phosphorylation as the mitotic spindle apparatus forms, and this phosphorylation persists until cells enter anaphase. We demonstrate that the dual-specificity kinase Mps1p is essential for the mitosis-specific phosphorylation of Spc110p in vivo and that Mps1p phosphorylates Spc110p in vitro. Phosphopeptides generated by proteolytic cleavage were identified and sequenced by mass spectrometry. Ser(60), Thr(64), and Thr(68) are the major sites in Spc110p phosphorylated by Mps1p in vitro, and alanine substitution at these sites abolishes the mitosis-specific isoform in vivo. This is the first time that phosphorylation sites of an SPB component have been determined, and these are the first sites of Mps1p phosphorylation identified. Alanine substitution for any one of these phosphorylated residues, in conjunction with an alanine substitution at residue Ser(36), is lethal in combination with alleles of SPC97, which encodes a component of the Tub4p complex. Consistent with a specific dysfunction for the alanine substitution mutations, simultaneous mutation of all four serine/threonine residues to aspartate does not confer any defect. Sites of Mps1p phosphorylation and Ser(36) are located within the N-terminal globular domain of Spc110p, which resides at the inner plaque of the SPB and binds the Tub4p complex.	[ "Yeast", "Mps1p", "phosphorylates", "the", "spindle", "pole", "component", "Spc110p", "in", "the", "N", "-", "terminal", "domain", ".", "\n", "The", "yeast", "spindle", "pole", "body", "(", "SPB", ")", "component", "Spc110p", "(", "Nuf1p", ")", "undergoes", "specific", "serine", "/", "threonine", "phosphorylation", "as", "the", "mitotic", "spindle", "apparatus", "forms", ",", "and", "this", "phosphorylation", "persists", "until", "cells", "enter", "anaphase", ".", "We", "demonstrate", "that", "the", "dual", "-", "specificity", "kinase", "Mps1p", "is", "essential", "for", "the", "mitosis", "-", "specific", "phosphorylation", "of", "Spc110p", "in", "vivo", "and", "that", "Mps1p", "phosphorylates", "Spc110p", "in", "vitro", ".", "Phosphopeptides", "generated", "by", "proteolytic", "cleavage", "were", "identified", "and", "sequenced", "by", "mass", "spectrometry", ".", "Ser(60", ")", ",", "Thr(64", ")", ",", "and", "Thr(68", ")", "are", "the", "major", "sites", "in", "Spc110p", "phosphorylated", "by", "Mps1p", "in", "vitro", ",", "and", "alanine", "substitution", "at", "these", "sites", "abolishes", "the", "mitosis", "-", "specific", "isoform", "in", "vivo", ".", "This", "is", "the", "first", "time", "that", "phosphorylation", "sites", "of", "an", "SPB", "component", "have", "been", "determined", ",", "and", "these", "are", "the", "first", "sites", "of", "Mps1p", "phosphorylation", "identified", ".", "Alanine", "substitution", "for", "any", "one", "of", "these", "phosphorylated", "residues", ",", "in", "conjunction", "with", "an", "alanine", "substitution", "at", "residue", "Ser(36", ")", ",", "is", "lethal", "in", "combination", "with", "alleles", "of", "SPC97", ",", "which", "encodes", "a", "component", "of", "the", "Tub4p", "complex", ".", "Consistent", "with", "a", "specific", "dysfunction", "for", "the", "alanine", "substitution", "mutations", ",", "simultaneous", "mutation", "of", "all", "four", "serine", "/", "threonine", "residues", "to", "aspartate", "does", "not", "confer", "any", "defect", ".", "Sites", "of", "Mps1p", "phosphorylation", "and", "Ser(36", ")", "are", "located", "within", "the", "N", "-", "terminal", "globular", "domain", "of", "Spc110p", ",", "which", "resides", "at", "the", "inner", "plaque", "of", "the", "SPB", "and", "binds", "the", "Tub4p", "complex", ".", "\n" ]	[ "Cellular_component", "Simple_chemical", "Gene_or_gene_product", "Complex" ]
Paclitaxel is an umlsterm, Mikrotubuli is an umlsterm, Signaltransduktion is an umlsterm, Paclitaxel is an umlsterm, Zelle is an umlsterm, Zelle is an umlsterm, Paclitaxel is an umlsterm, Medikamentenapplikation is an umlsterm, Arbeit is an umlsterm, Paclitaxel is an umlsterm, Gefaessmuskelzellen is an umlsterm, Endothelzellen is an umlsterm, Paclitaxel is an umlsterm, Wachstumshemmung is an umlsterm, selbst is an umlsterm, elektronenoptisch is an umlsterm, Muskelzellen is an umlsterm, Kaninchen is an umlsterm, Paclitaxel is an umlsterm, Erweiterung is an umlsterm, Kontrolltieren is an umlsterm, Kontraktionskraft is an umlsterm, Schweinemodell is an umlsterm	ZfuerKardiologie.00890390.ger.abstr_task0	Sentence: Paclitaxel eine sehr potente antiproliferative Substanz , , foerdert die Bildung ungewoehnlich stabiler und funktionsgestoerter Mikrotubuli und veraendert dadurch zellulaere Mechanismen , die letztlich zu verminderter Proliferation , Migration und Signaltransduktion fuehren . Paclitaxel ist lipophil , was eine rasche Aufnahme in die Zelle foerdert , und hat einen langanhaltenden Effekt in der Zelle aufgrund der strukturellen Veraenderung des Zytoskelettes . Diese Eigenschaften machen Paclitaxel zu einem vielversprechenden Kandidaten fuer die lokale Medikamentenapplikation zur Restenoseprophylaxe . In dieser Arbeit werden die in-vitro und in-vivo Ergebnisse aus unseren Forschungsarbeiten zu Paclitaxel vorgestellt . Zellkulturexperimente mit Monokulturen von humanen glatten Gefaessmuskelzellen sowie mit Co-Kulturen mit humanen Endothelzellen zeigten , dass Paclitaxel in einem Dosisbereich zwischen 1,0 und 10,0µmol/l zu einer beinahe vollstaendigen Wachstumshemmung , selbst nach kurzer ( 20 min . ) Einmalapplikation fuehrt . Nach Vergleich von 3 verschiedenen Kathetersystemen ( poroeser Ballon , mikroporoeser Ballon und Doppelballon ) wurde der Doppelballon fuer die in-vivo Anwendung favorisiert . Anhand von Anfaerbungen des Zytoskelettes sowie elektronenoptisch gelang der Nachweis der Paclitaxelwirkung in den glatten Muskelzellen der Gefaesswand . Im Kaninchen fuehrte lokal appliziertes Paclitaxel zu einer signifikanten Hemmung der neointimalen Proliferation und Erweiterung des Gefaessdurchmessers im Vergleich zu ballondilatierten Kontrolltieren . In Zusatzexperimenten konnte eine drastische Verringerung der vaskulaeren Kontraktionskraft nach Paclitaxelgabe gezeigt werden . Aehnlich eindeutige Ergebnisse fanden sich nach Stentimplantation im Schweinemodell nicht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Paclitaxel eine sehr potente antiproliferative Substanz , , foerdert die Bildung ungewoehnlich stabiler und funktionsgestoerter Mikrotubuli und veraendert dadurch zellulaere Mechanismen , die letztlich zu verminderter Proliferation , Migration und Signaltransduktion fuehren . Paclitaxel ist lipophil , was eine rasche Aufnahme in die Zelle foerdert , und hat einen langanhaltenden Effekt in der Zelle aufgrund der strukturellen Veraenderung des Zytoskelettes . Diese Eigenschaften machen Paclitaxel zu einem vielversprechenden Kandidaten fuer die lokale Medikamentenapplikation zur Restenoseprophylaxe . In dieser Arbeit werden die in-vitro und in-vivo Ergebnisse aus unseren Forschungsarbeiten zu Paclitaxel vorgestellt . Zellkulturexperimente mit Monokulturen von humanen glatten Gefaessmuskelzellen sowie mit Co-Kulturen mit humanen Endothelzellen zeigten , dass Paclitaxel in einem Dosisbereich zwischen 1,0 und 10,0µmol/l zu einer beinahe vollstaendigen Wachstumshemmung , selbst nach kurzer ( 20 min . ) Einmalapplikation fuehrt . Nach Vergleich von 3 verschiedenen Kathetersystemen ( poroeser Ballon , mikroporoeser Ballon und Doppelballon ) wurde der Doppelballon fuer die in-vivo Anwendung favorisiert . Anhand von Anfaerbungen des Zytoskelettes sowie elektronenoptisch gelang der Nachweis der Paclitaxelwirkung in den glatten Muskelzellen der Gefaesswand . Im Kaninchen fuehrte lokal appliziertes Paclitaxel zu einer signifikanten Hemmung der neointimalen Proliferation und Erweiterung des Gefaessdurchmessers im Vergleich zu ballondilatierten Kontrolltieren . In Zusatzexperimenten konnte eine drastische Verringerung der vaskulaeren Kontraktionskraft nach Paclitaxelgabe gezeigt werden . Aehnlich eindeutige Ergebnisse fanden sich nach Stentimplantation im Schweinemodell nicht .	[ "Paclitaxel", "eine", "sehr", "potente", "antiproliferative", "Substanz", ",", ",", "foerdert", "die", "Bildung", "ungewoehnlich", "stabiler", "und", "funktionsgestoerter", "Mikrotubuli", "und", "veraendert", "dadurch", "zellulaere", "Mechanismen", ",", "die", "letztlich", "zu", "verminderter", "Proliferation", ",", "Migration", "und", "Signaltransduktion", "fuehren", ".", "Paclitaxel", "ist", "lipophil", ",", "was", "eine", "rasche", "Aufnahme", "in", "die", "Zelle", "foerdert", ",", "und", "hat", "einen", "langanhaltenden", "Effekt", "in", "der", "Zelle", "aufgrund", "der", "strukturellen", "Veraenderung", "des", "Zytoskelettes", ".", "Diese", "Eigenschaften", "machen", "Paclitaxel", "zu", "einem", "vielversprechenden", "Kandidaten", "fuer", "die", "lokale", "Medikamentenapplikation", "zur", "Restenoseprophylaxe", ".", "In", "dieser", "Arbeit", "werden", "die", "in", "-", "vitro", "und", "in", "-", "vivo", "Ergebnisse", "aus", "unseren", "Forschungsarbeiten", "zu", "Paclitaxel", "vorgestellt", ".", "Zellkulturexperimente", "mit", "Monokulturen", "von", "humanen", "glatten", "Gefaessmuskelzellen", "sowie", "mit", "Co", "-", "Kulturen", "mit", "humanen", "Endothelzellen", "zeigten", ",", "dass", "Paclitaxel", "in", "einem", "Dosisbereich", "zwischen", "1,0", "und", "10,0µmol", "/", "l", "zu", "einer", "beinahe", "vollstaendigen", "Wachstumshemmung", ",", "selbst", "nach", "kurzer", "(", "20", "min", ".", ")", "Einmalapplikation", "fuehrt", ".", "Nach", "Vergleich", "von", "3", "verschiedenen", "Kathetersystemen", "(", "poroeser", "Ballon", ",", "mikroporoeser", "Ballon", "und", "Doppelballon", ")", "wurde", "der", "Doppelballon", "fuer", "die", "in", "-", "vivo", "Anwendung", "favorisiert", ".", "Anhand", "von", "Anfaerbungen", "des", "Zytoskelettes", "sowie", "elektronenoptisch", "gelang", "der", "Nachweis", "der", "Paclitaxelwirkung", "in", "den", "glatten", "Muskelzellen", "der", "Gefaesswand", ".", "Im", "Kaninchen", "fuehrte", "lokal", "appliziertes", "Paclitaxel", "zu", "einer", "signifikanten", "Hemmung", "der", "neointimalen", "Proliferation", "und", "Erweiterung", "des", "Gefaessdurchmessers", "im", "Vergleich", "zu", "ballondilatierten", "Kontrolltieren", ".", "In", "Zusatzexperimenten", "konnte", "eine", "drastische", "Verringerung", "der", "vaskulaeren", "Kontraktionskraft", "nach", "Paclitaxelgabe", "gezeigt", "werden", ".", "Aehnlich", "eindeutige", "Ergebnisse", "fanden", "sich", "nach", "Stentimplantation", "im", "Schweinemodell", "nicht", "." ]	[ "umlsterm" ]
Paclitaxel is an umlsterm, Mikrotubuli is an umlsterm, Signaltransduktion is an umlsterm, Paclitaxel is an umlsterm, Zelle is an umlsterm, Zelle is an umlsterm, Paclitaxel is an umlsterm, Medikamentenapplikation is an umlsterm, Arbeit is an umlsterm, Paclitaxel is an umlsterm, Gefaessmuskelzellen is an umlsterm, Endothelzellen is an umlsterm, Paclitaxel is an umlsterm, Wachstumshemmung is an umlsterm, selbst is an umlsterm, elektronenoptisch is an umlsterm, Muskelzellen is an umlsterm, Kaninchen is an umlsterm, Paclitaxel is an umlsterm, Erweiterung is an umlsterm, Kontrolltieren is an umlsterm, Kontraktionskraft is an umlsterm, Schweinemodell is an umlsterm	ZfuerKardiologie.00890390.ger.abstr_task1	Sentence: Paclitaxel eine sehr potente antiproliferative Substanz , , foerdert die Bildung ungewoehnlich stabiler und funktionsgestoerter Mikrotubuli und veraendert dadurch zellulaere Mechanismen , die letztlich zu verminderter Proliferation , Migration und Signaltransduktion fuehren . Paclitaxel ist lipophil , was eine rasche Aufnahme in die Zelle foerdert , und hat einen langanhaltenden Effekt in der Zelle aufgrund der strukturellen Veraenderung des Zytoskelettes . Diese Eigenschaften machen Paclitaxel zu einem vielversprechenden Kandidaten fuer die lokale Medikamentenapplikation zur Restenoseprophylaxe . In dieser Arbeit werden die in-vitro und in-vivo Ergebnisse aus unseren Forschungsarbeiten zu Paclitaxel vorgestellt . Zellkulturexperimente mit Monokulturen von humanen glatten Gefaessmuskelzellen sowie mit Co-Kulturen mit humanen Endothelzellen zeigten , dass Paclitaxel in einem Dosisbereich zwischen 1,0 und 10,0µmol/l zu einer beinahe vollstaendigen Wachstumshemmung , selbst nach kurzer ( 20 min . ) Einmalapplikation fuehrt . Nach Vergleich von 3 verschiedenen Kathetersystemen ( poroeser Ballon , mikroporoeser Ballon und Doppelballon ) wurde der Doppelballon fuer die in-vivo Anwendung favorisiert . Anhand von Anfaerbungen des Zytoskelettes sowie elektronenoptisch gelang der Nachweis der Paclitaxelwirkung in den glatten Muskelzellen der Gefaesswand . Im Kaninchen fuehrte lokal appliziertes Paclitaxel zu einer signifikanten Hemmung der neointimalen Proliferation und Erweiterung des Gefaessdurchmessers im Vergleich zu ballondilatierten Kontrolltieren . In Zusatzexperimenten konnte eine drastische Verringerung der vaskulaeren Kontraktionskraft nach Paclitaxelgabe gezeigt werden . Aehnlich eindeutige Ergebnisse fanden sich nach Stentimplantation im Schweinemodell nicht . Instructions: please typing these entity words according to sentence: Paclitaxel, Mikrotubuli, Signaltransduktion, Paclitaxel, Zelle, Zelle, Paclitaxel, Medikamentenapplikation, Arbeit, Paclitaxel, Gefaessmuskelzellen, Endothelzellen, Paclitaxel, Wachstumshemmung, selbst, elektronenoptisch, Muskelzellen, Kaninchen, Paclitaxel, Erweiterung, Kontrolltieren, Kontraktionskraft, Schweinemodell Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Paclitaxel eine sehr potente antiproliferative Substanz , , foerdert die Bildung ungewoehnlich stabiler und funktionsgestoerter Mikrotubuli und veraendert dadurch zellulaere Mechanismen , die letztlich zu verminderter Proliferation , Migration und Signaltransduktion fuehren . Paclitaxel ist lipophil , was eine rasche Aufnahme in die Zelle foerdert , und hat einen langanhaltenden Effekt in der Zelle aufgrund der strukturellen Veraenderung des Zytoskelettes . Diese Eigenschaften machen Paclitaxel zu einem vielversprechenden Kandidaten fuer die lokale Medikamentenapplikation zur Restenoseprophylaxe . In dieser Arbeit werden die in-vitro und in-vivo Ergebnisse aus unseren Forschungsarbeiten zu Paclitaxel vorgestellt . Zellkulturexperimente mit Monokulturen von humanen glatten Gefaessmuskelzellen sowie mit Co-Kulturen mit humanen Endothelzellen zeigten , dass Paclitaxel in einem Dosisbereich zwischen 1,0 und 10,0µmol/l zu einer beinahe vollstaendigen Wachstumshemmung , selbst nach kurzer ( 20 min . ) Einmalapplikation fuehrt . Nach Vergleich von 3 verschiedenen Kathetersystemen ( poroeser Ballon , mikroporoeser Ballon und Doppelballon ) wurde der Doppelballon fuer die in-vivo Anwendung favorisiert . Anhand von Anfaerbungen des Zytoskelettes sowie elektronenoptisch gelang der Nachweis der Paclitaxelwirkung in den glatten Muskelzellen der Gefaesswand . Im Kaninchen fuehrte lokal appliziertes Paclitaxel zu einer signifikanten Hemmung der neointimalen Proliferation und Erweiterung des Gefaessdurchmessers im Vergleich zu ballondilatierten Kontrolltieren . In Zusatzexperimenten konnte eine drastische Verringerung der vaskulaeren Kontraktionskraft nach Paclitaxelgabe gezeigt werden . Aehnlich eindeutige Ergebnisse fanden sich nach Stentimplantation im Schweinemodell nicht .	[ "Paclitaxel", "eine", "sehr", "potente", "antiproliferative", "Substanz", ",", ",", "foerdert", "die", "Bildung", "ungewoehnlich", "stabiler", "und", "funktionsgestoerter", "Mikrotubuli", "und", "veraendert", "dadurch", "zellulaere", "Mechanismen", ",", "die", "letztlich", "zu", "verminderter", "Proliferation", ",", "Migration", "und", "Signaltransduktion", "fuehren", ".", "Paclitaxel", "ist", "lipophil", ",", "was", "eine", "rasche", "Aufnahme", "in", "die", "Zelle", "foerdert", ",", "und", "hat", "einen", "langanhaltenden", "Effekt", "in", "der", "Zelle", "aufgrund", "der", "strukturellen", "Veraenderung", "des", "Zytoskelettes", ".", "Diese", "Eigenschaften", "machen", "Paclitaxel", "zu", "einem", "vielversprechenden", "Kandidaten", "fuer", "die", "lokale", "Medikamentenapplikation", "zur", "Restenoseprophylaxe", ".", "In", "dieser", "Arbeit", "werden", "die", "in", "-", "vitro", "und", "in", "-", "vivo", "Ergebnisse", "aus", "unseren", "Forschungsarbeiten", "zu", "Paclitaxel", "vorgestellt", ".", "Zellkulturexperimente", "mit", "Monokulturen", "von", "humanen", "glatten", "Gefaessmuskelzellen", "sowie", "mit", "Co", "-", "Kulturen", "mit", "humanen", "Endothelzellen", "zeigten", ",", "dass", "Paclitaxel", "in", "einem", "Dosisbereich", "zwischen", "1,0", "und", "10,0µmol", "/", "l", "zu", "einer", "beinahe", "vollstaendigen", "Wachstumshemmung", ",", "selbst", "nach", "kurzer", "(", "20", "min", ".", ")", "Einmalapplikation", "fuehrt", ".", "Nach", "Vergleich", "von", "3", "verschiedenen", "Kathetersystemen", "(", "poroeser", "Ballon", ",", "mikroporoeser", "Ballon", "und", "Doppelballon", ")", "wurde", "der", "Doppelballon", "fuer", "die", "in", "-", "vivo", "Anwendung", "favorisiert", ".", "Anhand", "von", "Anfaerbungen", "des", "Zytoskelettes", "sowie", "elektronenoptisch", "gelang", "der", "Nachweis", "der", "Paclitaxelwirkung", "in", "den", "glatten", "Muskelzellen", "der", "Gefaesswand", ".", "Im", "Kaninchen", "fuehrte", "lokal", "appliziertes", "Paclitaxel", "zu", "einer", "signifikanten", "Hemmung", "der", "neointimalen", "Proliferation", "und", "Erweiterung", "des", "Gefaessdurchmessers", "im", "Vergleich", "zu", "ballondilatierten", "Kontrolltieren", ".", "In", "Zusatzexperimenten", "konnte", "eine", "drastische", "Verringerung", "der", "vaskulaeren", "Kontraktionskraft", "nach", "Paclitaxelgabe", "gezeigt", "werden", ".", "Aehnlich", "eindeutige", "Ergebnisse", "fanden", "sich", "nach", "Stentimplantation", "im", "Schweinemodell", "nicht", "." ]	[ "umlsterm" ]
Paclitaxel, Mikrotubuli, Signaltransduktion, Paclitaxel, Zelle, Zelle, Paclitaxel, Medikamentenapplikation, Arbeit, Paclitaxel, Gefaessmuskelzellen, Endothelzellen, Paclitaxel, Wachstumshemmung, selbst, elektronenoptisch, Muskelzellen, Kaninchen, Paclitaxel, Erweiterung, Kontrolltieren, Kontraktionskraft, Schweinemodell	ZfuerKardiologie.00890390.ger.abstr_task2	Sentence: Paclitaxel eine sehr potente antiproliferative Substanz , , foerdert die Bildung ungewoehnlich stabiler und funktionsgestoerter Mikrotubuli und veraendert dadurch zellulaere Mechanismen , die letztlich zu verminderter Proliferation , Migration und Signaltransduktion fuehren . Paclitaxel ist lipophil , was eine rasche Aufnahme in die Zelle foerdert , und hat einen langanhaltenden Effekt in der Zelle aufgrund der strukturellen Veraenderung des Zytoskelettes . Diese Eigenschaften machen Paclitaxel zu einem vielversprechenden Kandidaten fuer die lokale Medikamentenapplikation zur Restenoseprophylaxe . In dieser Arbeit werden die in-vitro und in-vivo Ergebnisse aus unseren Forschungsarbeiten zu Paclitaxel vorgestellt . Zellkulturexperimente mit Monokulturen von humanen glatten Gefaessmuskelzellen sowie mit Co-Kulturen mit humanen Endothelzellen zeigten , dass Paclitaxel in einem Dosisbereich zwischen 1,0 und 10,0µmol/l zu einer beinahe vollstaendigen Wachstumshemmung , selbst nach kurzer ( 20 min . ) Einmalapplikation fuehrt . Nach Vergleich von 3 verschiedenen Kathetersystemen ( poroeser Ballon , mikroporoeser Ballon und Doppelballon ) wurde der Doppelballon fuer die in-vivo Anwendung favorisiert . Anhand von Anfaerbungen des Zytoskelettes sowie elektronenoptisch gelang der Nachweis der Paclitaxelwirkung in den glatten Muskelzellen der Gefaesswand . Im Kaninchen fuehrte lokal appliziertes Paclitaxel zu einer signifikanten Hemmung der neointimalen Proliferation und Erweiterung des Gefaessdurchmessers im Vergleich zu ballondilatierten Kontrolltieren . In Zusatzexperimenten konnte eine drastische Verringerung der vaskulaeren Kontraktionskraft nach Paclitaxelgabe gezeigt werden . Aehnlich eindeutige Ergebnisse fanden sich nach Stentimplantation im Schweinemodell nicht . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Paclitaxel eine sehr potente antiproliferative Substanz , , foerdert die Bildung ungewoehnlich stabiler und funktionsgestoerter Mikrotubuli und veraendert dadurch zellulaere Mechanismen , die letztlich zu verminderter Proliferation , Migration und Signaltransduktion fuehren . Paclitaxel ist lipophil , was eine rasche Aufnahme in die Zelle foerdert , und hat einen langanhaltenden Effekt in der Zelle aufgrund der strukturellen Veraenderung des Zytoskelettes . Diese Eigenschaften machen Paclitaxel zu einem vielversprechenden Kandidaten fuer die lokale Medikamentenapplikation zur Restenoseprophylaxe . In dieser Arbeit werden die in-vitro und in-vivo Ergebnisse aus unseren Forschungsarbeiten zu Paclitaxel vorgestellt . Zellkulturexperimente mit Monokulturen von humanen glatten Gefaessmuskelzellen sowie mit Co-Kulturen mit humanen Endothelzellen zeigten , dass Paclitaxel in einem Dosisbereich zwischen 1,0 und 10,0µmol/l zu einer beinahe vollstaendigen Wachstumshemmung , selbst nach kurzer ( 20 min . ) Einmalapplikation fuehrt . Nach Vergleich von 3 verschiedenen Kathetersystemen ( poroeser Ballon , mikroporoeser Ballon und Doppelballon ) wurde der Doppelballon fuer die in-vivo Anwendung favorisiert . Anhand von Anfaerbungen des Zytoskelettes sowie elektronenoptisch gelang der Nachweis der Paclitaxelwirkung in den glatten Muskelzellen der Gefaesswand . Im Kaninchen fuehrte lokal appliziertes Paclitaxel zu einer signifikanten Hemmung der neointimalen Proliferation und Erweiterung des Gefaessdurchmessers im Vergleich zu ballondilatierten Kontrolltieren . In Zusatzexperimenten konnte eine drastische Verringerung der vaskulaeren Kontraktionskraft nach Paclitaxelgabe gezeigt werden . Aehnlich eindeutige Ergebnisse fanden sich nach Stentimplantation im Schweinemodell nicht .	[ "Paclitaxel", "eine", "sehr", "potente", "antiproliferative", "Substanz", ",", ",", "foerdert", "die", "Bildung", "ungewoehnlich", "stabiler", "und", "funktionsgestoerter", "Mikrotubuli", "und", "veraendert", "dadurch", "zellulaere", "Mechanismen", ",", "die", "letztlich", "zu", "verminderter", "Proliferation", ",", "Migration", "und", "Signaltransduktion", "fuehren", ".", "Paclitaxel", "ist", "lipophil", ",", "was", "eine", "rasche", "Aufnahme", "in", "die", "Zelle", "foerdert", ",", "und", "hat", "einen", "langanhaltenden", "Effekt", "in", "der", "Zelle", "aufgrund", "der", "strukturellen", "Veraenderung", "des", "Zytoskelettes", ".", "Diese", "Eigenschaften", "machen", "Paclitaxel", "zu", "einem", "vielversprechenden", "Kandidaten", "fuer", "die", "lokale", "Medikamentenapplikation", "zur", "Restenoseprophylaxe", ".", "In", "dieser", "Arbeit", "werden", "die", "in", "-", "vitro", "und", "in", "-", "vivo", "Ergebnisse", "aus", "unseren", "Forschungsarbeiten", "zu", "Paclitaxel", "vorgestellt", ".", "Zellkulturexperimente", "mit", "Monokulturen", "von", "humanen", "glatten", "Gefaessmuskelzellen", "sowie", "mit", "Co", "-", "Kulturen", "mit", "humanen", "Endothelzellen", "zeigten", ",", "dass", "Paclitaxel", "in", "einem", "Dosisbereich", "zwischen", "1,0", "und", "10,0µmol", "/", "l", "zu", "einer", "beinahe", "vollstaendigen", "Wachstumshemmung", ",", "selbst", "nach", "kurzer", "(", "20", "min", ".", ")", "Einmalapplikation", "fuehrt", ".", "Nach", "Vergleich", "von", "3", "verschiedenen", "Kathetersystemen", "(", "poroeser", "Ballon", ",", "mikroporoeser", "Ballon", "und", "Doppelballon", ")", "wurde", "der", "Doppelballon", "fuer", "die", "in", "-", "vivo", "Anwendung", "favorisiert", ".", "Anhand", "von", "Anfaerbungen", "des", "Zytoskelettes", "sowie", "elektronenoptisch", "gelang", "der", "Nachweis", "der", "Paclitaxelwirkung", "in", "den", "glatten", "Muskelzellen", "der", "Gefaesswand", ".", "Im", "Kaninchen", "fuehrte", "lokal", "appliziertes", "Paclitaxel", "zu", "einer", "signifikanten", "Hemmung", "der", "neointimalen", "Proliferation", "und", "Erweiterung", "des", "Gefaessdurchmessers", "im", "Vergleich", "zu", "ballondilatierten", "Kontrolltieren", ".", "In", "Zusatzexperimenten", "konnte", "eine", "drastische", "Verringerung", "der", "vaskulaeren", "Kontraktionskraft", "nach", "Paclitaxelgabe", "gezeigt", "werden", ".", "Aehnlich", "eindeutige", "Ergebnisse", "fanden", "sich", "nach", "Stentimplantation", "im", "Schweinemodell", "nicht", "." ]	[ "umlsterm" ]
transcutaneous electrical stimulation is a Intervention_Physical, pressurization is a Intervention_Physical, side effects is a Outcome_Adverse-effects, incidence of PONV , the rate of metoclopramide , the VAS score is a Outcome_Physical, total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture is a Outcome_Physical, anal exhaust time and the volume of postoperative bleeding is a Outcome_Physical, incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section . is a Outcome_Physical	57395_task0	Sentence: [ Effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section ] . OBJECTIVE To investigate the effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section . METHODS After IRB approval and informed consent , one hundred and eighty singleton primiparas undergoing elective cesarean section , in Qingdao Municipal Hospital , and Qingdao Hiser Medical Center , from November 2011 to March 2012 , were randomly assigned to three groups : transcutaneous electrical stimulation of auricular Shenmen point group ( group A , n = 60 ) , transcutaneous electrical stimulation of auricular Eye point group ( group B , n = 60 ) and control group ( group C , n = 60 ) . Women of group A received transcutaneous electrical stimulation of auricular Shenmen point ( frequency 1.5 HZ ) at the time of preoperation , 4 , 10 and 22 hours of postoperation for 30 minutes . The strength was controlled by themselves . Women of group B received stimulation of auricular Eye point as group A . Women of group C received pressurization and connected line were the same with group A , but without electrical stimulation . The following indexes was observed : the incidence of postoperative nausea and vomiting ( PONV ) for 48 hours ; the rate of metoclopramide ; the visual analogue scale ( VAS ) score of rest pain , uterine contration pain and dynamic pain at the time of postoperation for 6 , 12 , 24 and 48 hours ( T ( 1 ) -T ( 4 ) ) ; the total number and effective compressions number of patient-controlled epidural analgesia ( PCEA ) ; the dose of analgesia mixture ; the anal exhaust time ; the volume of postoperative bleeding for 6 hours of postoperation and the other side effects . RESULTS Compared with group B and group C , the incidence of PONV , the rate of metoclopramide , the VAS score at the time T ( 1 ) -T ( 4 ) , the total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture were decreased in group A ( P < 0.05 ) , but no difference compared group B with group C ( P > 0.05 ) . The anal exhaust time and the volume of postoperative bleeding for 6 hours of postoperation were no difference in the three groups ( P > 0.05 ) . No other side effects were observed . CONCLUSION Transcutaneous electrical stimulation of auricular Shenmen point can reduce the incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Adverse-effects, Outcome_Physical	[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical" ]	[ Effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section ] . OBJECTIVE To investigate the effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section . METHODS After IRB approval and informed consent , one hundred and eighty singleton primiparas undergoing elective cesarean section , in Qingdao Municipal Hospital , and Qingdao Hiser Medical Center , from November 2011 to March 2012 , were randomly assigned to three groups : transcutaneous electrical stimulation of auricular Shenmen point group ( group A , n = 60 ) , transcutaneous electrical stimulation of auricular Eye point group ( group B , n = 60 ) and control group ( group C , n = 60 ) . Women of group A received transcutaneous electrical stimulation of auricular Shenmen point ( frequency 1.5 HZ ) at the time of preoperation , 4 , 10 and 22 hours of postoperation for 30 minutes . The strength was controlled by themselves . Women of group B received stimulation of auricular Eye point as group A . Women of group C received pressurization and connected line were the same with group A , but without electrical stimulation . The following indexes was observed : the incidence of postoperative nausea and vomiting ( PONV ) for 48 hours ; the rate of metoclopramide ; the visual analogue scale ( VAS ) score of rest pain , uterine contration pain and dynamic pain at the time of postoperation for 6 , 12 , 24 and 48 hours ( T ( 1 ) -T ( 4 ) ) ; the total number and effective compressions number of patient-controlled epidural analgesia ( PCEA ) ; the dose of analgesia mixture ; the anal exhaust time ; the volume of postoperative bleeding for 6 hours of postoperation and the other side effects . RESULTS Compared with group B and group C , the incidence of PONV , the rate of metoclopramide , the VAS score at the time T ( 1 ) -T ( 4 ) , the total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture were decreased in group A ( P < 0.05 ) , but no difference compared group B with group C ( P > 0.05 ) . The anal exhaust time and the volume of postoperative bleeding for 6 hours of postoperation were no difference in the three groups ( P > 0.05 ) . No other side effects were observed . CONCLUSION Transcutaneous electrical stimulation of auricular Shenmen point can reduce the incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section .	[ "[", "Effects", "of", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "on", "postoperative", "nausea", "and", "vomiting", "and", "patient", "-", "controlled", "epidural", "analgesia", "in", "cesarean", "section", "]", ".", "OBJECTIVE", "To", "investigate", "the", "effects", "of", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "on", "postoperative", "nausea", "and", "vomiting", "and", "patient", "-", "controlled", "epidural", "analgesia", "in", "cesarean", "section", ".", "METHODS", "After", "IRB", "approval", "and", "informed", "consent", ",", "one", "hundred", "and", "eighty", "singleton", "primiparas", "undergoing", "elective", "cesarean", "section", ",", "in", "Qingdao", "Municipal", "Hospital", ",", "and", "Qingdao", "Hiser", "Medical", "Center", ",", "from", "November", "2011", "to", "March", "2012", ",", "were", "randomly", "assigned", "to", "three", "groups", ":", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "group", "(", "group", "A", ",", "n", "=", "60", ")", ",", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Eye", "point", "group", "(", "group", "B", ",", "n", "=", "60", ")", "and", "control", "group", "(", "group", "C", ",", "n", "=", "60", ")", ".", "Women", "of", "group", "A", "received", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "(", "frequency", "1.5", "HZ", ")", "at", "the", "time", "of", "preoperation", ",", "4", ",", "10", "and", "22", "hours", "of", "postoperation", "for", "30", "minutes", ".", "The", "strength", "was", "controlled", "by", "themselves", ".", "Women", "of", "group", "B", "received", "stimulation", "of", "auricular", "Eye", "point", "as", "group", "A", ".", "Women", "of", "group", "C", "received", "pressurization", "and", "connected", "line", "were", "the", "same", "with", "group", "A", ",", "but", "without", "electrical", "stimulation", ".", "The", "following", "indexes", "was", "observed", ":", "the", "incidence", "of", "postoperative", "nausea", "and", "vomiting", "(", "PONV", ")", "for", "48", "hours", ";", "the", "rate", "of", "metoclopramide", ";", "the", "visual", "analogue", "scale", "(", "VAS", ")", "score", "of", "rest", "pain", ",", "uterine", "contration", "pain", "and", "dynamic", "pain", "at", "the", "time", "of", "postoperation", "for", "6", ",", "12", ",", "24", "and", "48", "hours", "(", "T", "(", "1", ")", "-T", "(", "4", ")", ")", ";", "the", "total", "number", "and", "effective", "compressions", "number", "of", "patient", "-", "controlled", "epidural", "analgesia", "(", "PCEA", ")", ";", "the", "dose", "of", "analgesia", "mixture", ";", "the", "anal", "exhaust", "time", ";", "the", "volume", "of", "postoperative", "bleeding", "for", "6", "hours", "of", "postoperation", "and", "the", "other", "side", "effects", ".", "RESULTS", "Compared", "with", "group", "B", "and", "group", "C", ",", "the", "incidence", "of", "PONV", ",", "the", "rate", "of", "metoclopramide", ",", "the", "VAS", "score", "at", "the", "time", "T", "(", "1", ")", "-T", "(", "4", ")", ",", "the", "total", "number", "and", "effective", "compressions", "number", "of", "PCEA", ",", "the", "ratio", "of", "the", "total", "number", "with", "effective", "compressions", "number", "and", "the", "dose", "of", "analgesia", "mixture", "were", "decreased", "in", "group", "A", "(", "P", "<", "0.05", ")", ",", "but", "no", "difference", "compared", "group", "B", "with", "group", "C", "(", "P", ">", "0.05", ")", ".", "The", "anal", "exhaust", "time", "and", "the", "volume", "of", "postoperative", "bleeding", "for", "6", "hours", "of", "postoperation", "were", "no", "difference", "in", "the", "three", "groups", "(", "P", ">", "0.05", ")", ".", "No", "other", "side", "effects", "were", "observed", ".", "CONCLUSION", "Transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "can", "reduce", "the", "incidence", "of", "PONV", "and", "improves", "analgesia", "effect", "of", "PCEA", "in", "postoperation", "of", "cesarean", "section", "." ]	[ "Outcome_Physical", "Intervention_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]
transcutaneous electrical stimulation is a Intervention_Physical, pressurization is a Intervention_Physical, side effects is a Outcome_Adverse-effects, incidence of PONV , the rate of metoclopramide , the VAS score is a Outcome_Physical, total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture is a Outcome_Physical, anal exhaust time and the volume of postoperative bleeding is a Outcome_Physical, incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section . is a Outcome_Physical	57395_task1	Sentence: [ Effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section ] . OBJECTIVE To investigate the effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section . METHODS After IRB approval and informed consent , one hundred and eighty singleton primiparas undergoing elective cesarean section , in Qingdao Municipal Hospital , and Qingdao Hiser Medical Center , from November 2011 to March 2012 , were randomly assigned to three groups : transcutaneous electrical stimulation of auricular Shenmen point group ( group A , n = 60 ) , transcutaneous electrical stimulation of auricular Eye point group ( group B , n = 60 ) and control group ( group C , n = 60 ) . Women of group A received transcutaneous electrical stimulation of auricular Shenmen point ( frequency 1.5 HZ ) at the time of preoperation , 4 , 10 and 22 hours of postoperation for 30 minutes . The strength was controlled by themselves . Women of group B received stimulation of auricular Eye point as group A . Women of group C received pressurization and connected line were the same with group A , but without electrical stimulation . The following indexes was observed : the incidence of postoperative nausea and vomiting ( PONV ) for 48 hours ; the rate of metoclopramide ; the visual analogue scale ( VAS ) score of rest pain , uterine contration pain and dynamic pain at the time of postoperation for 6 , 12 , 24 and 48 hours ( T ( 1 ) -T ( 4 ) ) ; the total number and effective compressions number of patient-controlled epidural analgesia ( PCEA ) ; the dose of analgesia mixture ; the anal exhaust time ; the volume of postoperative bleeding for 6 hours of postoperation and the other side effects . RESULTS Compared with group B and group C , the incidence of PONV , the rate of metoclopramide , the VAS score at the time T ( 1 ) -T ( 4 ) , the total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture were decreased in group A ( P < 0.05 ) , but no difference compared group B with group C ( P > 0.05 ) . The anal exhaust time and the volume of postoperative bleeding for 6 hours of postoperation were no difference in the three groups ( P > 0.05 ) . No other side effects were observed . CONCLUSION Transcutaneous electrical stimulation of auricular Shenmen point can reduce the incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section . Instructions: please typing these entity words according to sentence: transcutaneous electrical stimulation, pressurization, side effects, incidence of PONV , the rate of metoclopramide , the VAS score, total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture, anal exhaust time and the volume of postoperative bleeding, incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section . Options: Intervention_Physical, Outcome_Adverse-effects, Outcome_Physical	[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical" ]	[ Effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section ] . OBJECTIVE To investigate the effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section . METHODS After IRB approval and informed consent , one hundred and eighty singleton primiparas undergoing elective cesarean section , in Qingdao Municipal Hospital , and Qingdao Hiser Medical Center , from November 2011 to March 2012 , were randomly assigned to three groups : transcutaneous electrical stimulation of auricular Shenmen point group ( group A , n = 60 ) , transcutaneous electrical stimulation of auricular Eye point group ( group B , n = 60 ) and control group ( group C , n = 60 ) . Women of group A received transcutaneous electrical stimulation of auricular Shenmen point ( frequency 1.5 HZ ) at the time of preoperation , 4 , 10 and 22 hours of postoperation for 30 minutes . The strength was controlled by themselves . Women of group B received stimulation of auricular Eye point as group A . Women of group C received pressurization and connected line were the same with group A , but without electrical stimulation . The following indexes was observed : the incidence of postoperative nausea and vomiting ( PONV ) for 48 hours ; the rate of metoclopramide ; the visual analogue scale ( VAS ) score of rest pain , uterine contration pain and dynamic pain at the time of postoperation for 6 , 12 , 24 and 48 hours ( T ( 1 ) -T ( 4 ) ) ; the total number and effective compressions number of patient-controlled epidural analgesia ( PCEA ) ; the dose of analgesia mixture ; the anal exhaust time ; the volume of postoperative bleeding for 6 hours of postoperation and the other side effects . RESULTS Compared with group B and group C , the incidence of PONV , the rate of metoclopramide , the VAS score at the time T ( 1 ) -T ( 4 ) , the total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture were decreased in group A ( P < 0.05 ) , but no difference compared group B with group C ( P > 0.05 ) . The anal exhaust time and the volume of postoperative bleeding for 6 hours of postoperation were no difference in the three groups ( P > 0.05 ) . No other side effects were observed . CONCLUSION Transcutaneous electrical stimulation of auricular Shenmen point can reduce the incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section .	[ "[", "Effects", "of", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "on", "postoperative", "nausea", "and", "vomiting", "and", "patient", "-", "controlled", "epidural", "analgesia", "in", "cesarean", "section", "]", ".", "OBJECTIVE", "To", "investigate", "the", "effects", "of", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "on", "postoperative", "nausea", "and", "vomiting", "and", "patient", "-", "controlled", "epidural", "analgesia", "in", "cesarean", "section", ".", "METHODS", "After", "IRB", "approval", "and", "informed", "consent", ",", "one", "hundred", "and", "eighty", "singleton", "primiparas", "undergoing", "elective", "cesarean", "section", ",", "in", "Qingdao", "Municipal", "Hospital", ",", "and", "Qingdao", "Hiser", "Medical", "Center", ",", "from", "November", "2011", "to", "March", "2012", ",", "were", "randomly", "assigned", "to", "three", "groups", ":", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "group", "(", "group", "A", ",", "n", "=", "60", ")", ",", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Eye", "point", "group", "(", "group", "B", ",", "n", "=", "60", ")", "and", "control", "group", "(", "group", "C", ",", "n", "=", "60", ")", ".", "Women", "of", "group", "A", "received", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "(", "frequency", "1.5", "HZ", ")", "at", "the", "time", "of", "preoperation", ",", "4", ",", "10", "and", "22", "hours", "of", "postoperation", "for", "30", "minutes", ".", "The", "strength", "was", "controlled", "by", "themselves", ".", "Women", "of", "group", "B", "received", "stimulation", "of", "auricular", "Eye", "point", "as", "group", "A", ".", "Women", "of", "group", "C", "received", "pressurization", "and", "connected", "line", "were", "the", "same", "with", "group", "A", ",", "but", "without", "electrical", "stimulation", ".", "The", "following", "indexes", "was", "observed", ":", "the", "incidence", "of", "postoperative", "nausea", "and", "vomiting", "(", "PONV", ")", "for", "48", "hours", ";", "the", "rate", "of", "metoclopramide", ";", "the", "visual", "analogue", "scale", "(", "VAS", ")", "score", "of", "rest", "pain", ",", "uterine", "contration", "pain", "and", "dynamic", "pain", "at", "the", "time", "of", "postoperation", "for", "6", ",", "12", ",", "24", "and", "48", "hours", "(", "T", "(", "1", ")", "-T", "(", "4", ")", ")", ";", "the", "total", "number", "and", "effective", "compressions", "number", "of", "patient", "-", "controlled", "epidural", "analgesia", "(", "PCEA", ")", ";", "the", "dose", "of", "analgesia", "mixture", ";", "the", "anal", "exhaust", "time", ";", "the", "volume", "of", "postoperative", "bleeding", "for", "6", "hours", "of", "postoperation", "and", "the", "other", "side", "effects", ".", "RESULTS", "Compared", "with", "group", "B", "and", "group", "C", ",", "the", "incidence", "of", "PONV", ",", "the", "rate", "of", "metoclopramide", ",", "the", "VAS", "score", "at", "the", "time", "T", "(", "1", ")", "-T", "(", "4", ")", ",", "the", "total", "number", "and", "effective", "compressions", "number", "of", "PCEA", ",", "the", "ratio", "of", "the", "total", "number", "with", "effective", "compressions", "number", "and", "the", "dose", "of", "analgesia", "mixture", "were", "decreased", "in", "group", "A", "(", "P", "<", "0.05", ")", ",", "but", "no", "difference", "compared", "group", "B", "with", "group", "C", "(", "P", ">", "0.05", ")", ".", "The", "anal", "exhaust", "time", "and", "the", "volume", "of", "postoperative", "bleeding", "for", "6", "hours", "of", "postoperation", "were", "no", "difference", "in", "the", "three", "groups", "(", "P", ">", "0.05", ")", ".", "No", "other", "side", "effects", "were", "observed", ".", "CONCLUSION", "Transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "can", "reduce", "the", "incidence", "of", "PONV", "and", "improves", "analgesia", "effect", "of", "PCEA", "in", "postoperation", "of", "cesarean", "section", "." ]	[ "Outcome_Physical", "Intervention_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]
transcutaneous electrical stimulation, pressurization, side effects, incidence of PONV , the rate of metoclopramide , the VAS score, total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture, anal exhaust time and the volume of postoperative bleeding, incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section .	57395_task2	Sentence: [ Effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section ] . OBJECTIVE To investigate the effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section . METHODS After IRB approval and informed consent , one hundred and eighty singleton primiparas undergoing elective cesarean section , in Qingdao Municipal Hospital , and Qingdao Hiser Medical Center , from November 2011 to March 2012 , were randomly assigned to three groups : transcutaneous electrical stimulation of auricular Shenmen point group ( group A , n = 60 ) , transcutaneous electrical stimulation of auricular Eye point group ( group B , n = 60 ) and control group ( group C , n = 60 ) . Women of group A received transcutaneous electrical stimulation of auricular Shenmen point ( frequency 1.5 HZ ) at the time of preoperation , 4 , 10 and 22 hours of postoperation for 30 minutes . The strength was controlled by themselves . Women of group B received stimulation of auricular Eye point as group A . Women of group C received pressurization and connected line were the same with group A , but without electrical stimulation . The following indexes was observed : the incidence of postoperative nausea and vomiting ( PONV ) for 48 hours ; the rate of metoclopramide ; the visual analogue scale ( VAS ) score of rest pain , uterine contration pain and dynamic pain at the time of postoperation for 6 , 12 , 24 and 48 hours ( T ( 1 ) -T ( 4 ) ) ; the total number and effective compressions number of patient-controlled epidural analgesia ( PCEA ) ; the dose of analgesia mixture ; the anal exhaust time ; the volume of postoperative bleeding for 6 hours of postoperation and the other side effects . RESULTS Compared with group B and group C , the incidence of PONV , the rate of metoclopramide , the VAS score at the time T ( 1 ) -T ( 4 ) , the total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture were decreased in group A ( P < 0.05 ) , but no difference compared group B with group C ( P > 0.05 ) . The anal exhaust time and the volume of postoperative bleeding for 6 hours of postoperation were no difference in the three groups ( P > 0.05 ) . No other side effects were observed . CONCLUSION Transcutaneous electrical stimulation of auricular Shenmen point can reduce the incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical" ]	[ Effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section ] . OBJECTIVE To investigate the effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section . METHODS After IRB approval and informed consent , one hundred and eighty singleton primiparas undergoing elective cesarean section , in Qingdao Municipal Hospital , and Qingdao Hiser Medical Center , from November 2011 to March 2012 , were randomly assigned to three groups : transcutaneous electrical stimulation of auricular Shenmen point group ( group A , n = 60 ) , transcutaneous electrical stimulation of auricular Eye point group ( group B , n = 60 ) and control group ( group C , n = 60 ) . Women of group A received transcutaneous electrical stimulation of auricular Shenmen point ( frequency 1.5 HZ ) at the time of preoperation , 4 , 10 and 22 hours of postoperation for 30 minutes . The strength was controlled by themselves . Women of group B received stimulation of auricular Eye point as group A . Women of group C received pressurization and connected line were the same with group A , but without electrical stimulation . The following indexes was observed : the incidence of postoperative nausea and vomiting ( PONV ) for 48 hours ; the rate of metoclopramide ; the visual analogue scale ( VAS ) score of rest pain , uterine contration pain and dynamic pain at the time of postoperation for 6 , 12 , 24 and 48 hours ( T ( 1 ) -T ( 4 ) ) ; the total number and effective compressions number of patient-controlled epidural analgesia ( PCEA ) ; the dose of analgesia mixture ; the anal exhaust time ; the volume of postoperative bleeding for 6 hours of postoperation and the other side effects . RESULTS Compared with group B and group C , the incidence of PONV , the rate of metoclopramide , the VAS score at the time T ( 1 ) -T ( 4 ) , the total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture were decreased in group A ( P < 0.05 ) , but no difference compared group B with group C ( P > 0.05 ) . The anal exhaust time and the volume of postoperative bleeding for 6 hours of postoperation were no difference in the three groups ( P > 0.05 ) . No other side effects were observed . CONCLUSION Transcutaneous electrical stimulation of auricular Shenmen point can reduce the incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section .	[ "[", "Effects", "of", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "on", "postoperative", "nausea", "and", "vomiting", "and", "patient", "-", "controlled", "epidural", "analgesia", "in", "cesarean", "section", "]", ".", "OBJECTIVE", "To", "investigate", "the", "effects", "of", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "on", "postoperative", "nausea", "and", "vomiting", "and", "patient", "-", "controlled", "epidural", "analgesia", "in", "cesarean", "section", ".", "METHODS", "After", "IRB", "approval", "and", "informed", "consent", ",", "one", "hundred", "and", "eighty", "singleton", "primiparas", "undergoing", "elective", "cesarean", "section", ",", "in", "Qingdao", "Municipal", "Hospital", ",", "and", "Qingdao", "Hiser", "Medical", "Center", ",", "from", "November", "2011", "to", "March", "2012", ",", "were", "randomly", "assigned", "to", "three", "groups", ":", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "group", "(", "group", "A", ",", "n", "=", "60", ")", ",", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Eye", "point", "group", "(", "group", "B", ",", "n", "=", "60", ")", "and", "control", "group", "(", "group", "C", ",", "n", "=", "60", ")", ".", "Women", "of", "group", "A", "received", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "(", "frequency", "1.5", "HZ", ")", "at", "the", "time", "of", "preoperation", ",", "4", ",", "10", "and", "22", "hours", "of", "postoperation", "for", "30", "minutes", ".", "The", "strength", "was", "controlled", "by", "themselves", ".", "Women", "of", "group", "B", "received", "stimulation", "of", "auricular", "Eye", "point", "as", "group", "A", ".", "Women", "of", "group", "C", "received", "pressurization", "and", "connected", "line", "were", "the", "same", "with", "group", "A", ",", "but", "without", "electrical", "stimulation", ".", "The", "following", "indexes", "was", "observed", ":", "the", "incidence", "of", "postoperative", "nausea", "and", "vomiting", "(", "PONV", ")", "for", "48", "hours", ";", "the", "rate", "of", "metoclopramide", ";", "the", "visual", "analogue", "scale", "(", "VAS", ")", "score", "of", "rest", "pain", ",", "uterine", "contration", "pain", "and", "dynamic", "pain", "at", "the", "time", "of", "postoperation", "for", "6", ",", "12", ",", "24", "and", "48", "hours", "(", "T", "(", "1", ")", "-T", "(", "4", ")", ")", ";", "the", "total", "number", "and", "effective", "compressions", "number", "of", "patient", "-", "controlled", "epidural", "analgesia", "(", "PCEA", ")", ";", "the", "dose", "of", "analgesia", "mixture", ";", "the", "anal", "exhaust", "time", ";", "the", "volume", "of", "postoperative", "bleeding", "for", "6", "hours", "of", "postoperation", "and", "the", "other", "side", "effects", ".", "RESULTS", "Compared", "with", "group", "B", "and", "group", "C", ",", "the", "incidence", "of", "PONV", ",", "the", "rate", "of", "metoclopramide", ",", "the", "VAS", "score", "at", "the", "time", "T", "(", "1", ")", "-T", "(", "4", ")", ",", "the", "total", "number", "and", "effective", "compressions", "number", "of", "PCEA", ",", "the", "ratio", "of", "the", "total", "number", "with", "effective", "compressions", "number", "and", "the", "dose", "of", "analgesia", "mixture", "were", "decreased", "in", "group", "A", "(", "P", "<", "0.05", ")", ",", "but", "no", "difference", "compared", "group", "B", "with", "group", "C", "(", "P", ">", "0.05", ")", ".", "The", "anal", "exhaust", "time", "and", "the", "volume", "of", "postoperative", "bleeding", "for", "6", "hours", "of", "postoperation", "were", "no", "difference", "in", "the", "three", "groups", "(", "P", ">", "0.05", ")", ".", "No", "other", "side", "effects", "were", "observed", ".", "CONCLUSION", "Transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "can", "reduce", "the", "incidence", "of", "PONV", "and", "improves", "analgesia", "effect", "of", "PCEA", "in", "postoperation", "of", "cesarean", "section", "." ]	[ "Outcome_Physical", "Intervention_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]
E1A is a protein, p300 is a protein, p300 is a protein, E1A is a protein, p300 is a protein	1.0alpha7.train.1249_task0	Sentence: To investigate whether the binding of E1A to p300 correlates with a loss of p300 transcriptional activity, we examined the binding of full-length E1A to the series of mutant p300 proteins. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein	[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O" ]	To investigate whether the binding of E1A to p300 correlates with a loss of p300 transcriptional activity, we examined the binding of full-length E1A to the series of mutant p300 proteins.	[ "To", "investigate", "whether", "the", "binding", "of", " ", "E1A", "to", " ", "p300", "correlates", "with", "a", "loss", "of", " ", "p300", "transcriptional", "activity", ",", "we", "examined", "the", "binding", "of", "full", "-", "length", " ", "E1A", "to", "the", "series", "of", " ", "mutant", "p300", "proteins", "." ]	[ "protein" ]
E1A is a protein, p300 is a protein, p300 is a protein, E1A is a protein, p300 is a protein	1.0alpha7.train.1249_task1	Sentence: To investigate whether the binding of E1A to p300 correlates with a loss of p300 transcriptional activity, we examined the binding of full-length E1A to the series of mutant p300 proteins. Instructions: please typing these entity words according to sentence: E1A, p300, p300, E1A, p300 Options: protein	[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O" ]	To investigate whether the binding of E1A to p300 correlates with a loss of p300 transcriptional activity, we examined the binding of full-length E1A to the series of mutant p300 proteins.	[ "To", "investigate", "whether", "the", "binding", "of", " ", "E1A", "to", " ", "p300", "correlates", "with", "a", "loss", "of", " ", "p300", "transcriptional", "activity", ",", "we", "examined", "the", "binding", "of", "full", "-", "length", " ", "E1A", "to", "the", "series", "of", " ", "mutant", "p300", "proteins", "." ]	[ "protein" ]
E1A, p300, p300, E1A, p300	1.0alpha7.train.1249_task2	Sentence: To investigate whether the binding of E1A to p300 correlates with a loss of p300 transcriptional activity, we examined the binding of full-length E1A to the series of mutant p300 proteins. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O" ]	To investigate whether the binding of E1A to p300 correlates with a loss of p300 transcriptional activity, we examined the binding of full-length E1A to the series of mutant p300 proteins.	[ "To", "investigate", "whether", "the", "binding", "of", " ", "E1A", "to", " ", "p300", "correlates", "with", "a", "loss", "of", " ", "p300", "transcriptional", "activity", ",", "we", "examined", "the", "binding", "of", "full", "-", "length", " ", "E1A", "to", "the", "series", "of", " ", "mutant", "p300", "proteins", "." ]	[ "protein" ]
population is an umlsterm, health priority is an umlsterm, Italy is an umlsterm, age is an umlsterm, population is an umlsterm, old is an umlsterm, disease is an umlsterm, future is an umlsterm, generations is an umlsterm, disease is an umlsterm, prevention is an umlsterm, programs is an umlsterm	ZfuerGerontologie+Geriatrie.90320420.eng.abstr_task0	Sentence: The aging of the Italian population is an emerging public health priority . In 2025 Italy is expected to have the highest world median age with nearly half of the population over 50 years old . To avoid an unbearable burden of disease and disability on future generations , we must identify areas for intensive disease and disability prevention programs . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	The aging of the Italian population is an emerging public health priority . In 2025 Italy is expected to have the highest world median age with nearly half of the population over 50 years old . To avoid an unbearable burden of disease and disability on future generations , we must identify areas for intensive disease and disability prevention programs .	[ "The", "aging", "of", "the", "Italian", "population", "is", "an", "emerging", "public", "health", "priority", ".", "In", "2025", "Italy", "is", "expected", "to", "have", "the", "highest", "world", "median", "age", "with", "nearly", "half", "of", "the", "population", "over", "50", "years", "old", ".", "To", "avoid", "an", "unbearable", "burden", "of", "disease", "and", "disability", "on", "future", "generations", ",", "we", "must", "identify", "areas", "for", "intensive", "disease", "and", "disability", "prevention", "programs", "." ]	[ "umlsterm" ]
population is an umlsterm, health priority is an umlsterm, Italy is an umlsterm, age is an umlsterm, population is an umlsterm, old is an umlsterm, disease is an umlsterm, future is an umlsterm, generations is an umlsterm, disease is an umlsterm, prevention is an umlsterm, programs is an umlsterm	ZfuerGerontologie+Geriatrie.90320420.eng.abstr_task1	Sentence: The aging of the Italian population is an emerging public health priority . In 2025 Italy is expected to have the highest world median age with nearly half of the population over 50 years old . To avoid an unbearable burden of disease and disability on future generations , we must identify areas for intensive disease and disability prevention programs . Instructions: please typing these entity words according to sentence: population, health priority, Italy, age, population, old, disease, future, generations, disease, prevention, programs Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	The aging of the Italian population is an emerging public health priority . In 2025 Italy is expected to have the highest world median age with nearly half of the population over 50 years old . To avoid an unbearable burden of disease and disability on future generations , we must identify areas for intensive disease and disability prevention programs .	[ "The", "aging", "of", "the", "Italian", "population", "is", "an", "emerging", "public", "health", "priority", ".", "In", "2025", "Italy", "is", "expected", "to", "have", "the", "highest", "world", "median", "age", "with", "nearly", "half", "of", "the", "population", "over", "50", "years", "old", ".", "To", "avoid", "an", "unbearable", "burden", "of", "disease", "and", "disability", "on", "future", "generations", ",", "we", "must", "identify", "areas", "for", "intensive", "disease", "and", "disability", "prevention", "programs", "." ]	[ "umlsterm" ]
population, health priority, Italy, age, population, old, disease, future, generations, disease, prevention, programs	ZfuerGerontologie+Geriatrie.90320420.eng.abstr_task2	Sentence: The aging of the Italian population is an emerging public health priority . In 2025 Italy is expected to have the highest world median age with nearly half of the population over 50 years old . To avoid an unbearable burden of disease and disability on future generations , we must identify areas for intensive disease and disability prevention programs . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	The aging of the Italian population is an emerging public health priority . In 2025 Italy is expected to have the highest world median age with nearly half of the population over 50 years old . To avoid an unbearable burden of disease and disability on future generations , we must identify areas for intensive disease and disability prevention programs .	[ "The", "aging", "of", "the", "Italian", "population", "is", "an", "emerging", "public", "health", "priority", ".", "In", "2025", "Italy", "is", "expected", "to", "have", "the", "highest", "world", "median", "age", "with", "nearly", "half", "of", "the", "population", "over", "50", "years", "old", ".", "To", "avoid", "an", "unbearable", "burden", "of", "disease", "and", "disability", "on", "future", "generations", ",", "we", "must", "identify", "areas", "for", "intensive", "disease", "and", "disability", "prevention", "programs", "." ]	[ "umlsterm" ]
Activated platelets is a cell_type, monocyte chemotactic protein-1 secretion is an other_name, intercellular adhesion molecule-1 is a cell_type, endothelial cells is a cell_type	77463_task0	Sentence: Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells [see comments] Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, other_name	[ "B-cell_type", "I-cell_type", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "O" ]	Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells [see comments]	[ "Activated", "platelets", "induce", "monocyte", "chemotactic", "protein-1", "secretion", "and", "surface", "expression", "of", "intercellular", "adhesion", "molecule-1", "on", "endothelial", "cells", "[", "see", "comments", "]" ]	[ "polynucleotide", "(AND other_name other_name)", "protein_complex", "other_name", "cell_type", "", "protein_molecule", "tissue" ]
Activated platelets is a cell_type, monocyte chemotactic protein-1 secretion is an other_name, intercellular adhesion molecule-1 is a cell_type, endothelial cells is a cell_type	77463_task1	Sentence: Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells [see comments] Instructions: please typing these entity words according to sentence: Activated platelets, monocyte chemotactic protein-1 secretion, intercellular adhesion molecule-1, endothelial cells Options: cell_type, other_name	[ "B-cell_type", "I-cell_type", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "O" ]	Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells [see comments]	[ "Activated", "platelets", "induce", "monocyte", "chemotactic", "protein-1", "secretion", "and", "surface", "expression", "of", "intercellular", "adhesion", "molecule-1", "on", "endothelial", "cells", "[", "see", "comments", "]" ]	[ "polynucleotide", "(AND other_name other_name)", "protein_complex", "other_name", "cell_type", "", "protein_molecule", "tissue" ]
Activated platelets, monocyte chemotactic protein-1 secretion, intercellular adhesion molecule-1, endothelial cells	77463_task2	Sentence: Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells [see comments] Instructions: please extract entity words from the input sentence	[ "B-cell_type", "I-cell_type", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "O" ]	Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells [see comments]	[ "Activated", "platelets", "induce", "monocyte", "chemotactic", "protein-1", "secretion", "and", "surface", "expression", "of", "intercellular", "adhesion", "molecule-1", "on", "endothelial", "cells", "[", "see", "comments", "]" ]	[ "polynucleotide", "(AND other_name other_name)", "protein_complex", "other_name", "cell_type", "", "protein_molecule", "tissue" ]
serum is a Organism_substance, papillary mucinous neoplasms is a Pathological_formation, serum is a Organism_substance, intraductal papillary mucinous neoplasms is a Pathological_formation, pancreas is a Organ, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, tumor is a Pathological_formation, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, serum is a Organism_substance, IPMNs is a Pathological_formation, Serum is a Organism_substance, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, serum is a Organism_substance, IPMNs is a Pathological_formation	PMID-21416173_task0	Sentence: Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. BACKGROUND: The goal of the present study was to evaluate the predictive value of serum carbohydrate antigen 19-9 (CA 19-9) in the diagnosis of malignant intraductal papillary mucinous neoplasms of pancreas (IPMNs). METHODS: Eighty-six patients with pathological diagnosis of IPMNs in Zhongshan Hospital between March 1999 and November 2008 were retrospectively reviewed. Data reflecting clinical characteristics, tumor marker level, and prognosis were collected. The potential predictive value of CA 19-9 was analyzed by receiver operating characteristic (ROC) curve. RESULTS: Eighty-six consecutive patients with IPMNs all underwent surgical intervention. A high level of CA 19-9 or carcinoembryonic antigen (CEA) was associated with more advanced stage of malignant IPMNs. Carbohydrate antigen 19-9 was significant for judging malignant IPMNs in the binary logistic regression model (p=0.047). The hazard ratio was 1.014, whose 95.0% confidence interval was 0.91-1.028. Receiver operating characteristic analysis showed that the serum CA 19-9 level had good predictive value for malignant or invasive IPMNs, postoperative survival, and disease-specific recurrence. The area under the curve (AUC) was 0.856, 0.893, 0.815, and 0.857 (p<0.05), respectively. According to the follow-up, mean survival time for groups with CA 19-9>63.60 U/ml was dramatically shorter than that for groups with CA 19-9<=63.60 U/ml (57.38+/-2.85 versus 29.24+/-5.82 [months]; p<0.01). CONCLUSIONS: Serum CA 19-9 level has good predictive value for malignant or invasive IPMNs. Patients with CA 19-9 > 63.60 U/ml had poor postoperative prognosis in IPMNs. Preoperative abnormal serum CA 19-9 might be predictive for an aggressive surgical intervention in IPMNs. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Pathological_formation, Organ, Organism_substance	[ "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Organ", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O" ]	Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. BACKGROUND: The goal of the present study was to evaluate the predictive value of serum carbohydrate antigen 19-9 (CA 19-9) in the diagnosis of malignant intraductal papillary mucinous neoplasms of pancreas (IPMNs). METHODS: Eighty-six patients with pathological diagnosis of IPMNs in Zhongshan Hospital between March 1999 and November 2008 were retrospectively reviewed. Data reflecting clinical characteristics, tumor marker level, and prognosis were collected. The potential predictive value of CA 19-9 was analyzed by receiver operating characteristic (ROC) curve. RESULTS: Eighty-six consecutive patients with IPMNs all underwent surgical intervention. A high level of CA 19-9 or carcinoembryonic antigen (CEA) was associated with more advanced stage of malignant IPMNs. Carbohydrate antigen 19-9 was significant for judging malignant IPMNs in the binary logistic regression model (p=0.047). The hazard ratio was 1.014, whose 95.0% confidence interval was 0.91-1.028. Receiver operating characteristic analysis showed that the serum CA 19-9 level had good predictive value for malignant or invasive IPMNs, postoperative survival, and disease-specific recurrence. The area under the curve (AUC) was 0.856, 0.893, 0.815, and 0.857 (p<0.05), respectively. According to the follow-up, mean survival time for groups with CA 19-9>63.60 U/ml was dramatically shorter than that for groups with CA 19-9<=63.60 U/ml (57.38+/-2.85 versus 29.24+/-5.82 [months]; p<0.01). CONCLUSIONS: Serum CA 19-9 level has good predictive value for malignant or invasive IPMNs. Patients with CA 19-9 > 63.60 U/ml had poor postoperative prognosis in IPMNs. Preoperative abnormal serum CA 19-9 might be predictive for an aggressive surgical intervention in IPMNs.	[ "Predictive", "value", "of", "serum", "carbohydrate", "antigen", "19", "-", "9", "in", "malignant", "intraductal", "papillary", "mucinous", "neoplasms", ".", "\n", "BACKGROUND", ":", "\n", "The", "goal", "of", "the", "present", "study", "was", "to", "evaluate", "the", "predictive", "value", "of", "serum", "carbohydrate", "antigen", "19", "-", "9", "(", "CA", "19", "-", "9", ")", "in", "the", "diagnosis", "of", "malignant", "intraductal", "papillary", "mucinous", "neoplasms", "of", "pancreas", "(", "IPMNs", ")", ".", "\n", "METHODS", ":", "\n", "Eighty", "-", "six", "patients", "with", "pathological", "diagnosis", "of", "IPMNs", "in", "Zhongshan", "Hospital", "between", "March", "1999", "and", "November", "2008", "were", "retrospectively", "reviewed", ".", "Data", "reflecting", "clinical", "characteristics", ",", "tumor", "marker", "level", ",", "and", "prognosis", "were", "collected", ".", "The", "potential", "predictive", "value", "of", "CA", "19", "-", "9", "was", "analyzed", "by", "receiver", "operating", "characteristic", "(", "ROC", ")", "curve", ".", "\n", "RESULTS", ":", "\n", "Eighty", "-", "six", "consecutive", "patients", "with", "IPMNs", "all", "underwent", "surgical", "intervention", ".", "A", "high", "level", "of", "CA", "19", "-", "9", "or", "carcinoembryonic", "antigen", "(", "CEA", ")", "was", "associated", "with", "more", "advanced", "stage", "of", "malignant", "IPMNs", ".", "Carbohydrate", "antigen", "19", "-", "9", "was", "significant", "for", "judging", "malignant", "IPMNs", "in", "the", "binary", "logistic", "regression", "model", "(", "p=0.047", ")", ".", "The", "hazard", "ratio", "was", "1.014", ",", "whose", "95.0", "%", "confidence", "interval", "was", "0.91", "-", "1.028", ".", "Receiver", "operating", "characteristic", "analysis", "showed", "that", "the", "serum", "CA", "19", "-", "9", "level", "had", "good", "predictive", "value", "for", "malignant", "or", "invasive", "IPMNs", ",", "postoperative", "survival", ",", "and", "disease", "-", "specific", "recurrence", ".", "The", "area", "under", "the", "curve", "(", "AUC", ")", "was", "0.856", ",", "0.893", ",", "0.815", ",", "and", "0.857", "(", "p<0.05", ")", ",", "respectively", ".", "According", "to", "the", "follow", "-", "up", ",", "mean", "survival", "time", "for", "groups", "with", "CA", "19", "-", "9>63.60", "U", "/", "ml", "was", "dramatically", "shorter", "than", "that", "for", "groups", "with", "CA", "19", "-", "9<=63.60", "U", "/", "ml", "(", "57.38+/-2.85", "versus", "29.24+/-5.82", "[", "months", "]", ";", "p<0.01", ")", ".", "\n", "CONCLUSIONS", ":", "\n", "Serum", "CA", "19", "-", "9", "level", "has", "good", "predictive", "value", "for", "malignant", "or", "invasive", "IPMNs", ".", "Patients", "with", "CA", "19", "-", "9", ">", "63.60", "U", "/", "ml", "had", "poor", "postoperative", "prognosis", "in", "IPMNs", ".", "Preoperative", "abnormal", "serum", "CA", "19", "-", "9", "might", "be", "predictive", "for", "an", "aggressive", "surgical", "intervention", "in", "IPMNs", ".", "\n" ]	[ "Pathological_formation", "Organ", "Organism_substance" ]
serum is a Organism_substance, papillary mucinous neoplasms is a Pathological_formation, serum is a Organism_substance, intraductal papillary mucinous neoplasms is a Pathological_formation, pancreas is a Organ, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, tumor is a Pathological_formation, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, serum is a Organism_substance, IPMNs is a Pathological_formation, Serum is a Organism_substance, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, serum is a Organism_substance, IPMNs is a Pathological_formation	PMID-21416173_task1	Sentence: Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. BACKGROUND: The goal of the present study was to evaluate the predictive value of serum carbohydrate antigen 19-9 (CA 19-9) in the diagnosis of malignant intraductal papillary mucinous neoplasms of pancreas (IPMNs). METHODS: Eighty-six patients with pathological diagnosis of IPMNs in Zhongshan Hospital between March 1999 and November 2008 were retrospectively reviewed. Data reflecting clinical characteristics, tumor marker level, and prognosis were collected. The potential predictive value of CA 19-9 was analyzed by receiver operating characteristic (ROC) curve. RESULTS: Eighty-six consecutive patients with IPMNs all underwent surgical intervention. A high level of CA 19-9 or carcinoembryonic antigen (CEA) was associated with more advanced stage of malignant IPMNs. Carbohydrate antigen 19-9 was significant for judging malignant IPMNs in the binary logistic regression model (p=0.047). The hazard ratio was 1.014, whose 95.0% confidence interval was 0.91-1.028. Receiver operating characteristic analysis showed that the serum CA 19-9 level had good predictive value for malignant or invasive IPMNs, postoperative survival, and disease-specific recurrence. The area under the curve (AUC) was 0.856, 0.893, 0.815, and 0.857 (p<0.05), respectively. According to the follow-up, mean survival time for groups with CA 19-9>63.60 U/ml was dramatically shorter than that for groups with CA 19-9<=63.60 U/ml (57.38+/-2.85 versus 29.24+/-5.82 [months]; p<0.01). CONCLUSIONS: Serum CA 19-9 level has good predictive value for malignant or invasive IPMNs. Patients with CA 19-9 > 63.60 U/ml had poor postoperative prognosis in IPMNs. Preoperative abnormal serum CA 19-9 might be predictive for an aggressive surgical intervention in IPMNs. Instructions: please typing these entity words according to sentence: serum, papillary mucinous neoplasms, serum, intraductal papillary mucinous neoplasms, pancreas, IPMNs, IPMNs, tumor, IPMNs, IPMNs, IPMNs, serum, IPMNs, Serum, IPMNs, IPMNs, serum, IPMNs Options: Pathological_formation, Organ, Organism_substance	[ "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Organ", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O" ]	Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. BACKGROUND: The goal of the present study was to evaluate the predictive value of serum carbohydrate antigen 19-9 (CA 19-9) in the diagnosis of malignant intraductal papillary mucinous neoplasms of pancreas (IPMNs). METHODS: Eighty-six patients with pathological diagnosis of IPMNs in Zhongshan Hospital between March 1999 and November 2008 were retrospectively reviewed. Data reflecting clinical characteristics, tumor marker level, and prognosis were collected. The potential predictive value of CA 19-9 was analyzed by receiver operating characteristic (ROC) curve. RESULTS: Eighty-six consecutive patients with IPMNs all underwent surgical intervention. A high level of CA 19-9 or carcinoembryonic antigen (CEA) was associated with more advanced stage of malignant IPMNs. Carbohydrate antigen 19-9 was significant for judging malignant IPMNs in the binary logistic regression model (p=0.047). The hazard ratio was 1.014, whose 95.0% confidence interval was 0.91-1.028. Receiver operating characteristic analysis showed that the serum CA 19-9 level had good predictive value for malignant or invasive IPMNs, postoperative survival, and disease-specific recurrence. The area under the curve (AUC) was 0.856, 0.893, 0.815, and 0.857 (p<0.05), respectively. According to the follow-up, mean survival time for groups with CA 19-9>63.60 U/ml was dramatically shorter than that for groups with CA 19-9<=63.60 U/ml (57.38+/-2.85 versus 29.24+/-5.82 [months]; p<0.01). CONCLUSIONS: Serum CA 19-9 level has good predictive value for malignant or invasive IPMNs. Patients with CA 19-9 > 63.60 U/ml had poor postoperative prognosis in IPMNs. Preoperative abnormal serum CA 19-9 might be predictive for an aggressive surgical intervention in IPMNs.	[ "Predictive", "value", "of", "serum", "carbohydrate", "antigen", "19", "-", "9", "in", "malignant", "intraductal", "papillary", "mucinous", "neoplasms", ".", "\n", "BACKGROUND", ":", "\n", "The", "goal", "of", "the", "present", "study", "was", "to", "evaluate", "the", "predictive", "value", "of", "serum", "carbohydrate", "antigen", "19", "-", "9", "(", "CA", "19", "-", "9", ")", "in", "the", "diagnosis", "of", "malignant", "intraductal", "papillary", "mucinous", "neoplasms", "of", "pancreas", "(", "IPMNs", ")", ".", "\n", "METHODS", ":", "\n", "Eighty", "-", "six", "patients", "with", "pathological", "diagnosis", "of", "IPMNs", "in", "Zhongshan", "Hospital", "between", "March", "1999", "and", "November", "2008", "were", "retrospectively", "reviewed", ".", "Data", "reflecting", "clinical", "characteristics", ",", "tumor", "marker", "level", ",", "and", "prognosis", "were", "collected", ".", "The", "potential", "predictive", "value", "of", "CA", "19", "-", "9", "was", "analyzed", "by", "receiver", "operating", "characteristic", "(", "ROC", ")", "curve", ".", "\n", "RESULTS", ":", "\n", "Eighty", "-", "six", "consecutive", "patients", "with", "IPMNs", "all", "underwent", "surgical", "intervention", ".", "A", "high", "level", "of", "CA", "19", "-", "9", "or", "carcinoembryonic", "antigen", "(", "CEA", ")", "was", "associated", "with", "more", "advanced", "stage", "of", "malignant", "IPMNs", ".", "Carbohydrate", "antigen", "19", "-", "9", "was", "significant", "for", "judging", "malignant", "IPMNs", "in", "the", "binary", "logistic", "regression", "model", "(", "p=0.047", ")", ".", "The", "hazard", "ratio", "was", "1.014", ",", "whose", "95.0", "%", "confidence", "interval", "was", "0.91", "-", "1.028", ".", "Receiver", "operating", "characteristic", "analysis", "showed", "that", "the", "serum", "CA", "19", "-", "9", "level", "had", "good", "predictive", "value", "for", "malignant", "or", "invasive", "IPMNs", ",", "postoperative", "survival", ",", "and", "disease", "-", "specific", "recurrence", ".", "The", "area", "under", "the", "curve", "(", "AUC", ")", "was", "0.856", ",", "0.893", ",", "0.815", ",", "and", "0.857", "(", "p<0.05", ")", ",", "respectively", ".", "According", "to", "the", "follow", "-", "up", ",", "mean", "survival", "time", "for", "groups", "with", "CA", "19", "-", "9>63.60", "U", "/", "ml", "was", "dramatically", "shorter", "than", "that", "for", "groups", "with", "CA", "19", "-", "9<=63.60", "U", "/", "ml", "(", "57.38+/-2.85", "versus", "29.24+/-5.82", "[", "months", "]", ";", "p<0.01", ")", ".", "\n", "CONCLUSIONS", ":", "\n", "Serum", "CA", "19", "-", "9", "level", "has", "good", "predictive", "value", "for", "malignant", "or", "invasive", "IPMNs", ".", "Patients", "with", "CA", "19", "-", "9", ">", "63.60", "U", "/", "ml", "had", "poor", "postoperative", "prognosis", "in", "IPMNs", ".", "Preoperative", "abnormal", "serum", "CA", "19", "-", "9", "might", "be", "predictive", "for", "an", "aggressive", "surgical", "intervention", "in", "IPMNs", ".", "\n" ]	[ "Pathological_formation", "Organ", "Organism_substance" ]
serum, papillary mucinous neoplasms, serum, intraductal papillary mucinous neoplasms, pancreas, IPMNs, IPMNs, tumor, IPMNs, IPMNs, IPMNs, serum, IPMNs, Serum, IPMNs, IPMNs, serum, IPMNs	PMID-21416173_task2	Sentence: Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. BACKGROUND: The goal of the present study was to evaluate the predictive value of serum carbohydrate antigen 19-9 (CA 19-9) in the diagnosis of malignant intraductal papillary mucinous neoplasms of pancreas (IPMNs). METHODS: Eighty-six patients with pathological diagnosis of IPMNs in Zhongshan Hospital between March 1999 and November 2008 were retrospectively reviewed. Data reflecting clinical characteristics, tumor marker level, and prognosis were collected. The potential predictive value of CA 19-9 was analyzed by receiver operating characteristic (ROC) curve. RESULTS: Eighty-six consecutive patients with IPMNs all underwent surgical intervention. A high level of CA 19-9 or carcinoembryonic antigen (CEA) was associated with more advanced stage of malignant IPMNs. Carbohydrate antigen 19-9 was significant for judging malignant IPMNs in the binary logistic regression model (p=0.047). The hazard ratio was 1.014, whose 95.0% confidence interval was 0.91-1.028. Receiver operating characteristic analysis showed that the serum CA 19-9 level had good predictive value for malignant or invasive IPMNs, postoperative survival, and disease-specific recurrence. The area under the curve (AUC) was 0.856, 0.893, 0.815, and 0.857 (p<0.05), respectively. According to the follow-up, mean survival time for groups with CA 19-9>63.60 U/ml was dramatically shorter than that for groups with CA 19-9<=63.60 U/ml (57.38+/-2.85 versus 29.24+/-5.82 [months]; p<0.01). CONCLUSIONS: Serum CA 19-9 level has good predictive value for malignant or invasive IPMNs. Patients with CA 19-9 > 63.60 U/ml had poor postoperative prognosis in IPMNs. Preoperative abnormal serum CA 19-9 might be predictive for an aggressive surgical intervention in IPMNs. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Organ", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O" ]	Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. BACKGROUND: The goal of the present study was to evaluate the predictive value of serum carbohydrate antigen 19-9 (CA 19-9) in the diagnosis of malignant intraductal papillary mucinous neoplasms of pancreas (IPMNs). METHODS: Eighty-six patients with pathological diagnosis of IPMNs in Zhongshan Hospital between March 1999 and November 2008 were retrospectively reviewed. Data reflecting clinical characteristics, tumor marker level, and prognosis were collected. The potential predictive value of CA 19-9 was analyzed by receiver operating characteristic (ROC) curve. RESULTS: Eighty-six consecutive patients with IPMNs all underwent surgical intervention. A high level of CA 19-9 or carcinoembryonic antigen (CEA) was associated with more advanced stage of malignant IPMNs. Carbohydrate antigen 19-9 was significant for judging malignant IPMNs in the binary logistic regression model (p=0.047). The hazard ratio was 1.014, whose 95.0% confidence interval was 0.91-1.028. Receiver operating characteristic analysis showed that the serum CA 19-9 level had good predictive value for malignant or invasive IPMNs, postoperative survival, and disease-specific recurrence. The area under the curve (AUC) was 0.856, 0.893, 0.815, and 0.857 (p<0.05), respectively. According to the follow-up, mean survival time for groups with CA 19-9>63.60 U/ml was dramatically shorter than that for groups with CA 19-9<=63.60 U/ml (57.38+/-2.85 versus 29.24+/-5.82 [months]; p<0.01). CONCLUSIONS: Serum CA 19-9 level has good predictive value for malignant or invasive IPMNs. Patients with CA 19-9 > 63.60 U/ml had poor postoperative prognosis in IPMNs. Preoperative abnormal serum CA 19-9 might be predictive for an aggressive surgical intervention in IPMNs.	[ "Predictive", "value", "of", "serum", "carbohydrate", "antigen", "19", "-", "9", "in", "malignant", "intraductal", "papillary", "mucinous", "neoplasms", ".", "\n", "BACKGROUND", ":", "\n", "The", "goal", "of", "the", "present", "study", "was", "to", "evaluate", "the", "predictive", "value", "of", "serum", "carbohydrate", "antigen", "19", "-", "9", "(", "CA", "19", "-", "9", ")", "in", "the", "diagnosis", "of", "malignant", "intraductal", "papillary", "mucinous", "neoplasms", "of", "pancreas", "(", "IPMNs", ")", ".", "\n", "METHODS", ":", "\n", "Eighty", "-", "six", "patients", "with", "pathological", "diagnosis", "of", "IPMNs", "in", "Zhongshan", "Hospital", "between", "March", "1999", "and", "November", "2008", "were", "retrospectively", "reviewed", ".", "Data", "reflecting", "clinical", "characteristics", ",", "tumor", "marker", "level", ",", "and", "prognosis", "were", "collected", ".", "The", "potential", "predictive", "value", "of", "CA", "19", "-", "9", "was", "analyzed", "by", "receiver", "operating", "characteristic", "(", "ROC", ")", "curve", ".", "\n", "RESULTS", ":", "\n", "Eighty", "-", "six", "consecutive", "patients", "with", "IPMNs", "all", "underwent", "surgical", "intervention", ".", "A", "high", "level", "of", "CA", "19", "-", "9", "or", "carcinoembryonic", "antigen", "(", "CEA", ")", "was", "associated", "with", "more", "advanced", "stage", "of", "malignant", "IPMNs", ".", "Carbohydrate", "antigen", "19", "-", "9", "was", "significant", "for", "judging", "malignant", "IPMNs", "in", "the", "binary", "logistic", "regression", "model", "(", "p=0.047", ")", ".", "The", "hazard", "ratio", "was", "1.014", ",", "whose", "95.0", "%", "confidence", "interval", "was", "0.91", "-", "1.028", ".", "Receiver", "operating", "characteristic", "analysis", "showed", "that", "the", "serum", "CA", "19", "-", "9", "level", "had", "good", "predictive", "value", "for", "malignant", "or", "invasive", "IPMNs", ",", "postoperative", "survival", ",", "and", "disease", "-", "specific", "recurrence", ".", "The", "area", "under", "the", "curve", "(", "AUC", ")", "was", "0.856", ",", "0.893", ",", "0.815", ",", "and", "0.857", "(", "p<0.05", ")", ",", "respectively", ".", "According", "to", "the", "follow", "-", "up", ",", "mean", "survival", "time", "for", "groups", "with", "CA", "19", "-", "9>63.60", "U", "/", "ml", "was", "dramatically", "shorter", "than", "that", "for", "groups", "with", "CA", "19", "-", "9<=63.60", "U", "/", "ml", "(", "57.38+/-2.85", "versus", "29.24+/-5.82", "[", "months", "]", ";", "p<0.01", ")", ".", "\n", "CONCLUSIONS", ":", "\n", "Serum", "CA", "19", "-", "9", "level", "has", "good", "predictive", "value", "for", "malignant", "or", "invasive", "IPMNs", ".", "Patients", "with", "CA", "19", "-", "9", ">", "63.60", "U", "/", "ml", "had", "poor", "postoperative", "prognosis", "in", "IPMNs", ".", "Preoperative", "abnormal", "serum", "CA", "19", "-", "9", "might", "be", "predictive", "for", "an", "aggressive", "surgical", "intervention", "in", "IPMNs", ".", "\n" ]	[ "Pathological_formation", "Organ", "Organism_substance" ]
aminoglycoside is a GROUP, antibiotics is a GROUP, penicillins is a GROUP, cephalosporins is a GROUP, aminoglycoside is a GROUP, penicillin is a GROUP, aminoglycoside is a GROUP, aminoglycoside is a GROUP	Kanamycin_ddi_task0	Sentence: In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function. Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function.. See Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP	[ "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function. Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function.. See	[ "In", "vitro", "mixing", "of", "an", "aminoglycoside", "with", "beta", "-", "lactamtype", "antibiotics", "(", "penicillins", "or", "cephalosporins", ")", "may", "result", "in", "a", "significant", "mutual", "inactivation", ".", "Even", "when", "an", "aminoglycoside", "and", "a", "penicillin", "-", "type", "drug", "are", "administered", "separately", "by", "different", "routes", ",", "a", "reduction", "in", "aminoglycoside", "serum", "half", "-", "life", "or", "serum", "levels", "has", "been", "reported", "in", "patients", "with", "impaired", "renal", "function", "and", "in", "some", "patients", "with", "normal", "renal", "function", ".", "Usually", ",", "such", "inactivation", "of", "the", "aminoglycoside", "is", "clinically", "significant", "only", "in", "patients", "with", "severely", "impaired", "renal", "function", "..", "See" ]	[ "GROUP" ]
aminoglycoside is a GROUP, antibiotics is a GROUP, penicillins is a GROUP, cephalosporins is a GROUP, aminoglycoside is a GROUP, penicillin is a GROUP, aminoglycoside is a GROUP, aminoglycoside is a GROUP	Kanamycin_ddi_task1	Sentence: In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function. Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function.. See Instructions: please typing these entity words according to sentence: aminoglycoside, antibiotics, penicillins, cephalosporins, aminoglycoside, penicillin, aminoglycoside, aminoglycoside Options: GROUP	[ "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function. Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function.. See	[ "In", "vitro", "mixing", "of", "an", "aminoglycoside", "with", "beta", "-", "lactamtype", "antibiotics", "(", "penicillins", "or", "cephalosporins", ")", "may", "result", "in", "a", "significant", "mutual", "inactivation", ".", "Even", "when", "an", "aminoglycoside", "and", "a", "penicillin", "-", "type", "drug", "are", "administered", "separately", "by", "different", "routes", ",", "a", "reduction", "in", "aminoglycoside", "serum", "half", "-", "life", "or", "serum", "levels", "has", "been", "reported", "in", "patients", "with", "impaired", "renal", "function", "and", "in", "some", "patients", "with", "normal", "renal", "function", ".", "Usually", ",", "such", "inactivation", "of", "the", "aminoglycoside", "is", "clinically", "significant", "only", "in", "patients", "with", "severely", "impaired", "renal", "function", "..", "See" ]	[ "GROUP" ]
aminoglycoside, antibiotics, penicillins, cephalosporins, aminoglycoside, penicillin, aminoglycoside, aminoglycoside	Kanamycin_ddi_task2	Sentence: In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function. Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function.. See Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function. Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function.. See	[ "In", "vitro", "mixing", "of", "an", "aminoglycoside", "with", "beta", "-", "lactamtype", "antibiotics", "(", "penicillins", "or", "cephalosporins", ")", "may", "result", "in", "a", "significant", "mutual", "inactivation", ".", "Even", "when", "an", "aminoglycoside", "and", "a", "penicillin", "-", "type", "drug", "are", "administered", "separately", "by", "different", "routes", ",", "a", "reduction", "in", "aminoglycoside", "serum", "half", "-", "life", "or", "serum", "levels", "has", "been", "reported", "in", "patients", "with", "impaired", "renal", "function", "and", "in", "some", "patients", "with", "normal", "renal", "function", ".", "Usually", ",", "such", "inactivation", "of", "the", "aminoglycoside", "is", "clinically", "significant", "only", "in", "patients", "with", "severely", "impaired", "renal", "function", "..", "See" ]	[ "GROUP" ]
Lymphoms is an umlsterm, Differentialdiagnosen is an umlsterm, Paraffin is an umlsterm, Hautveraenderungen is an umlsterm, PCR is an umlsterm, Biopsien is an umlsterm, Hautveraenderungen is an umlsterm, Lymphome is an umlsterm, Kontrollbiopsien is an umlsterm, wachsende is an umlsterm, Technik is an umlsterm, Diagnostik is an umlsterm, Lymphomen is an umlsterm	DerPathologe.60170446.ger.abstr_task0	Sentence: Die Unterscheidung eines kutanen Lymphoms von einem reaktiven lymphoiden Infiltrat gehoert zu den anspruchsvollsten Differentialdiagnosen in der Dermatohistopathologie . Im Rahmen einer retrospektiven Studie untersuchten wir 24 in Paraffin eingebettete Proben von Hautveraenderungen , bei denen klinisch und histologisch ein T-Zellymphom diagnostiziert wurde , auf ein klonales Rearrangement des Gamma-T-Zellrezeptors mittels der Polymerasekettenreaktion ( PCR ) . Als Kontrollen wurden 7 Biopsien entzuendlicher Hautveraenderungen mit einem ausgepraegten lymphoiden Infiltrat untersucht . Der Klonalitaetsnachweis gelang in 22 von 24 Faellen der Lymphome ( 92 % ) . Bei den 7 Kontrollbiopsien konnte keine Klonalitaet nachgewiesen werden . Insofern ermoeglicht die von uns gewaehlte Primerkombination , die jede der vier Hauptgruppen des Gam- ma-T-Zellrezeptorgens ( V 1-8 , V 9 , V 10 und V 11 ) beruecksichtigt , eine hohe Sensitivitaet . Die Untersuchung bestaetigt die wachsende Bedeutung dieser Technik fuer die Diagnostik von Lymphomen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Die Unterscheidung eines kutanen Lymphoms von einem reaktiven lymphoiden Infiltrat gehoert zu den anspruchsvollsten Differentialdiagnosen in der Dermatohistopathologie . Im Rahmen einer retrospektiven Studie untersuchten wir 24 in Paraffin eingebettete Proben von Hautveraenderungen , bei denen klinisch und histologisch ein T-Zellymphom diagnostiziert wurde , auf ein klonales Rearrangement des Gamma-T-Zellrezeptors mittels der Polymerasekettenreaktion ( PCR ) . Als Kontrollen wurden 7 Biopsien entzuendlicher Hautveraenderungen mit einem ausgepraegten lymphoiden Infiltrat untersucht . Der Klonalitaetsnachweis gelang in 22 von 24 Faellen der Lymphome ( 92 % ) . Bei den 7 Kontrollbiopsien konnte keine Klonalitaet nachgewiesen werden . Insofern ermoeglicht die von uns gewaehlte Primerkombination , die jede der vier Hauptgruppen des Gam- ma-T-Zellrezeptorgens ( V 1-8 , V 9 , V 10 und V 11 ) beruecksichtigt , eine hohe Sensitivitaet . Die Untersuchung bestaetigt die wachsende Bedeutung dieser Technik fuer die Diagnostik von Lymphomen .	[ "Die", "Unterscheidung", "eines", "kutanen", "Lymphoms", "von", "einem", "reaktiven", "lymphoiden", "Infiltrat", "gehoert", "zu", "den", "anspruchsvollsten", "Differentialdiagnosen", "in", "der", "Dermatohistopathologie", ".", "Im", "Rahmen", "einer", "retrospektiven", "Studie", "untersuchten", "wir", "24", "in", "Paraffin", "eingebettete", "Proben", "von", "Hautveraenderungen", ",", "bei", "denen", "klinisch", "und", "histologisch", "ein", "T", "-", "Zellymphom", "diagnostiziert", "wurde", ",", "auf", "ein", "klonales", "Rearrangement", "des", "Gamma", "-", "T", "-", "Zellrezeptors", "mittels", "der", "Polymerasekettenreaktion", "(", "PCR", ")", ".", "Als", "Kontrollen", "wurden", "7", "Biopsien", "entzuendlicher", "Hautveraenderungen", "mit", "einem", "ausgepraegten", "lymphoiden", "Infiltrat", "untersucht", ".", "Der", "Klonalitaetsnachweis", "gelang", "in", "22", "von", "24", "Faellen", "der", "Lymphome", "(", "92", "%", ")", ".", "Bei", "den", "7", "Kontrollbiopsien", "konnte", "keine", "Klonalitaet", "nachgewiesen", "werden", ".", "Insofern", "ermoeglicht", "die", "von", "uns", "gewaehlte", "Primerkombination", ",", "die", "jede", "der", "vier", "Hauptgruppen", "des", "Gam-", "ma", "-", "T", "-", "Zellrezeptorgens", "(", "V", "1", "-", "8", ",", "V", "9", ",", "V", "10", "und", "V", "11", ")", "beruecksichtigt", ",", "eine", "hohe", "Sensitivitaet", ".", "Die", "Untersuchung", "bestaetigt", "die", "wachsende", "Bedeutung", "dieser", "Technik", "fuer", "die", "Diagnostik", "von", "Lymphomen", "." ]	[ "umlsterm" ]
Lymphoms is an umlsterm, Differentialdiagnosen is an umlsterm, Paraffin is an umlsterm, Hautveraenderungen is an umlsterm, PCR is an umlsterm, Biopsien is an umlsterm, Hautveraenderungen is an umlsterm, Lymphome is an umlsterm, Kontrollbiopsien is an umlsterm, wachsende is an umlsterm, Technik is an umlsterm, Diagnostik is an umlsterm, Lymphomen is an umlsterm	DerPathologe.60170446.ger.abstr_task1	Sentence: Die Unterscheidung eines kutanen Lymphoms von einem reaktiven lymphoiden Infiltrat gehoert zu den anspruchsvollsten Differentialdiagnosen in der Dermatohistopathologie . Im Rahmen einer retrospektiven Studie untersuchten wir 24 in Paraffin eingebettete Proben von Hautveraenderungen , bei denen klinisch und histologisch ein T-Zellymphom diagnostiziert wurde , auf ein klonales Rearrangement des Gamma-T-Zellrezeptors mittels der Polymerasekettenreaktion ( PCR ) . Als Kontrollen wurden 7 Biopsien entzuendlicher Hautveraenderungen mit einem ausgepraegten lymphoiden Infiltrat untersucht . Der Klonalitaetsnachweis gelang in 22 von 24 Faellen der Lymphome ( 92 % ) . Bei den 7 Kontrollbiopsien konnte keine Klonalitaet nachgewiesen werden . Insofern ermoeglicht die von uns gewaehlte Primerkombination , die jede der vier Hauptgruppen des Gam- ma-T-Zellrezeptorgens ( V 1-8 , V 9 , V 10 und V 11 ) beruecksichtigt , eine hohe Sensitivitaet . Die Untersuchung bestaetigt die wachsende Bedeutung dieser Technik fuer die Diagnostik von Lymphomen . Instructions: please typing these entity words according to sentence: Lymphoms, Differentialdiagnosen, Paraffin, Hautveraenderungen, PCR, Biopsien, Hautveraenderungen, Lymphome, Kontrollbiopsien, wachsende, Technik, Diagnostik, Lymphomen Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Die Unterscheidung eines kutanen Lymphoms von einem reaktiven lymphoiden Infiltrat gehoert zu den anspruchsvollsten Differentialdiagnosen in der Dermatohistopathologie . Im Rahmen einer retrospektiven Studie untersuchten wir 24 in Paraffin eingebettete Proben von Hautveraenderungen , bei denen klinisch und histologisch ein T-Zellymphom diagnostiziert wurde , auf ein klonales Rearrangement des Gamma-T-Zellrezeptors mittels der Polymerasekettenreaktion ( PCR ) . Als Kontrollen wurden 7 Biopsien entzuendlicher Hautveraenderungen mit einem ausgepraegten lymphoiden Infiltrat untersucht . Der Klonalitaetsnachweis gelang in 22 von 24 Faellen der Lymphome ( 92 % ) . Bei den 7 Kontrollbiopsien konnte keine Klonalitaet nachgewiesen werden . Insofern ermoeglicht die von uns gewaehlte Primerkombination , die jede der vier Hauptgruppen des Gam- ma-T-Zellrezeptorgens ( V 1-8 , V 9 , V 10 und V 11 ) beruecksichtigt , eine hohe Sensitivitaet . Die Untersuchung bestaetigt die wachsende Bedeutung dieser Technik fuer die Diagnostik von Lymphomen .	[ "Die", "Unterscheidung", "eines", "kutanen", "Lymphoms", "von", "einem", "reaktiven", "lymphoiden", "Infiltrat", "gehoert", "zu", "den", "anspruchsvollsten", "Differentialdiagnosen", "in", "der", "Dermatohistopathologie", ".", "Im", "Rahmen", "einer", "retrospektiven", "Studie", "untersuchten", "wir", "24", "in", "Paraffin", "eingebettete", "Proben", "von", "Hautveraenderungen", ",", "bei", "denen", "klinisch", "und", "histologisch", "ein", "T", "-", "Zellymphom", "diagnostiziert", "wurde", ",", "auf", "ein", "klonales", "Rearrangement", "des", "Gamma", "-", "T", "-", "Zellrezeptors", "mittels", "der", "Polymerasekettenreaktion", "(", "PCR", ")", ".", "Als", "Kontrollen", "wurden", "7", "Biopsien", "entzuendlicher", "Hautveraenderungen", "mit", "einem", "ausgepraegten", "lymphoiden", "Infiltrat", "untersucht", ".", "Der", "Klonalitaetsnachweis", "gelang", "in", "22", "von", "24", "Faellen", "der", "Lymphome", "(", "92", "%", ")", ".", "Bei", "den", "7", "Kontrollbiopsien", "konnte", "keine", "Klonalitaet", "nachgewiesen", "werden", ".", "Insofern", "ermoeglicht", "die", "von", "uns", "gewaehlte", "Primerkombination", ",", "die", "jede", "der", "vier", "Hauptgruppen", "des", "Gam-", "ma", "-", "T", "-", "Zellrezeptorgens", "(", "V", "1", "-", "8", ",", "V", "9", ",", "V", "10", "und", "V", "11", ")", "beruecksichtigt", ",", "eine", "hohe", "Sensitivitaet", ".", "Die", "Untersuchung", "bestaetigt", "die", "wachsende", "Bedeutung", "dieser", "Technik", "fuer", "die", "Diagnostik", "von", "Lymphomen", "." ]	[ "umlsterm" ]
Lymphoms, Differentialdiagnosen, Paraffin, Hautveraenderungen, PCR, Biopsien, Hautveraenderungen, Lymphome, Kontrollbiopsien, wachsende, Technik, Diagnostik, Lymphomen	DerPathologe.60170446.ger.abstr_task2	Sentence: Die Unterscheidung eines kutanen Lymphoms von einem reaktiven lymphoiden Infiltrat gehoert zu den anspruchsvollsten Differentialdiagnosen in der Dermatohistopathologie . Im Rahmen einer retrospektiven Studie untersuchten wir 24 in Paraffin eingebettete Proben von Hautveraenderungen , bei denen klinisch und histologisch ein T-Zellymphom diagnostiziert wurde , auf ein klonales Rearrangement des Gamma-T-Zellrezeptors mittels der Polymerasekettenreaktion ( PCR ) . Als Kontrollen wurden 7 Biopsien entzuendlicher Hautveraenderungen mit einem ausgepraegten lymphoiden Infiltrat untersucht . Der Klonalitaetsnachweis gelang in 22 von 24 Faellen der Lymphome ( 92 % ) . Bei den 7 Kontrollbiopsien konnte keine Klonalitaet nachgewiesen werden . Insofern ermoeglicht die von uns gewaehlte Primerkombination , die jede der vier Hauptgruppen des Gam- ma-T-Zellrezeptorgens ( V 1-8 , V 9 , V 10 und V 11 ) beruecksichtigt , eine hohe Sensitivitaet . Die Untersuchung bestaetigt die wachsende Bedeutung dieser Technik fuer die Diagnostik von Lymphomen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Die Unterscheidung eines kutanen Lymphoms von einem reaktiven lymphoiden Infiltrat gehoert zu den anspruchsvollsten Differentialdiagnosen in der Dermatohistopathologie . Im Rahmen einer retrospektiven Studie untersuchten wir 24 in Paraffin eingebettete Proben von Hautveraenderungen , bei denen klinisch und histologisch ein T-Zellymphom diagnostiziert wurde , auf ein klonales Rearrangement des Gamma-T-Zellrezeptors mittels der Polymerasekettenreaktion ( PCR ) . Als Kontrollen wurden 7 Biopsien entzuendlicher Hautveraenderungen mit einem ausgepraegten lymphoiden Infiltrat untersucht . Der Klonalitaetsnachweis gelang in 22 von 24 Faellen der Lymphome ( 92 % ) . Bei den 7 Kontrollbiopsien konnte keine Klonalitaet nachgewiesen werden . Insofern ermoeglicht die von uns gewaehlte Primerkombination , die jede der vier Hauptgruppen des Gam- ma-T-Zellrezeptorgens ( V 1-8 , V 9 , V 10 und V 11 ) beruecksichtigt , eine hohe Sensitivitaet . Die Untersuchung bestaetigt die wachsende Bedeutung dieser Technik fuer die Diagnostik von Lymphomen .	[ "Die", "Unterscheidung", "eines", "kutanen", "Lymphoms", "von", "einem", "reaktiven", "lymphoiden", "Infiltrat", "gehoert", "zu", "den", "anspruchsvollsten", "Differentialdiagnosen", "in", "der", "Dermatohistopathologie", ".", "Im", "Rahmen", "einer", "retrospektiven", "Studie", "untersuchten", "wir", "24", "in", "Paraffin", "eingebettete", "Proben", "von", "Hautveraenderungen", ",", "bei", "denen", "klinisch", "und", "histologisch", "ein", "T", "-", "Zellymphom", "diagnostiziert", "wurde", ",", "auf", "ein", "klonales", "Rearrangement", "des", "Gamma", "-", "T", "-", "Zellrezeptors", "mittels", "der", "Polymerasekettenreaktion", "(", "PCR", ")", ".", "Als", "Kontrollen", "wurden", "7", "Biopsien", "entzuendlicher", "Hautveraenderungen", "mit", "einem", "ausgepraegten", "lymphoiden", "Infiltrat", "untersucht", ".", "Der", "Klonalitaetsnachweis", "gelang", "in", "22", "von", "24", "Faellen", "der", "Lymphome", "(", "92", "%", ")", ".", "Bei", "den", "7", "Kontrollbiopsien", "konnte", "keine", "Klonalitaet", "nachgewiesen", "werden", ".", "Insofern", "ermoeglicht", "die", "von", "uns", "gewaehlte", "Primerkombination", ",", "die", "jede", "der", "vier", "Hauptgruppen", "des", "Gam-", "ma", "-", "T", "-", "Zellrezeptorgens", "(", "V", "1", "-", "8", ",", "V", "9", ",", "V", "10", "und", "V", "11", ")", "beruecksichtigt", ",", "eine", "hohe", "Sensitivitaet", ".", "Die", "Untersuchung", "bestaetigt", "die", "wachsende", "Bedeutung", "dieser", "Technik", "fuer", "die", "Diagnostik", "von", "Lymphomen", "." ]	[ "umlsterm" ]
Colon Cancer is a DISEASE, colon cancer is a DISEASE, gastrointestinal toxicities is a ADVERSE, liver toxicities is a ADVERSE	example-71_task0	Sentence: Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n=504 Raltitrexed) of whom respectively 146 and 148 died, respectively. RESULTS: The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23). CONCLUSION: The trial failed to demonstrate non-inferiority of raltitrexed. FUNDING: Free drugs and financial support from AstraZeneca. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE, DISEASE	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n=504 Raltitrexed) of whom respectively 146 and 148 died, respectively. RESULTS: The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23). CONCLUSION: The trial failed to demonstrate non-inferiority of raltitrexed. FUNDING: Free drugs and financial support from AstraZeneca.	[ "Raltitrexed", "(", "Tomudex", ")", "versus", "standard", "leucovorin", "-", "modulated", "bolus", "5-fluorouracil", ":", "Results", "from", "the", "randomised", "phase", "III", "Pan", "-", "European", "Trial", "in", "Adjuvant", "Colon", "Cancer", "01", "(", "PETACC-1", ")", ".", " ", "OBJECTIVES", ":", "PETACC-1", "assessed", "if", "raltitrexed", "is", "non", "-", "inferior", "to", "5-fluorouracil", "and", "leucovorin", "for", "relapse", "-", "free", "survival", "(", "RFS", ")", "and", "overall", "survival", "(", "OS", ")", "in", "adjuvant", "stage", "III", "colon", "cancer", ".", "METHODS", ":", "Non", "-", "inferiority", "required", "both", "HR", "for", "RFS", "and", "OS<1.25", "at", "1-sided", "alpha=0.05", ".", "Patients", "(", "1921", ")", "were", "randomised", "to", "six", "cycles", "of", "5-FU", "/", "LV", "(", "n=969", ")", "or", "eight", "cycles", "of", "raltitrexed", "(", "n=952", ")", ".", "We", "report", "the", "final", "results", "in", "993", "eligible", "patients", "who", "started", "and", "completed", "the", "allocated", "treatment", "(", "489", "5-FU", "/", "LV", "and", "n=504", "Raltitrexed", ")", "of", "whom", "respectively", "146", "and", "148", "died", ",", "respectively", ".", "RESULTS", ":", "The", "trial", "closed", "prematurely", "when", "17", "(", "1.9", "%", ")", "raltitrexed", "-", "related", "deaths", "were", "reported", ".", "Haematological", "and", "gastrointestinal", "toxicities", "were", "more", "frequent", "with", "5-FU", "/", "LV", ",", "liver", "toxicities", "with", "raltitrexed", ".", "Raltitrexed", "was", "stopped", "for", "toxicity", "in", "13.2", "%", "and", "5-FU", "/", "LV", "in", "8.5", "%", ".", "Sixty", "-", "day", "mortality", "was", "9", "%", "versus", "7", "%", ".", "With", "4.1", "years", "median", "follow", "-", "up", ",", "the", "HR", "for", "RFS", "was", "1.16", "(", "90", "%", "CI", "0.99", "-", "1.37", ")", "and", "that", "for", "OS", "was", "1.01", "(", "90", "%", "CI", "0.84", "-", "1.23", ")", ".", "CONCLUSION", ":", "The", "trial", "failed", "to", "demonstrate", "non", "-", "inferiority", "of", "raltitrexed", ".", "FUNDING", ":", "Free", "drugs", "and", "financial", "support", "from", "AstraZeneca", "." ]	[ "ADVERSE", "DISEASE" ]
Colon Cancer is a DISEASE, colon cancer is a DISEASE, gastrointestinal toxicities is a ADVERSE, liver toxicities is a ADVERSE	example-71_task1	Sentence: Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n=504 Raltitrexed) of whom respectively 146 and 148 died, respectively. RESULTS: The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23). CONCLUSION: The trial failed to demonstrate non-inferiority of raltitrexed. FUNDING: Free drugs and financial support from AstraZeneca. Instructions: please typing these entity words according to sentence: Colon Cancer, colon cancer, gastrointestinal toxicities, liver toxicities Options: ADVERSE, DISEASE	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n=504 Raltitrexed) of whom respectively 146 and 148 died, respectively. RESULTS: The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23). CONCLUSION: The trial failed to demonstrate non-inferiority of raltitrexed. FUNDING: Free drugs and financial support from AstraZeneca.	[ "Raltitrexed", "(", "Tomudex", ")", "versus", "standard", "leucovorin", "-", "modulated", "bolus", "5-fluorouracil", ":", "Results", "from", "the", "randomised", "phase", "III", "Pan", "-", "European", "Trial", "in", "Adjuvant", "Colon", "Cancer", "01", "(", "PETACC-1", ")", ".", " ", "OBJECTIVES", ":", "PETACC-1", "assessed", "if", "raltitrexed", "is", "non", "-", "inferior", "to", "5-fluorouracil", "and", "leucovorin", "for", "relapse", "-", "free", "survival", "(", "RFS", ")", "and", "overall", "survival", "(", "OS", ")", "in", "adjuvant", "stage", "III", "colon", "cancer", ".", "METHODS", ":", "Non", "-", "inferiority", "required", "both", "HR", "for", "RFS", "and", "OS<1.25", "at", "1-sided", "alpha=0.05", ".", "Patients", "(", "1921", ")", "were", "randomised", "to", "six", "cycles", "of", "5-FU", "/", "LV", "(", "n=969", ")", "or", "eight", "cycles", "of", "raltitrexed", "(", "n=952", ")", ".", "We", "report", "the", "final", "results", "in", "993", "eligible", "patients", "who", "started", "and", "completed", "the", "allocated", "treatment", "(", "489", "5-FU", "/", "LV", "and", "n=504", "Raltitrexed", ")", "of", "whom", "respectively", "146", "and", "148", "died", ",", "respectively", ".", "RESULTS", ":", "The", "trial", "closed", "prematurely", "when", "17", "(", "1.9", "%", ")", "raltitrexed", "-", "related", "deaths", "were", "reported", ".", "Haematological", "and", "gastrointestinal", "toxicities", "were", "more", "frequent", "with", "5-FU", "/", "LV", ",", "liver", "toxicities", "with", "raltitrexed", ".", "Raltitrexed", "was", "stopped", "for", "toxicity", "in", "13.2", "%", "and", "5-FU", "/", "LV", "in", "8.5", "%", ".", "Sixty", "-", "day", "mortality", "was", "9", "%", "versus", "7", "%", ".", "With", "4.1", "years", "median", "follow", "-", "up", ",", "the", "HR", "for", "RFS", "was", "1.16", "(", "90", "%", "CI", "0.99", "-", "1.37", ")", "and", "that", "for", "OS", "was", "1.01", "(", "90", "%", "CI", "0.84", "-", "1.23", ")", ".", "CONCLUSION", ":", "The", "trial", "failed", "to", "demonstrate", "non", "-", "inferiority", "of", "raltitrexed", ".", "FUNDING", ":", "Free", "drugs", "and", "financial", "support", "from", "AstraZeneca", "." ]	[ "ADVERSE", "DISEASE" ]
Colon Cancer, colon cancer, gastrointestinal toxicities, liver toxicities	example-71_task2	Sentence: Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n=504 Raltitrexed) of whom respectively 146 and 148 died, respectively. RESULTS: The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23). CONCLUSION: The trial failed to demonstrate non-inferiority of raltitrexed. FUNDING: Free drugs and financial support from AstraZeneca. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n=504 Raltitrexed) of whom respectively 146 and 148 died, respectively. RESULTS: The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23). CONCLUSION: The trial failed to demonstrate non-inferiority of raltitrexed. FUNDING: Free drugs and financial support from AstraZeneca.	[ "Raltitrexed", "(", "Tomudex", ")", "versus", "standard", "leucovorin", "-", "modulated", "bolus", "5-fluorouracil", ":", "Results", "from", "the", "randomised", "phase", "III", "Pan", "-", "European", "Trial", "in", "Adjuvant", "Colon", "Cancer", "01", "(", "PETACC-1", ")", ".", " ", "OBJECTIVES", ":", "PETACC-1", "assessed", "if", "raltitrexed", "is", "non", "-", "inferior", "to", "5-fluorouracil", "and", "leucovorin", "for", "relapse", "-", "free", "survival", "(", "RFS", ")", "and", "overall", "survival", "(", "OS", ")", "in", "adjuvant", "stage", "III", "colon", "cancer", ".", "METHODS", ":", "Non", "-", "inferiority", "required", "both", "HR", "for", "RFS", "and", "OS<1.25", "at", "1-sided", "alpha=0.05", ".", "Patients", "(", "1921", ")", "were", "randomised", "to", "six", "cycles", "of", "5-FU", "/", "LV", "(", "n=969", ")", "or", "eight", "cycles", "of", "raltitrexed", "(", "n=952", ")", ".", "We", "report", "the", "final", "results", "in", "993", "eligible", "patients", "who", "started", "and", "completed", "the", "allocated", "treatment", "(", "489", "5-FU", "/", "LV", "and", "n=504", "Raltitrexed", ")", "of", "whom", "respectively", "146", "and", "148", "died", ",", "respectively", ".", "RESULTS", ":", "The", "trial", "closed", "prematurely", "when", "17", "(", "1.9", "%", ")", "raltitrexed", "-", "related", "deaths", "were", "reported", ".", "Haematological", "and", "gastrointestinal", "toxicities", "were", "more", "frequent", "with", "5-FU", "/", "LV", ",", "liver", "toxicities", "with", "raltitrexed", ".", "Raltitrexed", "was", "stopped", "for", "toxicity", "in", "13.2", "%", "and", "5-FU", "/", "LV", "in", "8.5", "%", ".", "Sixty", "-", "day", "mortality", "was", "9", "%", "versus", "7", "%", ".", "With", "4.1", "years", "median", "follow", "-", "up", ",", "the", "HR", "for", "RFS", "was", "1.16", "(", "90", "%", "CI", "0.99", "-", "1.37", ")", "and", "that", "for", "OS", "was", "1.01", "(", "90", "%", "CI", "0.84", "-", "1.23", ")", ".", "CONCLUSION", ":", "The", "trial", "failed", "to", "demonstrate", "non", "-", "inferiority", "of", "raltitrexed", ".", "FUNDING", ":", "Free", "drugs", "and", "financial", "support", "from", "AstraZeneca", "." ]	[ "ADVERSE", "DISEASE" ]
Objective is an umlsterm, Body Mass Index is an umlsterm, BMI is an umlsterm, children is an umlsterm, prevalence is an umlsterm, overweight is an umlsterm, obesity is an umlsterm	MonatsschriftKinderheilkunde.81461192.eng.abstr_task0	Sentence: Objective : To examine changes in Body Mass Index ( BMI ) in children in the last twenty years and to determine the prevalence of overweight and obesity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Objective : To examine changes in Body Mass Index ( BMI ) in children in the last twenty years and to determine the prevalence of overweight and obesity .	[ "Objective", ":", "To", "examine", "changes", "in", "Body", "Mass", "Index", "(", "BMI", ")", "in", "children", "in", "the", "last", "twenty", "years", "and", "to", "determine", "the", "prevalence", "of", "overweight", "and", "obesity", "." ]	[ "umlsterm" ]
Objective is an umlsterm, Body Mass Index is an umlsterm, BMI is an umlsterm, children is an umlsterm, prevalence is an umlsterm, overweight is an umlsterm, obesity is an umlsterm	MonatsschriftKinderheilkunde.81461192.eng.abstr_task1	Sentence: Objective : To examine changes in Body Mass Index ( BMI ) in children in the last twenty years and to determine the prevalence of overweight and obesity . Instructions: please typing these entity words according to sentence: Objective, Body Mass Index, BMI, children, prevalence, overweight, obesity Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Objective : To examine changes in Body Mass Index ( BMI ) in children in the last twenty years and to determine the prevalence of overweight and obesity .	[ "Objective", ":", "To", "examine", "changes", "in", "Body", "Mass", "Index", "(", "BMI", ")", "in", "children", "in", "the", "last", "twenty", "years", "and", "to", "determine", "the", "prevalence", "of", "overweight", "and", "obesity", "." ]	[ "umlsterm" ]
Objective, Body Mass Index, BMI, children, prevalence, overweight, obesity	MonatsschriftKinderheilkunde.81461192.eng.abstr_task2	Sentence: Objective : To examine changes in Body Mass Index ( BMI ) in children in the last twenty years and to determine the prevalence of overweight and obesity . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Objective : To examine changes in Body Mass Index ( BMI ) in children in the last twenty years and to determine the prevalence of overweight and obesity .	[ "Objective", ":", "To", "examine", "changes", "in", "Body", "Mass", "Index", "(", "BMI", ")", "in", "children", "in", "the", "last", "twenty", "years", "and", "to", "determine", "the", "prevalence", "of", "overweight", "and", "obesity", "." ]	[ "umlsterm" ]
Verlaufsbeobachtung is an umlsterm, Arrhythmiepraediktoren is an umlsterm, Patienten is an umlsterm, Kardiomyopathie is an umlsterm, Klassifikation is an umlsterm, New York is an umlsterm, Vorhofflimmern is an umlsterm, EKG is an umlsterm, Turbulenzanalyse is an umlsterm, EKG is an umlsterm, Arrhythmien is an umlsterm, Belastung is an umlsterm	Herz.00250189.ger.abstr_task0	Sentence: Die Marburger Kardiomyopathie-Studie ( MACAS ) wurde als prospektive Verlaufsbeobachtung konzipiert , um die Wertigkeit der folgenden potentiellen nichtinvasiven Arrhythmiepraediktoren bei ueber 200 Patienten mit dilatativer Kardiomyopathie ( DCM ) im Verlauf von fuenf Jahren zu untersuchen : Stadium der Herzinsuffizienz nach der Klassifikation der New York Heart Association linksventrikulaerer enddiastolischer Diameter und Ejektionsfraktion , Linksschenkelblock und Vorhofflimmern , im EKG , QTc- und JTc-Dispersion , abnormale Time-domain-Analyse und spektrale Turbulenzanalyse des signalgemittelten EKG , ventrikulaere Arrhythmien und Herzfrequenzvariabilitaet im 24-Stunden-Langzeit-EKG, Baroreflexsensitivitaet und Mikrovolt-T-Wellen-Alternans unter Belastung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Die Marburger Kardiomyopathie-Studie ( MACAS ) wurde als prospektive Verlaufsbeobachtung konzipiert , um die Wertigkeit der folgenden potentiellen nichtinvasiven Arrhythmiepraediktoren bei ueber 200 Patienten mit dilatativer Kardiomyopathie ( DCM ) im Verlauf von fuenf Jahren zu untersuchen : Stadium der Herzinsuffizienz nach der Klassifikation der New York Heart Association linksventrikulaerer enddiastolischer Diameter und Ejektionsfraktion , Linksschenkelblock und Vorhofflimmern , im EKG , QTc- und JTc-Dispersion , abnormale Time-domain-Analyse und spektrale Turbulenzanalyse des signalgemittelten EKG , ventrikulaere Arrhythmien und Herzfrequenzvariabilitaet im 24-Stunden-Langzeit-EKG, Baroreflexsensitivitaet und Mikrovolt-T-Wellen-Alternans unter Belastung .	[ "Die", "Marburger", "Kardiomyopathie", "-", "Studie", "(", "MACAS", ")", "wurde", "als", "prospektive", "Verlaufsbeobachtung", "konzipiert", ",", "um", "die", "Wertigkeit", "der", "folgenden", "potentiellen", "nichtinvasiven", "Arrhythmiepraediktoren", "bei", "ueber", "200", "Patienten", "mit", "dilatativer", "Kardiomyopathie", "(", "DCM", ")", "im", "Verlauf", "von", "fuenf", "Jahren", "zu", "untersuchen", ":", "Stadium", "der", "Herzinsuffizienz", "nach", "der", "Klassifikation", "der", "New", "York", "Heart", "Association", "linksventrikulaerer", "enddiastolischer", "Diameter", "und", "Ejektionsfraktion", ",", "Linksschenkelblock", "und", "Vorhofflimmern", ",", "im", "EKG", ",", "QTc-", "und", "JTc", "-", "Dispersion", ",", "abnormale", "Time", "-", "domain", "-", "Analyse", "und", "spektrale", "Turbulenzanalyse", "des", "signalgemittelten", "EKG", ",", "ventrikulaere", "Arrhythmien", "und", "Herzfrequenzvariabilitaet", "im", "24-Stunden", "-", "Langzeit", "-", "EKG", ",", "Baroreflexsensitivitaet", "und", "Mikrovolt", "-", "T", "-", "Wellen", "-", "Alternans", "unter", "Belastung", "." ]	[ "umlsterm" ]
Verlaufsbeobachtung is an umlsterm, Arrhythmiepraediktoren is an umlsterm, Patienten is an umlsterm, Kardiomyopathie is an umlsterm, Klassifikation is an umlsterm, New York is an umlsterm, Vorhofflimmern is an umlsterm, EKG is an umlsterm, Turbulenzanalyse is an umlsterm, EKG is an umlsterm, Arrhythmien is an umlsterm, Belastung is an umlsterm	Herz.00250189.ger.abstr_task1	Sentence: Die Marburger Kardiomyopathie-Studie ( MACAS ) wurde als prospektive Verlaufsbeobachtung konzipiert , um die Wertigkeit der folgenden potentiellen nichtinvasiven Arrhythmiepraediktoren bei ueber 200 Patienten mit dilatativer Kardiomyopathie ( DCM ) im Verlauf von fuenf Jahren zu untersuchen : Stadium der Herzinsuffizienz nach der Klassifikation der New York Heart Association linksventrikulaerer enddiastolischer Diameter und Ejektionsfraktion , Linksschenkelblock und Vorhofflimmern , im EKG , QTc- und JTc-Dispersion , abnormale Time-domain-Analyse und spektrale Turbulenzanalyse des signalgemittelten EKG , ventrikulaere Arrhythmien und Herzfrequenzvariabilitaet im 24-Stunden-Langzeit-EKG, Baroreflexsensitivitaet und Mikrovolt-T-Wellen-Alternans unter Belastung . Instructions: please typing these entity words according to sentence: Verlaufsbeobachtung, Arrhythmiepraediktoren, Patienten, Kardiomyopathie, Klassifikation, New York, Vorhofflimmern, EKG, Turbulenzanalyse, EKG, Arrhythmien, Belastung Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Die Marburger Kardiomyopathie-Studie ( MACAS ) wurde als prospektive Verlaufsbeobachtung konzipiert , um die Wertigkeit der folgenden potentiellen nichtinvasiven Arrhythmiepraediktoren bei ueber 200 Patienten mit dilatativer Kardiomyopathie ( DCM ) im Verlauf von fuenf Jahren zu untersuchen : Stadium der Herzinsuffizienz nach der Klassifikation der New York Heart Association linksventrikulaerer enddiastolischer Diameter und Ejektionsfraktion , Linksschenkelblock und Vorhofflimmern , im EKG , QTc- und JTc-Dispersion , abnormale Time-domain-Analyse und spektrale Turbulenzanalyse des signalgemittelten EKG , ventrikulaere Arrhythmien und Herzfrequenzvariabilitaet im 24-Stunden-Langzeit-EKG, Baroreflexsensitivitaet und Mikrovolt-T-Wellen-Alternans unter Belastung .	[ "Die", "Marburger", "Kardiomyopathie", "-", "Studie", "(", "MACAS", ")", "wurde", "als", "prospektive", "Verlaufsbeobachtung", "konzipiert", ",", "um", "die", "Wertigkeit", "der", "folgenden", "potentiellen", "nichtinvasiven", "Arrhythmiepraediktoren", "bei", "ueber", "200", "Patienten", "mit", "dilatativer", "Kardiomyopathie", "(", "DCM", ")", "im", "Verlauf", "von", "fuenf", "Jahren", "zu", "untersuchen", ":", "Stadium", "der", "Herzinsuffizienz", "nach", "der", "Klassifikation", "der", "New", "York", "Heart", "Association", "linksventrikulaerer", "enddiastolischer", "Diameter", "und", "Ejektionsfraktion", ",", "Linksschenkelblock", "und", "Vorhofflimmern", ",", "im", "EKG", ",", "QTc-", "und", "JTc", "-", "Dispersion", ",", "abnormale", "Time", "-", "domain", "-", "Analyse", "und", "spektrale", "Turbulenzanalyse", "des", "signalgemittelten", "EKG", ",", "ventrikulaere", "Arrhythmien", "und", "Herzfrequenzvariabilitaet", "im", "24-Stunden", "-", "Langzeit", "-", "EKG", ",", "Baroreflexsensitivitaet", "und", "Mikrovolt", "-", "T", "-", "Wellen", "-", "Alternans", "unter", "Belastung", "." ]	[ "umlsterm" ]
Verlaufsbeobachtung, Arrhythmiepraediktoren, Patienten, Kardiomyopathie, Klassifikation, New York, Vorhofflimmern, EKG, Turbulenzanalyse, EKG, Arrhythmien, Belastung	Herz.00250189.ger.abstr_task2	Sentence: Die Marburger Kardiomyopathie-Studie ( MACAS ) wurde als prospektive Verlaufsbeobachtung konzipiert , um die Wertigkeit der folgenden potentiellen nichtinvasiven Arrhythmiepraediktoren bei ueber 200 Patienten mit dilatativer Kardiomyopathie ( DCM ) im Verlauf von fuenf Jahren zu untersuchen : Stadium der Herzinsuffizienz nach der Klassifikation der New York Heart Association linksventrikulaerer enddiastolischer Diameter und Ejektionsfraktion , Linksschenkelblock und Vorhofflimmern , im EKG , QTc- und JTc-Dispersion , abnormale Time-domain-Analyse und spektrale Turbulenzanalyse des signalgemittelten EKG , ventrikulaere Arrhythmien und Herzfrequenzvariabilitaet im 24-Stunden-Langzeit-EKG, Baroreflexsensitivitaet und Mikrovolt-T-Wellen-Alternans unter Belastung . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Die Marburger Kardiomyopathie-Studie ( MACAS ) wurde als prospektive Verlaufsbeobachtung konzipiert , um die Wertigkeit der folgenden potentiellen nichtinvasiven Arrhythmiepraediktoren bei ueber 200 Patienten mit dilatativer Kardiomyopathie ( DCM ) im Verlauf von fuenf Jahren zu untersuchen : Stadium der Herzinsuffizienz nach der Klassifikation der New York Heart Association linksventrikulaerer enddiastolischer Diameter und Ejektionsfraktion , Linksschenkelblock und Vorhofflimmern , im EKG , QTc- und JTc-Dispersion , abnormale Time-domain-Analyse und spektrale Turbulenzanalyse des signalgemittelten EKG , ventrikulaere Arrhythmien und Herzfrequenzvariabilitaet im 24-Stunden-Langzeit-EKG, Baroreflexsensitivitaet und Mikrovolt-T-Wellen-Alternans unter Belastung .	[ "Die", "Marburger", "Kardiomyopathie", "-", "Studie", "(", "MACAS", ")", "wurde", "als", "prospektive", "Verlaufsbeobachtung", "konzipiert", ",", "um", "die", "Wertigkeit", "der", "folgenden", "potentiellen", "nichtinvasiven", "Arrhythmiepraediktoren", "bei", "ueber", "200", "Patienten", "mit", "dilatativer", "Kardiomyopathie", "(", "DCM", ")", "im", "Verlauf", "von", "fuenf", "Jahren", "zu", "untersuchen", ":", "Stadium", "der", "Herzinsuffizienz", "nach", "der", "Klassifikation", "der", "New", "York", "Heart", "Association", "linksventrikulaerer", "enddiastolischer", "Diameter", "und", "Ejektionsfraktion", ",", "Linksschenkelblock", "und", "Vorhofflimmern", ",", "im", "EKG", ",", "QTc-", "und", "JTc", "-", "Dispersion", ",", "abnormale", "Time", "-", "domain", "-", "Analyse", "und", "spektrale", "Turbulenzanalyse", "des", "signalgemittelten", "EKG", ",", "ventrikulaere", "Arrhythmien", "und", "Herzfrequenzvariabilitaet", "im", "24-Stunden", "-", "Langzeit", "-", "EKG", ",", "Baroreflexsensitivitaet", "und", "Mikrovolt", "-", "T", "-", "Wellen", "-", "Alternans", "unter", "Belastung", "." ]	[ "umlsterm" ]
perforin is a Protein, granzyme B is a Protein, IFN - gamma is a Protein, T - bet is a Protein, Eomes is a Protein, IFN - gamma is a Protein, T - bet is a Protein, CD8 is a Protein, IFN - gamma is a Protein, Prf1 is a Protein, GzmB is a Protein, T - bet is a Protein, CD8 is a Protein, Eomes - VP16 is a Protein, Eo - VP16 is a Protein, GFP is a Protein, Granzyme B is a Protein, IFN - gamma is a Protein, IFN - gamma is a Protein, Eo - VP16 is a Protein, GFP is a Protein	134_task0	Sentence: Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments.	[ "Regulation", "of", "perforin", ",", "granzyme", "B", ",", "and", "IFN", "-", "gamma", "expression", "by", "T", "-", "bet", "and", "Eomes", "in", "differentiating", "CTLs", ".", "(", "A", ")", "IFN", "-", "gamma", "expression", "by", "WT", "(", "Tbx21+/+", ")", "and", "T", "-", "bet", "-", "deficient", "(", "Tbx21-/-", ")", "T", "cells", ".", "Naive", "CD8", "+", "T", "cells", ",", "or", "cells", "activated", "and", "cultured", "for", "4", "or", "6", "d", ",", "were", "restimulated", "with", "PMA", "and", "ionomycin", "for", "6", "h", ",", "and", "IFN", "-", "gamma", "expression", "was", "assessed", "by", "intracellular", "staining", ".", "Numbers", "show", "the", "percentage", "of", "IFN", "-", "gamma+", "cells", ".", "(", "B", ")", "Northern", "blot", "analysis", "of", "Prf1", "and", "GzmB", "mRNA", "expression", "in", "WT", "or", "T", "-", "bet", "-", "deficient", "CD8", "+", "T", "cells", "activated", "and", "either", "left", "uninfected", "(", "uninf", ")", "or", "transduced", "with", "retroviruses", "expressing", "Eomes", "-", "VP16", "(", "Eo", "-", "VP16", ")", "or", "an", "empty", "IRES", "-", "GFP", "cassette", "(", "GFP", ")", ".", "Total", "cellular", "RNA", "was", "analyzed", "on", "day", "6", "of", "culture", ".", "The", "frequency", "of", "transduced", "cells", "in", "the", "cultures", "was", "equivalent", "for", "both", "constructs", "(", "~65", "-", "70", "%", "GFP+", "cells", ";", "not", "depicted", ")", ".", "(", "C", ")", "Granzyme", "B", "and", "IFN", "-", "gamma", "expression", "by", "Tbx21+/+", "and", "Tbx21-/-", "T", "cells", "analyzed", "in", "restimulated", "cells", "that", "had", "been", "cultured", "for", "5", "d.", "(", "D", ")", "IFN", "-", "gamma", "production", "by", "cells", "transduced", "with", "Eo", "-", "VP16", "or", "control", "(", "GFP", ")", "retroviruses", "(", "RV", ")", "measured", "on", "day", "4", "after", "6", "h", "of", "restimulation", "with", "PMA", "and", "ionomycin", ".", "Numbers", "show", "the", "percentage", "of", "GFP+", "IFN", "-", "gamma+", "cells", ".", "Results", "are", "representative", "of", "three", "(", "A", "and", "C", ")", "or", "two", "(", "B", "and", "D", ")", "independent", "experiments", "." ]	[ "Protein" ]
perforin is a Protein, granzyme B is a Protein, IFN - gamma is a Protein, T - bet is a Protein, Eomes is a Protein, IFN - gamma is a Protein, T - bet is a Protein, CD8 is a Protein, IFN - gamma is a Protein, Prf1 is a Protein, GzmB is a Protein, T - bet is a Protein, CD8 is a Protein, Eomes - VP16 is a Protein, Eo - VP16 is a Protein, GFP is a Protein, Granzyme B is a Protein, IFN - gamma is a Protein, IFN - gamma is a Protein, Eo - VP16 is a Protein, GFP is a Protein	134_task1	Sentence: Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments. Instructions: please typing these entity words according to sentence: perforin, granzyme B, IFN - gamma, T - bet, Eomes, IFN - gamma, T - bet, CD8, IFN - gamma, Prf1, GzmB, T - bet, CD8, Eomes - VP16, Eo - VP16, GFP, Granzyme B, IFN - gamma, IFN - gamma, Eo - VP16, GFP Options: Protein	[ "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments.	[ "Regulation", "of", "perforin", ",", "granzyme", "B", ",", "and", "IFN", "-", "gamma", "expression", "by", "T", "-", "bet", "and", "Eomes", "in", "differentiating", "CTLs", ".", "(", "A", ")", "IFN", "-", "gamma", "expression", "by", "WT", "(", "Tbx21+/+", ")", "and", "T", "-", "bet", "-", "deficient", "(", "Tbx21-/-", ")", "T", "cells", ".", "Naive", "CD8", "+", "T", "cells", ",", "or", "cells", "activated", "and", "cultured", "for", "4", "or", "6", "d", ",", "were", "restimulated", "with", "PMA", "and", "ionomycin", "for", "6", "h", ",", "and", "IFN", "-", "gamma", "expression", "was", "assessed", "by", "intracellular", "staining", ".", "Numbers", "show", "the", "percentage", "of", "IFN", "-", "gamma+", "cells", ".", "(", "B", ")", "Northern", "blot", "analysis", "of", "Prf1", "and", "GzmB", "mRNA", "expression", "in", "WT", "or", "T", "-", "bet", "-", "deficient", "CD8", "+", "T", "cells", "activated", "and", "either", "left", "uninfected", "(", "uninf", ")", "or", "transduced", "with", "retroviruses", "expressing", "Eomes", "-", "VP16", "(", "Eo", "-", "VP16", ")", "or", "an", "empty", "IRES", "-", "GFP", "cassette", "(", "GFP", ")", ".", "Total", "cellular", "RNA", "was", "analyzed", "on", "day", "6", "of", "culture", ".", "The", "frequency", "of", "transduced", "cells", "in", "the", "cultures", "was", "equivalent", "for", "both", "constructs", "(", "~65", "-", "70", "%", "GFP+", "cells", ";", "not", "depicted", ")", ".", "(", "C", ")", "Granzyme", "B", "and", "IFN", "-", "gamma", "expression", "by", "Tbx21+/+", "and", "Tbx21-/-", "T", "cells", "analyzed", "in", "restimulated", "cells", "that", "had", "been", "cultured", "for", "5", "d.", "(", "D", ")", "IFN", "-", "gamma", "production", "by", "cells", "transduced", "with", "Eo", "-", "VP16", "or", "control", "(", "GFP", ")", "retroviruses", "(", "RV", ")", "measured", "on", "day", "4", "after", "6", "h", "of", "restimulation", "with", "PMA", "and", "ionomycin", ".", "Numbers", "show", "the", "percentage", "of", "GFP+", "IFN", "-", "gamma+", "cells", ".", "Results", "are", "representative", "of", "three", "(", "A", "and", "C", ")", "or", "two", "(", "B", "and", "D", ")", "independent", "experiments", "." ]	[ "Protein" ]
perforin, granzyme B, IFN - gamma, T - bet, Eomes, IFN - gamma, T - bet, CD8, IFN - gamma, Prf1, GzmB, T - bet, CD8, Eomes - VP16, Eo - VP16, GFP, Granzyme B, IFN - gamma, IFN - gamma, Eo - VP16, GFP	134_task2	Sentence: Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments.	[ "Regulation", "of", "perforin", ",", "granzyme", "B", ",", "and", "IFN", "-", "gamma", "expression", "by", "T", "-", "bet", "and", "Eomes", "in", "differentiating", "CTLs", ".", "(", "A", ")", "IFN", "-", "gamma", "expression", "by", "WT", "(", "Tbx21+/+", ")", "and", "T", "-", "bet", "-", "deficient", "(", "Tbx21-/-", ")", "T", "cells", ".", "Naive", "CD8", "+", "T", "cells", ",", "or", "cells", "activated", "and", "cultured", "for", "4", "or", "6", "d", ",", "were", "restimulated", "with", "PMA", "and", "ionomycin", "for", "6", "h", ",", "and", "IFN", "-", "gamma", "expression", "was", "assessed", "by", "intracellular", "staining", ".", "Numbers", "show", "the", "percentage", "of", "IFN", "-", "gamma+", "cells", ".", "(", "B", ")", "Northern", "blot", "analysis", "of", "Prf1", "and", "GzmB", "mRNA", "expression", "in", "WT", "or", "T", "-", "bet", "-", "deficient", "CD8", "+", "T", "cells", "activated", "and", "either", "left", "uninfected", "(", "uninf", ")", "or", "transduced", "with", "retroviruses", "expressing", "Eomes", "-", "VP16", "(", "Eo", "-", "VP16", ")", "or", "an", "empty", "IRES", "-", "GFP", "cassette", "(", "GFP", ")", ".", "Total", "cellular", "RNA", "was", "analyzed", "on", "day", "6", "of", "culture", ".", "The", "frequency", "of", "transduced", "cells", "in", "the", "cultures", "was", "equivalent", "for", "both", "constructs", "(", "~65", "-", "70", "%", "GFP+", "cells", ";", "not", "depicted", ")", ".", "(", "C", ")", "Granzyme", "B", "and", "IFN", "-", "gamma", "expression", "by", "Tbx21+/+", "and", "Tbx21-/-", "T", "cells", "analyzed", "in", "restimulated", "cells", "that", "had", "been", "cultured", "for", "5", "d.", "(", "D", ")", "IFN", "-", "gamma", "production", "by", "cells", "transduced", "with", "Eo", "-", "VP16", "or", "control", "(", "GFP", ")", "retroviruses", "(", "RV", ")", "measured", "on", "day", "4", "after", "6", "h", "of", "restimulation", "with", "PMA", "and", "ionomycin", ".", "Numbers", "show", "the", "percentage", "of", "GFP+", "IFN", "-", "gamma+", "cells", ".", "Results", "are", "representative", "of", "three", "(", "A", "and", "C", ")", "or", "two", "(", "B", "and", "D", ")", "independent", "experiments", "." ]	[ "Protein" ]
care is an umlsterm, patients is an umlsterm, patients is an umlsterm, need is an umlsterm, care is an umlsterm, care is an umlsterm, psychiatric hospitals is an umlsterm, inpatient care is an umlsterm, care is an umlsterm, patients is an umlsterm, psychiatric nursing is an umlsterm, population is an umlsterm, patients is an umlsterm, homeless is an umlsterm, needs is an umlsterm, needs is an umlsterm, patients is an umlsterm, therapeutic is an umlsterm	DerNervenarzt.00710915.eng.abstr_task0	Sentence: Psychiatric care for chronic schizophrenic patients has improved in recent years , but for severely ill patients , often with multiple comorbid psychiatric conditions and in great need of care , the situation remains unsatisfactory . Community-based psychiatric care is limited and psychiatric hospitals are now cutting back on inpatient care . The quality of care that chronically mentally ill patients receive at independant psychiatric nursing homes removed from population centers is undetermined , and many patients end up in asylums or homeless shelters unable to provide for their psychiatric needs . Neither a reliable way to assess the needs of these complicated patients nor a scientific basis for therapeutic intervention exists yet . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Psychiatric care for chronic schizophrenic patients has improved in recent years , but for severely ill patients , often with multiple comorbid psychiatric conditions and in great need of care , the situation remains unsatisfactory . Community-based psychiatric care is limited and psychiatric hospitals are now cutting back on inpatient care . The quality of care that chronically mentally ill patients receive at independant psychiatric nursing homes removed from population centers is undetermined , and many patients end up in asylums or homeless shelters unable to provide for their psychiatric needs . Neither a reliable way to assess the needs of these complicated patients nor a scientific basis for therapeutic intervention exists yet .	[ "Psychiatric", "care", "for", "chronic", "schizophrenic", "patients", "has", "improved", "in", "recent", "years", ",", "but", "for", "severely", "ill", "patients", ",", "often", "with", "multiple", "comorbid", "psychiatric", "conditions", "and", "in", "great", "need", "of", "care", ",", "the", "situation", "remains", "unsatisfactory", ".", "Community", "-", "based", "psychiatric", "care", "is", "limited", "and", "psychiatric", "hospitals", "are", "now", "cutting", "back", "on", "inpatient", "care", ".", "The", "quality", "of", "care", "that", "chronically", "mentally", "ill", "patients", "receive", "at", "independant", "psychiatric", "nursing", "homes", "removed", "from", "population", "centers", "is", "undetermined", ",", "and", "many", "patients", "end", "up", "in", "asylums", "or", "homeless", "shelters", "unable", "to", "provide", "for", "their", "psychiatric", "needs", ".", "Neither", "a", "reliable", "way", "to", "assess", "the", "needs", "of", "these", "complicated", "patients", "nor", "a", "scientific", "basis", "for", "therapeutic", "intervention", "exists", "yet", "." ]	[ "umlsterm" ]
care is an umlsterm, patients is an umlsterm, patients is an umlsterm, need is an umlsterm, care is an umlsterm, care is an umlsterm, psychiatric hospitals is an umlsterm, inpatient care is an umlsterm, care is an umlsterm, patients is an umlsterm, psychiatric nursing is an umlsterm, population is an umlsterm, patients is an umlsterm, homeless is an umlsterm, needs is an umlsterm, needs is an umlsterm, patients is an umlsterm, therapeutic is an umlsterm	DerNervenarzt.00710915.eng.abstr_task1	Sentence: Psychiatric care for chronic schizophrenic patients has improved in recent years , but for severely ill patients , often with multiple comorbid psychiatric conditions and in great need of care , the situation remains unsatisfactory . Community-based psychiatric care is limited and psychiatric hospitals are now cutting back on inpatient care . The quality of care that chronically mentally ill patients receive at independant psychiatric nursing homes removed from population centers is undetermined , and many patients end up in asylums or homeless shelters unable to provide for their psychiatric needs . Neither a reliable way to assess the needs of these complicated patients nor a scientific basis for therapeutic intervention exists yet . Instructions: please typing these entity words according to sentence: care, patients, patients, need, care, care, psychiatric hospitals, inpatient care, care, patients, psychiatric nursing, population, patients, homeless, needs, needs, patients, therapeutic Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Psychiatric care for chronic schizophrenic patients has improved in recent years , but for severely ill patients , often with multiple comorbid psychiatric conditions and in great need of care , the situation remains unsatisfactory . Community-based psychiatric care is limited and psychiatric hospitals are now cutting back on inpatient care . The quality of care that chronically mentally ill patients receive at independant psychiatric nursing homes removed from population centers is undetermined , and many patients end up in asylums or homeless shelters unable to provide for their psychiatric needs . Neither a reliable way to assess the needs of these complicated patients nor a scientific basis for therapeutic intervention exists yet .	[ "Psychiatric", "care", "for", "chronic", "schizophrenic", "patients", "has", "improved", "in", "recent", "years", ",", "but", "for", "severely", "ill", "patients", ",", "often", "with", "multiple", "comorbid", "psychiatric", "conditions", "and", "in", "great", "need", "of", "care", ",", "the", "situation", "remains", "unsatisfactory", ".", "Community", "-", "based", "psychiatric", "care", "is", "limited", "and", "psychiatric", "hospitals", "are", "now", "cutting", "back", "on", "inpatient", "care", ".", "The", "quality", "of", "care", "that", "chronically", "mentally", "ill", "patients", "receive", "at", "independant", "psychiatric", "nursing", "homes", "removed", "from", "population", "centers", "is", "undetermined", ",", "and", "many", "patients", "end", "up", "in", "asylums", "or", "homeless", "shelters", "unable", "to", "provide", "for", "their", "psychiatric", "needs", ".", "Neither", "a", "reliable", "way", "to", "assess", "the", "needs", "of", "these", "complicated", "patients", "nor", "a", "scientific", "basis", "for", "therapeutic", "intervention", "exists", "yet", "." ]	[ "umlsterm" ]
care, patients, patients, need, care, care, psychiatric hospitals, inpatient care, care, patients, psychiatric nursing, population, patients, homeless, needs, needs, patients, therapeutic	DerNervenarzt.00710915.eng.abstr_task2	Sentence: Psychiatric care for chronic schizophrenic patients has improved in recent years , but for severely ill patients , often with multiple comorbid psychiatric conditions and in great need of care , the situation remains unsatisfactory . Community-based psychiatric care is limited and psychiatric hospitals are now cutting back on inpatient care . The quality of care that chronically mentally ill patients receive at independant psychiatric nursing homes removed from population centers is undetermined , and many patients end up in asylums or homeless shelters unable to provide for their psychiatric needs . Neither a reliable way to assess the needs of these complicated patients nor a scientific basis for therapeutic intervention exists yet . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Psychiatric care for chronic schizophrenic patients has improved in recent years , but for severely ill patients , often with multiple comorbid psychiatric conditions and in great need of care , the situation remains unsatisfactory . Community-based psychiatric care is limited and psychiatric hospitals are now cutting back on inpatient care . The quality of care that chronically mentally ill patients receive at independant psychiatric nursing homes removed from population centers is undetermined , and many patients end up in asylums or homeless shelters unable to provide for their psychiatric needs . Neither a reliable way to assess the needs of these complicated patients nor a scientific basis for therapeutic intervention exists yet .	[ "Psychiatric", "care", "for", "chronic", "schizophrenic", "patients", "has", "improved", "in", "recent", "years", ",", "but", "for", "severely", "ill", "patients", ",", "often", "with", "multiple", "comorbid", "psychiatric", "conditions", "and", "in", "great", "need", "of", "care", ",", "the", "situation", "remains", "unsatisfactory", ".", "Community", "-", "based", "psychiatric", "care", "is", "limited", "and", "psychiatric", "hospitals", "are", "now", "cutting", "back", "on", "inpatient", "care", ".", "The", "quality", "of", "care", "that", "chronically", "mentally", "ill", "patients", "receive", "at", "independant", "psychiatric", "nursing", "homes", "removed", "from", "population", "centers", "is", "undetermined", ",", "and", "many", "patients", "end", "up", "in", "asylums", "or", "homeless", "shelters", "unable", "to", "provide", "for", "their", "psychiatric", "needs", ".", "Neither", "a", "reliable", "way", "to", "assess", "the", "needs", "of", "these", "complicated", "patients", "nor", "a", "scientific", "basis", "for", "therapeutic", "intervention", "exists", "yet", "." ]	[ "umlsterm" ]
amphiphysin dimer is a protein-complex, clathrin is a protein-complex, α - adaptin is a protein, clathrin is a protein-complex, AP-2 is a protein-complex, dynamin 1 is a protein, synaptojanin 1 is a protein, clathrin is a protein-complex	1.0alpha7.train.449_task0	Sentence: The amphiphysin dimer also binds to clathrin (10, 11) and to the α-adaptin subunit of the plasma membrane clathrin adaptor AP-2 (9, 12) and thus may mediate recruitment of dynamin 1 and synaptojanin 1 to the site of clathrin-mediated endocytosis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-complex, protein	[ "O", "B-protein-complex", "I-protein-complex", "O", "O", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "B-protein-complex", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "I-protein", "O", "O", "O", "O", "B-protein-complex", "O", "O", "O", "O" ]	The amphiphysin dimer also binds to clathrin (10, 11) and to the α-adaptin subunit of the plasma membrane clathrin adaptor AP-2 (9, 12) and thus may mediate recruitment of dynamin 1 and synaptojanin 1 to the site of clathrin-mediated endocytosis.	[ "The", "amphiphysin", "dimer", "also", "binds", "to", "clathrin", "(", "10", ",", "11", ")", "and", "to", "the", "α", "-", "adaptin", "subunit", "of", "the", "plasma", "membrane", "clathrin", "adaptor", "AP-2", "(", "9", ",", "12", ")", "and", "thus", "may", "mediate", "recruitment", "of", "dynamin", "1", "and", "synaptojanin", "1", "to", "the", "site", "of", "clathrin", "-", "mediated", "endocytosis", "." ]	[ "protein-complex", "protein", "protein-family" ]
amphiphysin dimer is a protein-complex, clathrin is a protein-complex, α - adaptin is a protein, clathrin is a protein-complex, AP-2 is a protein-complex, dynamin 1 is a protein, synaptojanin 1 is a protein, clathrin is a protein-complex	1.0alpha7.train.449_task1	Sentence: The amphiphysin dimer also binds to clathrin (10, 11) and to the α-adaptin subunit of the plasma membrane clathrin adaptor AP-2 (9, 12) and thus may mediate recruitment of dynamin 1 and synaptojanin 1 to the site of clathrin-mediated endocytosis. Instructions: please typing these entity words according to sentence: amphiphysin dimer, clathrin, α - adaptin, clathrin, AP-2, dynamin 1, synaptojanin 1, clathrin Options: protein-complex, protein	[ "O", "B-protein-complex", "I-protein-complex", "O", "O", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "B-protein-complex", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "I-protein", "O", "O", "O", "O", "B-protein-complex", "O", "O", "O", "O" ]	The amphiphysin dimer also binds to clathrin (10, 11) and to the α-adaptin subunit of the plasma membrane clathrin adaptor AP-2 (9, 12) and thus may mediate recruitment of dynamin 1 and synaptojanin 1 to the site of clathrin-mediated endocytosis.	[ "The", "amphiphysin", "dimer", "also", "binds", "to", "clathrin", "(", "10", ",", "11", ")", "and", "to", "the", "α", "-", "adaptin", "subunit", "of", "the", "plasma", "membrane", "clathrin", "adaptor", "AP-2", "(", "9", ",", "12", ")", "and", "thus", "may", "mediate", "recruitment", "of", "dynamin", "1", "and", "synaptojanin", "1", "to", "the", "site", "of", "clathrin", "-", "mediated", "endocytosis", "." ]	[ "protein-complex", "protein", "protein-family" ]
amphiphysin dimer, clathrin, α - adaptin, clathrin, AP-2, dynamin 1, synaptojanin 1, clathrin	1.0alpha7.train.449_task2	Sentence: The amphiphysin dimer also binds to clathrin (10, 11) and to the α-adaptin subunit of the plasma membrane clathrin adaptor AP-2 (9, 12) and thus may mediate recruitment of dynamin 1 and synaptojanin 1 to the site of clathrin-mediated endocytosis. Instructions: please extract entity words from the input sentence	[ "O", "B-protein-complex", "I-protein-complex", "O", "O", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "B-protein-complex", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "I-protein", "O", "O", "O", "O", "B-protein-complex", "O", "O", "O", "O" ]	The amphiphysin dimer also binds to clathrin (10, 11) and to the α-adaptin subunit of the plasma membrane clathrin adaptor AP-2 (9, 12) and thus may mediate recruitment of dynamin 1 and synaptojanin 1 to the site of clathrin-mediated endocytosis.	[ "The", "amphiphysin", "dimer", "also", "binds", "to", "clathrin", "(", "10", ",", "11", ")", "and", "to", "the", "α", "-", "adaptin", "subunit", "of", "the", "plasma", "membrane", "clathrin", "adaptor", "AP-2", "(", "9", ",", "12", ")", "and", "thus", "may", "mediate", "recruitment", "of", "dynamin", "1", "and", "synaptojanin", "1", "to", "the", "site", "of", "clathrin", "-", "mediated", "endocytosis", "." ]	[ "protein-complex", "protein", "protein-family" ]
Neuropeptide S is a GENE-Y, MK801 is a CHEMICAL, scopolamine is a CHEMICAL, Aβ1 - 42 is a GENE-Y	23454528_task0	Sentence: Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks.	[ "Neuropeptide", "S", "enhances", "memory", "and", "mitigates", "memory", "impairment", "induced", "by", "MK801", ",", "scopolamine", "or", "Aβ1", "-", "42", "in", "mice", "novel", "object", "and", "object", "location", "recognition", "tasks", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Neuropeptide S is a GENE-Y, MK801 is a CHEMICAL, scopolamine is a CHEMICAL, Aβ1 - 42 is a GENE-Y	23454528_task1	Sentence: Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks. Instructions: please typing these entity words according to sentence: Neuropeptide S, MK801, scopolamine, Aβ1 - 42 Options: GENE-Y, CHEMICAL	[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks.	[ "Neuropeptide", "S", "enhances", "memory", "and", "mitigates", "memory", "impairment", "induced", "by", "MK801", ",", "scopolamine", "or", "Aβ1", "-", "42", "in", "mice", "novel", "object", "and", "object", "location", "recognition", "tasks", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Neuropeptide S, MK801, scopolamine, Aβ1 - 42	23454528_task2	Sentence: Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks. Instructions: please extract entity words from the input sentence	[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks.	[ "Neuropeptide", "S", "enhances", "memory", "and", "mitigates", "memory", "impairment", "induced", "by", "MK801", ",", "scopolamine", "or", "Aβ1", "-", "42", "in", "mice", "novel", "object", "and", "object", "location", "recognition", "tasks", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Patienten is an umlsterm, malignem Melanom is an umlsterm, Diagnose is an umlsterm, Melanompatienten is an umlsterm, Behandlung is an umlsterm, Melanompatienten is an umlsterm, Patienten is an umlsterm, Tumordicke is an umlsterm, Lymphadenektomie is an umlsterm, Patienten is an umlsterm, Trends is an umlsterm, Tumoren is an umlsterm	DerHautarzt.50460762.ger.abstr_task0	Sentence: Mehr als 90% aller Patienten mit malignem Melanom kamen waehrend der letzten Dekade mit einem Primaertumor allein zur ersten Diagnose . Die operative Versorgung des Primaertumors war daher fuer Melanompatienten die entscheidende Behandlungsmassnahme . Die vorliegende Untersuchung hatte zum Ziel , die Anwendung verschiedener Vorgehensweisen im deutschen Sprachraum zu dokumentieren und ihre Entwicklung waehrend der Jahre 1983-1993 zu analysieren . Insgesamt wurde die Behandlung von 15054 Melanompatienten in den Stadien I und II ( Primaertumor allein ) untersucht . Im genannten Zeitraum nahm der Anteil zweizeitiger operativer Versorgungen von ca. 30% auf 60% zu . Eine Lokalanaesthesie wurde 1983 bei ca. 40% der Patienten durchgefuehrt , im Jahre 1993 war der Anteil der Erstversorgung in Lokalanaesthesie auf ca. 80% angestiegen . Gleichzeitig nahm der mittlere Sicherheitsabstand bei operativer Versorgung des Primaertumors 33 mm auf 21 mm ab , wobei auch die Tumordicke im Durchschnitt von 2,1 auf 1,5 mm abnahm . Die elektive Lymphadenektomie wurde 1983 bei etwa 5% aller Patienten , 1993 dagegen bei 9% aller Kranken durchgefuehrt . Insgesamt unterschied sich das therapeutische Vorgehen in den verschiedenen Zentren bei vergleichbaren Indikationsstellungen erheblich voneinander . Zusammenfassend hat im genannten Zeitraum ein Wandel des therapeutischen Vorgehens im deutschsprachigen Raum stattgefunden , mit staerkerer Bevorzugung eines zweizeitigen operativen Vorgehens mit Erstversorgung in Lokalanaesthesie und der Wahl kleinerer Sicherheitsabstaende . Gruende fuer diese Trends im therapeutischen Vorgehen sind sowohl in der deutlich verbesserten Frueherkennung der behandelten Tumoren , als auch in einer Aenderung konzeptioneller therapeutischen Vorstellungen zu suchen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mehr als 90% aller Patienten mit malignem Melanom kamen waehrend der letzten Dekade mit einem Primaertumor allein zur ersten Diagnose . Die operative Versorgung des Primaertumors war daher fuer Melanompatienten die entscheidende Behandlungsmassnahme . Die vorliegende Untersuchung hatte zum Ziel , die Anwendung verschiedener Vorgehensweisen im deutschen Sprachraum zu dokumentieren und ihre Entwicklung waehrend der Jahre 1983-1993 zu analysieren . Insgesamt wurde die Behandlung von 15054 Melanompatienten in den Stadien I und II ( Primaertumor allein ) untersucht . Im genannten Zeitraum nahm der Anteil zweizeitiger operativer Versorgungen von ca. 30% auf 60% zu . Eine Lokalanaesthesie wurde 1983 bei ca. 40% der Patienten durchgefuehrt , im Jahre 1993 war der Anteil der Erstversorgung in Lokalanaesthesie auf ca. 80% angestiegen . Gleichzeitig nahm der mittlere Sicherheitsabstand bei operativer Versorgung des Primaertumors 33 mm auf 21 mm ab , wobei auch die Tumordicke im Durchschnitt von 2,1 auf 1,5 mm abnahm . Die elektive Lymphadenektomie wurde 1983 bei etwa 5% aller Patienten , 1993 dagegen bei 9% aller Kranken durchgefuehrt . Insgesamt unterschied sich das therapeutische Vorgehen in den verschiedenen Zentren bei vergleichbaren Indikationsstellungen erheblich voneinander . Zusammenfassend hat im genannten Zeitraum ein Wandel des therapeutischen Vorgehens im deutschsprachigen Raum stattgefunden , mit staerkerer Bevorzugung eines zweizeitigen operativen Vorgehens mit Erstversorgung in Lokalanaesthesie und der Wahl kleinerer Sicherheitsabstaende . Gruende fuer diese Trends im therapeutischen Vorgehen sind sowohl in der deutlich verbesserten Frueherkennung der behandelten Tumoren , als auch in einer Aenderung konzeptioneller therapeutischen Vorstellungen zu suchen .	[ "Mehr", "als", "90", "%", "aller", "Patienten", "mit", "malignem", "Melanom", "kamen", "waehrend", "der", "letzten", "Dekade", "mit", "einem", "Primaertumor", "allein", "zur", "ersten", "Diagnose", ".", "Die", "operative", "Versorgung", "des", "Primaertumors", "war", "daher", "fuer", "Melanompatienten", "die", "entscheidende", "Behandlungsmassnahme", ".", "Die", "vorliegende", "Untersuchung", "hatte", "zum", "Ziel", ",", "die", "Anwendung", "verschiedener", "Vorgehensweisen", "im", "deutschen", "Sprachraum", "zu", "dokumentieren", "und", "ihre", "Entwicklung", "waehrend", "der", "Jahre", "1983", "-", "1993", "zu", "analysieren", ".", "Insgesamt", "wurde", "die", "Behandlung", "von", "15054", "Melanompatienten", "in", "den", "Stadien", "I", "und", "II", "(", "Primaertumor", "allein", ")", "untersucht", ".", "Im", "genannten", "Zeitraum", "nahm", "der", "Anteil", "zweizeitiger", "operativer", "Versorgungen", "von", "ca", ".", "30", "%", "auf", "60", "%", "zu", ".", "Eine", "Lokalanaesthesie", "wurde", "1983", "bei", "ca", ".", "40", "%", "der", "Patienten", "durchgefuehrt", ",", "im", "Jahre", "1993", "war", "der", "Anteil", "der", "Erstversorgung", "in", "Lokalanaesthesie", "auf", "ca", ".", "80", "%", "angestiegen", ".", "Gleichzeitig", "nahm", "der", "mittlere", "Sicherheitsabstand", "bei", "operativer", "Versorgung", "des", "Primaertumors", "33", "mm", "auf", "21", "mm", "ab", ",", "wobei", "auch", "die", "Tumordicke", "im", "Durchschnitt", "von", "2,1", "auf", "1,5", "mm", "abnahm", ".", "Die", "elektive", "Lymphadenektomie", "wurde", "1983", "bei", "etwa", "5", "%", "aller", "Patienten", ",", "1993", "dagegen", "bei", "9", "%", "aller", "Kranken", "durchgefuehrt", ".", "Insgesamt", "unterschied", "sich", "das", "therapeutische", "Vorgehen", "in", "den", "verschiedenen", "Zentren", "bei", "vergleichbaren", "Indikationsstellungen", "erheblich", "voneinander", ".", "Zusammenfassend", "hat", "im", "genannten", "Zeitraum", "ein", "Wandel", "des", "therapeutischen", "Vorgehens", "im", "deutschsprachigen", "Raum", "stattgefunden", ",", "mit", "staerkerer", "Bevorzugung", "eines", "zweizeitigen", "operativen", "Vorgehens", "mit", "Erstversorgung", "in", "Lokalanaesthesie", "und", "der", "Wahl", "kleinerer", "Sicherheitsabstaende", ".", "Gruende", "fuer", "diese", "Trends", "im", "therapeutischen", "Vorgehen", "sind", "sowohl", "in", "der", "deutlich", "verbesserten", "Frueherkennung", "der", "behandelten", "Tumoren", ",", "als", "auch", "in", "einer", "Aenderung", "konzeptioneller", "therapeutischen", "Vorstellungen", "zu", "suchen", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, malignem Melanom is an umlsterm, Diagnose is an umlsterm, Melanompatienten is an umlsterm, Behandlung is an umlsterm, Melanompatienten is an umlsterm, Patienten is an umlsterm, Tumordicke is an umlsterm, Lymphadenektomie is an umlsterm, Patienten is an umlsterm, Trends is an umlsterm, Tumoren is an umlsterm	DerHautarzt.50460762.ger.abstr_task1	Sentence: Mehr als 90% aller Patienten mit malignem Melanom kamen waehrend der letzten Dekade mit einem Primaertumor allein zur ersten Diagnose . Die operative Versorgung des Primaertumors war daher fuer Melanompatienten die entscheidende Behandlungsmassnahme . Die vorliegende Untersuchung hatte zum Ziel , die Anwendung verschiedener Vorgehensweisen im deutschen Sprachraum zu dokumentieren und ihre Entwicklung waehrend der Jahre 1983-1993 zu analysieren . Insgesamt wurde die Behandlung von 15054 Melanompatienten in den Stadien I und II ( Primaertumor allein ) untersucht . Im genannten Zeitraum nahm der Anteil zweizeitiger operativer Versorgungen von ca. 30% auf 60% zu . Eine Lokalanaesthesie wurde 1983 bei ca. 40% der Patienten durchgefuehrt , im Jahre 1993 war der Anteil der Erstversorgung in Lokalanaesthesie auf ca. 80% angestiegen . Gleichzeitig nahm der mittlere Sicherheitsabstand bei operativer Versorgung des Primaertumors 33 mm auf 21 mm ab , wobei auch die Tumordicke im Durchschnitt von 2,1 auf 1,5 mm abnahm . Die elektive Lymphadenektomie wurde 1983 bei etwa 5% aller Patienten , 1993 dagegen bei 9% aller Kranken durchgefuehrt . Insgesamt unterschied sich das therapeutische Vorgehen in den verschiedenen Zentren bei vergleichbaren Indikationsstellungen erheblich voneinander . Zusammenfassend hat im genannten Zeitraum ein Wandel des therapeutischen Vorgehens im deutschsprachigen Raum stattgefunden , mit staerkerer Bevorzugung eines zweizeitigen operativen Vorgehens mit Erstversorgung in Lokalanaesthesie und der Wahl kleinerer Sicherheitsabstaende . Gruende fuer diese Trends im therapeutischen Vorgehen sind sowohl in der deutlich verbesserten Frueherkennung der behandelten Tumoren , als auch in einer Aenderung konzeptioneller therapeutischen Vorstellungen zu suchen . Instructions: please typing these entity words according to sentence: Patienten, malignem Melanom, Diagnose, Melanompatienten, Behandlung, Melanompatienten, Patienten, Tumordicke, Lymphadenektomie, Patienten, Trends, Tumoren Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mehr als 90% aller Patienten mit malignem Melanom kamen waehrend der letzten Dekade mit einem Primaertumor allein zur ersten Diagnose . Die operative Versorgung des Primaertumors war daher fuer Melanompatienten die entscheidende Behandlungsmassnahme . Die vorliegende Untersuchung hatte zum Ziel , die Anwendung verschiedener Vorgehensweisen im deutschen Sprachraum zu dokumentieren und ihre Entwicklung waehrend der Jahre 1983-1993 zu analysieren . Insgesamt wurde die Behandlung von 15054 Melanompatienten in den Stadien I und II ( Primaertumor allein ) untersucht . Im genannten Zeitraum nahm der Anteil zweizeitiger operativer Versorgungen von ca. 30% auf 60% zu . Eine Lokalanaesthesie wurde 1983 bei ca. 40% der Patienten durchgefuehrt , im Jahre 1993 war der Anteil der Erstversorgung in Lokalanaesthesie auf ca. 80% angestiegen . Gleichzeitig nahm der mittlere Sicherheitsabstand bei operativer Versorgung des Primaertumors 33 mm auf 21 mm ab , wobei auch die Tumordicke im Durchschnitt von 2,1 auf 1,5 mm abnahm . Die elektive Lymphadenektomie wurde 1983 bei etwa 5% aller Patienten , 1993 dagegen bei 9% aller Kranken durchgefuehrt . Insgesamt unterschied sich das therapeutische Vorgehen in den verschiedenen Zentren bei vergleichbaren Indikationsstellungen erheblich voneinander . Zusammenfassend hat im genannten Zeitraum ein Wandel des therapeutischen Vorgehens im deutschsprachigen Raum stattgefunden , mit staerkerer Bevorzugung eines zweizeitigen operativen Vorgehens mit Erstversorgung in Lokalanaesthesie und der Wahl kleinerer Sicherheitsabstaende . Gruende fuer diese Trends im therapeutischen Vorgehen sind sowohl in der deutlich verbesserten Frueherkennung der behandelten Tumoren , als auch in einer Aenderung konzeptioneller therapeutischen Vorstellungen zu suchen .	[ "Mehr", "als", "90", "%", "aller", "Patienten", "mit", "malignem", "Melanom", "kamen", "waehrend", "der", "letzten", "Dekade", "mit", "einem", "Primaertumor", "allein", "zur", "ersten", "Diagnose", ".", "Die", "operative", "Versorgung", "des", "Primaertumors", "war", "daher", "fuer", "Melanompatienten", "die", "entscheidende", "Behandlungsmassnahme", ".", "Die", "vorliegende", "Untersuchung", "hatte", "zum", "Ziel", ",", "die", "Anwendung", "verschiedener", "Vorgehensweisen", "im", "deutschen", "Sprachraum", "zu", "dokumentieren", "und", "ihre", "Entwicklung", "waehrend", "der", "Jahre", "1983", "-", "1993", "zu", "analysieren", ".", "Insgesamt", "wurde", "die", "Behandlung", "von", "15054", "Melanompatienten", "in", "den", "Stadien", "I", "und", "II", "(", "Primaertumor", "allein", ")", "untersucht", ".", "Im", "genannten", "Zeitraum", "nahm", "der", "Anteil", "zweizeitiger", "operativer", "Versorgungen", "von", "ca", ".", "30", "%", "auf", "60", "%", "zu", ".", "Eine", "Lokalanaesthesie", "wurde", "1983", "bei", "ca", ".", "40", "%", "der", "Patienten", "durchgefuehrt", ",", "im", "Jahre", "1993", "war", "der", "Anteil", "der", "Erstversorgung", "in", "Lokalanaesthesie", "auf", "ca", ".", "80", "%", "angestiegen", ".", "Gleichzeitig", "nahm", "der", "mittlere", "Sicherheitsabstand", "bei", "operativer", "Versorgung", "des", "Primaertumors", "33", "mm", "auf", "21", "mm", "ab", ",", "wobei", "auch", "die", "Tumordicke", "im", "Durchschnitt", "von", "2,1", "auf", "1,5", "mm", "abnahm", ".", "Die", "elektive", "Lymphadenektomie", "wurde", "1983", "bei", "etwa", "5", "%", "aller", "Patienten", ",", "1993", "dagegen", "bei", "9", "%", "aller", "Kranken", "durchgefuehrt", ".", "Insgesamt", "unterschied", "sich", "das", "therapeutische", "Vorgehen", "in", "den", "verschiedenen", "Zentren", "bei", "vergleichbaren", "Indikationsstellungen", "erheblich", "voneinander", ".", "Zusammenfassend", "hat", "im", "genannten", "Zeitraum", "ein", "Wandel", "des", "therapeutischen", "Vorgehens", "im", "deutschsprachigen", "Raum", "stattgefunden", ",", "mit", "staerkerer", "Bevorzugung", "eines", "zweizeitigen", "operativen", "Vorgehens", "mit", "Erstversorgung", "in", "Lokalanaesthesie", "und", "der", "Wahl", "kleinerer", "Sicherheitsabstaende", ".", "Gruende", "fuer", "diese", "Trends", "im", "therapeutischen", "Vorgehen", "sind", "sowohl", "in", "der", "deutlich", "verbesserten", "Frueherkennung", "der", "behandelten", "Tumoren", ",", "als", "auch", "in", "einer", "Aenderung", "konzeptioneller", "therapeutischen", "Vorstellungen", "zu", "suchen", "." ]	[ "umlsterm" ]
Patienten, malignem Melanom, Diagnose, Melanompatienten, Behandlung, Melanompatienten, Patienten, Tumordicke, Lymphadenektomie, Patienten, Trends, Tumoren	DerHautarzt.50460762.ger.abstr_task2	Sentence: Mehr als 90% aller Patienten mit malignem Melanom kamen waehrend der letzten Dekade mit einem Primaertumor allein zur ersten Diagnose . Die operative Versorgung des Primaertumors war daher fuer Melanompatienten die entscheidende Behandlungsmassnahme . Die vorliegende Untersuchung hatte zum Ziel , die Anwendung verschiedener Vorgehensweisen im deutschen Sprachraum zu dokumentieren und ihre Entwicklung waehrend der Jahre 1983-1993 zu analysieren . Insgesamt wurde die Behandlung von 15054 Melanompatienten in den Stadien I und II ( Primaertumor allein ) untersucht . Im genannten Zeitraum nahm der Anteil zweizeitiger operativer Versorgungen von ca. 30% auf 60% zu . Eine Lokalanaesthesie wurde 1983 bei ca. 40% der Patienten durchgefuehrt , im Jahre 1993 war der Anteil der Erstversorgung in Lokalanaesthesie auf ca. 80% angestiegen . Gleichzeitig nahm der mittlere Sicherheitsabstand bei operativer Versorgung des Primaertumors 33 mm auf 21 mm ab , wobei auch die Tumordicke im Durchschnitt von 2,1 auf 1,5 mm abnahm . Die elektive Lymphadenektomie wurde 1983 bei etwa 5% aller Patienten , 1993 dagegen bei 9% aller Kranken durchgefuehrt . Insgesamt unterschied sich das therapeutische Vorgehen in den verschiedenen Zentren bei vergleichbaren Indikationsstellungen erheblich voneinander . Zusammenfassend hat im genannten Zeitraum ein Wandel des therapeutischen Vorgehens im deutschsprachigen Raum stattgefunden , mit staerkerer Bevorzugung eines zweizeitigen operativen Vorgehens mit Erstversorgung in Lokalanaesthesie und der Wahl kleinerer Sicherheitsabstaende . Gruende fuer diese Trends im therapeutischen Vorgehen sind sowohl in der deutlich verbesserten Frueherkennung der behandelten Tumoren , als auch in einer Aenderung konzeptioneller therapeutischen Vorstellungen zu suchen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Mehr als 90% aller Patienten mit malignem Melanom kamen waehrend der letzten Dekade mit einem Primaertumor allein zur ersten Diagnose . Die operative Versorgung des Primaertumors war daher fuer Melanompatienten die entscheidende Behandlungsmassnahme . Die vorliegende Untersuchung hatte zum Ziel , die Anwendung verschiedener Vorgehensweisen im deutschen Sprachraum zu dokumentieren und ihre Entwicklung waehrend der Jahre 1983-1993 zu analysieren . Insgesamt wurde die Behandlung von 15054 Melanompatienten in den Stadien I und II ( Primaertumor allein ) untersucht . Im genannten Zeitraum nahm der Anteil zweizeitiger operativer Versorgungen von ca. 30% auf 60% zu . Eine Lokalanaesthesie wurde 1983 bei ca. 40% der Patienten durchgefuehrt , im Jahre 1993 war der Anteil der Erstversorgung in Lokalanaesthesie auf ca. 80% angestiegen . Gleichzeitig nahm der mittlere Sicherheitsabstand bei operativer Versorgung des Primaertumors 33 mm auf 21 mm ab , wobei auch die Tumordicke im Durchschnitt von 2,1 auf 1,5 mm abnahm . Die elektive Lymphadenektomie wurde 1983 bei etwa 5% aller Patienten , 1993 dagegen bei 9% aller Kranken durchgefuehrt . Insgesamt unterschied sich das therapeutische Vorgehen in den verschiedenen Zentren bei vergleichbaren Indikationsstellungen erheblich voneinander . Zusammenfassend hat im genannten Zeitraum ein Wandel des therapeutischen Vorgehens im deutschsprachigen Raum stattgefunden , mit staerkerer Bevorzugung eines zweizeitigen operativen Vorgehens mit Erstversorgung in Lokalanaesthesie und der Wahl kleinerer Sicherheitsabstaende . Gruende fuer diese Trends im therapeutischen Vorgehen sind sowohl in der deutlich verbesserten Frueherkennung der behandelten Tumoren , als auch in einer Aenderung konzeptioneller therapeutischen Vorstellungen zu suchen .	[ "Mehr", "als", "90", "%", "aller", "Patienten", "mit", "malignem", "Melanom", "kamen", "waehrend", "der", "letzten", "Dekade", "mit", "einem", "Primaertumor", "allein", "zur", "ersten", "Diagnose", ".", "Die", "operative", "Versorgung", "des", "Primaertumors", "war", "daher", "fuer", "Melanompatienten", "die", "entscheidende", "Behandlungsmassnahme", ".", "Die", "vorliegende", "Untersuchung", "hatte", "zum", "Ziel", ",", "die", "Anwendung", "verschiedener", "Vorgehensweisen", "im", "deutschen", "Sprachraum", "zu", "dokumentieren", "und", "ihre", "Entwicklung", "waehrend", "der", "Jahre", "1983", "-", "1993", "zu", "analysieren", ".", "Insgesamt", "wurde", "die", "Behandlung", "von", "15054", "Melanompatienten", "in", "den", "Stadien", "I", "und", "II", "(", "Primaertumor", "allein", ")", "untersucht", ".", "Im", "genannten", "Zeitraum", "nahm", "der", "Anteil", "zweizeitiger", "operativer", "Versorgungen", "von", "ca", ".", "30", "%", "auf", "60", "%", "zu", ".", "Eine", "Lokalanaesthesie", "wurde", "1983", "bei", "ca", ".", "40", "%", "der", "Patienten", "durchgefuehrt", ",", "im", "Jahre", "1993", "war", "der", "Anteil", "der", "Erstversorgung", "in", "Lokalanaesthesie", "auf", "ca", ".", "80", "%", "angestiegen", ".", "Gleichzeitig", "nahm", "der", "mittlere", "Sicherheitsabstand", "bei", "operativer", "Versorgung", "des", "Primaertumors", "33", "mm", "auf", "21", "mm", "ab", ",", "wobei", "auch", "die", "Tumordicke", "im", "Durchschnitt", "von", "2,1", "auf", "1,5", "mm", "abnahm", ".", "Die", "elektive", "Lymphadenektomie", "wurde", "1983", "bei", "etwa", "5", "%", "aller", "Patienten", ",", "1993", "dagegen", "bei", "9", "%", "aller", "Kranken", "durchgefuehrt", ".", "Insgesamt", "unterschied", "sich", "das", "therapeutische", "Vorgehen", "in", "den", "verschiedenen", "Zentren", "bei", "vergleichbaren", "Indikationsstellungen", "erheblich", "voneinander", ".", "Zusammenfassend", "hat", "im", "genannten", "Zeitraum", "ein", "Wandel", "des", "therapeutischen", "Vorgehens", "im", "deutschsprachigen", "Raum", "stattgefunden", ",", "mit", "staerkerer", "Bevorzugung", "eines", "zweizeitigen", "operativen", "Vorgehens", "mit", "Erstversorgung", "in", "Lokalanaesthesie", "und", "der", "Wahl", "kleinerer", "Sicherheitsabstaende", ".", "Gruende", "fuer", "diese", "Trends", "im", "therapeutischen", "Vorgehen", "sind", "sowohl", "in", "der", "deutlich", "verbesserten", "Frueherkennung", "der", "behandelten", "Tumoren", ",", "als", "auch", "in", "einer", "Aenderung", "konzeptioneller", "therapeutischen", "Vorstellungen", "zu", "suchen", "." ]	[ "umlsterm" ]
care is an umlsterm, patients is an umlsterm, multiple injuries is an umlsterm, identification is an umlsterm, baseline is an umlsterm, treatment is an umlsterm, documentation is an umlsterm, treatment is an umlsterm, emergency is an umlsterm, set is an umlsterm, baseline is an umlsterm, treatment is an umlsterm, patients is an umlsterm, algorithm is an umlsterm, criteria is an umlsterm, judgement is an umlsterm, care is an umlsterm, algorithm is an umlsterm, single is an umlsterm, criterion is an umlsterm, procedure is an umlsterm, patient is an umlsterm, judgement is an umlsterm, criteria is an umlsterm, assessment is an umlsterm, baseline is an umlsterm, times is an umlsterm, trauma is an umlsterm, trauma is an umlsterm, time is an umlsterm, patients is an umlsterm, blood is an umlsterm, computerised tomography is an umlsterm, injuries is an umlsterm, trauma is an umlsterm, period is an umlsterm, patients is an umlsterm, intubation is an umlsterm, chest tube is an umlsterm, blood transfusion is an umlsterm, shock is an umlsterm, blood is an umlsterm, emergency is an umlsterm, operations is an umlsterm, shock is an umlsterm, operations is an umlsterm, craniotomy is an umlsterm, surgery is an umlsterm, intensive care unit is an umlsterm, patients is an umlsterm, care is an umlsterm, patients is an umlsterm, indicators is an umlsterm, emergency is an umlsterm, baseline is an umlsterm, measures is an umlsterm, data collection is an umlsterm, exact is an umlsterm, analysis is an umlsterm	DerUnfallchirurg.71000811.eng.abstr_task0	Sentence: Quality management in early clinical care of patients with multiple injuries ( description of actual process , identification of problems , implementation of quality improvement ) is not possible without sufficient baseline data about the present situation of medical treatment . This study investigates whether the current documentation of treatment in the emergency room is appropriate to judge upon the quality of the process and to detect problems . In addition , a set of baseline data is presented . The performance in the treatment of 126 multiple injured patients was prospectively recorded from 1988 to 1993 and compared with an idealized process based upon an algorithm . The quality of present data recording was analysed , and criteria for judgement of quality of care were assessed . The algorithm was devided into 117 possible steps ( one step consisting of a single decision criterion , the decision and the corresponding procedure ) . Per patient , only 61 % +/- 12 % of these steps were sufficiently documented to allow judgement . Using several criteria for assessment , the following baseline data could be observed ( times shown refer to admission to the trauma room ) : ( 1 ) trauma room time of 129 +/- 55 min ; ( 2 ) completition of basic radiological and sonographic diagnostics in 91 % of patients ; ( 3 ) first blood collection after 17 +/- 11 min ; ( 4 ) cranial computerised tomography after 55 +/- 20 min ; ( 5 ) missed injuries during the trauma room period in 32 % of patients ; ( 6 ) intubation after 20 +/- 19 min ; ( 7 ) insertion of a chest tube after 30 +/- 17 min ; ( 8 ) first blood transfusion in shock after 32 +/- 17 min ; ( 9 ) transfused blood within the first hour of 4.2 +/- 2.8 units and within the second hour of 8.5 +/- 4.7 units ; ( 10 ) emergency operations in shock after 98 +/- 55 min ; ( 11 ) early operations after 156 +/- 69 min ; ( 12 ) craniotomy after 124 +/- 37 min ; ( 13 ) unplanned surgery within 24 hours after admission to the intensive care unit in 11 % of patients . The study presented here supplies information on timing and other process data of the acute clinical care of seriously injured patients . In particular , the data represent indicators for the quality of emergency room management , which may be used as a baseline to compose improvement measures of structure and process . The quality of data collection has to be improved for carrying out an exact analysis of the process . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O" ]	Quality management in early clinical care of patients with multiple injuries ( description of actual process , identification of problems , implementation of quality improvement ) is not possible without sufficient baseline data about the present situation of medical treatment . This study investigates whether the current documentation of treatment in the emergency room is appropriate to judge upon the quality of the process and to detect problems . In addition , a set of baseline data is presented . The performance in the treatment of 126 multiple injured patients was prospectively recorded from 1988 to 1993 and compared with an idealized process based upon an algorithm . The quality of present data recording was analysed , and criteria for judgement of quality of care were assessed . The algorithm was devided into 117 possible steps ( one step consisting of a single decision criterion , the decision and the corresponding procedure ) . Per patient , only 61 % +/- 12 % of these steps were sufficiently documented to allow judgement . Using several criteria for assessment , the following baseline data could be observed ( times shown refer to admission to the trauma room ) : ( 1 ) trauma room time of 129 +/- 55 min ; ( 2 ) completition of basic radiological and sonographic diagnostics in 91 % of patients ; ( 3 ) first blood collection after 17 +/- 11 min ; ( 4 ) cranial computerised tomography after 55 +/- 20 min ; ( 5 ) missed injuries during the trauma room period in 32 % of patients ; ( 6 ) intubation after 20 +/- 19 min ; ( 7 ) insertion of a chest tube after 30 +/- 17 min ; ( 8 ) first blood transfusion in shock after 32 +/- 17 min ; ( 9 ) transfused blood within the first hour of 4.2 +/- 2.8 units and within the second hour of 8.5 +/- 4.7 units ; ( 10 ) emergency operations in shock after 98 +/- 55 min ; ( 11 ) early operations after 156 +/- 69 min ; ( 12 ) craniotomy after 124 +/- 37 min ; ( 13 ) unplanned surgery within 24 hours after admission to the intensive care unit in 11 % of patients . The study presented here supplies information on timing and other process data of the acute clinical care of seriously injured patients . In particular , the data represent indicators for the quality of emergency room management , which may be used as a baseline to compose improvement measures of structure and process . The quality of data collection has to be improved for carrying out an exact analysis of the process .	[ "Quality", "management", "in", "early", "clinical", "care", "of", "patients", "with", "multiple", "injuries", "(", "description", "of", "actual", "process", ",", "identification", "of", "problems", ",", "implementation", "of", "quality", "improvement", ")", "is", "not", "possible", "without", "sufficient", "baseline", "data", "about", "the", "present", "situation", "of", "medical", "treatment", ".", "This", "study", "investigates", "whether", "the", "current", "documentation", "of", "treatment", "in", "the", "emergency", "room", "is", "appropriate", "to", "judge", "upon", "the", "quality", "of", "the", "process", "and", "to", "detect", "problems", ".", "In", "addition", ",", "a", "set", "of", "baseline", "data", "is", "presented", ".", "The", "performance", "in", "the", "treatment", "of", "126", "multiple", "injured", "patients", "was", "prospectively", "recorded", "from", "1988", "to", "1993", "and", "compared", "with", "an", "idealized", "process", "based", "upon", "an", "algorithm", ".", "The", "quality", "of", "present", "data", "recording", "was", "analysed", ",", "and", "criteria", "for", "judgement", "of", "quality", "of", "care", "were", "assessed", ".", "The", "algorithm", "was", "devided", "into", "117", "possible", "steps", "(", "one", "step", "consisting", "of", "a", "single", "decision", "criterion", ",", "the", "decision", "and", "the", "corresponding", "procedure", ")", ".", "Per", "patient", ",", "only", "61", "%", "+", "/-", "12", "%", "of", "these", "steps", "were", "sufficiently", "documented", "to", "allow", "judgement", ".", "Using", "several", "criteria", "for", "assessment", ",", "the", "following", "baseline", "data", "could", "be", "observed", "(", "times", "shown", "refer", "to", "admission", "to", "the", "trauma", "room", ")", ":", "(", "1", ")", "trauma", "room", "time", "of", "129", "+", "/-", "55", "min", ";", "(", "2", ")", "completition", "of", "basic", "radiological", "and", "sonographic", "diagnostics", "in", "91", "%", "of", "patients", ";", "(", "3", ")", "first", "blood", "collection", "after", "17", "+", "/-", "11", "min", ";", "(", "4", ")", "cranial", "computerised", "tomography", "after", "55", "+", "/-", "20", "min", ";", "(", "5", ")", "missed", "injuries", "during", "the", "trauma", "room", "period", "in", "32", "%", "of", "patients", ";", "(", "6", ")", "intubation", "after", "20", "+", "/-", "19", "min", ";", "(", "7", ")", "insertion", "of", "a", "chest", "tube", "after", "30", "+", "/-", "17", "min", ";", "(", "8", ")", "first", "blood", "transfusion", "in", "shock", "after", "32", "+", "/-", "17", "min", ";", "(", "9", ")", "transfused", "blood", "within", "the", "first", "hour", "of", "4.2", "+", "/-", "2.8", "units", "and", "within", "the", "second", "hour", "of", "8.5", "+", "/-", "4.7", "units", ";", "(", "10", ")", "emergency", "operations", "in", "shock", "after", "98", "+", "/-", "55", "min", ";", "(", "11", ")", "early", "operations", "after", "156", "+", "/-", "69", "min", ";", "(", "12", ")", "craniotomy", "after", "124", "+", "/-", "37", "min", ";", "(", "13", ")", "unplanned", "surgery", "within", "24", "hours", "after", "admission", "to", "the", "intensive", "care", "unit", "in", "11", "%", "of", "patients", ".", "The", "study", "presented", "here", "supplies", "information", "on", "timing", "and", "other", "process", "data", "of", "the", "acute", "clinical", "care", "of", "seriously", "injured", "patients", ".", "In", "particular", ",", "the", "data", "represent", "indicators", "for", "the", "quality", "of", "emergency", "room", "management", ",", "which", "may", "be", "used", "as", "a", "baseline", "to", "compose", "improvement", "measures", "of", "structure", "and", "process", ".", "The", "quality", "of", "data", "collection", "has", "to", "be", "improved", "for", "carrying", "out", "an", "exact", "analysis", "of", "the", "process", "." ]	[ "umlsterm" ]
care is an umlsterm, patients is an umlsterm, multiple injuries is an umlsterm, identification is an umlsterm, baseline is an umlsterm, treatment is an umlsterm, documentation is an umlsterm, treatment is an umlsterm, emergency is an umlsterm, set is an umlsterm, baseline is an umlsterm, treatment is an umlsterm, patients is an umlsterm, algorithm is an umlsterm, criteria is an umlsterm, judgement is an umlsterm, care is an umlsterm, algorithm is an umlsterm, single is an umlsterm, criterion is an umlsterm, procedure is an umlsterm, patient is an umlsterm, judgement is an umlsterm, criteria is an umlsterm, assessment is an umlsterm, baseline is an umlsterm, times is an umlsterm, trauma is an umlsterm, trauma is an umlsterm, time is an umlsterm, patients is an umlsterm, blood is an umlsterm, computerised tomography is an umlsterm, injuries is an umlsterm, trauma is an umlsterm, period is an umlsterm, patients is an umlsterm, intubation is an umlsterm, chest tube is an umlsterm, blood transfusion is an umlsterm, shock is an umlsterm, blood is an umlsterm, emergency is an umlsterm, operations is an umlsterm, shock is an umlsterm, operations is an umlsterm, craniotomy is an umlsterm, surgery is an umlsterm, intensive care unit is an umlsterm, patients is an umlsterm, care is an umlsterm, patients is an umlsterm, indicators is an umlsterm, emergency is an umlsterm, baseline is an umlsterm, measures is an umlsterm, data collection is an umlsterm, exact is an umlsterm, analysis is an umlsterm	DerUnfallchirurg.71000811.eng.abstr_task1	Sentence: Quality management in early clinical care of patients with multiple injuries ( description of actual process , identification of problems , implementation of quality improvement ) is not possible without sufficient baseline data about the present situation of medical treatment . This study investigates whether the current documentation of treatment in the emergency room is appropriate to judge upon the quality of the process and to detect problems . In addition , a set of baseline data is presented . The performance in the treatment of 126 multiple injured patients was prospectively recorded from 1988 to 1993 and compared with an idealized process based upon an algorithm . The quality of present data recording was analysed , and criteria for judgement of quality of care were assessed . The algorithm was devided into 117 possible steps ( one step consisting of a single decision criterion , the decision and the corresponding procedure ) . Per patient , only 61 % +/- 12 % of these steps were sufficiently documented to allow judgement . Using several criteria for assessment , the following baseline data could be observed ( times shown refer to admission to the trauma room ) : ( 1 ) trauma room time of 129 +/- 55 min ; ( 2 ) completition of basic radiological and sonographic diagnostics in 91 % of patients ; ( 3 ) first blood collection after 17 +/- 11 min ; ( 4 ) cranial computerised tomography after 55 +/- 20 min ; ( 5 ) missed injuries during the trauma room period in 32 % of patients ; ( 6 ) intubation after 20 +/- 19 min ; ( 7 ) insertion of a chest tube after 30 +/- 17 min ; ( 8 ) first blood transfusion in shock after 32 +/- 17 min ; ( 9 ) transfused blood within the first hour of 4.2 +/- 2.8 units and within the second hour of 8.5 +/- 4.7 units ; ( 10 ) emergency operations in shock after 98 +/- 55 min ; ( 11 ) early operations after 156 +/- 69 min ; ( 12 ) craniotomy after 124 +/- 37 min ; ( 13 ) unplanned surgery within 24 hours after admission to the intensive care unit in 11 % of patients . The study presented here supplies information on timing and other process data of the acute clinical care of seriously injured patients . In particular , the data represent indicators for the quality of emergency room management , which may be used as a baseline to compose improvement measures of structure and process . The quality of data collection has to be improved for carrying out an exact analysis of the process . Instructions: please typing these entity words according to sentence: care, patients, multiple injuries, identification, baseline, treatment, documentation, treatment, emergency, set, baseline, treatment, patients, algorithm, criteria, judgement, care, algorithm, single, criterion, procedure, patient, judgement, criteria, assessment, baseline, times, trauma, trauma, time, patients, blood, computerised tomography, injuries, trauma, period, patients, intubation, chest tube, blood transfusion, shock, blood, emergency, operations, shock, operations, craniotomy, surgery, intensive care unit, patients, care, patients, indicators, emergency, baseline, measures, data collection, exact, analysis Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O" ]	Quality management in early clinical care of patients with multiple injuries ( description of actual process , identification of problems , implementation of quality improvement ) is not possible without sufficient baseline data about the present situation of medical treatment . This study investigates whether the current documentation of treatment in the emergency room is appropriate to judge upon the quality of the process and to detect problems . In addition , a set of baseline data is presented . The performance in the treatment of 126 multiple injured patients was prospectively recorded from 1988 to 1993 and compared with an idealized process based upon an algorithm . The quality of present data recording was analysed , and criteria for judgement of quality of care were assessed . The algorithm was devided into 117 possible steps ( one step consisting of a single decision criterion , the decision and the corresponding procedure ) . Per patient , only 61 % +/- 12 % of these steps were sufficiently documented to allow judgement . Using several criteria for assessment , the following baseline data could be observed ( times shown refer to admission to the trauma room ) : ( 1 ) trauma room time of 129 +/- 55 min ; ( 2 ) completition of basic radiological and sonographic diagnostics in 91 % of patients ; ( 3 ) first blood collection after 17 +/- 11 min ; ( 4 ) cranial computerised tomography after 55 +/- 20 min ; ( 5 ) missed injuries during the trauma room period in 32 % of patients ; ( 6 ) intubation after 20 +/- 19 min ; ( 7 ) insertion of a chest tube after 30 +/- 17 min ; ( 8 ) first blood transfusion in shock after 32 +/- 17 min ; ( 9 ) transfused blood within the first hour of 4.2 +/- 2.8 units and within the second hour of 8.5 +/- 4.7 units ; ( 10 ) emergency operations in shock after 98 +/- 55 min ; ( 11 ) early operations after 156 +/- 69 min ; ( 12 ) craniotomy after 124 +/- 37 min ; ( 13 ) unplanned surgery within 24 hours after admission to the intensive care unit in 11 % of patients . The study presented here supplies information on timing and other process data of the acute clinical care of seriously injured patients . In particular , the data represent indicators for the quality of emergency room management , which may be used as a baseline to compose improvement measures of structure and process . The quality of data collection has to be improved for carrying out an exact analysis of the process .	[ "Quality", "management", "in", "early", "clinical", "care", "of", "patients", "with", "multiple", "injuries", "(", "description", "of", "actual", "process", ",", "identification", "of", "problems", ",", "implementation", "of", "quality", "improvement", ")", "is", "not", "possible", "without", "sufficient", "baseline", "data", "about", "the", "present", "situation", "of", "medical", "treatment", ".", "This", "study", "investigates", "whether", "the", "current", "documentation", "of", "treatment", "in", "the", "emergency", "room", "is", "appropriate", "to", "judge", "upon", "the", "quality", "of", "the", "process", "and", "to", "detect", "problems", ".", "In", "addition", ",", "a", "set", "of", "baseline", "data", "is", "presented", ".", "The", "performance", "in", "the", "treatment", "of", "126", "multiple", "injured", "patients", "was", "prospectively", "recorded", "from", "1988", "to", "1993", "and", "compared", "with", "an", "idealized", "process", "based", "upon", "an", "algorithm", ".", "The", "quality", "of", "present", "data", "recording", "was", "analysed", ",", "and", "criteria", "for", "judgement", "of", "quality", "of", "care", "were", "assessed", ".", "The", "algorithm", "was", "devided", "into", "117", "possible", "steps", "(", "one", "step", "consisting", "of", "a", "single", "decision", "criterion", ",", "the", "decision", "and", "the", "corresponding", "procedure", ")", ".", "Per", "patient", ",", "only", "61", "%", "+", "/-", "12", "%", "of", "these", "steps", "were", "sufficiently", "documented", "to", "allow", "judgement", ".", "Using", "several", "criteria", "for", "assessment", ",", "the", "following", "baseline", "data", "could", "be", "observed", "(", "times", "shown", "refer", "to", "admission", "to", "the", "trauma", "room", ")", ":", "(", "1", ")", "trauma", "room", "time", "of", "129", "+", "/-", "55", "min", ";", "(", "2", ")", "completition", "of", "basic", "radiological", "and", "sonographic", "diagnostics", "in", "91", "%", "of", "patients", ";", "(", "3", ")", "first", "blood", "collection", "after", "17", "+", "/-", "11", "min", ";", "(", "4", ")", "cranial", "computerised", "tomography", "after", "55", "+", "/-", "20", "min", ";", "(", "5", ")", "missed", "injuries", "during", "the", "trauma", "room", "period", "in", "32", "%", "of", "patients", ";", "(", "6", ")", "intubation", "after", "20", "+", "/-", "19", "min", ";", "(", "7", ")", "insertion", "of", "a", "chest", "tube", "after", "30", "+", "/-", "17", "min", ";", "(", "8", ")", "first", "blood", "transfusion", "in", "shock", "after", "32", "+", "/-", "17", "min", ";", "(", "9", ")", "transfused", "blood", "within", "the", "first", "hour", "of", "4.2", "+", "/-", "2.8", "units", "and", "within", "the", "second", "hour", "of", "8.5", "+", "/-", "4.7", "units", ";", "(", "10", ")", "emergency", "operations", "in", "shock", "after", "98", "+", "/-", "55", "min", ";", "(", "11", ")", "early", "operations", "after", "156", "+", "/-", "69", "min", ";", "(", "12", ")", "craniotomy", "after", "124", "+", "/-", "37", "min", ";", "(", "13", ")", "unplanned", "surgery", "within", "24", "hours", "after", "admission", "to", "the", "intensive", "care", "unit", "in", "11", "%", "of", "patients", ".", "The", "study", "presented", "here", "supplies", "information", "on", "timing", "and", "other", "process", "data", "of", "the", "acute", "clinical", "care", "of", "seriously", "injured", "patients", ".", "In", "particular", ",", "the", "data", "represent", "indicators", "for", "the", "quality", "of", "emergency", "room", "management", ",", "which", "may", "be", "used", "as", "a", "baseline", "to", "compose", "improvement", "measures", "of", "structure", "and", "process", ".", "The", "quality", "of", "data", "collection", "has", "to", "be", "improved", "for", "carrying", "out", "an", "exact", "analysis", "of", "the", "process", "." ]	[ "umlsterm" ]
care, patients, multiple injuries, identification, baseline, treatment, documentation, treatment, emergency, set, baseline, treatment, patients, algorithm, criteria, judgement, care, algorithm, single, criterion, procedure, patient, judgement, criteria, assessment, baseline, times, trauma, trauma, time, patients, blood, computerised tomography, injuries, trauma, period, patients, intubation, chest tube, blood transfusion, shock, blood, emergency, operations, shock, operations, craniotomy, surgery, intensive care unit, patients, care, patients, indicators, emergency, baseline, measures, data collection, exact, analysis	DerUnfallchirurg.71000811.eng.abstr_task2	Sentence: Quality management in early clinical care of patients with multiple injuries ( description of actual process , identification of problems , implementation of quality improvement ) is not possible without sufficient baseline data about the present situation of medical treatment . This study investigates whether the current documentation of treatment in the emergency room is appropriate to judge upon the quality of the process and to detect problems . In addition , a set of baseline data is presented . The performance in the treatment of 126 multiple injured patients was prospectively recorded from 1988 to 1993 and compared with an idealized process based upon an algorithm . The quality of present data recording was analysed , and criteria for judgement of quality of care were assessed . The algorithm was devided into 117 possible steps ( one step consisting of a single decision criterion , the decision and the corresponding procedure ) . Per patient , only 61 % +/- 12 % of these steps were sufficiently documented to allow judgement . Using several criteria for assessment , the following baseline data could be observed ( times shown refer to admission to the trauma room ) : ( 1 ) trauma room time of 129 +/- 55 min ; ( 2 ) completition of basic radiological and sonographic diagnostics in 91 % of patients ; ( 3 ) first blood collection after 17 +/- 11 min ; ( 4 ) cranial computerised tomography after 55 +/- 20 min ; ( 5 ) missed injuries during the trauma room period in 32 % of patients ; ( 6 ) intubation after 20 +/- 19 min ; ( 7 ) insertion of a chest tube after 30 +/- 17 min ; ( 8 ) first blood transfusion in shock after 32 +/- 17 min ; ( 9 ) transfused blood within the first hour of 4.2 +/- 2.8 units and within the second hour of 8.5 +/- 4.7 units ; ( 10 ) emergency operations in shock after 98 +/- 55 min ; ( 11 ) early operations after 156 +/- 69 min ; ( 12 ) craniotomy after 124 +/- 37 min ; ( 13 ) unplanned surgery within 24 hours after admission to the intensive care unit in 11 % of patients . The study presented here supplies information on timing and other process data of the acute clinical care of seriously injured patients . In particular , the data represent indicators for the quality of emergency room management , which may be used as a baseline to compose improvement measures of structure and process . The quality of data collection has to be improved for carrying out an exact analysis of the process . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O" ]	Quality management in early clinical care of patients with multiple injuries ( description of actual process , identification of problems , implementation of quality improvement ) is not possible without sufficient baseline data about the present situation of medical treatment . This study investigates whether the current documentation of treatment in the emergency room is appropriate to judge upon the quality of the process and to detect problems . In addition , a set of baseline data is presented . The performance in the treatment of 126 multiple injured patients was prospectively recorded from 1988 to 1993 and compared with an idealized process based upon an algorithm . The quality of present data recording was analysed , and criteria for judgement of quality of care were assessed . The algorithm was devided into 117 possible steps ( one step consisting of a single decision criterion , the decision and the corresponding procedure ) . Per patient , only 61 % +/- 12 % of these steps were sufficiently documented to allow judgement . Using several criteria for assessment , the following baseline data could be observed ( times shown refer to admission to the trauma room ) : ( 1 ) trauma room time of 129 +/- 55 min ; ( 2 ) completition of basic radiological and sonographic diagnostics in 91 % of patients ; ( 3 ) first blood collection after 17 +/- 11 min ; ( 4 ) cranial computerised tomography after 55 +/- 20 min ; ( 5 ) missed injuries during the trauma room period in 32 % of patients ; ( 6 ) intubation after 20 +/- 19 min ; ( 7 ) insertion of a chest tube after 30 +/- 17 min ; ( 8 ) first blood transfusion in shock after 32 +/- 17 min ; ( 9 ) transfused blood within the first hour of 4.2 +/- 2.8 units and within the second hour of 8.5 +/- 4.7 units ; ( 10 ) emergency operations in shock after 98 +/- 55 min ; ( 11 ) early operations after 156 +/- 69 min ; ( 12 ) craniotomy after 124 +/- 37 min ; ( 13 ) unplanned surgery within 24 hours after admission to the intensive care unit in 11 % of patients . The study presented here supplies information on timing and other process data of the acute clinical care of seriously injured patients . In particular , the data represent indicators for the quality of emergency room management , which may be used as a baseline to compose improvement measures of structure and process . The quality of data collection has to be improved for carrying out an exact analysis of the process .	[ "Quality", "management", "in", "early", "clinical", "care", "of", "patients", "with", "multiple", "injuries", "(", "description", "of", "actual", "process", ",", "identification", "of", "problems", ",", "implementation", "of", "quality", "improvement", ")", "is", "not", "possible", "without", "sufficient", "baseline", "data", "about", "the", "present", "situation", "of", "medical", "treatment", ".", "This", "study", "investigates", "whether", "the", "current", "documentation", "of", "treatment", "in", "the", "emergency", "room", "is", "appropriate", "to", "judge", "upon", "the", "quality", "of", "the", "process", "and", "to", "detect", "problems", ".", "In", "addition", ",", "a", "set", "of", "baseline", "data", "is", "presented", ".", "The", "performance", "in", "the", "treatment", "of", "126", "multiple", "injured", "patients", "was", "prospectively", "recorded", "from", "1988", "to", "1993", "and", "compared", "with", "an", "idealized", "process", "based", "upon", "an", "algorithm", ".", "The", "quality", "of", "present", "data", "recording", "was", "analysed", ",", "and", "criteria", "for", "judgement", "of", "quality", "of", "care", "were", "assessed", ".", "The", "algorithm", "was", "devided", "into", "117", "possible", "steps", "(", "one", "step", "consisting", "of", "a", "single", "decision", "criterion", ",", "the", "decision", "and", "the", "corresponding", "procedure", ")", ".", "Per", "patient", ",", "only", "61", "%", "+", "/-", "12", "%", "of", "these", "steps", "were", "sufficiently", "documented", "to", "allow", "judgement", ".", "Using", "several", "criteria", "for", "assessment", ",", "the", "following", "baseline", "data", "could", "be", "observed", "(", "times", "shown", "refer", "to", "admission", "to", "the", "trauma", "room", ")", ":", "(", "1", ")", "trauma", "room", "time", "of", "129", "+", "/-", "55", "min", ";", "(", "2", ")", "completition", "of", "basic", "radiological", "and", "sonographic", "diagnostics", "in", "91", "%", "of", "patients", ";", "(", "3", ")", "first", "blood", "collection", "after", "17", "+", "/-", "11", "min", ";", "(", "4", ")", "cranial", "computerised", "tomography", "after", "55", "+", "/-", "20", "min", ";", "(", "5", ")", "missed", "injuries", "during", "the", "trauma", "room", "period", "in", "32", "%", "of", "patients", ";", "(", "6", ")", "intubation", "after", "20", "+", "/-", "19", "min", ";", "(", "7", ")", "insertion", "of", "a", "chest", "tube", "after", "30", "+", "/-", "17", "min", ";", "(", "8", ")", "first", "blood", "transfusion", "in", "shock", "after", "32", "+", "/-", "17", "min", ";", "(", "9", ")", "transfused", "blood", "within", "the", "first", "hour", "of", "4.2", "+", "/-", "2.8", "units", "and", "within", "the", "second", "hour", "of", "8.5", "+", "/-", "4.7", "units", ";", "(", "10", ")", "emergency", "operations", "in", "shock", "after", "98", "+", "/-", "55", "min", ";", "(", "11", ")", "early", "operations", "after", "156", "+", "/-", "69", "min", ";", "(", "12", ")", "craniotomy", "after", "124", "+", "/-", "37", "min", ";", "(", "13", ")", "unplanned", "surgery", "within", "24", "hours", "after", "admission", "to", "the", "intensive", "care", "unit", "in", "11", "%", "of", "patients", ".", "The", "study", "presented", "here", "supplies", "information", "on", "timing", "and", "other", "process", "data", "of", "the", "acute", "clinical", "care", "of", "seriously", "injured", "patients", ".", "In", "particular", ",", "the", "data", "represent", "indicators", "for", "the", "quality", "of", "emergency", "room", "management", ",", "which", "may", "be", "used", "as", "a", "baseline", "to", "compose", "improvement", "measures", "of", "structure", "and", "process", ".", "The", "quality", "of", "data", "collection", "has", "to", "be", "improved", "for", "carrying", "out", "an", "exact", "analysis", "of", "the", "process", "." ]	[ "umlsterm" ]
cinacalcet is a compound, parathormone is a protein	DS.d389_task0	Sentence: Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma.	[ "Therefore", ",", "cinacalcet", ",", "which", "inhibit", "the", "production", "of", "parathormone", "by", "negative", "feedback", ",", "was", "considered", "a", "treatment", "option", "to", "control", "the", "evolution", "of", "calciphylaxis", "in", "a", "dialysed", "patient", "suffering", "from", "cholangiocarcinoma", "." ]	[ "protein", "compound" ]
cinacalcet is a compound, parathormone is a protein	DS.d389_task1	Sentence: Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma. Instructions: please typing these entity words according to sentence: cinacalcet, parathormone Options: compound, protein	[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma.	[ "Therefore", ",", "cinacalcet", ",", "which", "inhibit", "the", "production", "of", "parathormone", "by", "negative", "feedback", ",", "was", "considered", "a", "treatment", "option", "to", "control", "the", "evolution", "of", "calciphylaxis", "in", "a", "dialysed", "patient", "suffering", "from", "cholangiocarcinoma", "." ]	[ "protein", "compound" ]
cinacalcet, parathormone	DS.d389_task2	Sentence: Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma.	[ "Therefore", ",", "cinacalcet", ",", "which", "inhibit", "the", "production", "of", "parathormone", "by", "negative", "feedback", ",", "was", "considered", "a", "treatment", "option", "to", "control", "the", "evolution", "of", "calciphylaxis", "in", "a", "dialysed", "patient", "suffering", "from", "cholangiocarcinoma", "." ]	[ "protein", "compound" ]
gp120 is a Protein	583_task0	Sentence: Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans.	[ "Alteration", "of", "glycosylation", "renders", "HIV", "sensitive", "to", "inactivation", "by", "normal", "human", "serum", ".", "\n", "Retroviruses", "from", "various", "mammalian", "species", ",", "excluding", "humans", ",", "are", "effectively", "inactivated", "in", "normal", "human", "serum", "(", "NHS", ")", ".", "Recent", "studies", "have", "shown", "that", "NHS", "inactivation", "of", "retroviruses", "occurs", "through", "natural", "Ab", "recognition", "of", "a", "terminal", "glycosidic", "moiety", "on", "the", "viral", "envelope", "that", "is", "acquired", "during", "replication", "in", "the", "host", "cell", ".", "This", "carbohydrate", "structure", "(", "the", "alpha", "-", "galactosyl", "epitope", ")", "is", "expressed", "on", "the", "cells", "of", "most", "mammals", ",", "with", "the", "exception", "of", "humans", "and", "other", "Old", "World", "primates", ".", "In", "this", "study", ",", "NHS", "sensitivity", "of", "HIV", "was", "assessed", "following", "viral", "propagation", "in", "human", "cells", "that", "were", "manipulated", "to", "express", "the", "alpha", "-", "galactosyl", "epitope", ".", "HUT-78", "cells", "were", "transduced", "with", "an", "exogenous", "alpha1", "-", "3-galactosyl", "transferase", "gene", ",", "which", "codes", "for", "the", "terminal", "glycosyl", "transferase", "responsible", "for", "generation", "of", "the", "alpha", "-", "galactosyl", "epitope", ".", "The", "transduced", "HUT-78", "cells", "expressed", "high", "levels", "of", "the", "alpha", "-", "galactosyl", "epitope", "on", "their", "membrane", "surface", ",", "rendering", "them", "sensitive", "to", "killing", "in", "NHS", ".", "Similarly", ",", "HIV", "passaged", "through", "these", "cells", "acquired", "the", "alpha", "-", "galactosyl", "epitope", "in", "association", "with", "the", "envelope", "glycoprotein", "gp120", "and", "was", "also", "effectively", "inactivated", "in", "NHS", ".", "Viral", "inactivation", "was", "abolished", "by", "the", "addition", "of", "a", "synthetic", "disaccharide", "that", "contains", "the", "alpha", "-", "galactosyl", "epitope", ",", "indicating", "that", "virolysis", "is", "mediated", "by", "anti", "-", "alpha", "-", "galactosyl", "natural", "Ab", ".", "These", "results", "demonstrate", "that", ",", "like", "other", "retroviruses", "bearing", "the", "alpha", "-", "galactosyl", "epitope", ",", "HIV", "modified", "to", "express", "this", "epitope", "is", "inactivated", "in", "NHS", ".", "Furthermore", ",", "these", "data", "suggest", "that", "expression", "of", "the", "alpha", "-", "galactosyl", "epitope", "on", "the", "surface", "of", "viruses", "may", "have", "implications", "in", "the", "interspecies", "transmission", "of", "such", "viruses", "to", "humans", ".", "\n" ]	[ "Protein" ]
gp120 is a Protein	583_task1	Sentence: Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans. Instructions: please typing these entity words according to sentence: gp120 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans.	[ "Alteration", "of", "glycosylation", "renders", "HIV", "sensitive", "to", "inactivation", "by", "normal", "human", "serum", ".", "\n", "Retroviruses", "from", "various", "mammalian", "species", ",", "excluding", "humans", ",", "are", "effectively", "inactivated", "in", "normal", "human", "serum", "(", "NHS", ")", ".", "Recent", "studies", "have", "shown", "that", "NHS", "inactivation", "of", "retroviruses", "occurs", "through", "natural", "Ab", "recognition", "of", "a", "terminal", "glycosidic", "moiety", "on", "the", "viral", "envelope", "that", "is", "acquired", "during", "replication", "in", "the", "host", "cell", ".", "This", "carbohydrate", "structure", "(", "the", "alpha", "-", "galactosyl", "epitope", ")", "is", "expressed", "on", "the", "cells", "of", "most", "mammals", ",", "with", "the", "exception", "of", "humans", "and", "other", "Old", "World", "primates", ".", "In", "this", "study", ",", "NHS", "sensitivity", "of", "HIV", "was", "assessed", "following", "viral", "propagation", "in", "human", "cells", "that", "were", "manipulated", "to", "express", "the", "alpha", "-", "galactosyl", "epitope", ".", "HUT-78", "cells", "were", "transduced", "with", "an", "exogenous", "alpha1", "-", "3-galactosyl", "transferase", "gene", ",", "which", "codes", "for", "the", "terminal", "glycosyl", "transferase", "responsible", "for", "generation", "of", "the", "alpha", "-", "galactosyl", "epitope", ".", "The", "transduced", "HUT-78", "cells", "expressed", "high", "levels", "of", "the", "alpha", "-", "galactosyl", "epitope", "on", "their", "membrane", "surface", ",", "rendering", "them", "sensitive", "to", "killing", "in", "NHS", ".", "Similarly", ",", "HIV", "passaged", "through", "these", "cells", "acquired", "the", "alpha", "-", "galactosyl", "epitope", "in", "association", "with", "the", "envelope", "glycoprotein", "gp120", "and", "was", "also", "effectively", "inactivated", "in", "NHS", ".", "Viral", "inactivation", "was", "abolished", "by", "the", "addition", "of", "a", "synthetic", "disaccharide", "that", "contains", "the", "alpha", "-", "galactosyl", "epitope", ",", "indicating", "that", "virolysis", "is", "mediated", "by", "anti", "-", "alpha", "-", "galactosyl", "natural", "Ab", ".", "These", "results", "demonstrate", "that", ",", "like", "other", "retroviruses", "bearing", "the", "alpha", "-", "galactosyl", "epitope", ",", "HIV", "modified", "to", "express", "this", "epitope", "is", "inactivated", "in", "NHS", ".", "Furthermore", ",", "these", "data", "suggest", "that", "expression", "of", "the", "alpha", "-", "galactosyl", "epitope", "on", "the", "surface", "of", "viruses", "may", "have", "implications", "in", "the", "interspecies", "transmission", "of", "such", "viruses", "to", "humans", ".", "\n" ]	[ "Protein" ]
gp120	583_task2	Sentence: Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans.	[ "Alteration", "of", "glycosylation", "renders", "HIV", "sensitive", "to", "inactivation", "by", "normal", "human", "serum", ".", "\n", "Retroviruses", "from", "various", "mammalian", "species", ",", "excluding", "humans", ",", "are", "effectively", "inactivated", "in", "normal", "human", "serum", "(", "NHS", ")", ".", "Recent", "studies", "have", "shown", "that", "NHS", "inactivation", "of", "retroviruses", "occurs", "through", "natural", "Ab", "recognition", "of", "a", "terminal", "glycosidic", "moiety", "on", "the", "viral", "envelope", "that", "is", "acquired", "during", "replication", "in", "the", "host", "cell", ".", "This", "carbohydrate", "structure", "(", "the", "alpha", "-", "galactosyl", "epitope", ")", "is", "expressed", "on", "the", "cells", "of", "most", "mammals", ",", "with", "the", "exception", "of", "humans", "and", "other", "Old", "World", "primates", ".", "In", "this", "study", ",", "NHS", "sensitivity", "of", "HIV", "was", "assessed", "following", "viral", "propagation", "in", "human", "cells", "that", "were", "manipulated", "to", "express", "the", "alpha", "-", "galactosyl", "epitope", ".", "HUT-78", "cells", "were", "transduced", "with", "an", "exogenous", "alpha1", "-", "3-galactosyl", "transferase", "gene", ",", "which", "codes", "for", "the", "terminal", "glycosyl", "transferase", "responsible", "for", "generation", "of", "the", "alpha", "-", "galactosyl", "epitope", ".", "The", "transduced", "HUT-78", "cells", "expressed", "high", "levels", "of", "the", "alpha", "-", "galactosyl", "epitope", "on", "their", "membrane", "surface", ",", "rendering", "them", "sensitive", "to", "killing", "in", "NHS", ".", "Similarly", ",", "HIV", "passaged", "through", "these", "cells", "acquired", "the", "alpha", "-", "galactosyl", "epitope", "in", "association", "with", "the", "envelope", "glycoprotein", "gp120", "and", "was", "also", "effectively", "inactivated", "in", "NHS", ".", "Viral", "inactivation", "was", "abolished", "by", "the", "addition", "of", "a", "synthetic", "disaccharide", "that", "contains", "the", "alpha", "-", "galactosyl", "epitope", ",", "indicating", "that", "virolysis", "is", "mediated", "by", "anti", "-", "alpha", "-", "galactosyl", "natural", "Ab", ".", "These", "results", "demonstrate", "that", ",", "like", "other", "retroviruses", "bearing", "the", "alpha", "-", "galactosyl", "epitope", ",", "HIV", "modified", "to", "express", "this", "epitope", "is", "inactivated", "in", "NHS", ".", "Furthermore", ",", "these", "data", "suggest", "that", "expression", "of", "the", "alpha", "-", "galactosyl", "epitope", "on", "the", "surface", "of", "viruses", "may", "have", "implications", "in", "the", "interspecies", "transmission", "of", "such", "viruses", "to", "humans", ".", "\n" ]	[ "Protein" ]
beta - catenin is a Gene/protein/RNA, alpha - catenin is a Gene/protein/RNA	690_task0	Sentence: The concentration of beta-catenin was constant during the follicular phase, whereas the content of alpha-catenin decreased in granulosa cells after treatment with diethylstilboestrol or hCG. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA	[ "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The concentration of beta-catenin was constant during the follicular phase, whereas the content of alpha-catenin decreased in granulosa cells after treatment with diethylstilboestrol or hCG.	[ "The", "concentration", "of", "beta", "-", "catenin", "was", "constant", "during", "the", "follicular", "phase", ",", "whereas", "the", "content", "of", "alpha", "-", "catenin", "decreased", "in", "granulosa", "cells", "after", "treatment", "with", "diethylstilboestrol", "or", "hCG", "." ]	[ "Gene/protein/RNA" ]
beta - catenin is a Gene/protein/RNA, alpha - catenin is a Gene/protein/RNA	690_task1	Sentence: The concentration of beta-catenin was constant during the follicular phase, whereas the content of alpha-catenin decreased in granulosa cells after treatment with diethylstilboestrol or hCG. Instructions: please typing these entity words according to sentence: beta - catenin, alpha - catenin Options: Gene/protein/RNA	[ "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The concentration of beta-catenin was constant during the follicular phase, whereas the content of alpha-catenin decreased in granulosa cells after treatment with diethylstilboestrol or hCG.	[ "The", "concentration", "of", "beta", "-", "catenin", "was", "constant", "during", "the", "follicular", "phase", ",", "whereas", "the", "content", "of", "alpha", "-", "catenin", "decreased", "in", "granulosa", "cells", "after", "treatment", "with", "diethylstilboestrol", "or", "hCG", "." ]	[ "Gene/protein/RNA" ]
beta - catenin, alpha - catenin	690_task2	Sentence: The concentration of beta-catenin was constant during the follicular phase, whereas the content of alpha-catenin decreased in granulosa cells after treatment with diethylstilboestrol or hCG. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The concentration of beta-catenin was constant during the follicular phase, whereas the content of alpha-catenin decreased in granulosa cells after treatment with diethylstilboestrol or hCG.	[ "The", "concentration", "of", "beta", "-", "catenin", "was", "constant", "during", "the", "follicular", "phase", ",", "whereas", "the", "content", "of", "alpha", "-", "catenin", "decreased", "in", "granulosa", "cells", "after", "treatment", "with", "diethylstilboestrol", "or", "hCG", "." ]	[ "Gene/protein/RNA" ]
iron is a CHEMICAL, deferasirox is a CHEMICAL	23074173_task0	Sentence: The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.	[ "The", "iron", "chelator", ",", "deferasirox", ",", "as", "a", "novel", "strategy", "for", "cancer", "treatment", ":", "oral", "activity", "against", "human", "lung", "tumor", "xenografts", "and", "molecular", "mechanism", "of", "action", "." ]	[ "GENE-Y", "CHEMICAL" ]
iron is a CHEMICAL, deferasirox is a CHEMICAL	23074173_task1	Sentence: The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Instructions: please typing these entity words according to sentence: iron, deferasirox Options: CHEMICAL	[ "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.	[ "The", "iron", "chelator", ",", "deferasirox", ",", "as", "a", "novel", "strategy", "for", "cancer", "treatment", ":", "oral", "activity", "against", "human", "lung", "tumor", "xenografts", "and", "molecular", "mechanism", "of", "action", "." ]	[ "GENE-Y", "CHEMICAL" ]
iron, deferasirox	23074173_task2	Sentence: The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Instructions: please extract entity words from the input sentence	[ "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.	[ "The", "iron", "chelator", ",", "deferasirox", ",", "as", "a", "novel", "strategy", "for", "cancer", "treatment", ":", "oral", "activity", "against", "human", "lung", "tumor", "xenografts", "and", "molecular", "mechanism", "of", "action", "." ]	[ "GENE-Y", "CHEMICAL" ]
Patienten is an umlsterm, Angina pectoris is an umlsterm, Herzerkrankung is an umlsterm, Ballondilatation is an umlsterm, koerperliche Belastbarkeit is an umlsterm, Herzen is an umlsterm, Epikard is an umlsterm, Myokard is an umlsterm, Laserkanaele is an umlsterm, Myokard is an umlsterm	ZfuerKardiologie.0089vii31.ger.abstr_task0	Sentence: Bei Patienten mit schwerer Angina pectoris aufgrund einer koronaren Herzerkrankung , bei denen aufgrund der Koronarmorphologie oder vorausgegangener Interventionen keine Moeglichkeit einer Ballondilatation oder einer Bypassoperation mehr besteht , kann die klinische Symptomatik und die koerperliche Belastbarkeit haeufig durch eine transmyokardiale Laserrevaskularisation ( TMR ) gebessert werden . Ein Nachteil der TMR ist die Notwendigkeit eines chirurgischen Zugangs zum Herzen , um die Kannaele vom Epikard aus in das Myokard einzubringen . Daher wurde ein Kathetersystem entwickelt , mit dem die Laserkanaele vom linksventrikulaeren Kavum aus in das Myokard eingebracht werden koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Bei Patienten mit schwerer Angina pectoris aufgrund einer koronaren Herzerkrankung , bei denen aufgrund der Koronarmorphologie oder vorausgegangener Interventionen keine Moeglichkeit einer Ballondilatation oder einer Bypassoperation mehr besteht , kann die klinische Symptomatik und die koerperliche Belastbarkeit haeufig durch eine transmyokardiale Laserrevaskularisation ( TMR ) gebessert werden . Ein Nachteil der TMR ist die Notwendigkeit eines chirurgischen Zugangs zum Herzen , um die Kannaele vom Epikard aus in das Myokard einzubringen . Daher wurde ein Kathetersystem entwickelt , mit dem die Laserkanaele vom linksventrikulaeren Kavum aus in das Myokard eingebracht werden koennen .	[ "Bei", "Patienten", "mit", "schwerer", "Angina", "pectoris", "aufgrund", "einer", "koronaren", "Herzerkrankung", ",", "bei", "denen", "aufgrund", "der", "Koronarmorphologie", "oder", "vorausgegangener", "Interventionen", "keine", "Moeglichkeit", "einer", "Ballondilatation", "oder", "einer", "Bypassoperation", "mehr", "besteht", ",", "kann", "die", "klinische", "Symptomatik", "und", "die", "koerperliche", "Belastbarkeit", "haeufig", "durch", "eine", "transmyokardiale", "Laserrevaskularisation", "(", "TMR", ")", "gebessert", "werden", ".", "Ein", "Nachteil", "der", "TMR", "ist", "die", "Notwendigkeit", "eines", "chirurgischen", "Zugangs", "zum", "Herzen", ",", "um", "die", "Kannaele", "vom", "Epikard", "aus", "in", "das", "Myokard", "einzubringen", ".", "Daher", "wurde", "ein", "Kathetersystem", "entwickelt", ",", "mit", "dem", "die", "Laserkanaele", "vom", "linksventrikulaeren", "Kavum", "aus", "in", "das", "Myokard", "eingebracht", "werden", "koennen", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Angina pectoris is an umlsterm, Herzerkrankung is an umlsterm, Ballondilatation is an umlsterm, koerperliche Belastbarkeit is an umlsterm, Herzen is an umlsterm, Epikard is an umlsterm, Myokard is an umlsterm, Laserkanaele is an umlsterm, Myokard is an umlsterm	ZfuerKardiologie.0089vii31.ger.abstr_task1	Sentence: Bei Patienten mit schwerer Angina pectoris aufgrund einer koronaren Herzerkrankung , bei denen aufgrund der Koronarmorphologie oder vorausgegangener Interventionen keine Moeglichkeit einer Ballondilatation oder einer Bypassoperation mehr besteht , kann die klinische Symptomatik und die koerperliche Belastbarkeit haeufig durch eine transmyokardiale Laserrevaskularisation ( TMR ) gebessert werden . Ein Nachteil der TMR ist die Notwendigkeit eines chirurgischen Zugangs zum Herzen , um die Kannaele vom Epikard aus in das Myokard einzubringen . Daher wurde ein Kathetersystem entwickelt , mit dem die Laserkanaele vom linksventrikulaeren Kavum aus in das Myokard eingebracht werden koennen . Instructions: please typing these entity words according to sentence: Patienten, Angina pectoris, Herzerkrankung, Ballondilatation, koerperliche Belastbarkeit, Herzen, Epikard, Myokard, Laserkanaele, Myokard Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Bei Patienten mit schwerer Angina pectoris aufgrund einer koronaren Herzerkrankung , bei denen aufgrund der Koronarmorphologie oder vorausgegangener Interventionen keine Moeglichkeit einer Ballondilatation oder einer Bypassoperation mehr besteht , kann die klinische Symptomatik und die koerperliche Belastbarkeit haeufig durch eine transmyokardiale Laserrevaskularisation ( TMR ) gebessert werden . Ein Nachteil der TMR ist die Notwendigkeit eines chirurgischen Zugangs zum Herzen , um die Kannaele vom Epikard aus in das Myokard einzubringen . Daher wurde ein Kathetersystem entwickelt , mit dem die Laserkanaele vom linksventrikulaeren Kavum aus in das Myokard eingebracht werden koennen .	[ "Bei", "Patienten", "mit", "schwerer", "Angina", "pectoris", "aufgrund", "einer", "koronaren", "Herzerkrankung", ",", "bei", "denen", "aufgrund", "der", "Koronarmorphologie", "oder", "vorausgegangener", "Interventionen", "keine", "Moeglichkeit", "einer", "Ballondilatation", "oder", "einer", "Bypassoperation", "mehr", "besteht", ",", "kann", "die", "klinische", "Symptomatik", "und", "die", "koerperliche", "Belastbarkeit", "haeufig", "durch", "eine", "transmyokardiale", "Laserrevaskularisation", "(", "TMR", ")", "gebessert", "werden", ".", "Ein", "Nachteil", "der", "TMR", "ist", "die", "Notwendigkeit", "eines", "chirurgischen", "Zugangs", "zum", "Herzen", ",", "um", "die", "Kannaele", "vom", "Epikard", "aus", "in", "das", "Myokard", "einzubringen", ".", "Daher", "wurde", "ein", "Kathetersystem", "entwickelt", ",", "mit", "dem", "die", "Laserkanaele", "vom", "linksventrikulaeren", "Kavum", "aus", "in", "das", "Myokard", "eingebracht", "werden", "koennen", "." ]	[ "umlsterm" ]
Patienten, Angina pectoris, Herzerkrankung, Ballondilatation, koerperliche Belastbarkeit, Herzen, Epikard, Myokard, Laserkanaele, Myokard	ZfuerKardiologie.0089vii31.ger.abstr_task2	Sentence: Bei Patienten mit schwerer Angina pectoris aufgrund einer koronaren Herzerkrankung , bei denen aufgrund der Koronarmorphologie oder vorausgegangener Interventionen keine Moeglichkeit einer Ballondilatation oder einer Bypassoperation mehr besteht , kann die klinische Symptomatik und die koerperliche Belastbarkeit haeufig durch eine transmyokardiale Laserrevaskularisation ( TMR ) gebessert werden . Ein Nachteil der TMR ist die Notwendigkeit eines chirurgischen Zugangs zum Herzen , um die Kannaele vom Epikard aus in das Myokard einzubringen . Daher wurde ein Kathetersystem entwickelt , mit dem die Laserkanaele vom linksventrikulaeren Kavum aus in das Myokard eingebracht werden koennen . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Bei Patienten mit schwerer Angina pectoris aufgrund einer koronaren Herzerkrankung , bei denen aufgrund der Koronarmorphologie oder vorausgegangener Interventionen keine Moeglichkeit einer Ballondilatation oder einer Bypassoperation mehr besteht , kann die klinische Symptomatik und die koerperliche Belastbarkeit haeufig durch eine transmyokardiale Laserrevaskularisation ( TMR ) gebessert werden . Ein Nachteil der TMR ist die Notwendigkeit eines chirurgischen Zugangs zum Herzen , um die Kannaele vom Epikard aus in das Myokard einzubringen . Daher wurde ein Kathetersystem entwickelt , mit dem die Laserkanaele vom linksventrikulaeren Kavum aus in das Myokard eingebracht werden koennen .	[ "Bei", "Patienten", "mit", "schwerer", "Angina", "pectoris", "aufgrund", "einer", "koronaren", "Herzerkrankung", ",", "bei", "denen", "aufgrund", "der", "Koronarmorphologie", "oder", "vorausgegangener", "Interventionen", "keine", "Moeglichkeit", "einer", "Ballondilatation", "oder", "einer", "Bypassoperation", "mehr", "besteht", ",", "kann", "die", "klinische", "Symptomatik", "und", "die", "koerperliche", "Belastbarkeit", "haeufig", "durch", "eine", "transmyokardiale", "Laserrevaskularisation", "(", "TMR", ")", "gebessert", "werden", ".", "Ein", "Nachteil", "der", "TMR", "ist", "die", "Notwendigkeit", "eines", "chirurgischen", "Zugangs", "zum", "Herzen", ",", "um", "die", "Kannaele", "vom", "Epikard", "aus", "in", "das", "Myokard", "einzubringen", ".", "Daher", "wurde", "ein", "Kathetersystem", "entwickelt", ",", "mit", "dem", "die", "Laserkanaele", "vom", "linksventrikulaeren", "Kavum", "aus", "in", "das", "Myokard", "eingebracht", "werden", "koennen", "." ]	[ "umlsterm" ]
Lebensqualitaet is an umlsterm, Lebensqualitaet is an umlsterm, kranker is an umlsterm, Kinder is an umlsterm, Arbeit is an umlsterm, Literatur is an umlsterm, Arbeiten is an umlsterm, Lebensqualitaet is an umlsterm, Kindern is an umlsterm, Methoden is an umlsterm, Forschung is an umlsterm, Arbeiten is an umlsterm, Lebensqualitaet is an umlsterm, Kindern is an umlsterm, Lebensqualitaet is an umlsterm, Kindern is an umlsterm, Therapieevaluation is an umlsterm, Rehabilitation is an umlsterm	Bundesgesundheitsblatt.00430198.ger.abstr_task0	Sentence: Waehrend die gesundheitsbezogene Lebensqualitaet Erwachsener zunehmend erforscht ist , wird die Lebensqualitaet gesunder und chronisch kranker Kinder und Jugendlicher erst juengst thematisiert . In der vorliegenden Arbeit werden in der Literatur publizierte Arbeiten zum Thema gesundheitsbezogene Lebensqualitaet von Kindern ausgewertet hinsichtlich Schwerpunkten und Methoden der Forschung . Der Ueberblick zeigt , dass empirische Arbeiten bisher rar sind , die vorhandenen Messinstrumente zur Lebensqualitaet von Kindern werden beschrieben . Verstaerkte Forschungsaktivitaeten sind notwendig , um die Erfassung der Lebensqualitaet von Kindern in der Praevention , den Gesundheitswissenschaften , in Therapieevaluation und Rehabilitation einsetzen zu koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	Waehrend die gesundheitsbezogene Lebensqualitaet Erwachsener zunehmend erforscht ist , wird die Lebensqualitaet gesunder und chronisch kranker Kinder und Jugendlicher erst juengst thematisiert . In der vorliegenden Arbeit werden in der Literatur publizierte Arbeiten zum Thema gesundheitsbezogene Lebensqualitaet von Kindern ausgewertet hinsichtlich Schwerpunkten und Methoden der Forschung . Der Ueberblick zeigt , dass empirische Arbeiten bisher rar sind , die vorhandenen Messinstrumente zur Lebensqualitaet von Kindern werden beschrieben . Verstaerkte Forschungsaktivitaeten sind notwendig , um die Erfassung der Lebensqualitaet von Kindern in der Praevention , den Gesundheitswissenschaften , in Therapieevaluation und Rehabilitation einsetzen zu koennen .	[ "Waehrend", "die", "gesundheitsbezogene", "Lebensqualitaet", "Erwachsener", "zunehmend", "erforscht", "ist", ",", "wird", "die", "Lebensqualitaet", "gesunder", "und", "chronisch", "kranker", "Kinder", "und", "Jugendlicher", "erst", "juengst", "thematisiert", ".", "In", "der", "vorliegenden", "Arbeit", "werden", "in", "der", "Literatur", "publizierte", "Arbeiten", "zum", "Thema", "gesundheitsbezogene", "Lebensqualitaet", "von", "Kindern", "ausgewertet", "hinsichtlich", "Schwerpunkten", "und", "Methoden", "der", "Forschung", ".", "Der", "Ueberblick", "zeigt", ",", "dass", "empirische", "Arbeiten", "bisher", "rar", "sind", ",", "die", "vorhandenen", "Messinstrumente", "zur", "Lebensqualitaet", "von", "Kindern", "werden", "beschrieben", ".", "Verstaerkte", "Forschungsaktivitaeten", "sind", "notwendig", ",", "um", "die", "Erfassung", "der", "Lebensqualitaet", "von", "Kindern", "in", "der", "Praevention", ",", "den", "Gesundheitswissenschaften", ",", "in", "Therapieevaluation", "und", "Rehabilitation", "einsetzen", "zu", "koennen", "." ]	[ "umlsterm" ]
Lebensqualitaet is an umlsterm, Lebensqualitaet is an umlsterm, kranker is an umlsterm, Kinder is an umlsterm, Arbeit is an umlsterm, Literatur is an umlsterm, Arbeiten is an umlsterm, Lebensqualitaet is an umlsterm, Kindern is an umlsterm, Methoden is an umlsterm, Forschung is an umlsterm, Arbeiten is an umlsterm, Lebensqualitaet is an umlsterm, Kindern is an umlsterm, Lebensqualitaet is an umlsterm, Kindern is an umlsterm, Therapieevaluation is an umlsterm, Rehabilitation is an umlsterm	Bundesgesundheitsblatt.00430198.ger.abstr_task1	Sentence: Waehrend die gesundheitsbezogene Lebensqualitaet Erwachsener zunehmend erforscht ist , wird die Lebensqualitaet gesunder und chronisch kranker Kinder und Jugendlicher erst juengst thematisiert . In der vorliegenden Arbeit werden in der Literatur publizierte Arbeiten zum Thema gesundheitsbezogene Lebensqualitaet von Kindern ausgewertet hinsichtlich Schwerpunkten und Methoden der Forschung . Der Ueberblick zeigt , dass empirische Arbeiten bisher rar sind , die vorhandenen Messinstrumente zur Lebensqualitaet von Kindern werden beschrieben . Verstaerkte Forschungsaktivitaeten sind notwendig , um die Erfassung der Lebensqualitaet von Kindern in der Praevention , den Gesundheitswissenschaften , in Therapieevaluation und Rehabilitation einsetzen zu koennen . Instructions: please typing these entity words according to sentence: Lebensqualitaet, Lebensqualitaet, kranker, Kinder, Arbeit, Literatur, Arbeiten, Lebensqualitaet, Kindern, Methoden, Forschung, Arbeiten, Lebensqualitaet, Kindern, Lebensqualitaet, Kindern, Therapieevaluation, Rehabilitation Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	Waehrend die gesundheitsbezogene Lebensqualitaet Erwachsener zunehmend erforscht ist , wird die Lebensqualitaet gesunder und chronisch kranker Kinder und Jugendlicher erst juengst thematisiert . In der vorliegenden Arbeit werden in der Literatur publizierte Arbeiten zum Thema gesundheitsbezogene Lebensqualitaet von Kindern ausgewertet hinsichtlich Schwerpunkten und Methoden der Forschung . Der Ueberblick zeigt , dass empirische Arbeiten bisher rar sind , die vorhandenen Messinstrumente zur Lebensqualitaet von Kindern werden beschrieben . Verstaerkte Forschungsaktivitaeten sind notwendig , um die Erfassung der Lebensqualitaet von Kindern in der Praevention , den Gesundheitswissenschaften , in Therapieevaluation und Rehabilitation einsetzen zu koennen .	[ "Waehrend", "die", "gesundheitsbezogene", "Lebensqualitaet", "Erwachsener", "zunehmend", "erforscht", "ist", ",", "wird", "die", "Lebensqualitaet", "gesunder", "und", "chronisch", "kranker", "Kinder", "und", "Jugendlicher", "erst", "juengst", "thematisiert", ".", "In", "der", "vorliegenden", "Arbeit", "werden", "in", "der", "Literatur", "publizierte", "Arbeiten", "zum", "Thema", "gesundheitsbezogene", "Lebensqualitaet", "von", "Kindern", "ausgewertet", "hinsichtlich", "Schwerpunkten", "und", "Methoden", "der", "Forschung", ".", "Der", "Ueberblick", "zeigt", ",", "dass", "empirische", "Arbeiten", "bisher", "rar", "sind", ",", "die", "vorhandenen", "Messinstrumente", "zur", "Lebensqualitaet", "von", "Kindern", "werden", "beschrieben", ".", "Verstaerkte", "Forschungsaktivitaeten", "sind", "notwendig", ",", "um", "die", "Erfassung", "der", "Lebensqualitaet", "von", "Kindern", "in", "der", "Praevention", ",", "den", "Gesundheitswissenschaften", ",", "in", "Therapieevaluation", "und", "Rehabilitation", "einsetzen", "zu", "koennen", "." ]	[ "umlsterm" ]
Lebensqualitaet, Lebensqualitaet, kranker, Kinder, Arbeit, Literatur, Arbeiten, Lebensqualitaet, Kindern, Methoden, Forschung, Arbeiten, Lebensqualitaet, Kindern, Lebensqualitaet, Kindern, Therapieevaluation, Rehabilitation	Bundesgesundheitsblatt.00430198.ger.abstr_task2	Sentence: Waehrend die gesundheitsbezogene Lebensqualitaet Erwachsener zunehmend erforscht ist , wird die Lebensqualitaet gesunder und chronisch kranker Kinder und Jugendlicher erst juengst thematisiert . In der vorliegenden Arbeit werden in der Literatur publizierte Arbeiten zum Thema gesundheitsbezogene Lebensqualitaet von Kindern ausgewertet hinsichtlich Schwerpunkten und Methoden der Forschung . Der Ueberblick zeigt , dass empirische Arbeiten bisher rar sind , die vorhandenen Messinstrumente zur Lebensqualitaet von Kindern werden beschrieben . Verstaerkte Forschungsaktivitaeten sind notwendig , um die Erfassung der Lebensqualitaet von Kindern in der Praevention , den Gesundheitswissenschaften , in Therapieevaluation und Rehabilitation einsetzen zu koennen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	Waehrend die gesundheitsbezogene Lebensqualitaet Erwachsener zunehmend erforscht ist , wird die Lebensqualitaet gesunder und chronisch kranker Kinder und Jugendlicher erst juengst thematisiert . In der vorliegenden Arbeit werden in der Literatur publizierte Arbeiten zum Thema gesundheitsbezogene Lebensqualitaet von Kindern ausgewertet hinsichtlich Schwerpunkten und Methoden der Forschung . Der Ueberblick zeigt , dass empirische Arbeiten bisher rar sind , die vorhandenen Messinstrumente zur Lebensqualitaet von Kindern werden beschrieben . Verstaerkte Forschungsaktivitaeten sind notwendig , um die Erfassung der Lebensqualitaet von Kindern in der Praevention , den Gesundheitswissenschaften , in Therapieevaluation und Rehabilitation einsetzen zu koennen .	[ "Waehrend", "die", "gesundheitsbezogene", "Lebensqualitaet", "Erwachsener", "zunehmend", "erforscht", "ist", ",", "wird", "die", "Lebensqualitaet", "gesunder", "und", "chronisch", "kranker", "Kinder", "und", "Jugendlicher", "erst", "juengst", "thematisiert", ".", "In", "der", "vorliegenden", "Arbeit", "werden", "in", "der", "Literatur", "publizierte", "Arbeiten", "zum", "Thema", "gesundheitsbezogene", "Lebensqualitaet", "von", "Kindern", "ausgewertet", "hinsichtlich", "Schwerpunkten", "und", "Methoden", "der", "Forschung", ".", "Der", "Ueberblick", "zeigt", ",", "dass", "empirische", "Arbeiten", "bisher", "rar", "sind", ",", "die", "vorhandenen", "Messinstrumente", "zur", "Lebensqualitaet", "von", "Kindern", "werden", "beschrieben", ".", "Verstaerkte", "Forschungsaktivitaeten", "sind", "notwendig", ",", "um", "die", "Erfassung", "der", "Lebensqualitaet", "von", "Kindern", "in", "der", "Praevention", ",", "den", "Gesundheitswissenschaften", ",", "in", "Therapieevaluation", "und", "Rehabilitation", "einsetzen", "zu", "koennen", "." ]	[ "umlsterm" ]
intravenous synthetic human secretin is a Intervention_Pharmacological, autism is a Participant_Condition, intravenous infusion of synthetic human secretin is a Intervention_Pharmacological, language is a Outcome_Mental, behavioral symptoms is a Outcome_Mental, children is a Participant_Age, Forty - two is a Participant_Sample-size, 2 IU / kg of intravenous synthetic human secretin is a Intervention_Pharmacological, intravenous saline placebo is a Intervention_Control, assessments of language , behavior , and autism symptomatology is a Outcome_Mental, mean scores on any measure of language , behavior , or autism symptom severity is a Outcome_Mental	11757_task0	Sentence: Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Participant_Age, Participant_Sample-size, Outcome_Mental	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Age", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism .	[ "Lack", "of", "benefit", "of", "intravenous", "synthetic", "human", "secretin", "in", "the", "treatment", "of", "autism", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "if", "an", "intravenous", "infusion", "of", "synthetic", "human", "secretin", "improves", "language", "and", "behavioral", "symptoms", "in", "children", "with", "autism", ".", "Forty", "-", "two", "children", "with", "the", "diagnosis", "of", "autism", "were", "randomized", "to", "one", "of", "two", "groups", "in", "this", "double", "-", "blind", "cross", "-", "over", "trial", ".", "One", "group", "received", "2", "IU", "/", "kg", "of", "intravenous", "synthetic", "human", "secretin", "at", "the", "first", "visit", ",", "followed", "by", "an", "equal", "volume", "of", "intravenous", "saline", "placebo", "at", "week", "6", ".", "The", "other", "group", "received", "treatments", "in", "the", "reverse", "order", ".", "All", "children", "were", "evaluated", "at", "weeks", "1", ",", "3", ",", "6", ",", "9", ",", "and", "12", "with", "standardized", "assessments", "of", "language", ",", "behavior", ",", "and", "autism", "symptomatology", ".", "There", "were", "no", "significant", "differences", "in", "the", "mean", "scores", "on", "any", "measure", "of", "language", ",", "behavior", ",", "or", "autism", "symptom", "severity", "after", "treatment", "with", "secretin", "compared", "to", "treatment", "with", "placebo", ".", "The", "results", "of", "this", "study", "do", "not", "support", "secretin", "as", "a", "treatment", "for", "autism", "." ]	[ "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size", "Participant_Age", "Participant_Condition" ]
intravenous synthetic human secretin is a Intervention_Pharmacological, autism is a Participant_Condition, intravenous infusion of synthetic human secretin is a Intervention_Pharmacological, language is a Outcome_Mental, behavioral symptoms is a Outcome_Mental, children is a Participant_Age, Forty - two is a Participant_Sample-size, 2 IU / kg of intravenous synthetic human secretin is a Intervention_Pharmacological, intravenous saline placebo is a Intervention_Control, assessments of language , behavior , and autism symptomatology is a Outcome_Mental, mean scores on any measure of language , behavior , or autism symptom severity is a Outcome_Mental	11757_task1	Sentence: Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism . Instructions: please typing these entity words according to sentence: intravenous synthetic human secretin, autism, intravenous infusion of synthetic human secretin, language, behavioral symptoms, children, Forty - two, 2 IU / kg of intravenous synthetic human secretin, intravenous saline placebo, assessments of language , behavior , and autism symptomatology, mean scores on any measure of language , behavior , or autism symptom severity Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Participant_Age, Participant_Sample-size, Outcome_Mental	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Age", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism .	[ "Lack", "of", "benefit", "of", "intravenous", "synthetic", "human", "secretin", "in", "the", "treatment", "of", "autism", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "if", "an", "intravenous", "infusion", "of", "synthetic", "human", "secretin", "improves", "language", "and", "behavioral", "symptoms", "in", "children", "with", "autism", ".", "Forty", "-", "two", "children", "with", "the", "diagnosis", "of", "autism", "were", "randomized", "to", "one", "of", "two", "groups", "in", "this", "double", "-", "blind", "cross", "-", "over", "trial", ".", "One", "group", "received", "2", "IU", "/", "kg", "of", "intravenous", "synthetic", "human", "secretin", "at", "the", "first", "visit", ",", "followed", "by", "an", "equal", "volume", "of", "intravenous", "saline", "placebo", "at", "week", "6", ".", "The", "other", "group", "received", "treatments", "in", "the", "reverse", "order", ".", "All", "children", "were", "evaluated", "at", "weeks", "1", ",", "3", ",", "6", ",", "9", ",", "and", "12", "with", "standardized", "assessments", "of", "language", ",", "behavior", ",", "and", "autism", "symptomatology", ".", "There", "were", "no", "significant", "differences", "in", "the", "mean", "scores", "on", "any", "measure", "of", "language", ",", "behavior", ",", "or", "autism", "symptom", "severity", "after", "treatment", "with", "secretin", "compared", "to", "treatment", "with", "placebo", ".", "The", "results", "of", "this", "study", "do", "not", "support", "secretin", "as", "a", "treatment", "for", "autism", "." ]	[ "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size", "Participant_Age", "Participant_Condition" ]
intravenous synthetic human secretin, autism, intravenous infusion of synthetic human secretin, language, behavioral symptoms, children, Forty - two, 2 IU / kg of intravenous synthetic human secretin, intravenous saline placebo, assessments of language , behavior , and autism symptomatology, mean scores on any measure of language , behavior , or autism symptom severity	11757_task2	Sentence: Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Age", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism .	[ "Lack", "of", "benefit", "of", "intravenous", "synthetic", "human", "secretin", "in", "the", "treatment", "of", "autism", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "if", "an", "intravenous", "infusion", "of", "synthetic", "human", "secretin", "improves", "language", "and", "behavioral", "symptoms", "in", "children", "with", "autism", ".", "Forty", "-", "two", "children", "with", "the", "diagnosis", "of", "autism", "were", "randomized", "to", "one", "of", "two", "groups", "in", "this", "double", "-", "blind", "cross", "-", "over", "trial", ".", "One", "group", "received", "2", "IU", "/", "kg", "of", "intravenous", "synthetic", "human", "secretin", "at", "the", "first", "visit", ",", "followed", "by", "an", "equal", "volume", "of", "intravenous", "saline", "placebo", "at", "week", "6", ".", "The", "other", "group", "received", "treatments", "in", "the", "reverse", "order", ".", "All", "children", "were", "evaluated", "at", "weeks", "1", ",", "3", ",", "6", ",", "9", ",", "and", "12", "with", "standardized", "assessments", "of", "language", ",", "behavior", ",", "and", "autism", "symptomatology", ".", "There", "were", "no", "significant", "differences", "in", "the", "mean", "scores", "on", "any", "measure", "of", "language", ",", "behavior", ",", "or", "autism", "symptom", "severity", "after", "treatment", "with", "secretin", "compared", "to", "treatment", "with", "placebo", ".", "The", "results", "of", "this", "study", "do", "not", "support", "secretin", "as", "a", "treatment", "for", "autism", "." ]	[ "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size", "Participant_Age", "Participant_Condition" ]
quinidine is a CHEMICAL, HERG is a GENE-Y	15673388_task0	Sentence: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O" ]	Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.	[ "Further", "insights", "into", "the", "effect", "of", "quinidine", "in", "short", "QT", "syndrome", "caused", "by", "a", "mutation", "in", "HERG", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
quinidine is a CHEMICAL, HERG is a GENE-Y	15673388_task1	Sentence: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. Instructions: please typing these entity words according to sentence: quinidine, HERG Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O" ]	Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.	[ "Further", "insights", "into", "the", "effect", "of", "quinidine", "in", "short", "QT", "syndrome", "caused", "by", "a", "mutation", "in", "HERG", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
quinidine, HERG	15673388_task2	Sentence: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O" ]	Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.	[ "Further", "insights", "into", "the", "effect", "of", "quinidine", "in", "short", "QT", "syndrome", "caused", "by", "a", "mutation", "in", "HERG", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Lef-1 is a protein, siamois promoter is a DNA, DNase I footprinting is an assay, Lef-1 is a protein, HMG is a protein-domain, S1234 restriction fragment is an experiment-tag	1.0alpha7.train.695_task0	Sentence: To further show the specificity of Lef-1 binding to the siamois promoter we performed DNase I footprinting assays by use of Lef-1 HMG domain and the S1234 restriction fragment used in the band shift assays described above. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA, assay, protein-domain, experiment-tag, protein	[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "B-assay", "I-assay", "I-assay", "O", "O", "O", "O", "O", "B-protein", "B-protein-domain", "O", "O", "O", "B-experiment-tag", "I-experiment-tag", "I-experiment-tag", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	To further show the specificity of Lef-1 binding to the siamois promoter we performed DNase I footprinting assays by use of Lef-1 HMG domain and the S1234 restriction fragment used in the band shift assays described above.	[ "To", "further", "show", "the", "specificity", "of", " ", "Lef-1", "binding", "to", "the", " ", "siamois", "promoter", "we", "performed", " ", "DNase", "I", "footprinting", "assays", "by", "use", "of", " ", "Lef-1", "HMG", "domain", "and", "the", "S1234", "restriction", "fragment", "used", "in", "the", "band", "shift", "assays", "described", "above", "." ]	[ "experiment-tag", "assay", "DNA", "protein", "protein-domain" ]
Lef-1 is a protein, siamois promoter is a DNA, DNase I footprinting is an assay, Lef-1 is a protein, HMG is a protein-domain, S1234 restriction fragment is an experiment-tag	1.0alpha7.train.695_task1	Sentence: To further show the specificity of Lef-1 binding to the siamois promoter we performed DNase I footprinting assays by use of Lef-1 HMG domain and the S1234 restriction fragment used in the band shift assays described above. Instructions: please typing these entity words according to sentence: Lef-1, siamois promoter, DNase I footprinting, Lef-1, HMG, S1234 restriction fragment Options: DNA, assay, protein-domain, experiment-tag, protein	[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "B-assay", "I-assay", "I-assay", "O", "O", "O", "O", "O", "B-protein", "B-protein-domain", "O", "O", "O", "B-experiment-tag", "I-experiment-tag", "I-experiment-tag", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	To further show the specificity of Lef-1 binding to the siamois promoter we performed DNase I footprinting assays by use of Lef-1 HMG domain and the S1234 restriction fragment used in the band shift assays described above.	[ "To", "further", "show", "the", "specificity", "of", " ", "Lef-1", "binding", "to", "the", " ", "siamois", "promoter", "we", "performed", " ", "DNase", "I", "footprinting", "assays", "by", "use", "of", " ", "Lef-1", "HMG", "domain", "and", "the", "S1234", "restriction", "fragment", "used", "in", "the", "band", "shift", "assays", "described", "above", "." ]	[ "experiment-tag", "assay", "DNA", "protein", "protein-domain" ]
Lef-1, siamois promoter, DNase I footprinting, Lef-1, HMG, S1234 restriction fragment	1.0alpha7.train.695_task2	Sentence: To further show the specificity of Lef-1 binding to the siamois promoter we performed DNase I footprinting assays by use of Lef-1 HMG domain and the S1234 restriction fragment used in the band shift assays described above. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "B-assay", "I-assay", "I-assay", "O", "O", "O", "O", "O", "B-protein", "B-protein-domain", "O", "O", "O", "B-experiment-tag", "I-experiment-tag", "I-experiment-tag", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	To further show the specificity of Lef-1 binding to the siamois promoter we performed DNase I footprinting assays by use of Lef-1 HMG domain and the S1234 restriction fragment used in the band shift assays described above.	[ "To", "further", "show", "the", "specificity", "of", " ", "Lef-1", "binding", "to", "the", " ", "siamois", "promoter", "we", "performed", " ", "DNase", "I", "footprinting", "assays", "by", "use", "of", " ", "Lef-1", "HMG", "domain", "and", "the", "S1234", "restriction", "fragment", "used", "in", "the", "band", "shift", "assays", "described", "above", "." ]	[ "experiment-tag", "assay", "DNA", "protein", "protein-domain" ]
Perfusion is an umlsterm, Peptids is an umlsterm, Endothelin-1 is an umlsterm, ANP is an umlsterm, Haemodynamik is an umlsterm, Patienten is an umlsterm, angeborenen is an umlsterm, pulmonaler Hypertension is an umlsterm, Stickstoffmonoxid is an umlsterm, NO - Synthase is an umlsterm, ANP is an umlsterm, Guanosinmonophosphat is an umlsterm, Sauerstoff is an umlsterm, Patienten is an umlsterm, pulmonaler Hypertension is an umlsterm, Patienten is an umlsterm, pulmonaler Hypertension is an umlsterm, Feedback - Mechanismus is an umlsterm, ANP is an umlsterm, ET-1 is an umlsterm, ANP is an umlsterm, Vasodilatation is an umlsterm, Sauerstoff is an umlsterm	ZfuerKardiologie.00890100.ger.abstr_task0	Sentence: Die pulmonale Perfusion wird von vasokonstriktorischen und vasodilatatorischen Faktoren reguliert . Ziel der Studie war es , den Einfluss des vasokonstriktorischen Peptids Endothelin-1 ( ET-1) und des vasodilatatorischen atrialen natriuretischen Peptis ( ANP ) auf die pulmonale Haemodynamik bei Patienten mit angeborenen Shuntvitien und konsekutiver pulmonaler Hypertension zu untersuchen . Sowohl Stickstoffmonoxid ( NO ) , das von einer konstitutiven endothelialen NO-Synthase ( eNOS ) gebildet wird , als auch ANP entfalten ihre vasodilatatorische Wirkung durch den intrazellulaeren Botenstoff ( second messenger zyklisches Guanosinmonophosphat ( ) cGMP ) . Sauerstoff ist ein Kofaktor der eNOS und ein bedeutsamer pulmonaler Vasodilatator bei Patienten mit pulmonaler Hypertension . Es wurde ueberprueft , ob bei Patienten mit pulmonaler Hypertension ein Feedback-Mechanismus zwischen ANP und ET-1 besteht und inwieweit die cGMP-Produktion von der Stimulation durch ANP abhaengt . Darueber hinaus sollte untersucht werden , ob das Phaenomen einer pulmonalen Vasodilatation durch Sauerstoff mit Aenderungen der ET-1- oder cGMP-Plasmaspiegel einhergeht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die pulmonale Perfusion wird von vasokonstriktorischen und vasodilatatorischen Faktoren reguliert . Ziel der Studie war es , den Einfluss des vasokonstriktorischen Peptids Endothelin-1 ( ET-1) und des vasodilatatorischen atrialen natriuretischen Peptis ( ANP ) auf die pulmonale Haemodynamik bei Patienten mit angeborenen Shuntvitien und konsekutiver pulmonaler Hypertension zu untersuchen . Sowohl Stickstoffmonoxid ( NO ) , das von einer konstitutiven endothelialen NO-Synthase ( eNOS ) gebildet wird , als auch ANP entfalten ihre vasodilatatorische Wirkung durch den intrazellulaeren Botenstoff ( second messenger zyklisches Guanosinmonophosphat ( ) cGMP ) . Sauerstoff ist ein Kofaktor der eNOS und ein bedeutsamer pulmonaler Vasodilatator bei Patienten mit pulmonaler Hypertension . Es wurde ueberprueft , ob bei Patienten mit pulmonaler Hypertension ein Feedback-Mechanismus zwischen ANP und ET-1 besteht und inwieweit die cGMP-Produktion von der Stimulation durch ANP abhaengt . Darueber hinaus sollte untersucht werden , ob das Phaenomen einer pulmonalen Vasodilatation durch Sauerstoff mit Aenderungen der ET-1- oder cGMP-Plasmaspiegel einhergeht .	[ "Die", "pulmonale", "Perfusion", "wird", "von", "vasokonstriktorischen", "und", "vasodilatatorischen", "Faktoren", "reguliert", ".", "Ziel", "der", "Studie", "war", "es", ",", "den", "Einfluss", "des", "vasokonstriktorischen", "Peptids", "Endothelin-1", "(", "ET-1", ")", "und", "des", "vasodilatatorischen", "atrialen", "natriuretischen", "Peptis", "(", "ANP", ")", "auf", "die", "pulmonale", "Haemodynamik", "bei", "Patienten", "mit", "angeborenen", "Shuntvitien", "und", "konsekutiver", "pulmonaler", "Hypertension", "zu", "untersuchen", ".", "Sowohl", "Stickstoffmonoxid", "(", "NO", ")", ",", "das", "von", "einer", "konstitutiven", "endothelialen", "NO", "-", "Synthase", "(", "eNOS", ")", "gebildet", "wird", ",", "als", "auch", "ANP", "entfalten", "ihre", "vasodilatatorische", "Wirkung", "durch", "den", "intrazellulaeren", "Botenstoff", "(", "second", "messenger", "zyklisches", "Guanosinmonophosphat", "(", ")", "cGMP", ")", ".", "Sauerstoff", "ist", "ein", "Kofaktor", "der", "eNOS", "und", "ein", "bedeutsamer", "pulmonaler", "Vasodilatator", "bei", "Patienten", "mit", "pulmonaler", "Hypertension", ".", "Es", "wurde", "ueberprueft", ",", "ob", "bei", "Patienten", "mit", "pulmonaler", "Hypertension", "ein", "Feedback", "-", "Mechanismus", "zwischen", "ANP", "und", "ET-1", "besteht", "und", "inwieweit", "die", "cGMP", "-", "Produktion", "von", "der", "Stimulation", "durch", "ANP", "abhaengt", ".", "Darueber", "hinaus", "sollte", "untersucht", "werden", ",", "ob", "das", "Phaenomen", "einer", "pulmonalen", "Vasodilatation", "durch", "Sauerstoff", "mit", "Aenderungen", "der", "ET-1-", "oder", "cGMP", "-", "Plasmaspiegel", "einhergeht", "." ]	[ "umlsterm" ]

inguinal herniorrhaphy . is a Intervention_Surgical, recurrence is a Outcome_Physical, satisfaction is a Outcome_Other, hematoma / seroma is a Outcome_Physical, orchitis is a Outcome_Physical, neuralgia is a Outcome_Physical, patient - reported pain is a Outcome_Pain, activity is a Outcome_Physical, less activity is a Outcome_Physical

27502_task0

Sentence: Patient-reported outcomes after inguinal herniorrhaphy . BACKGROUND Patient-reported outcomes ( PRO ) reflect the functional outcomes of inguinal herniorrhaphy . We studied the effect of hernia recurrence and complications on PRO for participants in the Veterans Affairs trial of Open or Laparoscopic Repair of Inguinal Hernia . METHODS Analyzed PRO included ( 1 ) the Medical Outcomes Study Short Form 36 , version 2 , ( 2 ) the Surgical Pain Scale , ( 3 ) the Activities Assessment Scale , and ( 4 ) patient satisfaction . Recurrences and complications were recorded at follow-up visits . Complications were categorized by ( 1 ) hematoma/seroma , ( 2 ) orchitis , ( 3 ) neuralgia , and ( 4 ) other . Univariate and multivariable regression analyses identified variables significantly associated with postoperative PRO . RESULTS Of the 1603 patients with PRO data , 105 had a recurrence and 342 had a complication at 2 years . Multivariable analyses showed neuralgia ( P < .0005 ) adversely affected all PRO , and recurrence ( P < .05 ) affected patient-reported pain , activity , and satisfaction , but not the score for the Medical Outcomes Study Short Form 3 . Patients with a recurrence after open repair had more pain than those with a recurrence after laparoscopic repair ( P = .0001 ) . Patients with other complications after laparoscopic repair reported more pain and less activity than those with other complications after open repair ( P = .003 and P = .009 , respectively ) . CONCLUSIONS The effectiveness of inguinal herniorrhaphy should be measured by the rate of recurrence and neuralgia . Postoperative neuralgias have a deleterious effect on all patient-reported outcomes . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Outcome_Physical, Intervention_Surgical, Outcome_Pain

[ "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Patient-reported outcomes after inguinal herniorrhaphy . BACKGROUND Patient-reported outcomes ( PRO ) reflect the functional outcomes of inguinal herniorrhaphy . We studied the effect of hernia recurrence and complications on PRO for participants in the Veterans Affairs trial of Open or Laparoscopic Repair of Inguinal Hernia . METHODS Analyzed PRO included ( 1 ) the Medical Outcomes Study Short Form 36 , version 2 , ( 2 ) the Surgical Pain Scale , ( 3 ) the Activities Assessment Scale , and ( 4 ) patient satisfaction . Recurrences and complications were recorded at follow-up visits . Complications were categorized by ( 1 ) hematoma/seroma , ( 2 ) orchitis , ( 3 ) neuralgia , and ( 4 ) other . Univariate and multivariable regression analyses identified variables significantly associated with postoperative PRO . RESULTS Of the 1603 patients with PRO data , 105 had a recurrence and 342 had a complication at 2 years . Multivariable analyses showed neuralgia ( P < .0005 ) adversely affected all PRO , and recurrence ( P < .05 ) affected patient-reported pain , activity , and satisfaction , but not the score for the Medical Outcomes Study Short Form 3 . Patients with a recurrence after open repair had more pain than those with a recurrence after laparoscopic repair ( P = .0001 ) . Patients with other complications after laparoscopic repair reported more pain and less activity than those with other complications after open repair ( P = .003 and P = .009 , respectively ) . CONCLUSIONS The effectiveness of inguinal herniorrhaphy should be measured by the rate of recurrence and neuralgia . Postoperative neuralgias have a deleterious effect on all patient-reported outcomes .

[ "Patient", "-", "reported", "outcomes", "after", "inguinal", "herniorrhaphy", ".", "BACKGROUND", "Patient", "-", "reported", "outcomes", "(", "PRO", ")", "reflect", "the", "functional", "outcomes", "of", "inguinal", "herniorrhaphy", ".", "We", "studied", "the", "effect", "of", "hernia", "recurrence", "and", "complications", "on", "PRO", "for", "participants", "in", "the", "Veterans", "Affairs", "trial", "of", "Open", "or", "Laparoscopic", "Repair", "of", "Inguinal", "Hernia", ".", "METHODS", "Analyzed", "PRO", "included", "(", "1", ")", "the", "Medical", "Outcomes", "Study", "Short", "Form", "36", ",", "version", "2", ",", "(", "2", ")", "the", "Surgical", "Pain", "Scale", ",", "(", "3", ")", "the", "Activities", "Assessment", "Scale", ",", "and", "(", "4", ")", "patient", "satisfaction", ".", "Recurrences", "and", "complications", "were", "recorded", "at", "follow", "-", "up", "visits", ".", "Complications", "were", "categorized", "by", "(", "1", ")", "hematoma", "/", "seroma", ",", "(", "2", ")", "orchitis", ",", "(", "3", ")", "neuralgia", ",", "and", "(", "4", ")", "other", ".", "Univariate", "and", "multivariable", "regression", "analyses", "identified", "variables", "significantly", "associated", "with", "postoperative", "PRO", ".", "RESULTS", "Of", "the", "1603", "patients", "with", "PRO", "data", ",", "105", "had", "a", "recurrence", "and", "342", "had", "a", "complication", "at", "2", "years", ".", "Multivariable", "analyses", "showed", "neuralgia", "(", "P", "<", ".0005", ")", "adversely", "affected", "all", "PRO", ",", "and", "recurrence", "(", "P", "<", ".05", ")", "affected", "patient", "-", "reported", "pain", ",", "activity", ",", "and", "satisfaction", ",", "but", "not", "the", "score", "for", "the", "Medical", "Outcomes", "Study", "Short", "Form", "3", ".", "Patients", "with", "a", "recurrence", "after", "open", "repair", "had", "more", "pain", "than", "those", "with", "a", "recurrence", "after", "laparoscopic", "repair", "(", "P", "=", ".0001", ")", ".", "Patients", "with", "other", "complications", "after", "laparoscopic", "repair", "reported", "more", "pain", "and", "less", "activity", "than", "those", "with", "other", "complications", "after", "open", "repair", "(", "P", "=", ".003", "and", "P", "=", ".009", ",", "respectively", ")", ".", "CONCLUSIONS", "The", "effectiveness", "of", "inguinal", "herniorrhaphy", "should", "be", "measured", "by", "the", "rate", "of", "recurrence", "and", "neuralgia", ".", "Postoperative", "neuralgias", "have", "a", "deleterious", "effect", "on", "all", "patient", "-", "reported", "outcomes", "." ]

[ "Outcome_Other", "Intervention_Surgical", "Outcome_Pain", "Outcome_Physical" ]

inguinal herniorrhaphy . is a Intervention_Surgical, recurrence is a Outcome_Physical, satisfaction is a Outcome_Other, hematoma / seroma is a Outcome_Physical, orchitis is a Outcome_Physical, neuralgia is a Outcome_Physical, patient - reported pain is a Outcome_Pain, activity is a Outcome_Physical, less activity is a Outcome_Physical

27502_task1

Sentence: Patient-reported outcomes after inguinal herniorrhaphy . BACKGROUND Patient-reported outcomes ( PRO ) reflect the functional outcomes of inguinal herniorrhaphy . We studied the effect of hernia recurrence and complications on PRO for participants in the Veterans Affairs trial of Open or Laparoscopic Repair of Inguinal Hernia . METHODS Analyzed PRO included ( 1 ) the Medical Outcomes Study Short Form 36 , version 2 , ( 2 ) the Surgical Pain Scale , ( 3 ) the Activities Assessment Scale , and ( 4 ) patient satisfaction . Recurrences and complications were recorded at follow-up visits . Complications were categorized by ( 1 ) hematoma/seroma , ( 2 ) orchitis , ( 3 ) neuralgia , and ( 4 ) other . Univariate and multivariable regression analyses identified variables significantly associated with postoperative PRO . RESULTS Of the 1603 patients with PRO data , 105 had a recurrence and 342 had a complication at 2 years . Multivariable analyses showed neuralgia ( P < .0005 ) adversely affected all PRO , and recurrence ( P < .05 ) affected patient-reported pain , activity , and satisfaction , but not the score for the Medical Outcomes Study Short Form 3 . Patients with a recurrence after open repair had more pain than those with a recurrence after laparoscopic repair ( P = .0001 ) . Patients with other complications after laparoscopic repair reported more pain and less activity than those with other complications after open repair ( P = .003 and P = .009 , respectively ) . CONCLUSIONS The effectiveness of inguinal herniorrhaphy should be measured by the rate of recurrence and neuralgia . Postoperative neuralgias have a deleterious effect on all patient-reported outcomes . Instructions: please typing these entity words according to sentence: inguinal herniorrhaphy ., recurrence, satisfaction, hematoma / seroma, orchitis, neuralgia, patient - reported pain, activity, less activity Options: Outcome_Other, Outcome_Physical, Intervention_Surgical, Outcome_Pain

[ "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Patient-reported outcomes after inguinal herniorrhaphy . BACKGROUND Patient-reported outcomes ( PRO ) reflect the functional outcomes of inguinal herniorrhaphy . We studied the effect of hernia recurrence and complications on PRO for participants in the Veterans Affairs trial of Open or Laparoscopic Repair of Inguinal Hernia . METHODS Analyzed PRO included ( 1 ) the Medical Outcomes Study Short Form 36 , version 2 , ( 2 ) the Surgical Pain Scale , ( 3 ) the Activities Assessment Scale , and ( 4 ) patient satisfaction . Recurrences and complications were recorded at follow-up visits . Complications were categorized by ( 1 ) hematoma/seroma , ( 2 ) orchitis , ( 3 ) neuralgia , and ( 4 ) other . Univariate and multivariable regression analyses identified variables significantly associated with postoperative PRO . RESULTS Of the 1603 patients with PRO data , 105 had a recurrence and 342 had a complication at 2 years . Multivariable analyses showed neuralgia ( P < .0005 ) adversely affected all PRO , and recurrence ( P < .05 ) affected patient-reported pain , activity , and satisfaction , but not the score for the Medical Outcomes Study Short Form 3 . Patients with a recurrence after open repair had more pain than those with a recurrence after laparoscopic repair ( P = .0001 ) . Patients with other complications after laparoscopic repair reported more pain and less activity than those with other complications after open repair ( P = .003 and P = .009 , respectively ) . CONCLUSIONS The effectiveness of inguinal herniorrhaphy should be measured by the rate of recurrence and neuralgia . Postoperative neuralgias have a deleterious effect on all patient-reported outcomes .

[ "Patient", "-", "reported", "outcomes", "after", "inguinal", "herniorrhaphy", ".", "BACKGROUND", "Patient", "-", "reported", "outcomes", "(", "PRO", ")", "reflect", "the", "functional", "outcomes", "of", "inguinal", "herniorrhaphy", ".", "We", "studied", "the", "effect", "of", "hernia", "recurrence", "and", "complications", "on", "PRO", "for", "participants", "in", "the", "Veterans", "Affairs", "trial", "of", "Open", "or", "Laparoscopic", "Repair", "of", "Inguinal", "Hernia", ".", "METHODS", "Analyzed", "PRO", "included", "(", "1", ")", "the", "Medical", "Outcomes", "Study", "Short", "Form", "36", ",", "version", "2", ",", "(", "2", ")", "the", "Surgical", "Pain", "Scale", ",", "(", "3", ")", "the", "Activities", "Assessment", "Scale", ",", "and", "(", "4", ")", "patient", "satisfaction", ".", "Recurrences", "and", "complications", "were", "recorded", "at", "follow", "-", "up", "visits", ".", "Complications", "were", "categorized", "by", "(", "1", ")", "hematoma", "/", "seroma", ",", "(", "2", ")", "orchitis", ",", "(", "3", ")", "neuralgia", ",", "and", "(", "4", ")", "other", ".", "Univariate", "and", "multivariable", "regression", "analyses", "identified", "variables", "significantly", "associated", "with", "postoperative", "PRO", ".", "RESULTS", "Of", "the", "1603", "patients", "with", "PRO", "data", ",", "105", "had", "a", "recurrence", "and", "342", "had", "a", "complication", "at", "2", "years", ".", "Multivariable", "analyses", "showed", "neuralgia", "(", "P", "<", ".0005", ")", "adversely", "affected", "all", "PRO", ",", "and", "recurrence", "(", "P", "<", ".05", ")", "affected", "patient", "-", "reported", "pain", ",", "activity", ",", "and", "satisfaction", ",", "but", "not", "the", "score", "for", "the", "Medical", "Outcomes", "Study", "Short", "Form", "3", ".", "Patients", "with", "a", "recurrence", "after", "open", "repair", "had", "more", "pain", "than", "those", "with", "a", "recurrence", "after", "laparoscopic", "repair", "(", "P", "=", ".0001", ")", ".", "Patients", "with", "other", "complications", "after", "laparoscopic", "repair", "reported", "more", "pain", "and", "less", "activity", "than", "those", "with", "other", "complications", "after", "open", "repair", "(", "P", "=", ".003", "and", "P", "=", ".009", ",", "respectively", ")", ".", "CONCLUSIONS", "The", "effectiveness", "of", "inguinal", "herniorrhaphy", "should", "be", "measured", "by", "the", "rate", "of", "recurrence", "and", "neuralgia", ".", "Postoperative", "neuralgias", "have", "a", "deleterious", "effect", "on", "all", "patient", "-", "reported", "outcomes", "." ]

[ "Outcome_Other", "Intervention_Surgical", "Outcome_Pain", "Outcome_Physical" ]

inguinal herniorrhaphy ., recurrence, satisfaction, hematoma / seroma, orchitis, neuralgia, patient - reported pain, activity, less activity

27502_task2

Sentence: Patient-reported outcomes after inguinal herniorrhaphy . BACKGROUND Patient-reported outcomes ( PRO ) reflect the functional outcomes of inguinal herniorrhaphy . We studied the effect of hernia recurrence and complications on PRO for participants in the Veterans Affairs trial of Open or Laparoscopic Repair of Inguinal Hernia . METHODS Analyzed PRO included ( 1 ) the Medical Outcomes Study Short Form 36 , version 2 , ( 2 ) the Surgical Pain Scale , ( 3 ) the Activities Assessment Scale , and ( 4 ) patient satisfaction . Recurrences and complications were recorded at follow-up visits . Complications were categorized by ( 1 ) hematoma/seroma , ( 2 ) orchitis , ( 3 ) neuralgia , and ( 4 ) other . Univariate and multivariable regression analyses identified variables significantly associated with postoperative PRO . RESULTS Of the 1603 patients with PRO data , 105 had a recurrence and 342 had a complication at 2 years . Multivariable analyses showed neuralgia ( P < .0005 ) adversely affected all PRO , and recurrence ( P < .05 ) affected patient-reported pain , activity , and satisfaction , but not the score for the Medical Outcomes Study Short Form 3 . Patients with a recurrence after open repair had more pain than those with a recurrence after laparoscopic repair ( P = .0001 ) . Patients with other complications after laparoscopic repair reported more pain and less activity than those with other complications after open repair ( P = .003 and P = .009 , respectively ) . CONCLUSIONS The effectiveness of inguinal herniorrhaphy should be measured by the rate of recurrence and neuralgia . Postoperative neuralgias have a deleterious effect on all patient-reported outcomes . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Patient-reported outcomes after inguinal herniorrhaphy . BACKGROUND Patient-reported outcomes ( PRO ) reflect the functional outcomes of inguinal herniorrhaphy . We studied the effect of hernia recurrence and complications on PRO for participants in the Veterans Affairs trial of Open or Laparoscopic Repair of Inguinal Hernia . METHODS Analyzed PRO included ( 1 ) the Medical Outcomes Study Short Form 36 , version 2 , ( 2 ) the Surgical Pain Scale , ( 3 ) the Activities Assessment Scale , and ( 4 ) patient satisfaction . Recurrences and complications were recorded at follow-up visits . Complications were categorized by ( 1 ) hematoma/seroma , ( 2 ) orchitis , ( 3 ) neuralgia , and ( 4 ) other . Univariate and multivariable regression analyses identified variables significantly associated with postoperative PRO . RESULTS Of the 1603 patients with PRO data , 105 had a recurrence and 342 had a complication at 2 years . Multivariable analyses showed neuralgia ( P < .0005 ) adversely affected all PRO , and recurrence ( P < .05 ) affected patient-reported pain , activity , and satisfaction , but not the score for the Medical Outcomes Study Short Form 3 . Patients with a recurrence after open repair had more pain than those with a recurrence after laparoscopic repair ( P = .0001 ) . Patients with other complications after laparoscopic repair reported more pain and less activity than those with other complications after open repair ( P = .003 and P = .009 , respectively ) . CONCLUSIONS The effectiveness of inguinal herniorrhaphy should be measured by the rate of recurrence and neuralgia . Postoperative neuralgias have a deleterious effect on all patient-reported outcomes .

[ "Patient", "-", "reported", "outcomes", "after", "inguinal", "herniorrhaphy", ".", "BACKGROUND", "Patient", "-", "reported", "outcomes", "(", "PRO", ")", "reflect", "the", "functional", "outcomes", "of", "inguinal", "herniorrhaphy", ".", "We", "studied", "the", "effect", "of", "hernia", "recurrence", "and", "complications", "on", "PRO", "for", "participants", "in", "the", "Veterans", "Affairs", "trial", "of", "Open", "or", "Laparoscopic", "Repair", "of", "Inguinal", "Hernia", ".", "METHODS", "Analyzed", "PRO", "included", "(", "1", ")", "the", "Medical", "Outcomes", "Study", "Short", "Form", "36", ",", "version", "2", ",", "(", "2", ")", "the", "Surgical", "Pain", "Scale", ",", "(", "3", ")", "the", "Activities", "Assessment", "Scale", ",", "and", "(", "4", ")", "patient", "satisfaction", ".", "Recurrences", "and", "complications", "were", "recorded", "at", "follow", "-", "up", "visits", ".", "Complications", "were", "categorized", "by", "(", "1", ")", "hematoma", "/", "seroma", ",", "(", "2", ")", "orchitis", ",", "(", "3", ")", "neuralgia", ",", "and", "(", "4", ")", "other", ".", "Univariate", "and", "multivariable", "regression", "analyses", "identified", "variables", "significantly", "associated", "with", "postoperative", "PRO", ".", "RESULTS", "Of", "the", "1603", "patients", "with", "PRO", "data", ",", "105", "had", "a", "recurrence", "and", "342", "had", "a", "complication", "at", "2", "years", ".", "Multivariable", "analyses", "showed", "neuralgia", "(", "P", "<", ".0005", ")", "adversely", "affected", "all", "PRO", ",", "and", "recurrence", "(", "P", "<", ".05", ")", "affected", "patient", "-", "reported", "pain", ",", "activity", ",", "and", "satisfaction", ",", "but", "not", "the", "score", "for", "the", "Medical", "Outcomes", "Study", "Short", "Form", "3", ".", "Patients", "with", "a", "recurrence", "after", "open", "repair", "had", "more", "pain", "than", "those", "with", "a", "recurrence", "after", "laparoscopic", "repair", "(", "P", "=", ".0001", ")", ".", "Patients", "with", "other", "complications", "after", "laparoscopic", "repair", "reported", "more", "pain", "and", "less", "activity", "than", "those", "with", "other", "complications", "after", "open", "repair", "(", "P", "=", ".003", "and", "P", "=", ".009", ",", "respectively", ")", ".", "CONCLUSIONS", "The", "effectiveness", "of", "inguinal", "herniorrhaphy", "should", "be", "measured", "by", "the", "rate", "of", "recurrence", "and", "neuralgia", ".", "Postoperative", "neuralgias", "have", "a", "deleterious", "effect", "on", "all", "patient", "-", "reported", "outcomes", "." ]

[ "Outcome_Other", "Intervention_Surgical", "Outcome_Pain", "Outcome_Physical" ]

genes is a Entity, p53 is a Protein, Bcl-2 is a Protein

372_task0

Sentence: The effect of Toremifene on the expression of some genes in human mononuclear cells. Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells. After short-term, in vitro exposure to therapeutical levels, distinct changes in P-glycoprotein, steroid receptors, p53 and Bcl-2 expression take place. In view of the increasing use of antiestrogens in cancer therapy and prevention, there is obvious merit in long-term in vivo studies to be conducted. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The effect of Toremifene on the expression of some genes in human mononuclear cells. Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells. After short-term, in vitro exposure to therapeutical levels, distinct changes in P-glycoprotein, steroid receptors, p53 and Bcl-2 expression take place. In view of the increasing use of antiestrogens in cancer therapy and prevention, there is obvious merit in long-term in vivo studies to be conducted.

[ "The", "effect", "of", "Toremifene", "on", "the", "expression", "of", "some", "genes", "in", "human", "mononuclear", "cells", ".", "\n", "Toremifene", "exerts", "multiple", "and", "varied", "effects", "on", "the", "gene", "expression", "of", "human", "peripheral", "mononuclear", "cells", ".", "After", "short", "-", "term", ",", "in", "vitro", "exposure", "to", "therapeutical", "levels", ",", "distinct", "changes", "in", "P", "-", "glycoprotein", ",", "steroid", "receptors", ",", "p53", "and", "Bcl-2", "expression", "take", "place", ".", "In", "view", "of", "the", "increasing", "use", "of", "antiestrogens", "in", "cancer", "therapy", "and", "prevention", ",", "there", "is", "obvious", "merit", "in", "long", "-", "term", "in", "vivo", "studies", "to", "be", "conducted", ".", "\n" ]

[ "Protein", "Entity" ]

genes is a Entity, p53 is a Protein, Bcl-2 is a Protein

372_task1

Sentence: The effect of Toremifene on the expression of some genes in human mononuclear cells. Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells. After short-term, in vitro exposure to therapeutical levels, distinct changes in P-glycoprotein, steroid receptors, p53 and Bcl-2 expression take place. In view of the increasing use of antiestrogens in cancer therapy and prevention, there is obvious merit in long-term in vivo studies to be conducted. Instructions: please typing these entity words according to sentence: genes, p53, Bcl-2 Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The effect of Toremifene on the expression of some genes in human mononuclear cells. Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells. After short-term, in vitro exposure to therapeutical levels, distinct changes in P-glycoprotein, steroid receptors, p53 and Bcl-2 expression take place. In view of the increasing use of antiestrogens in cancer therapy and prevention, there is obvious merit in long-term in vivo studies to be conducted.

[ "The", "effect", "of", "Toremifene", "on", "the", "expression", "of", "some", "genes", "in", "human", "mononuclear", "cells", ".", "\n", "Toremifene", "exerts", "multiple", "and", "varied", "effects", "on", "the", "gene", "expression", "of", "human", "peripheral", "mononuclear", "cells", ".", "After", "short", "-", "term", ",", "in", "vitro", "exposure", "to", "therapeutical", "levels", ",", "distinct", "changes", "in", "P", "-", "glycoprotein", ",", "steroid", "receptors", ",", "p53", "and", "Bcl-2", "expression", "take", "place", ".", "In", "view", "of", "the", "increasing", "use", "of", "antiestrogens", "in", "cancer", "therapy", "and", "prevention", ",", "there", "is", "obvious", "merit", "in", "long", "-", "term", "in", "vivo", "studies", "to", "be", "conducted", ".", "\n" ]

[ "Protein", "Entity" ]

genes, p53, Bcl-2

372_task2

Sentence: The effect of Toremifene on the expression of some genes in human mononuclear cells. Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells. After short-term, in vitro exposure to therapeutical levels, distinct changes in P-glycoprotein, steroid receptors, p53 and Bcl-2 expression take place. In view of the increasing use of antiestrogens in cancer therapy and prevention, there is obvious merit in long-term in vivo studies to be conducted. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The effect of Toremifene on the expression of some genes in human mononuclear cells. Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells. After short-term, in vitro exposure to therapeutical levels, distinct changes in P-glycoprotein, steroid receptors, p53 and Bcl-2 expression take place. In view of the increasing use of antiestrogens in cancer therapy and prevention, there is obvious merit in long-term in vivo studies to be conducted.

[ "The", "effect", "of", "Toremifene", "on", "the", "expression", "of", "some", "genes", "in", "human", "mononuclear", "cells", ".", "\n", "Toremifene", "exerts", "multiple", "and", "varied", "effects", "on", "the", "gene", "expression", "of", "human", "peripheral", "mononuclear", "cells", ".", "After", "short", "-", "term", ",", "in", "vitro", "exposure", "to", "therapeutical", "levels", ",", "distinct", "changes", "in", "P", "-", "glycoprotein", ",", "steroid", "receptors", ",", "p53", "and", "Bcl-2", "expression", "take", "place", ".", "In", "view", "of", "the", "increasing", "use", "of", "antiestrogens", "in", "cancer", "therapy", "and", "prevention", ",", "there", "is", "obvious", "merit", "in", "long", "-", "term", "in", "vivo", "studies", "to", "be", "conducted", ".", "\n" ]

[ "Protein", "Entity" ]

Gastrektomie is an umlsterm, Knochenstoffwechsels is an umlsterm, Parathormon is an umlsterm, Calcium is an umlsterm, Knochen is an umlsterm, Patienten is an umlsterm, Knochenmasse is an umlsterm, Vitamin D is an umlsterm, Calcium is an umlsterm, Knochenstoffwechsels is an umlsterm, Gastrektomie is an umlsterm

DerChirurg.70680784.ger.abstr_task0

Sentence: Zusammenfassung . Nach Magenresektion oder Gastrektomie sind Stoerungen der Calcium- und Knochenstoffwechsels bekannt . Wahrscheinlich kommt es postoperativ aufgrund einer verminderten Calciumabsorption zu einem Abfall des Serumcalciums . Als Gegenregulation wird Parathormon ausgeschuettet und 1,25-(OH)2-Vitamin D neu gebildet , welche beide Calcium aus dem Knochen mobilisieren . Bei einem Teil der Patienten kommt es in der Folge zu einer Abnahme der Knochenmasse mit einem erhoehten Frakturrisiko . Bisher liegen keine anerkannten Behandlungsempfehlungen dieser Stoerungen vor , lediglich die Substitution von Vitamin D und Calcium wurde wiederholt empfohlen . Es wird eine Uebersicht ueber die derzeitigen Vorstellungen zur Regulation des Calcium- und Knochenstoffwechsels nach Gastrektomie gegeben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Zusammenfassung . Nach Magenresektion oder Gastrektomie sind Stoerungen der Calcium- und Knochenstoffwechsels bekannt . Wahrscheinlich kommt es postoperativ aufgrund einer verminderten Calciumabsorption zu einem Abfall des Serumcalciums . Als Gegenregulation wird Parathormon ausgeschuettet und 1,25-(OH)2-Vitamin D neu gebildet , welche beide Calcium aus dem Knochen mobilisieren . Bei einem Teil der Patienten kommt es in der Folge zu einer Abnahme der Knochenmasse mit einem erhoehten Frakturrisiko . Bisher liegen keine anerkannten Behandlungsempfehlungen dieser Stoerungen vor , lediglich die Substitution von Vitamin D und Calcium wurde wiederholt empfohlen . Es wird eine Uebersicht ueber die derzeitigen Vorstellungen zur Regulation des Calcium- und Knochenstoffwechsels nach Gastrektomie gegeben .

[ "Zusammenfassung", ".", "Nach", "Magenresektion", "oder", "Gastrektomie", "sind", "Stoerungen", "der", "Calcium-", "und", "Knochenstoffwechsels", "bekannt", ".", "Wahrscheinlich", "kommt", "es", "postoperativ", "aufgrund", "einer", "verminderten", "Calciumabsorption", "zu", "einem", "Abfall", "des", "Serumcalciums", ".", "Als", "Gegenregulation", "wird", "Parathormon", "ausgeschuettet", "und", "1,25-(OH)2-Vitamin", "D", "neu", "gebildet", ",", "welche", "beide", "Calcium", "aus", "dem", "Knochen", "mobilisieren", ".", "Bei", "einem", "Teil", "der", "Patienten", "kommt", "es", "in", "der", "Folge", "zu", "einer", "Abnahme", "der", "Knochenmasse", "mit", "einem", "erhoehten", "Frakturrisiko", ".", "Bisher", "liegen", "keine", "anerkannten", "Behandlungsempfehlungen", "dieser", "Stoerungen", "vor", ",", "lediglich", "die", "Substitution", "von", "Vitamin", "D", "und", "Calcium", "wurde", "wiederholt", "empfohlen", ".", "Es", "wird", "eine", "Uebersicht", "ueber", "die", "derzeitigen", "Vorstellungen", "zur", "Regulation", "des", "Calcium-", "und", "Knochenstoffwechsels", "nach", "Gastrektomie", "gegeben", "." ]

[ "umlsterm" ]

Gastrektomie is an umlsterm, Knochenstoffwechsels is an umlsterm, Parathormon is an umlsterm, Calcium is an umlsterm, Knochen is an umlsterm, Patienten is an umlsterm, Knochenmasse is an umlsterm, Vitamin D is an umlsterm, Calcium is an umlsterm, Knochenstoffwechsels is an umlsterm, Gastrektomie is an umlsterm

DerChirurg.70680784.ger.abstr_task1

Sentence: Zusammenfassung . Nach Magenresektion oder Gastrektomie sind Stoerungen der Calcium- und Knochenstoffwechsels bekannt . Wahrscheinlich kommt es postoperativ aufgrund einer verminderten Calciumabsorption zu einem Abfall des Serumcalciums . Als Gegenregulation wird Parathormon ausgeschuettet und 1,25-(OH)2-Vitamin D neu gebildet , welche beide Calcium aus dem Knochen mobilisieren . Bei einem Teil der Patienten kommt es in der Folge zu einer Abnahme der Knochenmasse mit einem erhoehten Frakturrisiko . Bisher liegen keine anerkannten Behandlungsempfehlungen dieser Stoerungen vor , lediglich die Substitution von Vitamin D und Calcium wurde wiederholt empfohlen . Es wird eine Uebersicht ueber die derzeitigen Vorstellungen zur Regulation des Calcium- und Knochenstoffwechsels nach Gastrektomie gegeben . Instructions: please typing these entity words according to sentence: Gastrektomie, Knochenstoffwechsels, Parathormon, Calcium, Knochen, Patienten, Knochenmasse, Vitamin D, Calcium, Knochenstoffwechsels, Gastrektomie Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Zusammenfassung . Nach Magenresektion oder Gastrektomie sind Stoerungen der Calcium- und Knochenstoffwechsels bekannt . Wahrscheinlich kommt es postoperativ aufgrund einer verminderten Calciumabsorption zu einem Abfall des Serumcalciums . Als Gegenregulation wird Parathormon ausgeschuettet und 1,25-(OH)2-Vitamin D neu gebildet , welche beide Calcium aus dem Knochen mobilisieren . Bei einem Teil der Patienten kommt es in der Folge zu einer Abnahme der Knochenmasse mit einem erhoehten Frakturrisiko . Bisher liegen keine anerkannten Behandlungsempfehlungen dieser Stoerungen vor , lediglich die Substitution von Vitamin D und Calcium wurde wiederholt empfohlen . Es wird eine Uebersicht ueber die derzeitigen Vorstellungen zur Regulation des Calcium- und Knochenstoffwechsels nach Gastrektomie gegeben .

[ "Zusammenfassung", ".", "Nach", "Magenresektion", "oder", "Gastrektomie", "sind", "Stoerungen", "der", "Calcium-", "und", "Knochenstoffwechsels", "bekannt", ".", "Wahrscheinlich", "kommt", "es", "postoperativ", "aufgrund", "einer", "verminderten", "Calciumabsorption", "zu", "einem", "Abfall", "des", "Serumcalciums", ".", "Als", "Gegenregulation", "wird", "Parathormon", "ausgeschuettet", "und", "1,25-(OH)2-Vitamin", "D", "neu", "gebildet", ",", "welche", "beide", "Calcium", "aus", "dem", "Knochen", "mobilisieren", ".", "Bei", "einem", "Teil", "der", "Patienten", "kommt", "es", "in", "der", "Folge", "zu", "einer", "Abnahme", "der", "Knochenmasse", "mit", "einem", "erhoehten", "Frakturrisiko", ".", "Bisher", "liegen", "keine", "anerkannten", "Behandlungsempfehlungen", "dieser", "Stoerungen", "vor", ",", "lediglich", "die", "Substitution", "von", "Vitamin", "D", "und", "Calcium", "wurde", "wiederholt", "empfohlen", ".", "Es", "wird", "eine", "Uebersicht", "ueber", "die", "derzeitigen", "Vorstellungen", "zur", "Regulation", "des", "Calcium-", "und", "Knochenstoffwechsels", "nach", "Gastrektomie", "gegeben", "." ]

[ "umlsterm" ]

Gastrektomie, Knochenstoffwechsels, Parathormon, Calcium, Knochen, Patienten, Knochenmasse, Vitamin D, Calcium, Knochenstoffwechsels, Gastrektomie

DerChirurg.70680784.ger.abstr_task2

Sentence: Zusammenfassung . Nach Magenresektion oder Gastrektomie sind Stoerungen der Calcium- und Knochenstoffwechsels bekannt . Wahrscheinlich kommt es postoperativ aufgrund einer verminderten Calciumabsorption zu einem Abfall des Serumcalciums . Als Gegenregulation wird Parathormon ausgeschuettet und 1,25-(OH)2-Vitamin D neu gebildet , welche beide Calcium aus dem Knochen mobilisieren . Bei einem Teil der Patienten kommt es in der Folge zu einer Abnahme der Knochenmasse mit einem erhoehten Frakturrisiko . Bisher liegen keine anerkannten Behandlungsempfehlungen dieser Stoerungen vor , lediglich die Substitution von Vitamin D und Calcium wurde wiederholt empfohlen . Es wird eine Uebersicht ueber die derzeitigen Vorstellungen zur Regulation des Calcium- und Knochenstoffwechsels nach Gastrektomie gegeben . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Zusammenfassung . Nach Magenresektion oder Gastrektomie sind Stoerungen der Calcium- und Knochenstoffwechsels bekannt . Wahrscheinlich kommt es postoperativ aufgrund einer verminderten Calciumabsorption zu einem Abfall des Serumcalciums . Als Gegenregulation wird Parathormon ausgeschuettet und 1,25-(OH)2-Vitamin D neu gebildet , welche beide Calcium aus dem Knochen mobilisieren . Bei einem Teil der Patienten kommt es in der Folge zu einer Abnahme der Knochenmasse mit einem erhoehten Frakturrisiko . Bisher liegen keine anerkannten Behandlungsempfehlungen dieser Stoerungen vor , lediglich die Substitution von Vitamin D und Calcium wurde wiederholt empfohlen . Es wird eine Uebersicht ueber die derzeitigen Vorstellungen zur Regulation des Calcium- und Knochenstoffwechsels nach Gastrektomie gegeben .

[ "Zusammenfassung", ".", "Nach", "Magenresektion", "oder", "Gastrektomie", "sind", "Stoerungen", "der", "Calcium-", "und", "Knochenstoffwechsels", "bekannt", ".", "Wahrscheinlich", "kommt", "es", "postoperativ", "aufgrund", "einer", "verminderten", "Calciumabsorption", "zu", "einem", "Abfall", "des", "Serumcalciums", ".", "Als", "Gegenregulation", "wird", "Parathormon", "ausgeschuettet", "und", "1,25-(OH)2-Vitamin", "D", "neu", "gebildet", ",", "welche", "beide", "Calcium", "aus", "dem", "Knochen", "mobilisieren", ".", "Bei", "einem", "Teil", "der", "Patienten", "kommt", "es", "in", "der", "Folge", "zu", "einer", "Abnahme", "der", "Knochenmasse", "mit", "einem", "erhoehten", "Frakturrisiko", ".", "Bisher", "liegen", "keine", "anerkannten", "Behandlungsempfehlungen", "dieser", "Stoerungen", "vor", ",", "lediglich", "die", "Substitution", "von", "Vitamin", "D", "und", "Calcium", "wurde", "wiederholt", "empfohlen", ".", "Es", "wird", "eine", "Uebersicht", "ueber", "die", "derzeitigen", "Vorstellungen", "zur", "Regulation", "des", "Calcium-", "und", "Knochenstoffwechsels", "nach", "Gastrektomie", "gegeben", "." ]

[ "umlsterm" ]

Mycobacterium tuberculosis is a Microorganism, apoptotic cells is a Habitat, DCs is a Habitat, Mycobacterium tuberculosis is a Microorganism, Mtb is a Microorganism, DC is a Habitat, DCs is a Habitat, DC is a Habitat, Annexin1-deficient mice is a Habitat, Mtb is a Microorganism, Mtb is a Microorganism, CD8 + T cell is a Habitat, Mtb - infected human blood monocyte - derived DCs is a Habitat, Mtb is a Microorganism, Mtb is a Microorganism, DC is a Habitat

45_task0

Sentence: Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. The phagocytosis of apoptotic cells and associated vesicles (efferocytosis) by DCs is an important mechanism for both self tolerance and host defense. Although some of the engulfment ligands involved in efferocytosis have been identified and studied in vitro, the contributions of these ligands in vivo remain ill defined. Here, we determined that during Mycobacterium tuberculosis (Mtb) infection, the engulfment ligand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs and intrinsically enhances the capacity of the DC antigen-presenting machinery. Annexin1-deficient mice were highly susceptible to Mtb infection and showed an impaired Mtb antigen-specific CD8+ T cell response. Importantly, annexin1 expression was greatly downregulated in Mtb-infected human blood monocyte-derived DCs, indicating that reduction of annexin1 is a critical mechanism for immune evasion by Mtb. Collectively, these data indicate that annexin1 is essential in immunity to Mtb infection and mediates the power of DC efferocytosis and cross-presentation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Habitat

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O" ]

Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. The phagocytosis of apoptotic cells and associated vesicles (efferocytosis) by DCs is an important mechanism for both self tolerance and host defense. Although some of the engulfment ligands involved in efferocytosis have been identified and studied in vitro, the contributions of these ligands in vivo remain ill defined. Here, we determined that during Mycobacterium tuberculosis (Mtb) infection, the engulfment ligand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs and intrinsically enhances the capacity of the DC antigen-presenting machinery. Annexin1-deficient mice were highly susceptible to Mtb infection and showed an impaired Mtb antigen-specific CD8+ T cell response. Importantly, annexin1 expression was greatly downregulated in Mtb-infected human blood monocyte-derived DCs, indicating that reduction of annexin1 is a critical mechanism for immune evasion by Mtb. Collectively, these data indicate that annexin1 is essential in immunity to Mtb infection and mediates the power of DC efferocytosis and cross-presentation.

[ "Annexin1", "regulates", "DC", "efferocytosis", "and", "cross", "-", "presentation", "during", "Mycobacterium", "tuberculosis", "infection", ".", "The", "phagocytosis", "of", "apoptotic", "cells", "and", "associated", "vesicles", "(", "efferocytosis", ")", "by", "DCs", "is", "an", "important", "mechanism", "for", "both", "self", "tolerance", "and", "host", "defense", ".", "Although", "some", "of", "the", "engulfment", "ligands", "involved", "in", "efferocytosis", "have", "been", "identified", "and", "studied", "in", "vitro", ",", "the", "contributions", "of", "these", "ligands", "in", "vivo", "remain", "ill", "defined", ".", "Here", ",", "we", "determined", "that", "during", "Mycobacterium", "tuberculosis", "(", "Mtb", ")", "infection", ",", "the", "engulfment", "ligand", "annexin1", "is", "an", "important", "mediator", "in", "DC", "cross", "-", "presentation", "that", "increases", "efferocytosis", "in", "DCs", "and", "intrinsically", "enhances", "the", "capacity", "of", "the", "DC", "antigen", "-", "presenting", "machinery", ".", "Annexin1-deficient", "mice", "were", "highly", "susceptible", "to", "Mtb", "infection", "and", "showed", "an", "impaired", "Mtb", "antigen", "-", "specific", "CD8", "+", "T", "cell", "response", ".", "Importantly", ",", "annexin1", "expression", "was", "greatly", "downregulated", "in", "Mtb", "-", "infected", "human", "blood", "monocyte", "-", "derived", "DCs", ",", "indicating", "that", "reduction", "of", "annexin1", "is", "a", "critical", "mechanism", "for", "immune", "evasion", "by", "Mtb", ".", "Collectively", ",", "these", "data", "indicate", "that", "annexin1", "is", "essential", "in", "immunity", "to", "Mtb", "infection", "and", "mediates", "the", "power", "of", "DC", "efferocytosis", "and", "cross", "-", "presentation", ".", " " ]

[ "Habitat", "Microorganism" ]

Mycobacterium tuberculosis is a Microorganism, apoptotic cells is a Habitat, DCs is a Habitat, Mycobacterium tuberculosis is a Microorganism, Mtb is a Microorganism, DC is a Habitat, DCs is a Habitat, DC is a Habitat, Annexin1-deficient mice is a Habitat, Mtb is a Microorganism, Mtb is a Microorganism, CD8 + T cell is a Habitat, Mtb - infected human blood monocyte - derived DCs is a Habitat, Mtb is a Microorganism, Mtb is a Microorganism, DC is a Habitat

45_task1

Sentence: Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. The phagocytosis of apoptotic cells and associated vesicles (efferocytosis) by DCs is an important mechanism for both self tolerance and host defense. Although some of the engulfment ligands involved in efferocytosis have been identified and studied in vitro, the contributions of these ligands in vivo remain ill defined. Here, we determined that during Mycobacterium tuberculosis (Mtb) infection, the engulfment ligand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs and intrinsically enhances the capacity of the DC antigen-presenting machinery. Annexin1-deficient mice were highly susceptible to Mtb infection and showed an impaired Mtb antigen-specific CD8+ T cell response. Importantly, annexin1 expression was greatly downregulated in Mtb-infected human blood monocyte-derived DCs, indicating that reduction of annexin1 is a critical mechanism for immune evasion by Mtb. Collectively, these data indicate that annexin1 is essential in immunity to Mtb infection and mediates the power of DC efferocytosis and cross-presentation. Instructions: please typing these entity words according to sentence: Mycobacterium tuberculosis, apoptotic cells, DCs, Mycobacterium tuberculosis, Mtb, DC, DCs, DC, Annexin1-deficient mice, Mtb, Mtb, CD8 + T cell, Mtb - infected human blood monocyte - derived DCs, Mtb, Mtb, DC Options: Microorganism, Habitat

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O" ]

Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. The phagocytosis of apoptotic cells and associated vesicles (efferocytosis) by DCs is an important mechanism for both self tolerance and host defense. Although some of the engulfment ligands involved in efferocytosis have been identified and studied in vitro, the contributions of these ligands in vivo remain ill defined. Here, we determined that during Mycobacterium tuberculosis (Mtb) infection, the engulfment ligand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs and intrinsically enhances the capacity of the DC antigen-presenting machinery. Annexin1-deficient mice were highly susceptible to Mtb infection and showed an impaired Mtb antigen-specific CD8+ T cell response. Importantly, annexin1 expression was greatly downregulated in Mtb-infected human blood monocyte-derived DCs, indicating that reduction of annexin1 is a critical mechanism for immune evasion by Mtb. Collectively, these data indicate that annexin1 is essential in immunity to Mtb infection and mediates the power of DC efferocytosis and cross-presentation.

[ "Annexin1", "regulates", "DC", "efferocytosis", "and", "cross", "-", "presentation", "during", "Mycobacterium", "tuberculosis", "infection", ".", "The", "phagocytosis", "of", "apoptotic", "cells", "and", "associated", "vesicles", "(", "efferocytosis", ")", "by", "DCs", "is", "an", "important", "mechanism", "for", "both", "self", "tolerance", "and", "host", "defense", ".", "Although", "some", "of", "the", "engulfment", "ligands", "involved", "in", "efferocytosis", "have", "been", "identified", "and", "studied", "in", "vitro", ",", "the", "contributions", "of", "these", "ligands", "in", "vivo", "remain", "ill", "defined", ".", "Here", ",", "we", "determined", "that", "during", "Mycobacterium", "tuberculosis", "(", "Mtb", ")", "infection", ",", "the", "engulfment", "ligand", "annexin1", "is", "an", "important", "mediator", "in", "DC", "cross", "-", "presentation", "that", "increases", "efferocytosis", "in", "DCs", "and", "intrinsically", "enhances", "the", "capacity", "of", "the", "DC", "antigen", "-", "presenting", "machinery", ".", "Annexin1-deficient", "mice", "were", "highly", "susceptible", "to", "Mtb", "infection", "and", "showed", "an", "impaired", "Mtb", "antigen", "-", "specific", "CD8", "+", "T", "cell", "response", ".", "Importantly", ",", "annexin1", "expression", "was", "greatly", "downregulated", "in", "Mtb", "-", "infected", "human", "blood", "monocyte", "-", "derived", "DCs", ",", "indicating", "that", "reduction", "of", "annexin1", "is", "a", "critical", "mechanism", "for", "immune", "evasion", "by", "Mtb", ".", "Collectively", ",", "these", "data", "indicate", "that", "annexin1", "is", "essential", "in", "immunity", "to", "Mtb", "infection", "and", "mediates", "the", "power", "of", "DC", "efferocytosis", "and", "cross", "-", "presentation", ".", " " ]

[ "Habitat", "Microorganism" ]

Mycobacterium tuberculosis, apoptotic cells, DCs, Mycobacterium tuberculosis, Mtb, DC, DCs, DC, Annexin1-deficient mice, Mtb, Mtb, CD8 + T cell, Mtb - infected human blood monocyte - derived DCs, Mtb, Mtb, DC

45_task2

Sentence: Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. The phagocytosis of apoptotic cells and associated vesicles (efferocytosis) by DCs is an important mechanism for both self tolerance and host defense. Although some of the engulfment ligands involved in efferocytosis have been identified and studied in vitro, the contributions of these ligands in vivo remain ill defined. Here, we determined that during Mycobacterium tuberculosis (Mtb) infection, the engulfment ligand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs and intrinsically enhances the capacity of the DC antigen-presenting machinery. Annexin1-deficient mice were highly susceptible to Mtb infection and showed an impaired Mtb antigen-specific CD8+ T cell response. Importantly, annexin1 expression was greatly downregulated in Mtb-infected human blood monocyte-derived DCs, indicating that reduction of annexin1 is a critical mechanism for immune evasion by Mtb. Collectively, these data indicate that annexin1 is essential in immunity to Mtb infection and mediates the power of DC efferocytosis and cross-presentation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O" ]

Annexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. The phagocytosis of apoptotic cells and associated vesicles (efferocytosis) by DCs is an important mechanism for both self tolerance and host defense. Although some of the engulfment ligands involved in efferocytosis have been identified and studied in vitro, the contributions of these ligands in vivo remain ill defined. Here, we determined that during Mycobacterium tuberculosis (Mtb) infection, the engulfment ligand annexin1 is an important mediator in DC cross-presentation that increases efferocytosis in DCs and intrinsically enhances the capacity of the DC antigen-presenting machinery. Annexin1-deficient mice were highly susceptible to Mtb infection and showed an impaired Mtb antigen-specific CD8+ T cell response. Importantly, annexin1 expression was greatly downregulated in Mtb-infected human blood monocyte-derived DCs, indicating that reduction of annexin1 is a critical mechanism for immune evasion by Mtb. Collectively, these data indicate that annexin1 is essential in immunity to Mtb infection and mediates the power of DC efferocytosis and cross-presentation.

[ "Annexin1", "regulates", "DC", "efferocytosis", "and", "cross", "-", "presentation", "during", "Mycobacterium", "tuberculosis", "infection", ".", "The", "phagocytosis", "of", "apoptotic", "cells", "and", "associated", "vesicles", "(", "efferocytosis", ")", "by", "DCs", "is", "an", "important", "mechanism", "for", "both", "self", "tolerance", "and", "host", "defense", ".", "Although", "some", "of", "the", "engulfment", "ligands", "involved", "in", "efferocytosis", "have", "been", "identified", "and", "studied", "in", "vitro", ",", "the", "contributions", "of", "these", "ligands", "in", "vivo", "remain", "ill", "defined", ".", "Here", ",", "we", "determined", "that", "during", "Mycobacterium", "tuberculosis", "(", "Mtb", ")", "infection", ",", "the", "engulfment", "ligand", "annexin1", "is", "an", "important", "mediator", "in", "DC", "cross", "-", "presentation", "that", "increases", "efferocytosis", "in", "DCs", "and", "intrinsically", "enhances", "the", "capacity", "of", "the", "DC", "antigen", "-", "presenting", "machinery", ".", "Annexin1-deficient", "mice", "were", "highly", "susceptible", "to", "Mtb", "infection", "and", "showed", "an", "impaired", "Mtb", "antigen", "-", "specific", "CD8", "+", "T", "cell", "response", ".", "Importantly", ",", "annexin1", "expression", "was", "greatly", "downregulated", "in", "Mtb", "-", "infected", "human", "blood", "monocyte", "-", "derived", "DCs", ",", "indicating", "that", "reduction", "of", "annexin1", "is", "a", "critical", "mechanism", "for", "immune", "evasion", "by", "Mtb", ".", "Collectively", ",", "these", "data", "indicate", "that", "annexin1", "is", "essential", "in", "immunity", "to", "Mtb", "infection", "and", "mediates", "the", "power", "of", "DC", "efferocytosis", "and", "cross", "-", "presentation", ".", " " ]

[ "Habitat", "Microorganism" ]

Diagnose is an umlsterm, Osteoporose is an umlsterm, Beurteilung is an umlsterm, radiologischen is an umlsterm, Methoden is an umlsterm, Skelett is an umlsterm, Computertomographie is an umlsterm, Ultraschall is an umlsterm, geschlechts- is an umlsterm, rassenspezifischen is an umlsterm, Knochenmasse is an umlsterm, Patienten is an umlsterm, radiologische is an umlsterm, Diagnose is an umlsterm, Osteoporose is an umlsterm, Knochenmasse is an umlsterm, Frakturen is an umlsterm, Spitzenknochenmasse is an umlsterm, Normbevoelkerung is an umlsterm, Knochenmasse is an umlsterm, Patienten is an umlsterm, Staerken is an umlsterm, Technik is an umlsterm

DerRadiologe.90390222.ger.abstr_task0

Sentence: Eine fruehe Diagnose der Osteoporose und eine akkurate Beurteilung von Behandlungserfolgen stehen im Mittelpunkt der radiologischen Bestrebungen . Die haeufigsten klinisch angewendeten Methoden , um das periphere Skelett sowie das Achsensekelett zu beurteilen sind die 2-Spektren-Roentgenabsorptimetrie ( DXA , " dual x-ray absorptiometry " ) , die quantitative Computertomographie ( QCT ) and der quantitative Ultraschall ( QUS ) . Generell werden die Messergebnise eines Individuums mit einer alters- , geschlechts- , und rassenspezifischen Kontrollgruppen verglichen . In diesem Zusammenhang ist die Bestimmung der Knochenmasse ein Indikator des kuenftigen Frakturrisikos eines Patienten . Die radiologische Diagnose der Osteoporose kann durch die Bestimmung der Knochenmasse erfolgen , auch wenn keine praevalenten Frakturen vorliegen . Das Frakturrisiko fuer den Messwert eines Individuums steigt um etwa das 1,5- bis 2,5fache fuer jede Standardabweichung ( SD ) unter der Spitzenknochenmasse der Normbevoelkerung ( T-Wert ) . Die Wahl des Messortes und der Untersuchungstechnik zur Bestimmung der Knochenmasse oder des Frakturrisikos muss sich nach individuellen Gegebenheiten am Patienten sowie den Staerken und Limitationen der Technik richten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]

Eine fruehe Diagnose der Osteoporose und eine akkurate Beurteilung von Behandlungserfolgen stehen im Mittelpunkt der radiologischen Bestrebungen . Die haeufigsten klinisch angewendeten Methoden , um das periphere Skelett sowie das Achsensekelett zu beurteilen sind die 2-Spektren-Roentgenabsorptimetrie ( DXA , " dual x-ray absorptiometry " ) , die quantitative Computertomographie ( QCT ) and der quantitative Ultraschall ( QUS ) . Generell werden die Messergebnise eines Individuums mit einer alters- , geschlechts- , und rassenspezifischen Kontrollgruppen verglichen . In diesem Zusammenhang ist die Bestimmung der Knochenmasse ein Indikator des kuenftigen Frakturrisikos eines Patienten . Die radiologische Diagnose der Osteoporose kann durch die Bestimmung der Knochenmasse erfolgen , auch wenn keine praevalenten Frakturen vorliegen . Das Frakturrisiko fuer den Messwert eines Individuums steigt um etwa das 1,5- bis 2,5fache fuer jede Standardabweichung ( SD ) unter der Spitzenknochenmasse der Normbevoelkerung ( T-Wert ) . Die Wahl des Messortes und der Untersuchungstechnik zur Bestimmung der Knochenmasse oder des Frakturrisikos muss sich nach individuellen Gegebenheiten am Patienten sowie den Staerken und Limitationen der Technik richten .

[ "Eine", "fruehe", "Diagnose", "der", "Osteoporose", "und", "eine", "akkurate", "Beurteilung", "von", "Behandlungserfolgen", "stehen", "im", "Mittelpunkt", "der", "radiologischen", "Bestrebungen", ".", "Die", "haeufigsten", "klinisch", "angewendeten", "Methoden", ",", "um", "das", "periphere", "Skelett", "sowie", "das", "Achsensekelett", "zu", "beurteilen", "sind", "die", "2-Spektren", "-", "Roentgenabsorptimetrie", "(", "DXA", ",", "\"", "dual", "x", "-", "ray", "absorptiometry", "\"", ")", ",", "die", "quantitative", "Computertomographie", "(", "QCT", ")", "and", "der", "quantitative", "Ultraschall", "(", "QUS", ")", ".", "Generell", "werden", "die", "Messergebnise", "eines", "Individuums", "mit", "einer", "alters-", ",", "geschlechts-", ",", "und", "rassenspezifischen", "Kontrollgruppen", "verglichen", ".", "In", "diesem", "Zusammenhang", "ist", "die", "Bestimmung", "der", "Knochenmasse", "ein", "Indikator", "des", "kuenftigen", "Frakturrisikos", "eines", "Patienten", ".", "Die", "radiologische", "Diagnose", "der", "Osteoporose", "kann", "durch", "die", "Bestimmung", "der", "Knochenmasse", "erfolgen", ",", "auch", "wenn", "keine", "praevalenten", "Frakturen", "vorliegen", ".", "Das", "Frakturrisiko", "fuer", "den", "Messwert", "eines", "Individuums", "steigt", "um", "etwa", "das", "1,5-", "bis", "2,5fache", "fuer", "jede", "Standardabweichung", "(", "SD", ")", "unter", "der", "Spitzenknochenmasse", "der", "Normbevoelkerung", "(", "T", "-", "Wert", ")", ".", "Die", "Wahl", "des", "Messortes", "und", "der", "Untersuchungstechnik", "zur", "Bestimmung", "der", "Knochenmasse", "oder", "des", "Frakturrisikos", "muss", "sich", "nach", "individuellen", "Gegebenheiten", "am", "Patienten", "sowie", "den", "Staerken", "und", "Limitationen", "der", "Technik", "richten", "." ]

[ "umlsterm" ]

Diagnose is an umlsterm, Osteoporose is an umlsterm, Beurteilung is an umlsterm, radiologischen is an umlsterm, Methoden is an umlsterm, Skelett is an umlsterm, Computertomographie is an umlsterm, Ultraschall is an umlsterm, geschlechts- is an umlsterm, rassenspezifischen is an umlsterm, Knochenmasse is an umlsterm, Patienten is an umlsterm, radiologische is an umlsterm, Diagnose is an umlsterm, Osteoporose is an umlsterm, Knochenmasse is an umlsterm, Frakturen is an umlsterm, Spitzenknochenmasse is an umlsterm, Normbevoelkerung is an umlsterm, Knochenmasse is an umlsterm, Patienten is an umlsterm, Staerken is an umlsterm, Technik is an umlsterm

DerRadiologe.90390222.ger.abstr_task1

Sentence: Eine fruehe Diagnose der Osteoporose und eine akkurate Beurteilung von Behandlungserfolgen stehen im Mittelpunkt der radiologischen Bestrebungen . Die haeufigsten klinisch angewendeten Methoden , um das periphere Skelett sowie das Achsensekelett zu beurteilen sind die 2-Spektren-Roentgenabsorptimetrie ( DXA , " dual x-ray absorptiometry " ) , die quantitative Computertomographie ( QCT ) and der quantitative Ultraschall ( QUS ) . Generell werden die Messergebnise eines Individuums mit einer alters- , geschlechts- , und rassenspezifischen Kontrollgruppen verglichen . In diesem Zusammenhang ist die Bestimmung der Knochenmasse ein Indikator des kuenftigen Frakturrisikos eines Patienten . Die radiologische Diagnose der Osteoporose kann durch die Bestimmung der Knochenmasse erfolgen , auch wenn keine praevalenten Frakturen vorliegen . Das Frakturrisiko fuer den Messwert eines Individuums steigt um etwa das 1,5- bis 2,5fache fuer jede Standardabweichung ( SD ) unter der Spitzenknochenmasse der Normbevoelkerung ( T-Wert ) . Die Wahl des Messortes und der Untersuchungstechnik zur Bestimmung der Knochenmasse oder des Frakturrisikos muss sich nach individuellen Gegebenheiten am Patienten sowie den Staerken und Limitationen der Technik richten . Instructions: please typing these entity words according to sentence: Diagnose, Osteoporose, Beurteilung, radiologischen, Methoden, Skelett, Computertomographie, Ultraschall, geschlechts-, rassenspezifischen, Knochenmasse, Patienten, radiologische, Diagnose, Osteoporose, Knochenmasse, Frakturen, Spitzenknochenmasse, Normbevoelkerung, Knochenmasse, Patienten, Staerken, Technik Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]

Eine fruehe Diagnose der Osteoporose und eine akkurate Beurteilung von Behandlungserfolgen stehen im Mittelpunkt der radiologischen Bestrebungen . Die haeufigsten klinisch angewendeten Methoden , um das periphere Skelett sowie das Achsensekelett zu beurteilen sind die 2-Spektren-Roentgenabsorptimetrie ( DXA , " dual x-ray absorptiometry " ) , die quantitative Computertomographie ( QCT ) and der quantitative Ultraschall ( QUS ) . Generell werden die Messergebnise eines Individuums mit einer alters- , geschlechts- , und rassenspezifischen Kontrollgruppen verglichen . In diesem Zusammenhang ist die Bestimmung der Knochenmasse ein Indikator des kuenftigen Frakturrisikos eines Patienten . Die radiologische Diagnose der Osteoporose kann durch die Bestimmung der Knochenmasse erfolgen , auch wenn keine praevalenten Frakturen vorliegen . Das Frakturrisiko fuer den Messwert eines Individuums steigt um etwa das 1,5- bis 2,5fache fuer jede Standardabweichung ( SD ) unter der Spitzenknochenmasse der Normbevoelkerung ( T-Wert ) . Die Wahl des Messortes und der Untersuchungstechnik zur Bestimmung der Knochenmasse oder des Frakturrisikos muss sich nach individuellen Gegebenheiten am Patienten sowie den Staerken und Limitationen der Technik richten .

[ "Eine", "fruehe", "Diagnose", "der", "Osteoporose", "und", "eine", "akkurate", "Beurteilung", "von", "Behandlungserfolgen", "stehen", "im", "Mittelpunkt", "der", "radiologischen", "Bestrebungen", ".", "Die", "haeufigsten", "klinisch", "angewendeten", "Methoden", ",", "um", "das", "periphere", "Skelett", "sowie", "das", "Achsensekelett", "zu", "beurteilen", "sind", "die", "2-Spektren", "-", "Roentgenabsorptimetrie", "(", "DXA", ",", "\"", "dual", "x", "-", "ray", "absorptiometry", "\"", ")", ",", "die", "quantitative", "Computertomographie", "(", "QCT", ")", "and", "der", "quantitative", "Ultraschall", "(", "QUS", ")", ".", "Generell", "werden", "die", "Messergebnise", "eines", "Individuums", "mit", "einer", "alters-", ",", "geschlechts-", ",", "und", "rassenspezifischen", "Kontrollgruppen", "verglichen", ".", "In", "diesem", "Zusammenhang", "ist", "die", "Bestimmung", "der", "Knochenmasse", "ein", "Indikator", "des", "kuenftigen", "Frakturrisikos", "eines", "Patienten", ".", "Die", "radiologische", "Diagnose", "der", "Osteoporose", "kann", "durch", "die", "Bestimmung", "der", "Knochenmasse", "erfolgen", ",", "auch", "wenn", "keine", "praevalenten", "Frakturen", "vorliegen", ".", "Das", "Frakturrisiko", "fuer", "den", "Messwert", "eines", "Individuums", "steigt", "um", "etwa", "das", "1,5-", "bis", "2,5fache", "fuer", "jede", "Standardabweichung", "(", "SD", ")", "unter", "der", "Spitzenknochenmasse", "der", "Normbevoelkerung", "(", "T", "-", "Wert", ")", ".", "Die", "Wahl", "des", "Messortes", "und", "der", "Untersuchungstechnik", "zur", "Bestimmung", "der", "Knochenmasse", "oder", "des", "Frakturrisikos", "muss", "sich", "nach", "individuellen", "Gegebenheiten", "am", "Patienten", "sowie", "den", "Staerken", "und", "Limitationen", "der", "Technik", "richten", "." ]

[ "umlsterm" ]

Diagnose, Osteoporose, Beurteilung, radiologischen, Methoden, Skelett, Computertomographie, Ultraschall, geschlechts-, rassenspezifischen, Knochenmasse, Patienten, radiologische, Diagnose, Osteoporose, Knochenmasse, Frakturen, Spitzenknochenmasse, Normbevoelkerung, Knochenmasse, Patienten, Staerken, Technik

DerRadiologe.90390222.ger.abstr_task2

Sentence: Eine fruehe Diagnose der Osteoporose und eine akkurate Beurteilung von Behandlungserfolgen stehen im Mittelpunkt der radiologischen Bestrebungen . Die haeufigsten klinisch angewendeten Methoden , um das periphere Skelett sowie das Achsensekelett zu beurteilen sind die 2-Spektren-Roentgenabsorptimetrie ( DXA , " dual x-ray absorptiometry " ) , die quantitative Computertomographie ( QCT ) and der quantitative Ultraschall ( QUS ) . Generell werden die Messergebnise eines Individuums mit einer alters- , geschlechts- , und rassenspezifischen Kontrollgruppen verglichen . In diesem Zusammenhang ist die Bestimmung der Knochenmasse ein Indikator des kuenftigen Frakturrisikos eines Patienten . Die radiologische Diagnose der Osteoporose kann durch die Bestimmung der Knochenmasse erfolgen , auch wenn keine praevalenten Frakturen vorliegen . Das Frakturrisiko fuer den Messwert eines Individuums steigt um etwa das 1,5- bis 2,5fache fuer jede Standardabweichung ( SD ) unter der Spitzenknochenmasse der Normbevoelkerung ( T-Wert ) . Die Wahl des Messortes und der Untersuchungstechnik zur Bestimmung der Knochenmasse oder des Frakturrisikos muss sich nach individuellen Gegebenheiten am Patienten sowie den Staerken und Limitationen der Technik richten . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]

Eine fruehe Diagnose der Osteoporose und eine akkurate Beurteilung von Behandlungserfolgen stehen im Mittelpunkt der radiologischen Bestrebungen . Die haeufigsten klinisch angewendeten Methoden , um das periphere Skelett sowie das Achsensekelett zu beurteilen sind die 2-Spektren-Roentgenabsorptimetrie ( DXA , " dual x-ray absorptiometry " ) , die quantitative Computertomographie ( QCT ) and der quantitative Ultraschall ( QUS ) . Generell werden die Messergebnise eines Individuums mit einer alters- , geschlechts- , und rassenspezifischen Kontrollgruppen verglichen . In diesem Zusammenhang ist die Bestimmung der Knochenmasse ein Indikator des kuenftigen Frakturrisikos eines Patienten . Die radiologische Diagnose der Osteoporose kann durch die Bestimmung der Knochenmasse erfolgen , auch wenn keine praevalenten Frakturen vorliegen . Das Frakturrisiko fuer den Messwert eines Individuums steigt um etwa das 1,5- bis 2,5fache fuer jede Standardabweichung ( SD ) unter der Spitzenknochenmasse der Normbevoelkerung ( T-Wert ) . Die Wahl des Messortes und der Untersuchungstechnik zur Bestimmung der Knochenmasse oder des Frakturrisikos muss sich nach individuellen Gegebenheiten am Patienten sowie den Staerken und Limitationen der Technik richten .

[ "Eine", "fruehe", "Diagnose", "der", "Osteoporose", "und", "eine", "akkurate", "Beurteilung", "von", "Behandlungserfolgen", "stehen", "im", "Mittelpunkt", "der", "radiologischen", "Bestrebungen", ".", "Die", "haeufigsten", "klinisch", "angewendeten", "Methoden", ",", "um", "das", "periphere", "Skelett", "sowie", "das", "Achsensekelett", "zu", "beurteilen", "sind", "die", "2-Spektren", "-", "Roentgenabsorptimetrie", "(", "DXA", ",", "\"", "dual", "x", "-", "ray", "absorptiometry", "\"", ")", ",", "die", "quantitative", "Computertomographie", "(", "QCT", ")", "and", "der", "quantitative", "Ultraschall", "(", "QUS", ")", ".", "Generell", "werden", "die", "Messergebnise", "eines", "Individuums", "mit", "einer", "alters-", ",", "geschlechts-", ",", "und", "rassenspezifischen", "Kontrollgruppen", "verglichen", ".", "In", "diesem", "Zusammenhang", "ist", "die", "Bestimmung", "der", "Knochenmasse", "ein", "Indikator", "des", "kuenftigen", "Frakturrisikos", "eines", "Patienten", ".", "Die", "radiologische", "Diagnose", "der", "Osteoporose", "kann", "durch", "die", "Bestimmung", "der", "Knochenmasse", "erfolgen", ",", "auch", "wenn", "keine", "praevalenten", "Frakturen", "vorliegen", ".", "Das", "Frakturrisiko", "fuer", "den", "Messwert", "eines", "Individuums", "steigt", "um", "etwa", "das", "1,5-", "bis", "2,5fache", "fuer", "jede", "Standardabweichung", "(", "SD", ")", "unter", "der", "Spitzenknochenmasse", "der", "Normbevoelkerung", "(", "T", "-", "Wert", ")", ".", "Die", "Wahl", "des", "Messortes", "und", "der", "Untersuchungstechnik", "zur", "Bestimmung", "der", "Knochenmasse", "oder", "des", "Frakturrisikos", "muss", "sich", "nach", "individuellen", "Gegebenheiten", "am", "Patienten", "sowie", "den", "Staerken", "und", "Limitationen", "der", "Technik", "richten", "." ]

[ "umlsterm" ]

Kindesmisshandlung is an umlsterm, Kind is an umlsterm, erziehungsberechtigte is an umlsterm, Person is an umlsterm, Diagnose is an umlsterm, Kindesmisshandlungen is an umlsterm, Arzt is an umlsterm, Kindesmisshandlung is an umlsterm, Kindes is an umlsterm, Gesundheit is an umlsterm, Eltern is an umlsterm, Erziehungsberechtigten is an umlsterm, Kindesmisshandlung is an umlsterm, Polizei is an umlsterm

Notfall+Rettungsmedizin.80010013.ger.abstr_task0

Sentence: Im Falle einer Kindesmisshandlung steht das Kind , und nicht die erziehungsberechtigte Person im Mittelpunkt jeder diagnostischen und therapeutischen Massnahme . Bei Unsicherheiten kann eine Diagnose durch konsiliarische Beiziehung eines mit Kindesmisshandlungen erfahrenen Kollegen bzw. durch rechtsmedizinische Institute abgesichert werden . Unter bestimmten Voraussetzungen kann der Arzt Tatbestaende im Zusammenhang mit einer Kindesmisshandlung offenbaren . Das Interesse des Kindes auf seine Gesundheit hat dann Vorrang vor der aerztlichen Schweigepflicht und dem Geheimhaltungsinteresse der Eltern oder Erziehungsberechtigten , sollten diese fuer die Misshandlung verantwortlich sein . Beim Bekanntwerden einer Kindesmisshandlung sollte eine Mitteilung an das zustaendige Jugendamt , das in eigener Kompetenz ueber das weitere Vorgehen entscheidet , oder auch an die Polizei erfolgen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Im Falle einer Kindesmisshandlung steht das Kind , und nicht die erziehungsberechtigte Person im Mittelpunkt jeder diagnostischen und therapeutischen Massnahme . Bei Unsicherheiten kann eine Diagnose durch konsiliarische Beiziehung eines mit Kindesmisshandlungen erfahrenen Kollegen bzw. durch rechtsmedizinische Institute abgesichert werden . Unter bestimmten Voraussetzungen kann der Arzt Tatbestaende im Zusammenhang mit einer Kindesmisshandlung offenbaren . Das Interesse des Kindes auf seine Gesundheit hat dann Vorrang vor der aerztlichen Schweigepflicht und dem Geheimhaltungsinteresse der Eltern oder Erziehungsberechtigten , sollten diese fuer die Misshandlung verantwortlich sein . Beim Bekanntwerden einer Kindesmisshandlung sollte eine Mitteilung an das zustaendige Jugendamt , das in eigener Kompetenz ueber das weitere Vorgehen entscheidet , oder auch an die Polizei erfolgen .

[ "Im", "Falle", "einer", "Kindesmisshandlung", "steht", "das", "Kind", ",", "und", "nicht", "die", "erziehungsberechtigte", "Person", "im", "Mittelpunkt", "jeder", "diagnostischen", "und", "therapeutischen", "Massnahme", ".", "Bei", "Unsicherheiten", "kann", "eine", "Diagnose", "durch", "konsiliarische", "Beiziehung", "eines", "mit", "Kindesmisshandlungen", "erfahrenen", "Kollegen", "bzw", ".", "durch", "rechtsmedizinische", "Institute", "abgesichert", "werden", ".", "Unter", "bestimmten", "Voraussetzungen", "kann", "der", "Arzt", "Tatbestaende", "im", "Zusammenhang", "mit", "einer", "Kindesmisshandlung", "offenbaren", ".", "Das", "Interesse", "des", "Kindes", "auf", "seine", "Gesundheit", "hat", "dann", "Vorrang", "vor", "der", "aerztlichen", "Schweigepflicht", "und", "dem", "Geheimhaltungsinteresse", "der", "Eltern", "oder", "Erziehungsberechtigten", ",", "sollten", "diese", "fuer", "die", "Misshandlung", "verantwortlich", "sein", ".", "Beim", "Bekanntwerden", "einer", "Kindesmisshandlung", "sollte", "eine", "Mitteilung", "an", "das", "zustaendige", "Jugendamt", ",", "das", "in", "eigener", "Kompetenz", "ueber", "das", "weitere", "Vorgehen", "entscheidet", ",", "oder", "auch", "an", "die", "Polizei", "erfolgen", "." ]

[ "umlsterm" ]

Kindesmisshandlung is an umlsterm, Kind is an umlsterm, erziehungsberechtigte is an umlsterm, Person is an umlsterm, Diagnose is an umlsterm, Kindesmisshandlungen is an umlsterm, Arzt is an umlsterm, Kindesmisshandlung is an umlsterm, Kindes is an umlsterm, Gesundheit is an umlsterm, Eltern is an umlsterm, Erziehungsberechtigten is an umlsterm, Kindesmisshandlung is an umlsterm, Polizei is an umlsterm

Notfall+Rettungsmedizin.80010013.ger.abstr_task1

Sentence: Im Falle einer Kindesmisshandlung steht das Kind , und nicht die erziehungsberechtigte Person im Mittelpunkt jeder diagnostischen und therapeutischen Massnahme . Bei Unsicherheiten kann eine Diagnose durch konsiliarische Beiziehung eines mit Kindesmisshandlungen erfahrenen Kollegen bzw. durch rechtsmedizinische Institute abgesichert werden . Unter bestimmten Voraussetzungen kann der Arzt Tatbestaende im Zusammenhang mit einer Kindesmisshandlung offenbaren . Das Interesse des Kindes auf seine Gesundheit hat dann Vorrang vor der aerztlichen Schweigepflicht und dem Geheimhaltungsinteresse der Eltern oder Erziehungsberechtigten , sollten diese fuer die Misshandlung verantwortlich sein . Beim Bekanntwerden einer Kindesmisshandlung sollte eine Mitteilung an das zustaendige Jugendamt , das in eigener Kompetenz ueber das weitere Vorgehen entscheidet , oder auch an die Polizei erfolgen . Instructions: please typing these entity words according to sentence: Kindesmisshandlung, Kind, erziehungsberechtigte, Person, Diagnose, Kindesmisshandlungen, Arzt, Kindesmisshandlung, Kindes, Gesundheit, Eltern, Erziehungsberechtigten, Kindesmisshandlung, Polizei Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Im Falle einer Kindesmisshandlung steht das Kind , und nicht die erziehungsberechtigte Person im Mittelpunkt jeder diagnostischen und therapeutischen Massnahme . Bei Unsicherheiten kann eine Diagnose durch konsiliarische Beiziehung eines mit Kindesmisshandlungen erfahrenen Kollegen bzw. durch rechtsmedizinische Institute abgesichert werden . Unter bestimmten Voraussetzungen kann der Arzt Tatbestaende im Zusammenhang mit einer Kindesmisshandlung offenbaren . Das Interesse des Kindes auf seine Gesundheit hat dann Vorrang vor der aerztlichen Schweigepflicht und dem Geheimhaltungsinteresse der Eltern oder Erziehungsberechtigten , sollten diese fuer die Misshandlung verantwortlich sein . Beim Bekanntwerden einer Kindesmisshandlung sollte eine Mitteilung an das zustaendige Jugendamt , das in eigener Kompetenz ueber das weitere Vorgehen entscheidet , oder auch an die Polizei erfolgen .

[ "Im", "Falle", "einer", "Kindesmisshandlung", "steht", "das", "Kind", ",", "und", "nicht", "die", "erziehungsberechtigte", "Person", "im", "Mittelpunkt", "jeder", "diagnostischen", "und", "therapeutischen", "Massnahme", ".", "Bei", "Unsicherheiten", "kann", "eine", "Diagnose", "durch", "konsiliarische", "Beiziehung", "eines", "mit", "Kindesmisshandlungen", "erfahrenen", "Kollegen", "bzw", ".", "durch", "rechtsmedizinische", "Institute", "abgesichert", "werden", ".", "Unter", "bestimmten", "Voraussetzungen", "kann", "der", "Arzt", "Tatbestaende", "im", "Zusammenhang", "mit", "einer", "Kindesmisshandlung", "offenbaren", ".", "Das", "Interesse", "des", "Kindes", "auf", "seine", "Gesundheit", "hat", "dann", "Vorrang", "vor", "der", "aerztlichen", "Schweigepflicht", "und", "dem", "Geheimhaltungsinteresse", "der", "Eltern", "oder", "Erziehungsberechtigten", ",", "sollten", "diese", "fuer", "die", "Misshandlung", "verantwortlich", "sein", ".", "Beim", "Bekanntwerden", "einer", "Kindesmisshandlung", "sollte", "eine", "Mitteilung", "an", "das", "zustaendige", "Jugendamt", ",", "das", "in", "eigener", "Kompetenz", "ueber", "das", "weitere", "Vorgehen", "entscheidet", ",", "oder", "auch", "an", "die", "Polizei", "erfolgen", "." ]

[ "umlsterm" ]

Kindesmisshandlung, Kind, erziehungsberechtigte, Person, Diagnose, Kindesmisshandlungen, Arzt, Kindesmisshandlung, Kindes, Gesundheit, Eltern, Erziehungsberechtigten, Kindesmisshandlung, Polizei

Notfall+Rettungsmedizin.80010013.ger.abstr_task2

Sentence: Im Falle einer Kindesmisshandlung steht das Kind , und nicht die erziehungsberechtigte Person im Mittelpunkt jeder diagnostischen und therapeutischen Massnahme . Bei Unsicherheiten kann eine Diagnose durch konsiliarische Beiziehung eines mit Kindesmisshandlungen erfahrenen Kollegen bzw. durch rechtsmedizinische Institute abgesichert werden . Unter bestimmten Voraussetzungen kann der Arzt Tatbestaende im Zusammenhang mit einer Kindesmisshandlung offenbaren . Das Interesse des Kindes auf seine Gesundheit hat dann Vorrang vor der aerztlichen Schweigepflicht und dem Geheimhaltungsinteresse der Eltern oder Erziehungsberechtigten , sollten diese fuer die Misshandlung verantwortlich sein . Beim Bekanntwerden einer Kindesmisshandlung sollte eine Mitteilung an das zustaendige Jugendamt , das in eigener Kompetenz ueber das weitere Vorgehen entscheidet , oder auch an die Polizei erfolgen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Im Falle einer Kindesmisshandlung steht das Kind , und nicht die erziehungsberechtigte Person im Mittelpunkt jeder diagnostischen und therapeutischen Massnahme . Bei Unsicherheiten kann eine Diagnose durch konsiliarische Beiziehung eines mit Kindesmisshandlungen erfahrenen Kollegen bzw. durch rechtsmedizinische Institute abgesichert werden . Unter bestimmten Voraussetzungen kann der Arzt Tatbestaende im Zusammenhang mit einer Kindesmisshandlung offenbaren . Das Interesse des Kindes auf seine Gesundheit hat dann Vorrang vor der aerztlichen Schweigepflicht und dem Geheimhaltungsinteresse der Eltern oder Erziehungsberechtigten , sollten diese fuer die Misshandlung verantwortlich sein . Beim Bekanntwerden einer Kindesmisshandlung sollte eine Mitteilung an das zustaendige Jugendamt , das in eigener Kompetenz ueber das weitere Vorgehen entscheidet , oder auch an die Polizei erfolgen .

[ "Im", "Falle", "einer", "Kindesmisshandlung", "steht", "das", "Kind", ",", "und", "nicht", "die", "erziehungsberechtigte", "Person", "im", "Mittelpunkt", "jeder", "diagnostischen", "und", "therapeutischen", "Massnahme", ".", "Bei", "Unsicherheiten", "kann", "eine", "Diagnose", "durch", "konsiliarische", "Beiziehung", "eines", "mit", "Kindesmisshandlungen", "erfahrenen", "Kollegen", "bzw", ".", "durch", "rechtsmedizinische", "Institute", "abgesichert", "werden", ".", "Unter", "bestimmten", "Voraussetzungen", "kann", "der", "Arzt", "Tatbestaende", "im", "Zusammenhang", "mit", "einer", "Kindesmisshandlung", "offenbaren", ".", "Das", "Interesse", "des", "Kindes", "auf", "seine", "Gesundheit", "hat", "dann", "Vorrang", "vor", "der", "aerztlichen", "Schweigepflicht", "und", "dem", "Geheimhaltungsinteresse", "der", "Eltern", "oder", "Erziehungsberechtigten", ",", "sollten", "diese", "fuer", "die", "Misshandlung", "verantwortlich", "sein", ".", "Beim", "Bekanntwerden", "einer", "Kindesmisshandlung", "sollte", "eine", "Mitteilung", "an", "das", "zustaendige", "Jugendamt", ",", "das", "in", "eigener", "Kompetenz", "ueber", "das", "weitere", "Vorgehen", "entscheidet", ",", "oder", "auch", "an", "die", "Polizei", "erfolgen", "." ]

[ "umlsterm" ]

Mps1p is a Gene_or_gene_product, spindle pole is a Cellular_component, Spc110p is a Gene_or_gene_product, spindle pole body is a Cellular_component, SPB is a Cellular_component, Spc110p is a Gene_or_gene_product, Nuf1p is a Gene_or_gene_product, serine is a Simple_chemical, threonine is a Simple_chemical, spindle apparatus is a Cellular_component, Mps1p is a Gene_or_gene_product, Spc110p is a Gene_or_gene_product, Mps1p is a Gene_or_gene_product, Spc110p is a Gene_or_gene_product, Ser(60 ) is a Simple_chemical, Thr(64 ) is a Simple_chemical, Thr(68 ) is a Simple_chemical, Spc110p is a Gene_or_gene_product, Mps1p is a Gene_or_gene_product, alanine is a Simple_chemical, SPB is a Cellular_component, Mps1p is a Gene_or_gene_product, Alanine is a Simple_chemical, alanine is a Simple_chemical, Ser(36 ) is a Simple_chemical, SPC97 is a Gene_or_gene_product, Tub4p is a Complex, alanine is a Simple_chemical, serine is a Simple_chemical, threonine is a Simple_chemical, aspartate is a Simple_chemical, Mps1p is a Gene_or_gene_product, Ser(36 ) is a Simple_chemical, Spc110p is a Gene_or_gene_product, inner plaque is a Cellular_component, SPB is a Cellular_component, Tub4p is a Complex

40_task0

Sentence: Yeast Mps1p phosphorylates the spindle pole component Spc110p in the N-terminal domain. The yeast spindle pole body (SPB) component Spc110p (Nuf1p) undergoes specific serine/threonine phosphorylation as the mitotic spindle apparatus forms, and this phosphorylation persists until cells enter anaphase. We demonstrate that the dual-specificity kinase Mps1p is essential for the mitosis-specific phosphorylation of Spc110p in vivo and that Mps1p phosphorylates Spc110p in vitro. Phosphopeptides generated by proteolytic cleavage were identified and sequenced by mass spectrometry. Ser(60), Thr(64), and Thr(68) are the major sites in Spc110p phosphorylated by Mps1p in vitro, and alanine substitution at these sites abolishes the mitosis-specific isoform in vivo. This is the first time that phosphorylation sites of an SPB component have been determined, and these are the first sites of Mps1p phosphorylation identified. Alanine substitution for any one of these phosphorylated residues, in conjunction with an alanine substitution at residue Ser(36), is lethal in combination with alleles of SPC97, which encodes a component of the Tub4p complex. Consistent with a specific dysfunction for the alanine substitution mutations, simultaneous mutation of all four serine/threonine residues to aspartate does not confer any defect. Sites of Mps1p phosphorylation and Ser(36) are located within the N-terminal globular domain of Spc110p, which resides at the inner plaque of the SPB and binds the Tub4p complex. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Simple_chemical, Complex, Gene_or_gene_product, Cellular_component

[ "O", "B-Gene_or_gene_product", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "I-Cellular_component", "O", "B-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Cellular_component", "O", "O", "O", "B-Complex", "O", "O", "O" ]

Yeast Mps1p phosphorylates the spindle pole component Spc110p in the N-terminal domain. The yeast spindle pole body (SPB) component Spc110p (Nuf1p) undergoes specific serine/threonine phosphorylation as the mitotic spindle apparatus forms, and this phosphorylation persists until cells enter anaphase. We demonstrate that the dual-specificity kinase Mps1p is essential for the mitosis-specific phosphorylation of Spc110p in vivo and that Mps1p phosphorylates Spc110p in vitro. Phosphopeptides generated by proteolytic cleavage were identified and sequenced by mass spectrometry. Ser(60), Thr(64), and Thr(68) are the major sites in Spc110p phosphorylated by Mps1p in vitro, and alanine substitution at these sites abolishes the mitosis-specific isoform in vivo. This is the first time that phosphorylation sites of an SPB component have been determined, and these are the first sites of Mps1p phosphorylation identified. Alanine substitution for any one of these phosphorylated residues, in conjunction with an alanine substitution at residue Ser(36), is lethal in combination with alleles of SPC97, which encodes a component of the Tub4p complex. Consistent with a specific dysfunction for the alanine substitution mutations, simultaneous mutation of all four serine/threonine residues to aspartate does not confer any defect. Sites of Mps1p phosphorylation and Ser(36) are located within the N-terminal globular domain of Spc110p, which resides at the inner plaque of the SPB and binds the Tub4p complex.

[ "Yeast", "Mps1p", "phosphorylates", "the", "spindle", "pole", "component", "Spc110p", "in", "the", "N", "-", "terminal", "domain", ".", "\n", "The", "yeast", "spindle", "pole", "body", "(", "SPB", ")", "component", "Spc110p", "(", "Nuf1p", ")", "undergoes", "specific", "serine", "/", "threonine", "phosphorylation", "as", "the", "mitotic", "spindle", "apparatus", "forms", ",", "and", "this", "phosphorylation", "persists", "until", "cells", "enter", "anaphase", ".", "We", "demonstrate", "that", "the", "dual", "-", "specificity", "kinase", "Mps1p", "is", "essential", "for", "the", "mitosis", "-", "specific", "phosphorylation", "of", "Spc110p", "in", "vivo", "and", "that", "Mps1p", "phosphorylates", "Spc110p", "in", "vitro", ".", "Phosphopeptides", "generated", "by", "proteolytic", "cleavage", "were", "identified", "and", "sequenced", "by", "mass", "spectrometry", ".", "Ser(60", ")", ",", "Thr(64", ")", ",", "and", "Thr(68", ")", "are", "the", "major", "sites", "in", "Spc110p", "phosphorylated", "by", "Mps1p", "in", "vitro", ",", "and", "alanine", "substitution", "at", "these", "sites", "abolishes", "the", "mitosis", "-", "specific", "isoform", "in", "vivo", ".", "This", "is", "the", "first", "time", "that", "phosphorylation", "sites", "of", "an", "SPB", "component", "have", "been", "determined", ",", "and", "these", "are", "the", "first", "sites", "of", "Mps1p", "phosphorylation", "identified", ".", "Alanine", "substitution", "for", "any", "one", "of", "these", "phosphorylated", "residues", ",", "in", "conjunction", "with", "an", "alanine", "substitution", "at", "residue", "Ser(36", ")", ",", "is", "lethal", "in", "combination", "with", "alleles", "of", "SPC97", ",", "which", "encodes", "a", "component", "of", "the", "Tub4p", "complex", ".", "Consistent", "with", "a", "specific", "dysfunction", "for", "the", "alanine", "substitution", "mutations", ",", "simultaneous", "mutation", "of", "all", "four", "serine", "/", "threonine", "residues", "to", "aspartate", "does", "not", "confer", "any", "defect", ".", "Sites", "of", "Mps1p", "phosphorylation", "and", "Ser(36", ")", "are", "located", "within", "the", "N", "-", "terminal", "globular", "domain", "of", "Spc110p", ",", "which", "resides", "at", "the", "inner", "plaque", "of", "the", "SPB", "and", "binds", "the", "Tub4p", "complex", ".", "\n" ]

[ "Cellular_component", "Simple_chemical", "Gene_or_gene_product", "Complex" ]

Mps1p is a Gene_or_gene_product, spindle pole is a Cellular_component, Spc110p is a Gene_or_gene_product, spindle pole body is a Cellular_component, SPB is a Cellular_component, Spc110p is a Gene_or_gene_product, Nuf1p is a Gene_or_gene_product, serine is a Simple_chemical, threonine is a Simple_chemical, spindle apparatus is a Cellular_component, Mps1p is a Gene_or_gene_product, Spc110p is a Gene_or_gene_product, Mps1p is a Gene_or_gene_product, Spc110p is a Gene_or_gene_product, Ser(60 ) is a Simple_chemical, Thr(64 ) is a Simple_chemical, Thr(68 ) is a Simple_chemical, Spc110p is a Gene_or_gene_product, Mps1p is a Gene_or_gene_product, alanine is a Simple_chemical, SPB is a Cellular_component, Mps1p is a Gene_or_gene_product, Alanine is a Simple_chemical, alanine is a Simple_chemical, Ser(36 ) is a Simple_chemical, SPC97 is a Gene_or_gene_product, Tub4p is a Complex, alanine is a Simple_chemical, serine is a Simple_chemical, threonine is a Simple_chemical, aspartate is a Simple_chemical, Mps1p is a Gene_or_gene_product, Ser(36 ) is a Simple_chemical, Spc110p is a Gene_or_gene_product, inner plaque is a Cellular_component, SPB is a Cellular_component, Tub4p is a Complex

40_task1

Sentence: Yeast Mps1p phosphorylates the spindle pole component Spc110p in the N-terminal domain. The yeast spindle pole body (SPB) component Spc110p (Nuf1p) undergoes specific serine/threonine phosphorylation as the mitotic spindle apparatus forms, and this phosphorylation persists until cells enter anaphase. We demonstrate that the dual-specificity kinase Mps1p is essential for the mitosis-specific phosphorylation of Spc110p in vivo and that Mps1p phosphorylates Spc110p in vitro. Phosphopeptides generated by proteolytic cleavage were identified and sequenced by mass spectrometry. Ser(60), Thr(64), and Thr(68) are the major sites in Spc110p phosphorylated by Mps1p in vitro, and alanine substitution at these sites abolishes the mitosis-specific isoform in vivo. This is the first time that phosphorylation sites of an SPB component have been determined, and these are the first sites of Mps1p phosphorylation identified. Alanine substitution for any one of these phosphorylated residues, in conjunction with an alanine substitution at residue Ser(36), is lethal in combination with alleles of SPC97, which encodes a component of the Tub4p complex. Consistent with a specific dysfunction for the alanine substitution mutations, simultaneous mutation of all four serine/threonine residues to aspartate does not confer any defect. Sites of Mps1p phosphorylation and Ser(36) are located within the N-terminal globular domain of Spc110p, which resides at the inner plaque of the SPB and binds the Tub4p complex. Instructions: please typing these entity words according to sentence: Mps1p, spindle pole, Spc110p, spindle pole body, SPB, Spc110p, Nuf1p, serine, threonine, spindle apparatus, Mps1p, Spc110p, Mps1p, Spc110p, Ser(60 ), Thr(64 ), Thr(68 ), Spc110p, Mps1p, alanine, SPB, Mps1p, Alanine, alanine, Ser(36 ), SPC97, Tub4p, alanine, serine, threonine, aspartate, Mps1p, Ser(36 ), Spc110p, inner plaque, SPB, Tub4p Options: Simple_chemical, Complex, Gene_or_gene_product, Cellular_component

[ "O", "B-Gene_or_gene_product", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "I-Cellular_component", "O", "B-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Cellular_component", "O", "O", "O", "B-Complex", "O", "O", "O" ]

Yeast Mps1p phosphorylates the spindle pole component Spc110p in the N-terminal domain. The yeast spindle pole body (SPB) component Spc110p (Nuf1p) undergoes specific serine/threonine phosphorylation as the mitotic spindle apparatus forms, and this phosphorylation persists until cells enter anaphase. We demonstrate that the dual-specificity kinase Mps1p is essential for the mitosis-specific phosphorylation of Spc110p in vivo and that Mps1p phosphorylates Spc110p in vitro. Phosphopeptides generated by proteolytic cleavage were identified and sequenced by mass spectrometry. Ser(60), Thr(64), and Thr(68) are the major sites in Spc110p phosphorylated by Mps1p in vitro, and alanine substitution at these sites abolishes the mitosis-specific isoform in vivo. This is the first time that phosphorylation sites of an SPB component have been determined, and these are the first sites of Mps1p phosphorylation identified. Alanine substitution for any one of these phosphorylated residues, in conjunction with an alanine substitution at residue Ser(36), is lethal in combination with alleles of SPC97, which encodes a component of the Tub4p complex. Consistent with a specific dysfunction for the alanine substitution mutations, simultaneous mutation of all four serine/threonine residues to aspartate does not confer any defect. Sites of Mps1p phosphorylation and Ser(36) are located within the N-terminal globular domain of Spc110p, which resides at the inner plaque of the SPB and binds the Tub4p complex.

[ "Yeast", "Mps1p", "phosphorylates", "the", "spindle", "pole", "component", "Spc110p", "in", "the", "N", "-", "terminal", "domain", ".", "\n", "The", "yeast", "spindle", "pole", "body", "(", "SPB", ")", "component", "Spc110p", "(", "Nuf1p", ")", "undergoes", "specific", "serine", "/", "threonine", "phosphorylation", "as", "the", "mitotic", "spindle", "apparatus", "forms", ",", "and", "this", "phosphorylation", "persists", "until", "cells", "enter", "anaphase", ".", "We", "demonstrate", "that", "the", "dual", "-", "specificity", "kinase", "Mps1p", "is", "essential", "for", "the", "mitosis", "-", "specific", "phosphorylation", "of", "Spc110p", "in", "vivo", "and", "that", "Mps1p", "phosphorylates", "Spc110p", "in", "vitro", ".", "Phosphopeptides", "generated", "by", "proteolytic", "cleavage", "were", "identified", "and", "sequenced", "by", "mass", "spectrometry", ".", "Ser(60", ")", ",", "Thr(64", ")", ",", "and", "Thr(68", ")", "are", "the", "major", "sites", "in", "Spc110p", "phosphorylated", "by", "Mps1p", "in", "vitro", ",", "and", "alanine", "substitution", "at", "these", "sites", "abolishes", "the", "mitosis", "-", "specific", "isoform", "in", "vivo", ".", "This", "is", "the", "first", "time", "that", "phosphorylation", "sites", "of", "an", "SPB", "component", "have", "been", "determined", ",", "and", "these", "are", "the", "first", "sites", "of", "Mps1p", "phosphorylation", "identified", ".", "Alanine", "substitution", "for", "any", "one", "of", "these", "phosphorylated", "residues", ",", "in", "conjunction", "with", "an", "alanine", "substitution", "at", "residue", "Ser(36", ")", ",", "is", "lethal", "in", "combination", "with", "alleles", "of", "SPC97", ",", "which", "encodes", "a", "component", "of", "the", "Tub4p", "complex", ".", "Consistent", "with", "a", "specific", "dysfunction", "for", "the", "alanine", "substitution", "mutations", ",", "simultaneous", "mutation", "of", "all", "four", "serine", "/", "threonine", "residues", "to", "aspartate", "does", "not", "confer", "any", "defect", ".", "Sites", "of", "Mps1p", "phosphorylation", "and", "Ser(36", ")", "are", "located", "within", "the", "N", "-", "terminal", "globular", "domain", "of", "Spc110p", ",", "which", "resides", "at", "the", "inner", "plaque", "of", "the", "SPB", "and", "binds", "the", "Tub4p", "complex", ".", "\n" ]

[ "Cellular_component", "Simple_chemical", "Gene_or_gene_product", "Complex" ]

Mps1p, spindle pole, Spc110p, spindle pole body, SPB, Spc110p, Nuf1p, serine, threonine, spindle apparatus, Mps1p, Spc110p, Mps1p, Spc110p, Ser(60 ), Thr(64 ), Thr(68 ), Spc110p, Mps1p, alanine, SPB, Mps1p, Alanine, alanine, Ser(36 ), SPC97, Tub4p, alanine, serine, threonine, aspartate, Mps1p, Ser(36 ), Spc110p, inner plaque, SPB, Tub4p

40_task2

Sentence: Yeast Mps1p phosphorylates the spindle pole component Spc110p in the N-terminal domain. The yeast spindle pole body (SPB) component Spc110p (Nuf1p) undergoes specific serine/threonine phosphorylation as the mitotic spindle apparatus forms, and this phosphorylation persists until cells enter anaphase. We demonstrate that the dual-specificity kinase Mps1p is essential for the mitosis-specific phosphorylation of Spc110p in vivo and that Mps1p phosphorylates Spc110p in vitro. Phosphopeptides generated by proteolytic cleavage were identified and sequenced by mass spectrometry. Ser(60), Thr(64), and Thr(68) are the major sites in Spc110p phosphorylated by Mps1p in vitro, and alanine substitution at these sites abolishes the mitosis-specific isoform in vivo. This is the first time that phosphorylation sites of an SPB component have been determined, and these are the first sites of Mps1p phosphorylation identified. Alanine substitution for any one of these phosphorylated residues, in conjunction with an alanine substitution at residue Ser(36), is lethal in combination with alleles of SPC97, which encodes a component of the Tub4p complex. Consistent with a specific dysfunction for the alanine substitution mutations, simultaneous mutation of all four serine/threonine residues to aspartate does not confer any defect. Sites of Mps1p phosphorylation and Ser(36) are located within the N-terminal globular domain of Spc110p, which resides at the inner plaque of the SPB and binds the Tub4p complex. Instructions: please extract entity words from the input sentence

[ "O", "B-Gene_or_gene_product", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "I-Cellular_component", "O", "B-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Cellular_component", "O", "O", "O", "B-Complex", "O", "O", "O" ]

Yeast Mps1p phosphorylates the spindle pole component Spc110p in the N-terminal domain. The yeast spindle pole body (SPB) component Spc110p (Nuf1p) undergoes specific serine/threonine phosphorylation as the mitotic spindle apparatus forms, and this phosphorylation persists until cells enter anaphase. We demonstrate that the dual-specificity kinase Mps1p is essential for the mitosis-specific phosphorylation of Spc110p in vivo and that Mps1p phosphorylates Spc110p in vitro. Phosphopeptides generated by proteolytic cleavage were identified and sequenced by mass spectrometry. Ser(60), Thr(64), and Thr(68) are the major sites in Spc110p phosphorylated by Mps1p in vitro, and alanine substitution at these sites abolishes the mitosis-specific isoform in vivo. This is the first time that phosphorylation sites of an SPB component have been determined, and these are the first sites of Mps1p phosphorylation identified. Alanine substitution for any one of these phosphorylated residues, in conjunction with an alanine substitution at residue Ser(36), is lethal in combination with alleles of SPC97, which encodes a component of the Tub4p complex. Consistent with a specific dysfunction for the alanine substitution mutations, simultaneous mutation of all four serine/threonine residues to aspartate does not confer any defect. Sites of Mps1p phosphorylation and Ser(36) are located within the N-terminal globular domain of Spc110p, which resides at the inner plaque of the SPB and binds the Tub4p complex.

[ "Yeast", "Mps1p", "phosphorylates", "the", "spindle", "pole", "component", "Spc110p", "in", "the", "N", "-", "terminal", "domain", ".", "\n", "The", "yeast", "spindle", "pole", "body", "(", "SPB", ")", "component", "Spc110p", "(", "Nuf1p", ")", "undergoes", "specific", "serine", "/", "threonine", "phosphorylation", "as", "the", "mitotic", "spindle", "apparatus", "forms", ",", "and", "this", "phosphorylation", "persists", "until", "cells", "enter", "anaphase", ".", "We", "demonstrate", "that", "the", "dual", "-", "specificity", "kinase", "Mps1p", "is", "essential", "for", "the", "mitosis", "-", "specific", "phosphorylation", "of", "Spc110p", "in", "vivo", "and", "that", "Mps1p", "phosphorylates", "Spc110p", "in", "vitro", ".", "Phosphopeptides", "generated", "by", "proteolytic", "cleavage", "were", "identified", "and", "sequenced", "by", "mass", "spectrometry", ".", "Ser(60", ")", ",", "Thr(64", ")", ",", "and", "Thr(68", ")", "are", "the", "major", "sites", "in", "Spc110p", "phosphorylated", "by", "Mps1p", "in", "vitro", ",", "and", "alanine", "substitution", "at", "these", "sites", "abolishes", "the", "mitosis", "-", "specific", "isoform", "in", "vivo", ".", "This", "is", "the", "first", "time", "that", "phosphorylation", "sites", "of", "an", "SPB", "component", "have", "been", "determined", ",", "and", "these", "are", "the", "first", "sites", "of", "Mps1p", "phosphorylation", "identified", ".", "Alanine", "substitution", "for", "any", "one", "of", "these", "phosphorylated", "residues", ",", "in", "conjunction", "with", "an", "alanine", "substitution", "at", "residue", "Ser(36", ")", ",", "is", "lethal", "in", "combination", "with", "alleles", "of", "SPC97", ",", "which", "encodes", "a", "component", "of", "the", "Tub4p", "complex", ".", "Consistent", "with", "a", "specific", "dysfunction", "for", "the", "alanine", "substitution", "mutations", ",", "simultaneous", "mutation", "of", "all", "four", "serine", "/", "threonine", "residues", "to", "aspartate", "does", "not", "confer", "any", "defect", ".", "Sites", "of", "Mps1p", "phosphorylation", "and", "Ser(36", ")", "are", "located", "within", "the", "N", "-", "terminal", "globular", "domain", "of", "Spc110p", ",", "which", "resides", "at", "the", "inner", "plaque", "of", "the", "SPB", "and", "binds", "the", "Tub4p", "complex", ".", "\n" ]

[ "Cellular_component", "Simple_chemical", "Gene_or_gene_product", "Complex" ]

Paclitaxel is an umlsterm, Mikrotubuli is an umlsterm, Signaltransduktion is an umlsterm, Paclitaxel is an umlsterm, Zelle is an umlsterm, Zelle is an umlsterm, Paclitaxel is an umlsterm, Medikamentenapplikation is an umlsterm, Arbeit is an umlsterm, Paclitaxel is an umlsterm, Gefaessmuskelzellen is an umlsterm, Endothelzellen is an umlsterm, Paclitaxel is an umlsterm, Wachstumshemmung is an umlsterm, selbst is an umlsterm, elektronenoptisch is an umlsterm, Muskelzellen is an umlsterm, Kaninchen is an umlsterm, Paclitaxel is an umlsterm, Erweiterung is an umlsterm, Kontrolltieren is an umlsterm, Kontraktionskraft is an umlsterm, Schweinemodell is an umlsterm

ZfuerKardiologie.00890390.ger.abstr_task0

Sentence: Paclitaxel eine sehr potente antiproliferative Substanz , , foerdert die Bildung ungewoehnlich stabiler und funktionsgestoerter Mikrotubuli und veraendert dadurch zellulaere Mechanismen , die letztlich zu verminderter Proliferation , Migration und Signaltransduktion fuehren . Paclitaxel ist lipophil , was eine rasche Aufnahme in die Zelle foerdert , und hat einen langanhaltenden Effekt in der Zelle aufgrund der strukturellen Veraenderung des Zytoskelettes . Diese Eigenschaften machen Paclitaxel zu einem vielversprechenden Kandidaten fuer die lokale Medikamentenapplikation zur Restenoseprophylaxe . In dieser Arbeit werden die in-vitro und in-vivo Ergebnisse aus unseren Forschungsarbeiten zu Paclitaxel vorgestellt . Zellkulturexperimente mit Monokulturen von humanen glatten Gefaessmuskelzellen sowie mit Co-Kulturen mit humanen Endothelzellen zeigten , dass Paclitaxel in einem Dosisbereich zwischen 1,0 und 10,0µmol/l zu einer beinahe vollstaendigen Wachstumshemmung , selbst nach kurzer ( 20 min . ) Einmalapplikation fuehrt . Nach Vergleich von 3 verschiedenen Kathetersystemen ( poroeser Ballon , mikroporoeser Ballon und Doppelballon ) wurde der Doppelballon fuer die in-vivo Anwendung favorisiert . Anhand von Anfaerbungen des Zytoskelettes sowie elektronenoptisch gelang der Nachweis der Paclitaxelwirkung in den glatten Muskelzellen der Gefaesswand . Im Kaninchen fuehrte lokal appliziertes Paclitaxel zu einer signifikanten Hemmung der neointimalen Proliferation und Erweiterung des Gefaessdurchmessers im Vergleich zu ballondilatierten Kontrolltieren . In Zusatzexperimenten konnte eine drastische Verringerung der vaskulaeren Kontraktionskraft nach Paclitaxelgabe gezeigt werden . Aehnlich eindeutige Ergebnisse fanden sich nach Stentimplantation im Schweinemodell nicht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Paclitaxel eine sehr potente antiproliferative Substanz , , foerdert die Bildung ungewoehnlich stabiler und funktionsgestoerter Mikrotubuli und veraendert dadurch zellulaere Mechanismen , die letztlich zu verminderter Proliferation , Migration und Signaltransduktion fuehren . Paclitaxel ist lipophil , was eine rasche Aufnahme in die Zelle foerdert , und hat einen langanhaltenden Effekt in der Zelle aufgrund der strukturellen Veraenderung des Zytoskelettes . Diese Eigenschaften machen Paclitaxel zu einem vielversprechenden Kandidaten fuer die lokale Medikamentenapplikation zur Restenoseprophylaxe . In dieser Arbeit werden die in-vitro und in-vivo Ergebnisse aus unseren Forschungsarbeiten zu Paclitaxel vorgestellt . Zellkulturexperimente mit Monokulturen von humanen glatten Gefaessmuskelzellen sowie mit Co-Kulturen mit humanen Endothelzellen zeigten , dass Paclitaxel in einem Dosisbereich zwischen 1,0 und 10,0µmol/l zu einer beinahe vollstaendigen Wachstumshemmung , selbst nach kurzer ( 20 min . ) Einmalapplikation fuehrt . Nach Vergleich von 3 verschiedenen Kathetersystemen ( poroeser Ballon , mikroporoeser Ballon und Doppelballon ) wurde der Doppelballon fuer die in-vivo Anwendung favorisiert . Anhand von Anfaerbungen des Zytoskelettes sowie elektronenoptisch gelang der Nachweis der Paclitaxelwirkung in den glatten Muskelzellen der Gefaesswand . Im Kaninchen fuehrte lokal appliziertes Paclitaxel zu einer signifikanten Hemmung der neointimalen Proliferation und Erweiterung des Gefaessdurchmessers im Vergleich zu ballondilatierten Kontrolltieren . In Zusatzexperimenten konnte eine drastische Verringerung der vaskulaeren Kontraktionskraft nach Paclitaxelgabe gezeigt werden . Aehnlich eindeutige Ergebnisse fanden sich nach Stentimplantation im Schweinemodell nicht .

[ "Paclitaxel", "eine", "sehr", "potente", "antiproliferative", "Substanz", ",", ",", "foerdert", "die", "Bildung", "ungewoehnlich", "stabiler", "und", "funktionsgestoerter", "Mikrotubuli", "und", "veraendert", "dadurch", "zellulaere", "Mechanismen", ",", "die", "letztlich", "zu", "verminderter", "Proliferation", ",", "Migration", "und", "Signaltransduktion", "fuehren", ".", "Paclitaxel", "ist", "lipophil", ",", "was", "eine", "rasche", "Aufnahme", "in", "die", "Zelle", "foerdert", ",", "und", "hat", "einen", "langanhaltenden", "Effekt", "in", "der", "Zelle", "aufgrund", "der", "strukturellen", "Veraenderung", "des", "Zytoskelettes", ".", "Diese", "Eigenschaften", "machen", "Paclitaxel", "zu", "einem", "vielversprechenden", "Kandidaten", "fuer", "die", "lokale", "Medikamentenapplikation", "zur", "Restenoseprophylaxe", ".", "In", "dieser", "Arbeit", "werden", "die", "in", "-", "vitro", "und", "in", "-", "vivo", "Ergebnisse", "aus", "unseren", "Forschungsarbeiten", "zu", "Paclitaxel", "vorgestellt", ".", "Zellkulturexperimente", "mit", "Monokulturen", "von", "humanen", "glatten", "Gefaessmuskelzellen", "sowie", "mit", "Co", "-", "Kulturen", "mit", "humanen", "Endothelzellen", "zeigten", ",", "dass", "Paclitaxel", "in", "einem", "Dosisbereich", "zwischen", "1,0", "und", "10,0µmol", "/", "l", "zu", "einer", "beinahe", "vollstaendigen", "Wachstumshemmung", ",", "selbst", "nach", "kurzer", "(", "20", "min", ".", ")", "Einmalapplikation", "fuehrt", ".", "Nach", "Vergleich", "von", "3", "verschiedenen", "Kathetersystemen", "(", "poroeser", "Ballon", ",", "mikroporoeser", "Ballon", "und", "Doppelballon", ")", "wurde", "der", "Doppelballon", "fuer", "die", "in", "-", "vivo", "Anwendung", "favorisiert", ".", "Anhand", "von", "Anfaerbungen", "des", "Zytoskelettes", "sowie", "elektronenoptisch", "gelang", "der", "Nachweis", "der", "Paclitaxelwirkung", "in", "den", "glatten", "Muskelzellen", "der", "Gefaesswand", ".", "Im", "Kaninchen", "fuehrte", "lokal", "appliziertes", "Paclitaxel", "zu", "einer", "signifikanten", "Hemmung", "der", "neointimalen", "Proliferation", "und", "Erweiterung", "des", "Gefaessdurchmessers", "im", "Vergleich", "zu", "ballondilatierten", "Kontrolltieren", ".", "In", "Zusatzexperimenten", "konnte", "eine", "drastische", "Verringerung", "der", "vaskulaeren", "Kontraktionskraft", "nach", "Paclitaxelgabe", "gezeigt", "werden", ".", "Aehnlich", "eindeutige", "Ergebnisse", "fanden", "sich", "nach", "Stentimplantation", "im", "Schweinemodell", "nicht", "." ]

[ "umlsterm" ]

Paclitaxel is an umlsterm, Mikrotubuli is an umlsterm, Signaltransduktion is an umlsterm, Paclitaxel is an umlsterm, Zelle is an umlsterm, Zelle is an umlsterm, Paclitaxel is an umlsterm, Medikamentenapplikation is an umlsterm, Arbeit is an umlsterm, Paclitaxel is an umlsterm, Gefaessmuskelzellen is an umlsterm, Endothelzellen is an umlsterm, Paclitaxel is an umlsterm, Wachstumshemmung is an umlsterm, selbst is an umlsterm, elektronenoptisch is an umlsterm, Muskelzellen is an umlsterm, Kaninchen is an umlsterm, Paclitaxel is an umlsterm, Erweiterung is an umlsterm, Kontrolltieren is an umlsterm, Kontraktionskraft is an umlsterm, Schweinemodell is an umlsterm

ZfuerKardiologie.00890390.ger.abstr_task1

Sentence: Paclitaxel eine sehr potente antiproliferative Substanz , , foerdert die Bildung ungewoehnlich stabiler und funktionsgestoerter Mikrotubuli und veraendert dadurch zellulaere Mechanismen , die letztlich zu verminderter Proliferation , Migration und Signaltransduktion fuehren . Paclitaxel ist lipophil , was eine rasche Aufnahme in die Zelle foerdert , und hat einen langanhaltenden Effekt in der Zelle aufgrund der strukturellen Veraenderung des Zytoskelettes . Diese Eigenschaften machen Paclitaxel zu einem vielversprechenden Kandidaten fuer die lokale Medikamentenapplikation zur Restenoseprophylaxe . In dieser Arbeit werden die in-vitro und in-vivo Ergebnisse aus unseren Forschungsarbeiten zu Paclitaxel vorgestellt . Zellkulturexperimente mit Monokulturen von humanen glatten Gefaessmuskelzellen sowie mit Co-Kulturen mit humanen Endothelzellen zeigten , dass Paclitaxel in einem Dosisbereich zwischen 1,0 und 10,0µmol/l zu einer beinahe vollstaendigen Wachstumshemmung , selbst nach kurzer ( 20 min . ) Einmalapplikation fuehrt . Nach Vergleich von 3 verschiedenen Kathetersystemen ( poroeser Ballon , mikroporoeser Ballon und Doppelballon ) wurde der Doppelballon fuer die in-vivo Anwendung favorisiert . Anhand von Anfaerbungen des Zytoskelettes sowie elektronenoptisch gelang der Nachweis der Paclitaxelwirkung in den glatten Muskelzellen der Gefaesswand . Im Kaninchen fuehrte lokal appliziertes Paclitaxel zu einer signifikanten Hemmung der neointimalen Proliferation und Erweiterung des Gefaessdurchmessers im Vergleich zu ballondilatierten Kontrolltieren . In Zusatzexperimenten konnte eine drastische Verringerung der vaskulaeren Kontraktionskraft nach Paclitaxelgabe gezeigt werden . Aehnlich eindeutige Ergebnisse fanden sich nach Stentimplantation im Schweinemodell nicht . Instructions: please typing these entity words according to sentence: Paclitaxel, Mikrotubuli, Signaltransduktion, Paclitaxel, Zelle, Zelle, Paclitaxel, Medikamentenapplikation, Arbeit, Paclitaxel, Gefaessmuskelzellen, Endothelzellen, Paclitaxel, Wachstumshemmung, selbst, elektronenoptisch, Muskelzellen, Kaninchen, Paclitaxel, Erweiterung, Kontrolltieren, Kontraktionskraft, Schweinemodell Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Paclitaxel eine sehr potente antiproliferative Substanz , , foerdert die Bildung ungewoehnlich stabiler und funktionsgestoerter Mikrotubuli und veraendert dadurch zellulaere Mechanismen , die letztlich zu verminderter Proliferation , Migration und Signaltransduktion fuehren . Paclitaxel ist lipophil , was eine rasche Aufnahme in die Zelle foerdert , und hat einen langanhaltenden Effekt in der Zelle aufgrund der strukturellen Veraenderung des Zytoskelettes . Diese Eigenschaften machen Paclitaxel zu einem vielversprechenden Kandidaten fuer die lokale Medikamentenapplikation zur Restenoseprophylaxe . In dieser Arbeit werden die in-vitro und in-vivo Ergebnisse aus unseren Forschungsarbeiten zu Paclitaxel vorgestellt . Zellkulturexperimente mit Monokulturen von humanen glatten Gefaessmuskelzellen sowie mit Co-Kulturen mit humanen Endothelzellen zeigten , dass Paclitaxel in einem Dosisbereich zwischen 1,0 und 10,0µmol/l zu einer beinahe vollstaendigen Wachstumshemmung , selbst nach kurzer ( 20 min . ) Einmalapplikation fuehrt . Nach Vergleich von 3 verschiedenen Kathetersystemen ( poroeser Ballon , mikroporoeser Ballon und Doppelballon ) wurde der Doppelballon fuer die in-vivo Anwendung favorisiert . Anhand von Anfaerbungen des Zytoskelettes sowie elektronenoptisch gelang der Nachweis der Paclitaxelwirkung in den glatten Muskelzellen der Gefaesswand . Im Kaninchen fuehrte lokal appliziertes Paclitaxel zu einer signifikanten Hemmung der neointimalen Proliferation und Erweiterung des Gefaessdurchmessers im Vergleich zu ballondilatierten Kontrolltieren . In Zusatzexperimenten konnte eine drastische Verringerung der vaskulaeren Kontraktionskraft nach Paclitaxelgabe gezeigt werden . Aehnlich eindeutige Ergebnisse fanden sich nach Stentimplantation im Schweinemodell nicht .

[ "Paclitaxel", "eine", "sehr", "potente", "antiproliferative", "Substanz", ",", ",", "foerdert", "die", "Bildung", "ungewoehnlich", "stabiler", "und", "funktionsgestoerter", "Mikrotubuli", "und", "veraendert", "dadurch", "zellulaere", "Mechanismen", ",", "die", "letztlich", "zu", "verminderter", "Proliferation", ",", "Migration", "und", "Signaltransduktion", "fuehren", ".", "Paclitaxel", "ist", "lipophil", ",", "was", "eine", "rasche", "Aufnahme", "in", "die", "Zelle", "foerdert", ",", "und", "hat", "einen", "langanhaltenden", "Effekt", "in", "der", "Zelle", "aufgrund", "der", "strukturellen", "Veraenderung", "des", "Zytoskelettes", ".", "Diese", "Eigenschaften", "machen", "Paclitaxel", "zu", "einem", "vielversprechenden", "Kandidaten", "fuer", "die", "lokale", "Medikamentenapplikation", "zur", "Restenoseprophylaxe", ".", "In", "dieser", "Arbeit", "werden", "die", "in", "-", "vitro", "und", "in", "-", "vivo", "Ergebnisse", "aus", "unseren", "Forschungsarbeiten", "zu", "Paclitaxel", "vorgestellt", ".", "Zellkulturexperimente", "mit", "Monokulturen", "von", "humanen", "glatten", "Gefaessmuskelzellen", "sowie", "mit", "Co", "-", "Kulturen", "mit", "humanen", "Endothelzellen", "zeigten", ",", "dass", "Paclitaxel", "in", "einem", "Dosisbereich", "zwischen", "1,0", "und", "10,0µmol", "/", "l", "zu", "einer", "beinahe", "vollstaendigen", "Wachstumshemmung", ",", "selbst", "nach", "kurzer", "(", "20", "min", ".", ")", "Einmalapplikation", "fuehrt", ".", "Nach", "Vergleich", "von", "3", "verschiedenen", "Kathetersystemen", "(", "poroeser", "Ballon", ",", "mikroporoeser", "Ballon", "und", "Doppelballon", ")", "wurde", "der", "Doppelballon", "fuer", "die", "in", "-", "vivo", "Anwendung", "favorisiert", ".", "Anhand", "von", "Anfaerbungen", "des", "Zytoskelettes", "sowie", "elektronenoptisch", "gelang", "der", "Nachweis", "der", "Paclitaxelwirkung", "in", "den", "glatten", "Muskelzellen", "der", "Gefaesswand", ".", "Im", "Kaninchen", "fuehrte", "lokal", "appliziertes", "Paclitaxel", "zu", "einer", "signifikanten", "Hemmung", "der", "neointimalen", "Proliferation", "und", "Erweiterung", "des", "Gefaessdurchmessers", "im", "Vergleich", "zu", "ballondilatierten", "Kontrolltieren", ".", "In", "Zusatzexperimenten", "konnte", "eine", "drastische", "Verringerung", "der", "vaskulaeren", "Kontraktionskraft", "nach", "Paclitaxelgabe", "gezeigt", "werden", ".", "Aehnlich", "eindeutige", "Ergebnisse", "fanden", "sich", "nach", "Stentimplantation", "im", "Schweinemodell", "nicht", "." ]

[ "umlsterm" ]

Paclitaxel, Mikrotubuli, Signaltransduktion, Paclitaxel, Zelle, Zelle, Paclitaxel, Medikamentenapplikation, Arbeit, Paclitaxel, Gefaessmuskelzellen, Endothelzellen, Paclitaxel, Wachstumshemmung, selbst, elektronenoptisch, Muskelzellen, Kaninchen, Paclitaxel, Erweiterung, Kontrolltieren, Kontraktionskraft, Schweinemodell

ZfuerKardiologie.00890390.ger.abstr_task2

Sentence: Paclitaxel eine sehr potente antiproliferative Substanz , , foerdert die Bildung ungewoehnlich stabiler und funktionsgestoerter Mikrotubuli und veraendert dadurch zellulaere Mechanismen , die letztlich zu verminderter Proliferation , Migration und Signaltransduktion fuehren . Paclitaxel ist lipophil , was eine rasche Aufnahme in die Zelle foerdert , und hat einen langanhaltenden Effekt in der Zelle aufgrund der strukturellen Veraenderung des Zytoskelettes . Diese Eigenschaften machen Paclitaxel zu einem vielversprechenden Kandidaten fuer die lokale Medikamentenapplikation zur Restenoseprophylaxe . In dieser Arbeit werden die in-vitro und in-vivo Ergebnisse aus unseren Forschungsarbeiten zu Paclitaxel vorgestellt . Zellkulturexperimente mit Monokulturen von humanen glatten Gefaessmuskelzellen sowie mit Co-Kulturen mit humanen Endothelzellen zeigten , dass Paclitaxel in einem Dosisbereich zwischen 1,0 und 10,0µmol/l zu einer beinahe vollstaendigen Wachstumshemmung , selbst nach kurzer ( 20 min . ) Einmalapplikation fuehrt . Nach Vergleich von 3 verschiedenen Kathetersystemen ( poroeser Ballon , mikroporoeser Ballon und Doppelballon ) wurde der Doppelballon fuer die in-vivo Anwendung favorisiert . Anhand von Anfaerbungen des Zytoskelettes sowie elektronenoptisch gelang der Nachweis der Paclitaxelwirkung in den glatten Muskelzellen der Gefaesswand . Im Kaninchen fuehrte lokal appliziertes Paclitaxel zu einer signifikanten Hemmung der neointimalen Proliferation und Erweiterung des Gefaessdurchmessers im Vergleich zu ballondilatierten Kontrolltieren . In Zusatzexperimenten konnte eine drastische Verringerung der vaskulaeren Kontraktionskraft nach Paclitaxelgabe gezeigt werden . Aehnlich eindeutige Ergebnisse fanden sich nach Stentimplantation im Schweinemodell nicht . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Paclitaxel eine sehr potente antiproliferative Substanz , , foerdert die Bildung ungewoehnlich stabiler und funktionsgestoerter Mikrotubuli und veraendert dadurch zellulaere Mechanismen , die letztlich zu verminderter Proliferation , Migration und Signaltransduktion fuehren . Paclitaxel ist lipophil , was eine rasche Aufnahme in die Zelle foerdert , und hat einen langanhaltenden Effekt in der Zelle aufgrund der strukturellen Veraenderung des Zytoskelettes . Diese Eigenschaften machen Paclitaxel zu einem vielversprechenden Kandidaten fuer die lokale Medikamentenapplikation zur Restenoseprophylaxe . In dieser Arbeit werden die in-vitro und in-vivo Ergebnisse aus unseren Forschungsarbeiten zu Paclitaxel vorgestellt . Zellkulturexperimente mit Monokulturen von humanen glatten Gefaessmuskelzellen sowie mit Co-Kulturen mit humanen Endothelzellen zeigten , dass Paclitaxel in einem Dosisbereich zwischen 1,0 und 10,0µmol/l zu einer beinahe vollstaendigen Wachstumshemmung , selbst nach kurzer ( 20 min . ) Einmalapplikation fuehrt . Nach Vergleich von 3 verschiedenen Kathetersystemen ( poroeser Ballon , mikroporoeser Ballon und Doppelballon ) wurde der Doppelballon fuer die in-vivo Anwendung favorisiert . Anhand von Anfaerbungen des Zytoskelettes sowie elektronenoptisch gelang der Nachweis der Paclitaxelwirkung in den glatten Muskelzellen der Gefaesswand . Im Kaninchen fuehrte lokal appliziertes Paclitaxel zu einer signifikanten Hemmung der neointimalen Proliferation und Erweiterung des Gefaessdurchmessers im Vergleich zu ballondilatierten Kontrolltieren . In Zusatzexperimenten konnte eine drastische Verringerung der vaskulaeren Kontraktionskraft nach Paclitaxelgabe gezeigt werden . Aehnlich eindeutige Ergebnisse fanden sich nach Stentimplantation im Schweinemodell nicht .

[ "Paclitaxel", "eine", "sehr", "potente", "antiproliferative", "Substanz", ",", ",", "foerdert", "die", "Bildung", "ungewoehnlich", "stabiler", "und", "funktionsgestoerter", "Mikrotubuli", "und", "veraendert", "dadurch", "zellulaere", "Mechanismen", ",", "die", "letztlich", "zu", "verminderter", "Proliferation", ",", "Migration", "und", "Signaltransduktion", "fuehren", ".", "Paclitaxel", "ist", "lipophil", ",", "was", "eine", "rasche", "Aufnahme", "in", "die", "Zelle", "foerdert", ",", "und", "hat", "einen", "langanhaltenden", "Effekt", "in", "der", "Zelle", "aufgrund", "der", "strukturellen", "Veraenderung", "des", "Zytoskelettes", ".", "Diese", "Eigenschaften", "machen", "Paclitaxel", "zu", "einem", "vielversprechenden", "Kandidaten", "fuer", "die", "lokale", "Medikamentenapplikation", "zur", "Restenoseprophylaxe", ".", "In", "dieser", "Arbeit", "werden", "die", "in", "-", "vitro", "und", "in", "-", "vivo", "Ergebnisse", "aus", "unseren", "Forschungsarbeiten", "zu", "Paclitaxel", "vorgestellt", ".", "Zellkulturexperimente", "mit", "Monokulturen", "von", "humanen", "glatten", "Gefaessmuskelzellen", "sowie", "mit", "Co", "-", "Kulturen", "mit", "humanen", "Endothelzellen", "zeigten", ",", "dass", "Paclitaxel", "in", "einem", "Dosisbereich", "zwischen", "1,0", "und", "10,0µmol", "/", "l", "zu", "einer", "beinahe", "vollstaendigen", "Wachstumshemmung", ",", "selbst", "nach", "kurzer", "(", "20", "min", ".", ")", "Einmalapplikation", "fuehrt", ".", "Nach", "Vergleich", "von", "3", "verschiedenen", "Kathetersystemen", "(", "poroeser", "Ballon", ",", "mikroporoeser", "Ballon", "und", "Doppelballon", ")", "wurde", "der", "Doppelballon", "fuer", "die", "in", "-", "vivo", "Anwendung", "favorisiert", ".", "Anhand", "von", "Anfaerbungen", "des", "Zytoskelettes", "sowie", "elektronenoptisch", "gelang", "der", "Nachweis", "der", "Paclitaxelwirkung", "in", "den", "glatten", "Muskelzellen", "der", "Gefaesswand", ".", "Im", "Kaninchen", "fuehrte", "lokal", "appliziertes", "Paclitaxel", "zu", "einer", "signifikanten", "Hemmung", "der", "neointimalen", "Proliferation", "und", "Erweiterung", "des", "Gefaessdurchmessers", "im", "Vergleich", "zu", "ballondilatierten", "Kontrolltieren", ".", "In", "Zusatzexperimenten", "konnte", "eine", "drastische", "Verringerung", "der", "vaskulaeren", "Kontraktionskraft", "nach", "Paclitaxelgabe", "gezeigt", "werden", ".", "Aehnlich", "eindeutige", "Ergebnisse", "fanden", "sich", "nach", "Stentimplantation", "im", "Schweinemodell", "nicht", "." ]

[ "umlsterm" ]

transcutaneous electrical stimulation is a Intervention_Physical, pressurization is a Intervention_Physical, side effects is a Outcome_Adverse-effects, incidence of PONV , the rate of metoclopramide , the VAS score is a Outcome_Physical, total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture is a Outcome_Physical, anal exhaust time and the volume of postoperative bleeding is a Outcome_Physical, incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section . is a Outcome_Physical

57395_task0

Sentence: [ Effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section ] . OBJECTIVE To investigate the effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section . METHODS After IRB approval and informed consent , one hundred and eighty singleton primiparas undergoing elective cesarean section , in Qingdao Municipal Hospital , and Qingdao Hiser Medical Center , from November 2011 to March 2012 , were randomly assigned to three groups : transcutaneous electrical stimulation of auricular Shenmen point group ( group A , n = 60 ) , transcutaneous electrical stimulation of auricular Eye point group ( group B , n = 60 ) and control group ( group C , n = 60 ) . Women of group A received transcutaneous electrical stimulation of auricular Shenmen point ( frequency 1.5 HZ ) at the time of preoperation , 4 , 10 and 22 hours of postoperation for 30 minutes . The strength was controlled by themselves . Women of group B received stimulation of auricular Eye point as group A . Women of group C received pressurization and connected line were the same with group A , but without electrical stimulation . The following indexes was observed : the incidence of postoperative nausea and vomiting ( PONV ) for 48 hours ; the rate of metoclopramide ; the visual analogue scale ( VAS ) score of rest pain , uterine contration pain and dynamic pain at the time of postoperation for 6 , 12 , 24 and 48 hours ( T ( 1 ) -T ( 4 ) ) ; the total number and effective compressions number of patient-controlled epidural analgesia ( PCEA ) ; the dose of analgesia mixture ; the anal exhaust time ; the volume of postoperative bleeding for 6 hours of postoperation and the other side effects . RESULTS Compared with group B and group C , the incidence of PONV , the rate of metoclopramide , the VAS score at the time T ( 1 ) -T ( 4 ) , the total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture were decreased in group A ( P < 0.05 ) , but no difference compared group B with group C ( P > 0.05 ) . The anal exhaust time and the volume of postoperative bleeding for 6 hours of postoperation were no difference in the three groups ( P > 0.05 ) . No other side effects were observed . CONCLUSION Transcutaneous electrical stimulation of auricular Shenmen point can reduce the incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Adverse-effects, Outcome_Physical

[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical" ]

[ Effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section ] . OBJECTIVE To investigate the effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section . METHODS After IRB approval and informed consent , one hundred and eighty singleton primiparas undergoing elective cesarean section , in Qingdao Municipal Hospital , and Qingdao Hiser Medical Center , from November 2011 to March 2012 , were randomly assigned to three groups : transcutaneous electrical stimulation of auricular Shenmen point group ( group A , n = 60 ) , transcutaneous electrical stimulation of auricular Eye point group ( group B , n = 60 ) and control group ( group C , n = 60 ) . Women of group A received transcutaneous electrical stimulation of auricular Shenmen point ( frequency 1.5 HZ ) at the time of preoperation , 4 , 10 and 22 hours of postoperation for 30 minutes . The strength was controlled by themselves . Women of group B received stimulation of auricular Eye point as group A . Women of group C received pressurization and connected line were the same with group A , but without electrical stimulation . The following indexes was observed : the incidence of postoperative nausea and vomiting ( PONV ) for 48 hours ; the rate of metoclopramide ; the visual analogue scale ( VAS ) score of rest pain , uterine contration pain and dynamic pain at the time of postoperation for 6 , 12 , 24 and 48 hours ( T ( 1 ) -T ( 4 ) ) ; the total number and effective compressions number of patient-controlled epidural analgesia ( PCEA ) ; the dose of analgesia mixture ; the anal exhaust time ; the volume of postoperative bleeding for 6 hours of postoperation and the other side effects . RESULTS Compared with group B and group C , the incidence of PONV , the rate of metoclopramide , the VAS score at the time T ( 1 ) -T ( 4 ) , the total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture were decreased in group A ( P < 0.05 ) , but no difference compared group B with group C ( P > 0.05 ) . The anal exhaust time and the volume of postoperative bleeding for 6 hours of postoperation were no difference in the three groups ( P > 0.05 ) . No other side effects were observed . CONCLUSION Transcutaneous electrical stimulation of auricular Shenmen point can reduce the incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section .

[ "[", "Effects", "of", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "on", "postoperative", "nausea", "and", "vomiting", "and", "patient", "-", "controlled", "epidural", "analgesia", "in", "cesarean", "section", "]", ".", "OBJECTIVE", "To", "investigate", "the", "effects", "of", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "on", "postoperative", "nausea", "and", "vomiting", "and", "patient", "-", "controlled", "epidural", "analgesia", "in", "cesarean", "section", ".", "METHODS", "After", "IRB", "approval", "and", "informed", "consent", ",", "one", "hundred", "and", "eighty", "singleton", "primiparas", "undergoing", "elective", "cesarean", "section", ",", "in", "Qingdao", "Municipal", "Hospital", ",", "and", "Qingdao", "Hiser", "Medical", "Center", ",", "from", "November", "2011", "to", "March", "2012", ",", "were", "randomly", "assigned", "to", "three", "groups", ":", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "group", "(", "group", "A", ",", "n", "=", "60", ")", ",", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Eye", "point", "group", "(", "group", "B", ",", "n", "=", "60", ")", "and", "control", "group", "(", "group", "C", ",", "n", "=", "60", ")", ".", "Women", "of", "group", "A", "received", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "(", "frequency", "1.5", "HZ", ")", "at", "the", "time", "of", "preoperation", ",", "4", ",", "10", "and", "22", "hours", "of", "postoperation", "for", "30", "minutes", ".", "The", "strength", "was", "controlled", "by", "themselves", ".", "Women", "of", "group", "B", "received", "stimulation", "of", "auricular", "Eye", "point", "as", "group", "A", ".", "Women", "of", "group", "C", "received", "pressurization", "and", "connected", "line", "were", "the", "same", "with", "group", "A", ",", "but", "without", "electrical", "stimulation", ".", "The", "following", "indexes", "was", "observed", ":", "the", "incidence", "of", "postoperative", "nausea", "and", "vomiting", "(", "PONV", ")", "for", "48", "hours", ";", "the", "rate", "of", "metoclopramide", ";", "the", "visual", "analogue", "scale", "(", "VAS", ")", "score", "of", "rest", "pain", ",", "uterine", "contration", "pain", "and", "dynamic", "pain", "at", "the", "time", "of", "postoperation", "for", "6", ",", "12", ",", "24", "and", "48", "hours", "(", "T", "(", "1", ")", "-T", "(", "4", ")", ")", ";", "the", "total", "number", "and", "effective", "compressions", "number", "of", "patient", "-", "controlled", "epidural", "analgesia", "(", "PCEA", ")", ";", "the", "dose", "of", "analgesia", "mixture", ";", "the", "anal", "exhaust", "time", ";", "the", "volume", "of", "postoperative", "bleeding", "for", "6", "hours", "of", "postoperation", "and", "the", "other", "side", "effects", ".", "RESULTS", "Compared", "with", "group", "B", "and", "group", "C", ",", "the", "incidence", "of", "PONV", ",", "the", "rate", "of", "metoclopramide", ",", "the", "VAS", "score", "at", "the", "time", "T", "(", "1", ")", "-T", "(", "4", ")", ",", "the", "total", "number", "and", "effective", "compressions", "number", "of", "PCEA", ",", "the", "ratio", "of", "the", "total", "number", "with", "effective", "compressions", "number", "and", "the", "dose", "of", "analgesia", "mixture", "were", "decreased", "in", "group", "A", "(", "P", "<", "0.05", ")", ",", "but", "no", "difference", "compared", "group", "B", "with", "group", "C", "(", "P", ">", "0.05", ")", ".", "The", "anal", "exhaust", "time", "and", "the", "volume", "of", "postoperative", "bleeding", "for", "6", "hours", "of", "postoperation", "were", "no", "difference", "in", "the", "three", "groups", "(", "P", ">", "0.05", ")", ".", "No", "other", "side", "effects", "were", "observed", ".", "CONCLUSION", "Transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "can", "reduce", "the", "incidence", "of", "PONV", "and", "improves", "analgesia", "effect", "of", "PCEA", "in", "postoperation", "of", "cesarean", "section", "." ]

[ "Outcome_Physical", "Intervention_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]

transcutaneous electrical stimulation is a Intervention_Physical, pressurization is a Intervention_Physical, side effects is a Outcome_Adverse-effects, incidence of PONV , the rate of metoclopramide , the VAS score is a Outcome_Physical, total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture is a Outcome_Physical, anal exhaust time and the volume of postoperative bleeding is a Outcome_Physical, incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section . is a Outcome_Physical

57395_task1

Sentence: [ Effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section ] . OBJECTIVE To investigate the effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section . METHODS After IRB approval and informed consent , one hundred and eighty singleton primiparas undergoing elective cesarean section , in Qingdao Municipal Hospital , and Qingdao Hiser Medical Center , from November 2011 to March 2012 , were randomly assigned to three groups : transcutaneous electrical stimulation of auricular Shenmen point group ( group A , n = 60 ) , transcutaneous electrical stimulation of auricular Eye point group ( group B , n = 60 ) and control group ( group C , n = 60 ) . Women of group A received transcutaneous electrical stimulation of auricular Shenmen point ( frequency 1.5 HZ ) at the time of preoperation , 4 , 10 and 22 hours of postoperation for 30 minutes . The strength was controlled by themselves . Women of group B received stimulation of auricular Eye point as group A . Women of group C received pressurization and connected line were the same with group A , but without electrical stimulation . The following indexes was observed : the incidence of postoperative nausea and vomiting ( PONV ) for 48 hours ; the rate of metoclopramide ; the visual analogue scale ( VAS ) score of rest pain , uterine contration pain and dynamic pain at the time of postoperation for 6 , 12 , 24 and 48 hours ( T ( 1 ) -T ( 4 ) ) ; the total number and effective compressions number of patient-controlled epidural analgesia ( PCEA ) ; the dose of analgesia mixture ; the anal exhaust time ; the volume of postoperative bleeding for 6 hours of postoperation and the other side effects . RESULTS Compared with group B and group C , the incidence of PONV , the rate of metoclopramide , the VAS score at the time T ( 1 ) -T ( 4 ) , the total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture were decreased in group A ( P < 0.05 ) , but no difference compared group B with group C ( P > 0.05 ) . The anal exhaust time and the volume of postoperative bleeding for 6 hours of postoperation were no difference in the three groups ( P > 0.05 ) . No other side effects were observed . CONCLUSION Transcutaneous electrical stimulation of auricular Shenmen point can reduce the incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section . Instructions: please typing these entity words according to sentence: transcutaneous electrical stimulation, pressurization, side effects, incidence of PONV , the rate of metoclopramide , the VAS score, total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture, anal exhaust time and the volume of postoperative bleeding, incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section . Options: Intervention_Physical, Outcome_Adverse-effects, Outcome_Physical

[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical" ]

[ Effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section ] . OBJECTIVE To investigate the effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section . METHODS After IRB approval and informed consent , one hundred and eighty singleton primiparas undergoing elective cesarean section , in Qingdao Municipal Hospital , and Qingdao Hiser Medical Center , from November 2011 to March 2012 , were randomly assigned to three groups : transcutaneous electrical stimulation of auricular Shenmen point group ( group A , n = 60 ) , transcutaneous electrical stimulation of auricular Eye point group ( group B , n = 60 ) and control group ( group C , n = 60 ) . Women of group A received transcutaneous electrical stimulation of auricular Shenmen point ( frequency 1.5 HZ ) at the time of preoperation , 4 , 10 and 22 hours of postoperation for 30 minutes . The strength was controlled by themselves . Women of group B received stimulation of auricular Eye point as group A . Women of group C received pressurization and connected line were the same with group A , but without electrical stimulation . The following indexes was observed : the incidence of postoperative nausea and vomiting ( PONV ) for 48 hours ; the rate of metoclopramide ; the visual analogue scale ( VAS ) score of rest pain , uterine contration pain and dynamic pain at the time of postoperation for 6 , 12 , 24 and 48 hours ( T ( 1 ) -T ( 4 ) ) ; the total number and effective compressions number of patient-controlled epidural analgesia ( PCEA ) ; the dose of analgesia mixture ; the anal exhaust time ; the volume of postoperative bleeding for 6 hours of postoperation and the other side effects . RESULTS Compared with group B and group C , the incidence of PONV , the rate of metoclopramide , the VAS score at the time T ( 1 ) -T ( 4 ) , the total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture were decreased in group A ( P < 0.05 ) , but no difference compared group B with group C ( P > 0.05 ) . The anal exhaust time and the volume of postoperative bleeding for 6 hours of postoperation were no difference in the three groups ( P > 0.05 ) . No other side effects were observed . CONCLUSION Transcutaneous electrical stimulation of auricular Shenmen point can reduce the incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section .

[ "[", "Effects", "of", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "on", "postoperative", "nausea", "and", "vomiting", "and", "patient", "-", "controlled", "epidural", "analgesia", "in", "cesarean", "section", "]", ".", "OBJECTIVE", "To", "investigate", "the", "effects", "of", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "on", "postoperative", "nausea", "and", "vomiting", "and", "patient", "-", "controlled", "epidural", "analgesia", "in", "cesarean", "section", ".", "METHODS", "After", "IRB", "approval", "and", "informed", "consent", ",", "one", "hundred", "and", "eighty", "singleton", "primiparas", "undergoing", "elective", "cesarean", "section", ",", "in", "Qingdao", "Municipal", "Hospital", ",", "and", "Qingdao", "Hiser", "Medical", "Center", ",", "from", "November", "2011", "to", "March", "2012", ",", "were", "randomly", "assigned", "to", "three", "groups", ":", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "group", "(", "group", "A", ",", "n", "=", "60", ")", ",", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Eye", "point", "group", "(", "group", "B", ",", "n", "=", "60", ")", "and", "control", "group", "(", "group", "C", ",", "n", "=", "60", ")", ".", "Women", "of", "group", "A", "received", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "(", "frequency", "1.5", "HZ", ")", "at", "the", "time", "of", "preoperation", ",", "4", ",", "10", "and", "22", "hours", "of", "postoperation", "for", "30", "minutes", ".", "The", "strength", "was", "controlled", "by", "themselves", ".", "Women", "of", "group", "B", "received", "stimulation", "of", "auricular", "Eye", "point", "as", "group", "A", ".", "Women", "of", "group", "C", "received", "pressurization", "and", "connected", "line", "were", "the", "same", "with", "group", "A", ",", "but", "without", "electrical", "stimulation", ".", "The", "following", "indexes", "was", "observed", ":", "the", "incidence", "of", "postoperative", "nausea", "and", "vomiting", "(", "PONV", ")", "for", "48", "hours", ";", "the", "rate", "of", "metoclopramide", ";", "the", "visual", "analogue", "scale", "(", "VAS", ")", "score", "of", "rest", "pain", ",", "uterine", "contration", "pain", "and", "dynamic", "pain", "at", "the", "time", "of", "postoperation", "for", "6", ",", "12", ",", "24", "and", "48", "hours", "(", "T", "(", "1", ")", "-T", "(", "4", ")", ")", ";", "the", "total", "number", "and", "effective", "compressions", "number", "of", "patient", "-", "controlled", "epidural", "analgesia", "(", "PCEA", ")", ";", "the", "dose", "of", "analgesia", "mixture", ";", "the", "anal", "exhaust", "time", ";", "the", "volume", "of", "postoperative", "bleeding", "for", "6", "hours", "of", "postoperation", "and", "the", "other", "side", "effects", ".", "RESULTS", "Compared", "with", "group", "B", "and", "group", "C", ",", "the", "incidence", "of", "PONV", ",", "the", "rate", "of", "metoclopramide", ",", "the", "VAS", "score", "at", "the", "time", "T", "(", "1", ")", "-T", "(", "4", ")", ",", "the", "total", "number", "and", "effective", "compressions", "number", "of", "PCEA", ",", "the", "ratio", "of", "the", "total", "number", "with", "effective", "compressions", "number", "and", "the", "dose", "of", "analgesia", "mixture", "were", "decreased", "in", "group", "A", "(", "P", "<", "0.05", ")", ",", "but", "no", "difference", "compared", "group", "B", "with", "group", "C", "(", "P", ">", "0.05", ")", ".", "The", "anal", "exhaust", "time", "and", "the", "volume", "of", "postoperative", "bleeding", "for", "6", "hours", "of", "postoperation", "were", "no", "difference", "in", "the", "three", "groups", "(", "P", ">", "0.05", ")", ".", "No", "other", "side", "effects", "were", "observed", ".", "CONCLUSION", "Transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "can", "reduce", "the", "incidence", "of", "PONV", "and", "improves", "analgesia", "effect", "of", "PCEA", "in", "postoperation", "of", "cesarean", "section", "." ]

[ "Outcome_Physical", "Intervention_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]

transcutaneous electrical stimulation, pressurization, side effects, incidence of PONV , the rate of metoclopramide , the VAS score, total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture, anal exhaust time and the volume of postoperative bleeding, incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section .

57395_task2

Sentence: [ Effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section ] . OBJECTIVE To investigate the effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section . METHODS After IRB approval and informed consent , one hundred and eighty singleton primiparas undergoing elective cesarean section , in Qingdao Municipal Hospital , and Qingdao Hiser Medical Center , from November 2011 to March 2012 , were randomly assigned to three groups : transcutaneous electrical stimulation of auricular Shenmen point group ( group A , n = 60 ) , transcutaneous electrical stimulation of auricular Eye point group ( group B , n = 60 ) and control group ( group C , n = 60 ) . Women of group A received transcutaneous electrical stimulation of auricular Shenmen point ( frequency 1.5 HZ ) at the time of preoperation , 4 , 10 and 22 hours of postoperation for 30 minutes . The strength was controlled by themselves . Women of group B received stimulation of auricular Eye point as group A . Women of group C received pressurization and connected line were the same with group A , but without electrical stimulation . The following indexes was observed : the incidence of postoperative nausea and vomiting ( PONV ) for 48 hours ; the rate of metoclopramide ; the visual analogue scale ( VAS ) score of rest pain , uterine contration pain and dynamic pain at the time of postoperation for 6 , 12 , 24 and 48 hours ( T ( 1 ) -T ( 4 ) ) ; the total number and effective compressions number of patient-controlled epidural analgesia ( PCEA ) ; the dose of analgesia mixture ; the anal exhaust time ; the volume of postoperative bleeding for 6 hours of postoperation and the other side effects . RESULTS Compared with group B and group C , the incidence of PONV , the rate of metoclopramide , the VAS score at the time T ( 1 ) -T ( 4 ) , the total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture were decreased in group A ( P < 0.05 ) , but no difference compared group B with group C ( P > 0.05 ) . The anal exhaust time and the volume of postoperative bleeding for 6 hours of postoperation were no difference in the three groups ( P > 0.05 ) . No other side effects were observed . CONCLUSION Transcutaneous electrical stimulation of auricular Shenmen point can reduce the incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical" ]

[ Effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section ] . OBJECTIVE To investigate the effects of transcutaneous electrical stimulation of auricular Shenmen point on postoperative nausea and vomiting and patient-controlled epidural analgesia in cesarean section . METHODS After IRB approval and informed consent , one hundred and eighty singleton primiparas undergoing elective cesarean section , in Qingdao Municipal Hospital , and Qingdao Hiser Medical Center , from November 2011 to March 2012 , were randomly assigned to three groups : transcutaneous electrical stimulation of auricular Shenmen point group ( group A , n = 60 ) , transcutaneous electrical stimulation of auricular Eye point group ( group B , n = 60 ) and control group ( group C , n = 60 ) . Women of group A received transcutaneous electrical stimulation of auricular Shenmen point ( frequency 1.5 HZ ) at the time of preoperation , 4 , 10 and 22 hours of postoperation for 30 minutes . The strength was controlled by themselves . Women of group B received stimulation of auricular Eye point as group A . Women of group C received pressurization and connected line were the same with group A , but without electrical stimulation . The following indexes was observed : the incidence of postoperative nausea and vomiting ( PONV ) for 48 hours ; the rate of metoclopramide ; the visual analogue scale ( VAS ) score of rest pain , uterine contration pain and dynamic pain at the time of postoperation for 6 , 12 , 24 and 48 hours ( T ( 1 ) -T ( 4 ) ) ; the total number and effective compressions number of patient-controlled epidural analgesia ( PCEA ) ; the dose of analgesia mixture ; the anal exhaust time ; the volume of postoperative bleeding for 6 hours of postoperation and the other side effects . RESULTS Compared with group B and group C , the incidence of PONV , the rate of metoclopramide , the VAS score at the time T ( 1 ) -T ( 4 ) , the total number and effective compressions number of PCEA , the ratio of the total number with effective compressions number and the dose of analgesia mixture were decreased in group A ( P < 0.05 ) , but no difference compared group B with group C ( P > 0.05 ) . The anal exhaust time and the volume of postoperative bleeding for 6 hours of postoperation were no difference in the three groups ( P > 0.05 ) . No other side effects were observed . CONCLUSION Transcutaneous electrical stimulation of auricular Shenmen point can reduce the incidence of PONV and improves analgesia effect of PCEA in postoperation of cesarean section .

[ "[", "Effects", "of", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "on", "postoperative", "nausea", "and", "vomiting", "and", "patient", "-", "controlled", "epidural", "analgesia", "in", "cesarean", "section", "]", ".", "OBJECTIVE", "To", "investigate", "the", "effects", "of", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "on", "postoperative", "nausea", "and", "vomiting", "and", "patient", "-", "controlled", "epidural", "analgesia", "in", "cesarean", "section", ".", "METHODS", "After", "IRB", "approval", "and", "informed", "consent", ",", "one", "hundred", "and", "eighty", "singleton", "primiparas", "undergoing", "elective", "cesarean", "section", ",", "in", "Qingdao", "Municipal", "Hospital", ",", "and", "Qingdao", "Hiser", "Medical", "Center", ",", "from", "November", "2011", "to", "March", "2012", ",", "were", "randomly", "assigned", "to", "three", "groups", ":", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "group", "(", "group", "A", ",", "n", "=", "60", ")", ",", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Eye", "point", "group", "(", "group", "B", ",", "n", "=", "60", ")", "and", "control", "group", "(", "group", "C", ",", "n", "=", "60", ")", ".", "Women", "of", "group", "A", "received", "transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "(", "frequency", "1.5", "HZ", ")", "at", "the", "time", "of", "preoperation", ",", "4", ",", "10", "and", "22", "hours", "of", "postoperation", "for", "30", "minutes", ".", "The", "strength", "was", "controlled", "by", "themselves", ".", "Women", "of", "group", "B", "received", "stimulation", "of", "auricular", "Eye", "point", "as", "group", "A", ".", "Women", "of", "group", "C", "received", "pressurization", "and", "connected", "line", "were", "the", "same", "with", "group", "A", ",", "but", "without", "electrical", "stimulation", ".", "The", "following", "indexes", "was", "observed", ":", "the", "incidence", "of", "postoperative", "nausea", "and", "vomiting", "(", "PONV", ")", "for", "48", "hours", ";", "the", "rate", "of", "metoclopramide", ";", "the", "visual", "analogue", "scale", "(", "VAS", ")", "score", "of", "rest", "pain", ",", "uterine", "contration", "pain", "and", "dynamic", "pain", "at", "the", "time", "of", "postoperation", "for", "6", ",", "12", ",", "24", "and", "48", "hours", "(", "T", "(", "1", ")", "-T", "(", "4", ")", ")", ";", "the", "total", "number", "and", "effective", "compressions", "number", "of", "patient", "-", "controlled", "epidural", "analgesia", "(", "PCEA", ")", ";", "the", "dose", "of", "analgesia", "mixture", ";", "the", "anal", "exhaust", "time", ";", "the", "volume", "of", "postoperative", "bleeding", "for", "6", "hours", "of", "postoperation", "and", "the", "other", "side", "effects", ".", "RESULTS", "Compared", "with", "group", "B", "and", "group", "C", ",", "the", "incidence", "of", "PONV", ",", "the", "rate", "of", "metoclopramide", ",", "the", "VAS", "score", "at", "the", "time", "T", "(", "1", ")", "-T", "(", "4", ")", ",", "the", "total", "number", "and", "effective", "compressions", "number", "of", "PCEA", ",", "the", "ratio", "of", "the", "total", "number", "with", "effective", "compressions", "number", "and", "the", "dose", "of", "analgesia", "mixture", "were", "decreased", "in", "group", "A", "(", "P", "<", "0.05", ")", ",", "but", "no", "difference", "compared", "group", "B", "with", "group", "C", "(", "P", ">", "0.05", ")", ".", "The", "anal", "exhaust", "time", "and", "the", "volume", "of", "postoperative", "bleeding", "for", "6", "hours", "of", "postoperation", "were", "no", "difference", "in", "the", "three", "groups", "(", "P", ">", "0.05", ")", ".", "No", "other", "side", "effects", "were", "observed", ".", "CONCLUSION", "Transcutaneous", "electrical", "stimulation", "of", "auricular", "Shenmen", "point", "can", "reduce", "the", "incidence", "of", "PONV", "and", "improves", "analgesia", "effect", "of", "PCEA", "in", "postoperation", "of", "cesarean", "section", "." ]

[ "Outcome_Physical", "Intervention_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]

E1A is a protein, p300 is a protein, p300 is a protein, E1A is a protein, p300 is a protein

1.0alpha7.train.1249_task0

Sentence: To investigate whether the binding of E1A to p300 correlates with a loss of p300 transcriptional activity, we examined the binding of full-length E1A to the series of mutant p300 proteins. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein

[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O" ]

To investigate whether the binding of E1A to p300 correlates with a loss of p300 transcriptional activity, we examined the binding of full-length E1A to the series of mutant p300 proteins.

[ "To", "investigate", "whether", "the", "binding", "of", " ", "E1A", "to", " ", "p300", "correlates", "with", "a", "loss", "of", " ", "p300", "transcriptional", "activity", ",", "we", "examined", "the", "binding", "of", "full", "-", "length", " ", "E1A", "to", "the", "series", "of", " ", "mutant", "p300", "proteins", "." ]

[ "protein" ]

E1A is a protein, p300 is a protein, p300 is a protein, E1A is a protein, p300 is a protein

1.0alpha7.train.1249_task1

Sentence: To investigate whether the binding of E1A to p300 correlates with a loss of p300 transcriptional activity, we examined the binding of full-length E1A to the series of mutant p300 proteins. Instructions: please typing these entity words according to sentence: E1A, p300, p300, E1A, p300 Options: protein

[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O" ]

To investigate whether the binding of E1A to p300 correlates with a loss of p300 transcriptional activity, we examined the binding of full-length E1A to the series of mutant p300 proteins.

[ "To", "investigate", "whether", "the", "binding", "of", " ", "E1A", "to", " ", "p300", "correlates", "with", "a", "loss", "of", " ", "p300", "transcriptional", "activity", ",", "we", "examined", "the", "binding", "of", "full", "-", "length", " ", "E1A", "to", "the", "series", "of", " ", "mutant", "p300", "proteins", "." ]

[ "protein" ]

E1A, p300, p300, E1A, p300

1.0alpha7.train.1249_task2

Sentence: To investigate whether the binding of E1A to p300 correlates with a loss of p300 transcriptional activity, we examined the binding of full-length E1A to the series of mutant p300 proteins. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O" ]

To investigate whether the binding of E1A to p300 correlates with a loss of p300 transcriptional activity, we examined the binding of full-length E1A to the series of mutant p300 proteins.

[ "To", "investigate", "whether", "the", "binding", "of", " ", "E1A", "to", " ", "p300", "correlates", "with", "a", "loss", "of", " ", "p300", "transcriptional", "activity", ",", "we", "examined", "the", "binding", "of", "full", "-", "length", " ", "E1A", "to", "the", "series", "of", " ", "mutant", "p300", "proteins", "." ]

[ "protein" ]

population is an umlsterm, health priority is an umlsterm, Italy is an umlsterm, age is an umlsterm, population is an umlsterm, old is an umlsterm, disease is an umlsterm, future is an umlsterm, generations is an umlsterm, disease is an umlsterm, prevention is an umlsterm, programs is an umlsterm

ZfuerGerontologie+Geriatrie.90320420.eng.abstr_task0

Sentence: The aging of the Italian population is an emerging public health priority . In 2025 Italy is expected to have the highest world median age with nearly half of the population over 50 years old . To avoid an unbearable burden of disease and disability on future generations , we must identify areas for intensive disease and disability prevention programs . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

The aging of the Italian population is an emerging public health priority . In 2025 Italy is expected to have the highest world median age with nearly half of the population over 50 years old . To avoid an unbearable burden of disease and disability on future generations , we must identify areas for intensive disease and disability prevention programs .

[ "The", "aging", "of", "the", "Italian", "population", "is", "an", "emerging", "public", "health", "priority", ".", "In", "2025", "Italy", "is", "expected", "to", "have", "the", "highest", "world", "median", "age", "with", "nearly", "half", "of", "the", "population", "over", "50", "years", "old", ".", "To", "avoid", "an", "unbearable", "burden", "of", "disease", "and", "disability", "on", "future", "generations", ",", "we", "must", "identify", "areas", "for", "intensive", "disease", "and", "disability", "prevention", "programs", "." ]

[ "umlsterm" ]

population is an umlsterm, health priority is an umlsterm, Italy is an umlsterm, age is an umlsterm, population is an umlsterm, old is an umlsterm, disease is an umlsterm, future is an umlsterm, generations is an umlsterm, disease is an umlsterm, prevention is an umlsterm, programs is an umlsterm

ZfuerGerontologie+Geriatrie.90320420.eng.abstr_task1

Sentence: The aging of the Italian population is an emerging public health priority . In 2025 Italy is expected to have the highest world median age with nearly half of the population over 50 years old . To avoid an unbearable burden of disease and disability on future generations , we must identify areas for intensive disease and disability prevention programs . Instructions: please typing these entity words according to sentence: population, health priority, Italy, age, population, old, disease, future, generations, disease, prevention, programs Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

The aging of the Italian population is an emerging public health priority . In 2025 Italy is expected to have the highest world median age with nearly half of the population over 50 years old . To avoid an unbearable burden of disease and disability on future generations , we must identify areas for intensive disease and disability prevention programs .

[ "The", "aging", "of", "the", "Italian", "population", "is", "an", "emerging", "public", "health", "priority", ".", "In", "2025", "Italy", "is", "expected", "to", "have", "the", "highest", "world", "median", "age", "with", "nearly", "half", "of", "the", "population", "over", "50", "years", "old", ".", "To", "avoid", "an", "unbearable", "burden", "of", "disease", "and", "disability", "on", "future", "generations", ",", "we", "must", "identify", "areas", "for", "intensive", "disease", "and", "disability", "prevention", "programs", "." ]

[ "umlsterm" ]

population, health priority, Italy, age, population, old, disease, future, generations, disease, prevention, programs

ZfuerGerontologie+Geriatrie.90320420.eng.abstr_task2

Sentence: The aging of the Italian population is an emerging public health priority . In 2025 Italy is expected to have the highest world median age with nearly half of the population over 50 years old . To avoid an unbearable burden of disease and disability on future generations , we must identify areas for intensive disease and disability prevention programs . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

The aging of the Italian population is an emerging public health priority . In 2025 Italy is expected to have the highest world median age with nearly half of the population over 50 years old . To avoid an unbearable burden of disease and disability on future generations , we must identify areas for intensive disease and disability prevention programs .

[ "The", "aging", "of", "the", "Italian", "population", "is", "an", "emerging", "public", "health", "priority", ".", "In", "2025", "Italy", "is", "expected", "to", "have", "the", "highest", "world", "median", "age", "with", "nearly", "half", "of", "the", "population", "over", "50", "years", "old", ".", "To", "avoid", "an", "unbearable", "burden", "of", "disease", "and", "disability", "on", "future", "generations", ",", "we", "must", "identify", "areas", "for", "intensive", "disease", "and", "disability", "prevention", "programs", "." ]

[ "umlsterm" ]

Activated platelets is a cell_type, monocyte chemotactic protein-1 secretion is an other_name, intercellular adhesion molecule-1 is a cell_type, endothelial cells is a cell_type

77463_task0

Sentence: Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells [see comments] Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, other_name

[ "B-cell_type", "I-cell_type", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "O" ]

Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells [see comments]

[ "Activated", "platelets", "induce", "monocyte", "chemotactic", "protein-1", "secretion", "and", "surface", "expression", "of", "intercellular", "adhesion", "molecule-1", "on", "endothelial", "cells", "[", "see", "comments", "]" ]

[ "polynucleotide", "(AND other_name other_name)", "protein_complex", "other_name", "cell_type", "", "protein_molecule", "tissue" ]

Activated platelets is a cell_type, monocyte chemotactic protein-1 secretion is an other_name, intercellular adhesion molecule-1 is a cell_type, endothelial cells is a cell_type

77463_task1

Sentence: Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells [see comments] Instructions: please typing these entity words according to sentence: Activated platelets, monocyte chemotactic protein-1 secretion, intercellular adhesion molecule-1, endothelial cells Options: cell_type, other_name

[ "B-cell_type", "I-cell_type", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "O" ]

Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells [see comments]

[ "Activated", "platelets", "induce", "monocyte", "chemotactic", "protein-1", "secretion", "and", "surface", "expression", "of", "intercellular", "adhesion", "molecule-1", "on", "endothelial", "cells", "[", "see", "comments", "]" ]

[ "polynucleotide", "(AND other_name other_name)", "protein_complex", "other_name", "cell_type", "", "protein_molecule", "tissue" ]

Activated platelets, monocyte chemotactic protein-1 secretion, intercellular adhesion molecule-1, endothelial cells

77463_task2

Sentence: Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells [see comments] Instructions: please extract entity words from the input sentence

[ "B-cell_type", "I-cell_type", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O", "B-cell_type", "I-cell_type", "O", "O", "O", "O" ]

Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells [see comments]

[ "Activated", "platelets", "induce", "monocyte", "chemotactic", "protein-1", "secretion", "and", "surface", "expression", "of", "intercellular", "adhesion", "molecule-1", "on", "endothelial", "cells", "[", "see", "comments", "]" ]

[ "polynucleotide", "(AND other_name other_name)", "protein_complex", "other_name", "cell_type", "", "protein_molecule", "tissue" ]

serum is a Organism_substance, papillary mucinous neoplasms is a Pathological_formation, serum is a Organism_substance, intraductal papillary mucinous neoplasms is a Pathological_formation, pancreas is a Organ, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, tumor is a Pathological_formation, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, serum is a Organism_substance, IPMNs is a Pathological_formation, Serum is a Organism_substance, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, serum is a Organism_substance, IPMNs is a Pathological_formation

PMID-21416173_task0

Sentence: Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. BACKGROUND: The goal of the present study was to evaluate the predictive value of serum carbohydrate antigen 19-9 (CA 19-9) in the diagnosis of malignant intraductal papillary mucinous neoplasms of pancreas (IPMNs). METHODS: Eighty-six patients with pathological diagnosis of IPMNs in Zhongshan Hospital between March 1999 and November 2008 were retrospectively reviewed. Data reflecting clinical characteristics, tumor marker level, and prognosis were collected. The potential predictive value of CA 19-9 was analyzed by receiver operating characteristic (ROC) curve. RESULTS: Eighty-six consecutive patients with IPMNs all underwent surgical intervention. A high level of CA 19-9 or carcinoembryonic antigen (CEA) was associated with more advanced stage of malignant IPMNs. Carbohydrate antigen 19-9 was significant for judging malignant IPMNs in the binary logistic regression model (p=0.047). The hazard ratio was 1.014, whose 95.0% confidence interval was 0.91-1.028. Receiver operating characteristic analysis showed that the serum CA 19-9 level had good predictive value for malignant or invasive IPMNs, postoperative survival, and disease-specific recurrence. The area under the curve (AUC) was 0.856, 0.893, 0.815, and 0.857 (p<0.05), respectively. According to the follow-up, mean survival time for groups with CA 19-9>63.60 U/ml was dramatically shorter than that for groups with CA 19-9<=63.60 U/ml (57.38+/-2.85 versus 29.24+/-5.82 [months]; p<0.01). CONCLUSIONS: Serum CA 19-9 level has good predictive value for malignant or invasive IPMNs. Patients with CA 19-9 > 63.60 U/ml had poor postoperative prognosis in IPMNs. Preoperative abnormal serum CA 19-9 might be predictive for an aggressive surgical intervention in IPMNs. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Pathological_formation, Organ, Organism_substance

[ "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Organ", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O" ]

Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. BACKGROUND: The goal of the present study was to evaluate the predictive value of serum carbohydrate antigen 19-9 (CA 19-9) in the diagnosis of malignant intraductal papillary mucinous neoplasms of pancreas (IPMNs). METHODS: Eighty-six patients with pathological diagnosis of IPMNs in Zhongshan Hospital between March 1999 and November 2008 were retrospectively reviewed. Data reflecting clinical characteristics, tumor marker level, and prognosis were collected. The potential predictive value of CA 19-9 was analyzed by receiver operating characteristic (ROC) curve. RESULTS: Eighty-six consecutive patients with IPMNs all underwent surgical intervention. A high level of CA 19-9 or carcinoembryonic antigen (CEA) was associated with more advanced stage of malignant IPMNs. Carbohydrate antigen 19-9 was significant for judging malignant IPMNs in the binary logistic regression model (p=0.047). The hazard ratio was 1.014, whose 95.0% confidence interval was 0.91-1.028. Receiver operating characteristic analysis showed that the serum CA 19-9 level had good predictive value for malignant or invasive IPMNs, postoperative survival, and disease-specific recurrence. The area under the curve (AUC) was 0.856, 0.893, 0.815, and 0.857 (p<0.05), respectively. According to the follow-up, mean survival time for groups with CA 19-9>63.60 U/ml was dramatically shorter than that for groups with CA 19-9<=63.60 U/ml (57.38+/-2.85 versus 29.24+/-5.82 [months]; p<0.01). CONCLUSIONS: Serum CA 19-9 level has good predictive value for malignant or invasive IPMNs. Patients with CA 19-9 > 63.60 U/ml had poor postoperative prognosis in IPMNs. Preoperative abnormal serum CA 19-9 might be predictive for an aggressive surgical intervention in IPMNs.

[ "Predictive", "value", "of", "serum", "carbohydrate", "antigen", "19", "-", "9", "in", "malignant", "intraductal", "papillary", "mucinous", "neoplasms", ".", "\n", "BACKGROUND", ":", "\n", "The", "goal", "of", "the", "present", "study", "was", "to", "evaluate", "the", "predictive", "value", "of", "serum", "carbohydrate", "antigen", "19", "-", "9", "(", "CA", "19", "-", "9", ")", "in", "the", "diagnosis", "of", "malignant", "intraductal", "papillary", "mucinous", "neoplasms", "of", "pancreas", "(", "IPMNs", ")", ".", "\n", "METHODS", ":", "\n", "Eighty", "-", "six", "patients", "with", "pathological", "diagnosis", "of", "IPMNs", "in", "Zhongshan", "Hospital", "between", "March", "1999", "and", "November", "2008", "were", "retrospectively", "reviewed", ".", "Data", "reflecting", "clinical", "characteristics", ",", "tumor", "marker", "level", ",", "and", "prognosis", "were", "collected", ".", "The", "potential", "predictive", "value", "of", "CA", "19", "-", "9", "was", "analyzed", "by", "receiver", "operating", "characteristic", "(", "ROC", ")", "curve", ".", "\n", "RESULTS", ":", "\n", "Eighty", "-", "six", "consecutive", "patients", "with", "IPMNs", "all", "underwent", "surgical", "intervention", ".", "A", "high", "level", "of", "CA", "19", "-", "9", "or", "carcinoembryonic", "antigen", "(", "CEA", ")", "was", "associated", "with", "more", "advanced", "stage", "of", "malignant", "IPMNs", ".", "Carbohydrate", "antigen", "19", "-", "9", "was", "significant", "for", "judging", "malignant", "IPMNs", "in", "the", "binary", "logistic", "regression", "model", "(", "p=0.047", ")", ".", "The", "hazard", "ratio", "was", "1.014", ",", "whose", "95.0", "%", "confidence", "interval", "was", "0.91", "-", "1.028", ".", "Receiver", "operating", "characteristic", "analysis", "showed", "that", "the", "serum", "CA", "19", "-", "9", "level", "had", "good", "predictive", "value", "for", "malignant", "or", "invasive", "IPMNs", ",", "postoperative", "survival", ",", "and", "disease", "-", "specific", "recurrence", ".", "The", "area", "under", "the", "curve", "(", "AUC", ")", "was", "0.856", ",", "0.893", ",", "0.815", ",", "and", "0.857", "(", "p<0.05", ")", ",", "respectively", ".", "According", "to", "the", "follow", "-", "up", ",", "mean", "survival", "time", "for", "groups", "with", "CA", "19", "-", "9>63.60", "U", "/", "ml", "was", "dramatically", "shorter", "than", "that", "for", "groups", "with", "CA", "19", "-", "9<=63.60", "U", "/", "ml", "(", "57.38+/-2.85", "versus", "29.24+/-5.82", "[", "months", "]", ";", "p<0.01", ")", ".", "\n", "CONCLUSIONS", ":", "\n", "Serum", "CA", "19", "-", "9", "level", "has", "good", "predictive", "value", "for", "malignant", "or", "invasive", "IPMNs", ".", "Patients", "with", "CA", "19", "-", "9", ">", "63.60", "U", "/", "ml", "had", "poor", "postoperative", "prognosis", "in", "IPMNs", ".", "Preoperative", "abnormal", "serum", "CA", "19", "-", "9", "might", "be", "predictive", "for", "an", "aggressive", "surgical", "intervention", "in", "IPMNs", ".", "\n" ]

[ "Pathological_formation", "Organ", "Organism_substance" ]

serum is a Organism_substance, papillary mucinous neoplasms is a Pathological_formation, serum is a Organism_substance, intraductal papillary mucinous neoplasms is a Pathological_formation, pancreas is a Organ, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, tumor is a Pathological_formation, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, serum is a Organism_substance, IPMNs is a Pathological_formation, Serum is a Organism_substance, IPMNs is a Pathological_formation, IPMNs is a Pathological_formation, serum is a Organism_substance, IPMNs is a Pathological_formation

PMID-21416173_task1

Sentence: Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. BACKGROUND: The goal of the present study was to evaluate the predictive value of serum carbohydrate antigen 19-9 (CA 19-9) in the diagnosis of malignant intraductal papillary mucinous neoplasms of pancreas (IPMNs). METHODS: Eighty-six patients with pathological diagnosis of IPMNs in Zhongshan Hospital between March 1999 and November 2008 were retrospectively reviewed. Data reflecting clinical characteristics, tumor marker level, and prognosis were collected. The potential predictive value of CA 19-9 was analyzed by receiver operating characteristic (ROC) curve. RESULTS: Eighty-six consecutive patients with IPMNs all underwent surgical intervention. A high level of CA 19-9 or carcinoembryonic antigen (CEA) was associated with more advanced stage of malignant IPMNs. Carbohydrate antigen 19-9 was significant for judging malignant IPMNs in the binary logistic regression model (p=0.047). The hazard ratio was 1.014, whose 95.0% confidence interval was 0.91-1.028. Receiver operating characteristic analysis showed that the serum CA 19-9 level had good predictive value for malignant or invasive IPMNs, postoperative survival, and disease-specific recurrence. The area under the curve (AUC) was 0.856, 0.893, 0.815, and 0.857 (p<0.05), respectively. According to the follow-up, mean survival time for groups with CA 19-9>63.60 U/ml was dramatically shorter than that for groups with CA 19-9<=63.60 U/ml (57.38+/-2.85 versus 29.24+/-5.82 [months]; p<0.01). CONCLUSIONS: Serum CA 19-9 level has good predictive value for malignant or invasive IPMNs. Patients with CA 19-9 > 63.60 U/ml had poor postoperative prognosis in IPMNs. Preoperative abnormal serum CA 19-9 might be predictive for an aggressive surgical intervention in IPMNs. Instructions: please typing these entity words according to sentence: serum, papillary mucinous neoplasms, serum, intraductal papillary mucinous neoplasms, pancreas, IPMNs, IPMNs, tumor, IPMNs, IPMNs, IPMNs, serum, IPMNs, Serum, IPMNs, IPMNs, serum, IPMNs Options: Pathological_formation, Organ, Organism_substance

[ "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Organ", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O" ]

Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. BACKGROUND: The goal of the present study was to evaluate the predictive value of serum carbohydrate antigen 19-9 (CA 19-9) in the diagnosis of malignant intraductal papillary mucinous neoplasms of pancreas (IPMNs). METHODS: Eighty-six patients with pathological diagnosis of IPMNs in Zhongshan Hospital between March 1999 and November 2008 were retrospectively reviewed. Data reflecting clinical characteristics, tumor marker level, and prognosis were collected. The potential predictive value of CA 19-9 was analyzed by receiver operating characteristic (ROC) curve. RESULTS: Eighty-six consecutive patients with IPMNs all underwent surgical intervention. A high level of CA 19-9 or carcinoembryonic antigen (CEA) was associated with more advanced stage of malignant IPMNs. Carbohydrate antigen 19-9 was significant for judging malignant IPMNs in the binary logistic regression model (p=0.047). The hazard ratio was 1.014, whose 95.0% confidence interval was 0.91-1.028. Receiver operating characteristic analysis showed that the serum CA 19-9 level had good predictive value for malignant or invasive IPMNs, postoperative survival, and disease-specific recurrence. The area under the curve (AUC) was 0.856, 0.893, 0.815, and 0.857 (p<0.05), respectively. According to the follow-up, mean survival time for groups with CA 19-9>63.60 U/ml was dramatically shorter than that for groups with CA 19-9<=63.60 U/ml (57.38+/-2.85 versus 29.24+/-5.82 [months]; p<0.01). CONCLUSIONS: Serum CA 19-9 level has good predictive value for malignant or invasive IPMNs. Patients with CA 19-9 > 63.60 U/ml had poor postoperative prognosis in IPMNs. Preoperative abnormal serum CA 19-9 might be predictive for an aggressive surgical intervention in IPMNs.

[ "Predictive", "value", "of", "serum", "carbohydrate", "antigen", "19", "-", "9", "in", "malignant", "intraductal", "papillary", "mucinous", "neoplasms", ".", "\n", "BACKGROUND", ":", "\n", "The", "goal", "of", "the", "present", "study", "was", "to", "evaluate", "the", "predictive", "value", "of", "serum", "carbohydrate", "antigen", "19", "-", "9", "(", "CA", "19", "-", "9", ")", "in", "the", "diagnosis", "of", "malignant", "intraductal", "papillary", "mucinous", "neoplasms", "of", "pancreas", "(", "IPMNs", ")", ".", "\n", "METHODS", ":", "\n", "Eighty", "-", "six", "patients", "with", "pathological", "diagnosis", "of", "IPMNs", "in", "Zhongshan", "Hospital", "between", "March", "1999", "and", "November", "2008", "were", "retrospectively", "reviewed", ".", "Data", "reflecting", "clinical", "characteristics", ",", "tumor", "marker", "level", ",", "and", "prognosis", "were", "collected", ".", "The", "potential", "predictive", "value", "of", "CA", "19", "-", "9", "was", "analyzed", "by", "receiver", "operating", "characteristic", "(", "ROC", ")", "curve", ".", "\n", "RESULTS", ":", "\n", "Eighty", "-", "six", "consecutive", "patients", "with", "IPMNs", "all", "underwent", "surgical", "intervention", ".", "A", "high", "level", "of", "CA", "19", "-", "9", "or", "carcinoembryonic", "antigen", "(", "CEA", ")", "was", "associated", "with", "more", "advanced", "stage", "of", "malignant", "IPMNs", ".", "Carbohydrate", "antigen", "19", "-", "9", "was", "significant", "for", "judging", "malignant", "IPMNs", "in", "the", "binary", "logistic", "regression", "model", "(", "p=0.047", ")", ".", "The", "hazard", "ratio", "was", "1.014", ",", "whose", "95.0", "%", "confidence", "interval", "was", "0.91", "-", "1.028", ".", "Receiver", "operating", "characteristic", "analysis", "showed", "that", "the", "serum", "CA", "19", "-", "9", "level", "had", "good", "predictive", "value", "for", "malignant", "or", "invasive", "IPMNs", ",", "postoperative", "survival", ",", "and", "disease", "-", "specific", "recurrence", ".", "The", "area", "under", "the", "curve", "(", "AUC", ")", "was", "0.856", ",", "0.893", ",", "0.815", ",", "and", "0.857", "(", "p<0.05", ")", ",", "respectively", ".", "According", "to", "the", "follow", "-", "up", ",", "mean", "survival", "time", "for", "groups", "with", "CA", "19", "-", "9>63.60", "U", "/", "ml", "was", "dramatically", "shorter", "than", "that", "for", "groups", "with", "CA", "19", "-", "9<=63.60", "U", "/", "ml", "(", "57.38+/-2.85", "versus", "29.24+/-5.82", "[", "months", "]", ";", "p<0.01", ")", ".", "\n", "CONCLUSIONS", ":", "\n", "Serum", "CA", "19", "-", "9", "level", "has", "good", "predictive", "value", "for", "malignant", "or", "invasive", "IPMNs", ".", "Patients", "with", "CA", "19", "-", "9", ">", "63.60", "U", "/", "ml", "had", "poor", "postoperative", "prognosis", "in", "IPMNs", ".", "Preoperative", "abnormal", "serum", "CA", "19", "-", "9", "might", "be", "predictive", "for", "an", "aggressive", "surgical", "intervention", "in", "IPMNs", ".", "\n" ]

[ "Pathological_formation", "Organ", "Organism_substance" ]

serum, papillary mucinous neoplasms, serum, intraductal papillary mucinous neoplasms, pancreas, IPMNs, IPMNs, tumor, IPMNs, IPMNs, IPMNs, serum, IPMNs, Serum, IPMNs, IPMNs, serum, IPMNs

PMID-21416173_task2

Sentence: Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. BACKGROUND: The goal of the present study was to evaluate the predictive value of serum carbohydrate antigen 19-9 (CA 19-9) in the diagnosis of malignant intraductal papillary mucinous neoplasms of pancreas (IPMNs). METHODS: Eighty-six patients with pathological diagnosis of IPMNs in Zhongshan Hospital between March 1999 and November 2008 were retrospectively reviewed. Data reflecting clinical characteristics, tumor marker level, and prognosis were collected. The potential predictive value of CA 19-9 was analyzed by receiver operating characteristic (ROC) curve. RESULTS: Eighty-six consecutive patients with IPMNs all underwent surgical intervention. A high level of CA 19-9 or carcinoembryonic antigen (CEA) was associated with more advanced stage of malignant IPMNs. Carbohydrate antigen 19-9 was significant for judging malignant IPMNs in the binary logistic regression model (p=0.047). The hazard ratio was 1.014, whose 95.0% confidence interval was 0.91-1.028. Receiver operating characteristic analysis showed that the serum CA 19-9 level had good predictive value for malignant or invasive IPMNs, postoperative survival, and disease-specific recurrence. The area under the curve (AUC) was 0.856, 0.893, 0.815, and 0.857 (p<0.05), respectively. According to the follow-up, mean survival time for groups with CA 19-9>63.60 U/ml was dramatically shorter than that for groups with CA 19-9<=63.60 U/ml (57.38+/-2.85 versus 29.24+/-5.82 [months]; p<0.01). CONCLUSIONS: Serum CA 19-9 level has good predictive value for malignant or invasive IPMNs. Patients with CA 19-9 > 63.60 U/ml had poor postoperative prognosis in IPMNs. Preoperative abnormal serum CA 19-9 might be predictive for an aggressive surgical intervention in IPMNs. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Organ", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O" ]

Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. BACKGROUND: The goal of the present study was to evaluate the predictive value of serum carbohydrate antigen 19-9 (CA 19-9) in the diagnosis of malignant intraductal papillary mucinous neoplasms of pancreas (IPMNs). METHODS: Eighty-six patients with pathological diagnosis of IPMNs in Zhongshan Hospital between March 1999 and November 2008 were retrospectively reviewed. Data reflecting clinical characteristics, tumor marker level, and prognosis were collected. The potential predictive value of CA 19-9 was analyzed by receiver operating characteristic (ROC) curve. RESULTS: Eighty-six consecutive patients with IPMNs all underwent surgical intervention. A high level of CA 19-9 or carcinoembryonic antigen (CEA) was associated with more advanced stage of malignant IPMNs. Carbohydrate antigen 19-9 was significant for judging malignant IPMNs in the binary logistic regression model (p=0.047). The hazard ratio was 1.014, whose 95.0% confidence interval was 0.91-1.028. Receiver operating characteristic analysis showed that the serum CA 19-9 level had good predictive value for malignant or invasive IPMNs, postoperative survival, and disease-specific recurrence. The area under the curve (AUC) was 0.856, 0.893, 0.815, and 0.857 (p<0.05), respectively. According to the follow-up, mean survival time for groups with CA 19-9>63.60 U/ml was dramatically shorter than that for groups with CA 19-9<=63.60 U/ml (57.38+/-2.85 versus 29.24+/-5.82 [months]; p<0.01). CONCLUSIONS: Serum CA 19-9 level has good predictive value for malignant or invasive IPMNs. Patients with CA 19-9 > 63.60 U/ml had poor postoperative prognosis in IPMNs. Preoperative abnormal serum CA 19-9 might be predictive for an aggressive surgical intervention in IPMNs.

[ "Predictive", "value", "of", "serum", "carbohydrate", "antigen", "19", "-", "9", "in", "malignant", "intraductal", "papillary", "mucinous", "neoplasms", ".", "\n", "BACKGROUND", ":", "\n", "The", "goal", "of", "the", "present", "study", "was", "to", "evaluate", "the", "predictive", "value", "of", "serum", "carbohydrate", "antigen", "19", "-", "9", "(", "CA", "19", "-", "9", ")", "in", "the", "diagnosis", "of", "malignant", "intraductal", "papillary", "mucinous", "neoplasms", "of", "pancreas", "(", "IPMNs", ")", ".", "\n", "METHODS", ":", "\n", "Eighty", "-", "six", "patients", "with", "pathological", "diagnosis", "of", "IPMNs", "in", "Zhongshan", "Hospital", "between", "March", "1999", "and", "November", "2008", "were", "retrospectively", "reviewed", ".", "Data", "reflecting", "clinical", "characteristics", ",", "tumor", "marker", "level", ",", "and", "prognosis", "were", "collected", ".", "The", "potential", "predictive", "value", "of", "CA", "19", "-", "9", "was", "analyzed", "by", "receiver", "operating", "characteristic", "(", "ROC", ")", "curve", ".", "\n", "RESULTS", ":", "\n", "Eighty", "-", "six", "consecutive", "patients", "with", "IPMNs", "all", "underwent", "surgical", "intervention", ".", "A", "high", "level", "of", "CA", "19", "-", "9", "or", "carcinoembryonic", "antigen", "(", "CEA", ")", "was", "associated", "with", "more", "advanced", "stage", "of", "malignant", "IPMNs", ".", "Carbohydrate", "antigen", "19", "-", "9", "was", "significant", "for", "judging", "malignant", "IPMNs", "in", "the", "binary", "logistic", "regression", "model", "(", "p=0.047", ")", ".", "The", "hazard", "ratio", "was", "1.014", ",", "whose", "95.0", "%", "confidence", "interval", "was", "0.91", "-", "1.028", ".", "Receiver", "operating", "characteristic", "analysis", "showed", "that", "the", "serum", "CA", "19", "-", "9", "level", "had", "good", "predictive", "value", "for", "malignant", "or", "invasive", "IPMNs", ",", "postoperative", "survival", ",", "and", "disease", "-", "specific", "recurrence", ".", "The", "area", "under", "the", "curve", "(", "AUC", ")", "was", "0.856", ",", "0.893", ",", "0.815", ",", "and", "0.857", "(", "p<0.05", ")", ",", "respectively", ".", "According", "to", "the", "follow", "-", "up", ",", "mean", "survival", "time", "for", "groups", "with", "CA", "19", "-", "9>63.60", "U", "/", "ml", "was", "dramatically", "shorter", "than", "that", "for", "groups", "with", "CA", "19", "-", "9<=63.60", "U", "/", "ml", "(", "57.38+/-2.85", "versus", "29.24+/-5.82", "[", "months", "]", ";", "p<0.01", ")", ".", "\n", "CONCLUSIONS", ":", "\n", "Serum", "CA", "19", "-", "9", "level", "has", "good", "predictive", "value", "for", "malignant", "or", "invasive", "IPMNs", ".", "Patients", "with", "CA", "19", "-", "9", ">", "63.60", "U", "/", "ml", "had", "poor", "postoperative", "prognosis", "in", "IPMNs", ".", "Preoperative", "abnormal", "serum", "CA", "19", "-", "9", "might", "be", "predictive", "for", "an", "aggressive", "surgical", "intervention", "in", "IPMNs", ".", "\n" ]

[ "Pathological_formation", "Organ", "Organism_substance" ]

aminoglycoside is a GROUP, antibiotics is a GROUP, penicillins is a GROUP, cephalosporins is a GROUP, aminoglycoside is a GROUP, penicillin is a GROUP, aminoglycoside is a GROUP, aminoglycoside is a GROUP

Kanamycin_ddi_task0

Sentence: In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function. Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function.. See Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP

[ "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function. Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function.. See

[ "In", "vitro", "mixing", "of", "an", "aminoglycoside", "with", "beta", "-", "lactamtype", "antibiotics", "(", "penicillins", "or", "cephalosporins", ")", "may", "result", "in", "a", "significant", "mutual", "inactivation", ".", "Even", "when", "an", "aminoglycoside", "and", "a", "penicillin", "-", "type", "drug", "are", "administered", "separately", "by", "different", "routes", ",", "a", "reduction", "in", "aminoglycoside", "serum", "half", "-", "life", "or", "serum", "levels", "has", "been", "reported", "in", "patients", "with", "impaired", "renal", "function", "and", "in", "some", "patients", "with", "normal", "renal", "function", ".", "Usually", ",", "such", "inactivation", "of", "the", "aminoglycoside", "is", "clinically", "significant", "only", "in", "patients", "with", "severely", "impaired", "renal", "function", "..", "See" ]

[ "GROUP" ]

aminoglycoside is a GROUP, antibiotics is a GROUP, penicillins is a GROUP, cephalosporins is a GROUP, aminoglycoside is a GROUP, penicillin is a GROUP, aminoglycoside is a GROUP, aminoglycoside is a GROUP

Kanamycin_ddi_task1

Sentence: In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function. Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function.. See Instructions: please typing these entity words according to sentence: aminoglycoside, antibiotics, penicillins, cephalosporins, aminoglycoside, penicillin, aminoglycoside, aminoglycoside Options: GROUP

[ "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function. Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function.. See

[ "In", "vitro", "mixing", "of", "an", "aminoglycoside", "with", "beta", "-", "lactamtype", "antibiotics", "(", "penicillins", "or", "cephalosporins", ")", "may", "result", "in", "a", "significant", "mutual", "inactivation", ".", "Even", "when", "an", "aminoglycoside", "and", "a", "penicillin", "-", "type", "drug", "are", "administered", "separately", "by", "different", "routes", ",", "a", "reduction", "in", "aminoglycoside", "serum", "half", "-", "life", "or", "serum", "levels", "has", "been", "reported", "in", "patients", "with", "impaired", "renal", "function", "and", "in", "some", "patients", "with", "normal", "renal", "function", ".", "Usually", ",", "such", "inactivation", "of", "the", "aminoglycoside", "is", "clinically", "significant", "only", "in", "patients", "with", "severely", "impaired", "renal", "function", "..", "See" ]

[ "GROUP" ]

aminoglycoside, antibiotics, penicillins, cephalosporins, aminoglycoside, penicillin, aminoglycoside, aminoglycoside

Kanamycin_ddi_task2

Sentence: In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function. Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function.. See Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function. Usually, such inactivation of the aminoglycoside is clinically significant only in patients with severely impaired renal function.. See

[ "In", "vitro", "mixing", "of", "an", "aminoglycoside", "with", "beta", "-", "lactamtype", "antibiotics", "(", "penicillins", "or", "cephalosporins", ")", "may", "result", "in", "a", "significant", "mutual", "inactivation", ".", "Even", "when", "an", "aminoglycoside", "and", "a", "penicillin", "-", "type", "drug", "are", "administered", "separately", "by", "different", "routes", ",", "a", "reduction", "in", "aminoglycoside", "serum", "half", "-", "life", "or", "serum", "levels", "has", "been", "reported", "in", "patients", "with", "impaired", "renal", "function", "and", "in", "some", "patients", "with", "normal", "renal", "function", ".", "Usually", ",", "such", "inactivation", "of", "the", "aminoglycoside", "is", "clinically", "significant", "only", "in", "patients", "with", "severely", "impaired", "renal", "function", "..", "See" ]

[ "GROUP" ]

Lymphoms is an umlsterm, Differentialdiagnosen is an umlsterm, Paraffin is an umlsterm, Hautveraenderungen is an umlsterm, PCR is an umlsterm, Biopsien is an umlsterm, Hautveraenderungen is an umlsterm, Lymphome is an umlsterm, Kontrollbiopsien is an umlsterm, wachsende is an umlsterm, Technik is an umlsterm, Diagnostik is an umlsterm, Lymphomen is an umlsterm

DerPathologe.60170446.ger.abstr_task0

Sentence: Die Unterscheidung eines kutanen Lymphoms von einem reaktiven lymphoiden Infiltrat gehoert zu den anspruchsvollsten Differentialdiagnosen in der Dermatohistopathologie . Im Rahmen einer retrospektiven Studie untersuchten wir 24 in Paraffin eingebettete Proben von Hautveraenderungen , bei denen klinisch und histologisch ein T-Zellymphom diagnostiziert wurde , auf ein klonales Rearrangement des Gamma-T-Zellrezeptors mittels der Polymerasekettenreaktion ( PCR ) . Als Kontrollen wurden 7 Biopsien entzuendlicher Hautveraenderungen mit einem ausgepraegten lymphoiden Infiltrat untersucht . Der Klonalitaetsnachweis gelang in 22 von 24 Faellen der Lymphome ( 92 % ) . Bei den 7 Kontrollbiopsien konnte keine Klonalitaet nachgewiesen werden . Insofern ermoeglicht die von uns gewaehlte Primerkombination , die jede der vier Hauptgruppen des Gam- ma-T-Zellrezeptorgens ( V 1-8 , V 9 , V 10 und V 11 ) beruecksichtigt , eine hohe Sensitivitaet . Die Untersuchung bestaetigt die wachsende Bedeutung dieser Technik fuer die Diagnostik von Lymphomen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Die Unterscheidung eines kutanen Lymphoms von einem reaktiven lymphoiden Infiltrat gehoert zu den anspruchsvollsten Differentialdiagnosen in der Dermatohistopathologie . Im Rahmen einer retrospektiven Studie untersuchten wir 24 in Paraffin eingebettete Proben von Hautveraenderungen , bei denen klinisch und histologisch ein T-Zellymphom diagnostiziert wurde , auf ein klonales Rearrangement des Gamma-T-Zellrezeptors mittels der Polymerasekettenreaktion ( PCR ) . Als Kontrollen wurden 7 Biopsien entzuendlicher Hautveraenderungen mit einem ausgepraegten lymphoiden Infiltrat untersucht . Der Klonalitaetsnachweis gelang in 22 von 24 Faellen der Lymphome ( 92 % ) . Bei den 7 Kontrollbiopsien konnte keine Klonalitaet nachgewiesen werden . Insofern ermoeglicht die von uns gewaehlte Primerkombination , die jede der vier Hauptgruppen des Gam- ma-T-Zellrezeptorgens ( V 1-8 , V 9 , V 10 und V 11 ) beruecksichtigt , eine hohe Sensitivitaet . Die Untersuchung bestaetigt die wachsende Bedeutung dieser Technik fuer die Diagnostik von Lymphomen .

[ "Die", "Unterscheidung", "eines", "kutanen", "Lymphoms", "von", "einem", "reaktiven", "lymphoiden", "Infiltrat", "gehoert", "zu", "den", "anspruchsvollsten", "Differentialdiagnosen", "in", "der", "Dermatohistopathologie", ".", "Im", "Rahmen", "einer", "retrospektiven", "Studie", "untersuchten", "wir", "24", "in", "Paraffin", "eingebettete", "Proben", "von", "Hautveraenderungen", ",", "bei", "denen", "klinisch", "und", "histologisch", "ein", "T", "-", "Zellymphom", "diagnostiziert", "wurde", ",", "auf", "ein", "klonales", "Rearrangement", "des", "Gamma", "-", "T", "-", "Zellrezeptors", "mittels", "der", "Polymerasekettenreaktion", "(", "PCR", ")", ".", "Als", "Kontrollen", "wurden", "7", "Biopsien", "entzuendlicher", "Hautveraenderungen", "mit", "einem", "ausgepraegten", "lymphoiden", "Infiltrat", "untersucht", ".", "Der", "Klonalitaetsnachweis", "gelang", "in", "22", "von", "24", "Faellen", "der", "Lymphome", "(", "92", "%", ")", ".", "Bei", "den", "7", "Kontrollbiopsien", "konnte", "keine", "Klonalitaet", "nachgewiesen", "werden", ".", "Insofern", "ermoeglicht", "die", "von", "uns", "gewaehlte", "Primerkombination", ",", "die", "jede", "der", "vier", "Hauptgruppen", "des", "Gam-", "ma", "-", "T", "-", "Zellrezeptorgens", "(", "V", "1", "-", "8", ",", "V", "9", ",", "V", "10", "und", "V", "11", ")", "beruecksichtigt", ",", "eine", "hohe", "Sensitivitaet", ".", "Die", "Untersuchung", "bestaetigt", "die", "wachsende", "Bedeutung", "dieser", "Technik", "fuer", "die", "Diagnostik", "von", "Lymphomen", "." ]

[ "umlsterm" ]

Lymphoms is an umlsterm, Differentialdiagnosen is an umlsterm, Paraffin is an umlsterm, Hautveraenderungen is an umlsterm, PCR is an umlsterm, Biopsien is an umlsterm, Hautveraenderungen is an umlsterm, Lymphome is an umlsterm, Kontrollbiopsien is an umlsterm, wachsende is an umlsterm, Technik is an umlsterm, Diagnostik is an umlsterm, Lymphomen is an umlsterm

DerPathologe.60170446.ger.abstr_task1

Sentence: Die Unterscheidung eines kutanen Lymphoms von einem reaktiven lymphoiden Infiltrat gehoert zu den anspruchsvollsten Differentialdiagnosen in der Dermatohistopathologie . Im Rahmen einer retrospektiven Studie untersuchten wir 24 in Paraffin eingebettete Proben von Hautveraenderungen , bei denen klinisch und histologisch ein T-Zellymphom diagnostiziert wurde , auf ein klonales Rearrangement des Gamma-T-Zellrezeptors mittels der Polymerasekettenreaktion ( PCR ) . Als Kontrollen wurden 7 Biopsien entzuendlicher Hautveraenderungen mit einem ausgepraegten lymphoiden Infiltrat untersucht . Der Klonalitaetsnachweis gelang in 22 von 24 Faellen der Lymphome ( 92 % ) . Bei den 7 Kontrollbiopsien konnte keine Klonalitaet nachgewiesen werden . Insofern ermoeglicht die von uns gewaehlte Primerkombination , die jede der vier Hauptgruppen des Gam- ma-T-Zellrezeptorgens ( V 1-8 , V 9 , V 10 und V 11 ) beruecksichtigt , eine hohe Sensitivitaet . Die Untersuchung bestaetigt die wachsende Bedeutung dieser Technik fuer die Diagnostik von Lymphomen . Instructions: please typing these entity words according to sentence: Lymphoms, Differentialdiagnosen, Paraffin, Hautveraenderungen, PCR, Biopsien, Hautveraenderungen, Lymphome, Kontrollbiopsien, wachsende, Technik, Diagnostik, Lymphomen Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Die Unterscheidung eines kutanen Lymphoms von einem reaktiven lymphoiden Infiltrat gehoert zu den anspruchsvollsten Differentialdiagnosen in der Dermatohistopathologie . Im Rahmen einer retrospektiven Studie untersuchten wir 24 in Paraffin eingebettete Proben von Hautveraenderungen , bei denen klinisch und histologisch ein T-Zellymphom diagnostiziert wurde , auf ein klonales Rearrangement des Gamma-T-Zellrezeptors mittels der Polymerasekettenreaktion ( PCR ) . Als Kontrollen wurden 7 Biopsien entzuendlicher Hautveraenderungen mit einem ausgepraegten lymphoiden Infiltrat untersucht . Der Klonalitaetsnachweis gelang in 22 von 24 Faellen der Lymphome ( 92 % ) . Bei den 7 Kontrollbiopsien konnte keine Klonalitaet nachgewiesen werden . Insofern ermoeglicht die von uns gewaehlte Primerkombination , die jede der vier Hauptgruppen des Gam- ma-T-Zellrezeptorgens ( V 1-8 , V 9 , V 10 und V 11 ) beruecksichtigt , eine hohe Sensitivitaet . Die Untersuchung bestaetigt die wachsende Bedeutung dieser Technik fuer die Diagnostik von Lymphomen .

[ "Die", "Unterscheidung", "eines", "kutanen", "Lymphoms", "von", "einem", "reaktiven", "lymphoiden", "Infiltrat", "gehoert", "zu", "den", "anspruchsvollsten", "Differentialdiagnosen", "in", "der", "Dermatohistopathologie", ".", "Im", "Rahmen", "einer", "retrospektiven", "Studie", "untersuchten", "wir", "24", "in", "Paraffin", "eingebettete", "Proben", "von", "Hautveraenderungen", ",", "bei", "denen", "klinisch", "und", "histologisch", "ein", "T", "-", "Zellymphom", "diagnostiziert", "wurde", ",", "auf", "ein", "klonales", "Rearrangement", "des", "Gamma", "-", "T", "-", "Zellrezeptors", "mittels", "der", "Polymerasekettenreaktion", "(", "PCR", ")", ".", "Als", "Kontrollen", "wurden", "7", "Biopsien", "entzuendlicher", "Hautveraenderungen", "mit", "einem", "ausgepraegten", "lymphoiden", "Infiltrat", "untersucht", ".", "Der", "Klonalitaetsnachweis", "gelang", "in", "22", "von", "24", "Faellen", "der", "Lymphome", "(", "92", "%", ")", ".", "Bei", "den", "7", "Kontrollbiopsien", "konnte", "keine", "Klonalitaet", "nachgewiesen", "werden", ".", "Insofern", "ermoeglicht", "die", "von", "uns", "gewaehlte", "Primerkombination", ",", "die", "jede", "der", "vier", "Hauptgruppen", "des", "Gam-", "ma", "-", "T", "-", "Zellrezeptorgens", "(", "V", "1", "-", "8", ",", "V", "9", ",", "V", "10", "und", "V", "11", ")", "beruecksichtigt", ",", "eine", "hohe", "Sensitivitaet", ".", "Die", "Untersuchung", "bestaetigt", "die", "wachsende", "Bedeutung", "dieser", "Technik", "fuer", "die", "Diagnostik", "von", "Lymphomen", "." ]

[ "umlsterm" ]

Lymphoms, Differentialdiagnosen, Paraffin, Hautveraenderungen, PCR, Biopsien, Hautveraenderungen, Lymphome, Kontrollbiopsien, wachsende, Technik, Diagnostik, Lymphomen

DerPathologe.60170446.ger.abstr_task2

Sentence: Die Unterscheidung eines kutanen Lymphoms von einem reaktiven lymphoiden Infiltrat gehoert zu den anspruchsvollsten Differentialdiagnosen in der Dermatohistopathologie . Im Rahmen einer retrospektiven Studie untersuchten wir 24 in Paraffin eingebettete Proben von Hautveraenderungen , bei denen klinisch und histologisch ein T-Zellymphom diagnostiziert wurde , auf ein klonales Rearrangement des Gamma-T-Zellrezeptors mittels der Polymerasekettenreaktion ( PCR ) . Als Kontrollen wurden 7 Biopsien entzuendlicher Hautveraenderungen mit einem ausgepraegten lymphoiden Infiltrat untersucht . Der Klonalitaetsnachweis gelang in 22 von 24 Faellen der Lymphome ( 92 % ) . Bei den 7 Kontrollbiopsien konnte keine Klonalitaet nachgewiesen werden . Insofern ermoeglicht die von uns gewaehlte Primerkombination , die jede der vier Hauptgruppen des Gam- ma-T-Zellrezeptorgens ( V 1-8 , V 9 , V 10 und V 11 ) beruecksichtigt , eine hohe Sensitivitaet . Die Untersuchung bestaetigt die wachsende Bedeutung dieser Technik fuer die Diagnostik von Lymphomen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Die Unterscheidung eines kutanen Lymphoms von einem reaktiven lymphoiden Infiltrat gehoert zu den anspruchsvollsten Differentialdiagnosen in der Dermatohistopathologie . Im Rahmen einer retrospektiven Studie untersuchten wir 24 in Paraffin eingebettete Proben von Hautveraenderungen , bei denen klinisch und histologisch ein T-Zellymphom diagnostiziert wurde , auf ein klonales Rearrangement des Gamma-T-Zellrezeptors mittels der Polymerasekettenreaktion ( PCR ) . Als Kontrollen wurden 7 Biopsien entzuendlicher Hautveraenderungen mit einem ausgepraegten lymphoiden Infiltrat untersucht . Der Klonalitaetsnachweis gelang in 22 von 24 Faellen der Lymphome ( 92 % ) . Bei den 7 Kontrollbiopsien konnte keine Klonalitaet nachgewiesen werden . Insofern ermoeglicht die von uns gewaehlte Primerkombination , die jede der vier Hauptgruppen des Gam- ma-T-Zellrezeptorgens ( V 1-8 , V 9 , V 10 und V 11 ) beruecksichtigt , eine hohe Sensitivitaet . Die Untersuchung bestaetigt die wachsende Bedeutung dieser Technik fuer die Diagnostik von Lymphomen .

[ "Die", "Unterscheidung", "eines", "kutanen", "Lymphoms", "von", "einem", "reaktiven", "lymphoiden", "Infiltrat", "gehoert", "zu", "den", "anspruchsvollsten", "Differentialdiagnosen", "in", "der", "Dermatohistopathologie", ".", "Im", "Rahmen", "einer", "retrospektiven", "Studie", "untersuchten", "wir", "24", "in", "Paraffin", "eingebettete", "Proben", "von", "Hautveraenderungen", ",", "bei", "denen", "klinisch", "und", "histologisch", "ein", "T", "-", "Zellymphom", "diagnostiziert", "wurde", ",", "auf", "ein", "klonales", "Rearrangement", "des", "Gamma", "-", "T", "-", "Zellrezeptors", "mittels", "der", "Polymerasekettenreaktion", "(", "PCR", ")", ".", "Als", "Kontrollen", "wurden", "7", "Biopsien", "entzuendlicher", "Hautveraenderungen", "mit", "einem", "ausgepraegten", "lymphoiden", "Infiltrat", "untersucht", ".", "Der", "Klonalitaetsnachweis", "gelang", "in", "22", "von", "24", "Faellen", "der", "Lymphome", "(", "92", "%", ")", ".", "Bei", "den", "7", "Kontrollbiopsien", "konnte", "keine", "Klonalitaet", "nachgewiesen", "werden", ".", "Insofern", "ermoeglicht", "die", "von", "uns", "gewaehlte", "Primerkombination", ",", "die", "jede", "der", "vier", "Hauptgruppen", "des", "Gam-", "ma", "-", "T", "-", "Zellrezeptorgens", "(", "V", "1", "-", "8", ",", "V", "9", ",", "V", "10", "und", "V", "11", ")", "beruecksichtigt", ",", "eine", "hohe", "Sensitivitaet", ".", "Die", "Untersuchung", "bestaetigt", "die", "wachsende", "Bedeutung", "dieser", "Technik", "fuer", "die", "Diagnostik", "von", "Lymphomen", "." ]

[ "umlsterm" ]

Colon Cancer is a DISEASE, colon cancer is a DISEASE, gastrointestinal toxicities is a ADVERSE, liver toxicities is a ADVERSE

example-71_task0

Sentence: Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n=504 Raltitrexed) of whom respectively 146 and 148 died, respectively. RESULTS: The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23). CONCLUSION: The trial failed to demonstrate non-inferiority of raltitrexed. FUNDING: Free drugs and financial support from AstraZeneca. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE, DISEASE

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n=504 Raltitrexed) of whom respectively 146 and 148 died, respectively. RESULTS: The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23). CONCLUSION: The trial failed to demonstrate non-inferiority of raltitrexed. FUNDING: Free drugs and financial support from AstraZeneca.

[ "Raltitrexed", "(", "Tomudex", ")", "versus", "standard", "leucovorin", "-", "modulated", "bolus", "5-fluorouracil", ":", "Results", "from", "the", "randomised", "phase", "III", "Pan", "-", "European", "Trial", "in", "Adjuvant", "Colon", "Cancer", "01", "(", "PETACC-1", ")", ".", " ", "OBJECTIVES", ":", "PETACC-1", "assessed", "if", "raltitrexed", "is", "non", "-", "inferior", "to", "5-fluorouracil", "and", "leucovorin", "for", "relapse", "-", "free", "survival", "(", "RFS", ")", "and", "overall", "survival", "(", "OS", ")", "in", "adjuvant", "stage", "III", "colon", "cancer", ".", "METHODS", ":", "Non", "-", "inferiority", "required", "both", "HR", "for", "RFS", "and", "OS<1.25", "at", "1-sided", "alpha=0.05", ".", "Patients", "(", "1921", ")", "were", "randomised", "to", "six", "cycles", "of", "5-FU", "/", "LV", "(", "n=969", ")", "or", "eight", "cycles", "of", "raltitrexed", "(", "n=952", ")", ".", "We", "report", "the", "final", "results", "in", "993", "eligible", "patients", "who", "started", "and", "completed", "the", "allocated", "treatment", "(", "489", "5-FU", "/", "LV", "and", "n=504", "Raltitrexed", ")", "of", "whom", "respectively", "146", "and", "148", "died", ",", "respectively", ".", "RESULTS", ":", "The", "trial", "closed", "prematurely", "when", "17", "(", "1.9", "%", ")", "raltitrexed", "-", "related", "deaths", "were", "reported", ".", "Haematological", "and", "gastrointestinal", "toxicities", "were", "more", "frequent", "with", "5-FU", "/", "LV", ",", "liver", "toxicities", "with", "raltitrexed", ".", "Raltitrexed", "was", "stopped", "for", "toxicity", "in", "13.2", "%", "and", "5-FU", "/", "LV", "in", "8.5", "%", ".", "Sixty", "-", "day", "mortality", "was", "9", "%", "versus", "7", "%", ".", "With", "4.1", "years", "median", "follow", "-", "up", ",", "the", "HR", "for", "RFS", "was", "1.16", "(", "90", "%", "CI", "0.99", "-", "1.37", ")", "and", "that", "for", "OS", "was", "1.01", "(", "90", "%", "CI", "0.84", "-", "1.23", ")", ".", "CONCLUSION", ":", "The", "trial", "failed", "to", "demonstrate", "non", "-", "inferiority", "of", "raltitrexed", ".", "FUNDING", ":", "Free", "drugs", "and", "financial", "support", "from", "AstraZeneca", "." ]

[ "ADVERSE", "DISEASE" ]

Colon Cancer is a DISEASE, colon cancer is a DISEASE, gastrointestinal toxicities is a ADVERSE, liver toxicities is a ADVERSE

example-71_task1

Sentence: Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n=504 Raltitrexed) of whom respectively 146 and 148 died, respectively. RESULTS: The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23). CONCLUSION: The trial failed to demonstrate non-inferiority of raltitrexed. FUNDING: Free drugs and financial support from AstraZeneca. Instructions: please typing these entity words according to sentence: Colon Cancer, colon cancer, gastrointestinal toxicities, liver toxicities Options: ADVERSE, DISEASE

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n=504 Raltitrexed) of whom respectively 146 and 148 died, respectively. RESULTS: The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23). CONCLUSION: The trial failed to demonstrate non-inferiority of raltitrexed. FUNDING: Free drugs and financial support from AstraZeneca.

[ "Raltitrexed", "(", "Tomudex", ")", "versus", "standard", "leucovorin", "-", "modulated", "bolus", "5-fluorouracil", ":", "Results", "from", "the", "randomised", "phase", "III", "Pan", "-", "European", "Trial", "in", "Adjuvant", "Colon", "Cancer", "01", "(", "PETACC-1", ")", ".", " ", "OBJECTIVES", ":", "PETACC-1", "assessed", "if", "raltitrexed", "is", "non", "-", "inferior", "to", "5-fluorouracil", "and", "leucovorin", "for", "relapse", "-", "free", "survival", "(", "RFS", ")", "and", "overall", "survival", "(", "OS", ")", "in", "adjuvant", "stage", "III", "colon", "cancer", ".", "METHODS", ":", "Non", "-", "inferiority", "required", "both", "HR", "for", "RFS", "and", "OS<1.25", "at", "1-sided", "alpha=0.05", ".", "Patients", "(", "1921", ")", "were", "randomised", "to", "six", "cycles", "of", "5-FU", "/", "LV", "(", "n=969", ")", "or", "eight", "cycles", "of", "raltitrexed", "(", "n=952", ")", ".", "We", "report", "the", "final", "results", "in", "993", "eligible", "patients", "who", "started", "and", "completed", "the", "allocated", "treatment", "(", "489", "5-FU", "/", "LV", "and", "n=504", "Raltitrexed", ")", "of", "whom", "respectively", "146", "and", "148", "died", ",", "respectively", ".", "RESULTS", ":", "The", "trial", "closed", "prematurely", "when", "17", "(", "1.9", "%", ")", "raltitrexed", "-", "related", "deaths", "were", "reported", ".", "Haematological", "and", "gastrointestinal", "toxicities", "were", "more", "frequent", "with", "5-FU", "/", "LV", ",", "liver", "toxicities", "with", "raltitrexed", ".", "Raltitrexed", "was", "stopped", "for", "toxicity", "in", "13.2", "%", "and", "5-FU", "/", "LV", "in", "8.5", "%", ".", "Sixty", "-", "day", "mortality", "was", "9", "%", "versus", "7", "%", ".", "With", "4.1", "years", "median", "follow", "-", "up", ",", "the", "HR", "for", "RFS", "was", "1.16", "(", "90", "%", "CI", "0.99", "-", "1.37", ")", "and", "that", "for", "OS", "was", "1.01", "(", "90", "%", "CI", "0.84", "-", "1.23", ")", ".", "CONCLUSION", ":", "The", "trial", "failed", "to", "demonstrate", "non", "-", "inferiority", "of", "raltitrexed", ".", "FUNDING", ":", "Free", "drugs", "and", "financial", "support", "from", "AstraZeneca", "." ]

[ "ADVERSE", "DISEASE" ]

Colon Cancer, colon cancer, gastrointestinal toxicities, liver toxicities

example-71_task2

Sentence: Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n=504 Raltitrexed) of whom respectively 146 and 148 died, respectively. RESULTS: The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23). CONCLUSION: The trial failed to demonstrate non-inferiority of raltitrexed. FUNDING: Free drugs and financial support from AstraZeneca. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). OBJECTIVES: PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer. METHODS: Non-inferiority required both HR for RFS and OS<1.25 at 1-sided alpha=0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n=969) or eight cycles of raltitrexed (n=952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n=504 Raltitrexed) of whom respectively 146 and 148 died, respectively. RESULTS: The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23). CONCLUSION: The trial failed to demonstrate non-inferiority of raltitrexed. FUNDING: Free drugs and financial support from AstraZeneca.

[ "Raltitrexed", "(", "Tomudex", ")", "versus", "standard", "leucovorin", "-", "modulated", "bolus", "5-fluorouracil", ":", "Results", "from", "the", "randomised", "phase", "III", "Pan", "-", "European", "Trial", "in", "Adjuvant", "Colon", "Cancer", "01", "(", "PETACC-1", ")", ".", " ", "OBJECTIVES", ":", "PETACC-1", "assessed", "if", "raltitrexed", "is", "non", "-", "inferior", "to", "5-fluorouracil", "and", "leucovorin", "for", "relapse", "-", "free", "survival", "(", "RFS", ")", "and", "overall", "survival", "(", "OS", ")", "in", "adjuvant", "stage", "III", "colon", "cancer", ".", "METHODS", ":", "Non", "-", "inferiority", "required", "both", "HR", "for", "RFS", "and", "OS<1.25", "at", "1-sided", "alpha=0.05", ".", "Patients", "(", "1921", ")", "were", "randomised", "to", "six", "cycles", "of", "5-FU", "/", "LV", "(", "n=969", ")", "or", "eight", "cycles", "of", "raltitrexed", "(", "n=952", ")", ".", "We", "report", "the", "final", "results", "in", "993", "eligible", "patients", "who", "started", "and", "completed", "the", "allocated", "treatment", "(", "489", "5-FU", "/", "LV", "and", "n=504", "Raltitrexed", ")", "of", "whom", "respectively", "146", "and", "148", "died", ",", "respectively", ".", "RESULTS", ":", "The", "trial", "closed", "prematurely", "when", "17", "(", "1.9", "%", ")", "raltitrexed", "-", "related", "deaths", "were", "reported", ".", "Haematological", "and", "gastrointestinal", "toxicities", "were", "more", "frequent", "with", "5-FU", "/", "LV", ",", "liver", "toxicities", "with", "raltitrexed", ".", "Raltitrexed", "was", "stopped", "for", "toxicity", "in", "13.2", "%", "and", "5-FU", "/", "LV", "in", "8.5", "%", ".", "Sixty", "-", "day", "mortality", "was", "9", "%", "versus", "7", "%", ".", "With", "4.1", "years", "median", "follow", "-", "up", ",", "the", "HR", "for", "RFS", "was", "1.16", "(", "90", "%", "CI", "0.99", "-", "1.37", ")", "and", "that", "for", "OS", "was", "1.01", "(", "90", "%", "CI", "0.84", "-", "1.23", ")", ".", "CONCLUSION", ":", "The", "trial", "failed", "to", "demonstrate", "non", "-", "inferiority", "of", "raltitrexed", ".", "FUNDING", ":", "Free", "drugs", "and", "financial", "support", "from", "AstraZeneca", "." ]

[ "ADVERSE", "DISEASE" ]

Objective is an umlsterm, Body Mass Index is an umlsterm, BMI is an umlsterm, children is an umlsterm, prevalence is an umlsterm, overweight is an umlsterm, obesity is an umlsterm

MonatsschriftKinderheilkunde.81461192.eng.abstr_task0

Sentence: Objective : To examine changes in Body Mass Index ( BMI ) in children in the last twenty years and to determine the prevalence of overweight and obesity . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Objective : To examine changes in Body Mass Index ( BMI ) in children in the last twenty years and to determine the prevalence of overweight and obesity .

[ "Objective", ":", "To", "examine", "changes", "in", "Body", "Mass", "Index", "(", "BMI", ")", "in", "children", "in", "the", "last", "twenty", "years", "and", "to", "determine", "the", "prevalence", "of", "overweight", "and", "obesity", "." ]

[ "umlsterm" ]

Objective is an umlsterm, Body Mass Index is an umlsterm, BMI is an umlsterm, children is an umlsterm, prevalence is an umlsterm, overweight is an umlsterm, obesity is an umlsterm

MonatsschriftKinderheilkunde.81461192.eng.abstr_task1

Sentence: Objective : To examine changes in Body Mass Index ( BMI ) in children in the last twenty years and to determine the prevalence of overweight and obesity . Instructions: please typing these entity words according to sentence: Objective, Body Mass Index, BMI, children, prevalence, overweight, obesity Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Objective : To examine changes in Body Mass Index ( BMI ) in children in the last twenty years and to determine the prevalence of overweight and obesity .

[ "Objective", ":", "To", "examine", "changes", "in", "Body", "Mass", "Index", "(", "BMI", ")", "in", "children", "in", "the", "last", "twenty", "years", "and", "to", "determine", "the", "prevalence", "of", "overweight", "and", "obesity", "." ]

[ "umlsterm" ]

Objective, Body Mass Index, BMI, children, prevalence, overweight, obesity

MonatsschriftKinderheilkunde.81461192.eng.abstr_task2

Sentence: Objective : To examine changes in Body Mass Index ( BMI ) in children in the last twenty years and to determine the prevalence of overweight and obesity . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Objective : To examine changes in Body Mass Index ( BMI ) in children in the last twenty years and to determine the prevalence of overweight and obesity .

[ "Objective", ":", "To", "examine", "changes", "in", "Body", "Mass", "Index", "(", "BMI", ")", "in", "children", "in", "the", "last", "twenty", "years", "and", "to", "determine", "the", "prevalence", "of", "overweight", "and", "obesity", "." ]

[ "umlsterm" ]

Verlaufsbeobachtung is an umlsterm, Arrhythmiepraediktoren is an umlsterm, Patienten is an umlsterm, Kardiomyopathie is an umlsterm, Klassifikation is an umlsterm, New York is an umlsterm, Vorhofflimmern is an umlsterm, EKG is an umlsterm, Turbulenzanalyse is an umlsterm, EKG is an umlsterm, Arrhythmien is an umlsterm, Belastung is an umlsterm

Herz.00250189.ger.abstr_task0

Sentence: Die Marburger Kardiomyopathie-Studie ( MACAS ) wurde als prospektive Verlaufsbeobachtung konzipiert , um die Wertigkeit der folgenden potentiellen nichtinvasiven Arrhythmiepraediktoren bei ueber 200 Patienten mit dilatativer Kardiomyopathie ( DCM ) im Verlauf von fuenf Jahren zu untersuchen : Stadium der Herzinsuffizienz nach der Klassifikation der New York Heart Association linksventrikulaerer enddiastolischer Diameter und Ejektionsfraktion , Linksschenkelblock und Vorhofflimmern , im EKG , QTc- und JTc-Dispersion , abnormale Time-domain-Analyse und spektrale Turbulenzanalyse des signalgemittelten EKG , ventrikulaere Arrhythmien und Herzfrequenzvariabilitaet im 24-Stunden-Langzeit-EKG, Baroreflexsensitivitaet und Mikrovolt-T-Wellen-Alternans unter Belastung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Die Marburger Kardiomyopathie-Studie ( MACAS ) wurde als prospektive Verlaufsbeobachtung konzipiert , um die Wertigkeit der folgenden potentiellen nichtinvasiven Arrhythmiepraediktoren bei ueber 200 Patienten mit dilatativer Kardiomyopathie ( DCM ) im Verlauf von fuenf Jahren zu untersuchen : Stadium der Herzinsuffizienz nach der Klassifikation der New York Heart Association linksventrikulaerer enddiastolischer Diameter und Ejektionsfraktion , Linksschenkelblock und Vorhofflimmern , im EKG , QTc- und JTc-Dispersion , abnormale Time-domain-Analyse und spektrale Turbulenzanalyse des signalgemittelten EKG , ventrikulaere Arrhythmien und Herzfrequenzvariabilitaet im 24-Stunden-Langzeit-EKG, Baroreflexsensitivitaet und Mikrovolt-T-Wellen-Alternans unter Belastung .

[ "Die", "Marburger", "Kardiomyopathie", "-", "Studie", "(", "MACAS", ")", "wurde", "als", "prospektive", "Verlaufsbeobachtung", "konzipiert", ",", "um", "die", "Wertigkeit", "der", "folgenden", "potentiellen", "nichtinvasiven", "Arrhythmiepraediktoren", "bei", "ueber", "200", "Patienten", "mit", "dilatativer", "Kardiomyopathie", "(", "DCM", ")", "im", "Verlauf", "von", "fuenf", "Jahren", "zu", "untersuchen", ":", "Stadium", "der", "Herzinsuffizienz", "nach", "der", "Klassifikation", "der", "New", "York", "Heart", "Association", "linksventrikulaerer", "enddiastolischer", "Diameter", "und", "Ejektionsfraktion", ",", "Linksschenkelblock", "und", "Vorhofflimmern", ",", "im", "EKG", ",", "QTc-", "und", "JTc", "-", "Dispersion", ",", "abnormale", "Time", "-", "domain", "-", "Analyse", "und", "spektrale", "Turbulenzanalyse", "des", "signalgemittelten", "EKG", ",", "ventrikulaere", "Arrhythmien", "und", "Herzfrequenzvariabilitaet", "im", "24-Stunden", "-", "Langzeit", "-", "EKG", ",", "Baroreflexsensitivitaet", "und", "Mikrovolt", "-", "T", "-", "Wellen", "-", "Alternans", "unter", "Belastung", "." ]

[ "umlsterm" ]

Verlaufsbeobachtung is an umlsterm, Arrhythmiepraediktoren is an umlsterm, Patienten is an umlsterm, Kardiomyopathie is an umlsterm, Klassifikation is an umlsterm, New York is an umlsterm, Vorhofflimmern is an umlsterm, EKG is an umlsterm, Turbulenzanalyse is an umlsterm, EKG is an umlsterm, Arrhythmien is an umlsterm, Belastung is an umlsterm

Herz.00250189.ger.abstr_task1

Sentence: Die Marburger Kardiomyopathie-Studie ( MACAS ) wurde als prospektive Verlaufsbeobachtung konzipiert , um die Wertigkeit der folgenden potentiellen nichtinvasiven Arrhythmiepraediktoren bei ueber 200 Patienten mit dilatativer Kardiomyopathie ( DCM ) im Verlauf von fuenf Jahren zu untersuchen : Stadium der Herzinsuffizienz nach der Klassifikation der New York Heart Association linksventrikulaerer enddiastolischer Diameter und Ejektionsfraktion , Linksschenkelblock und Vorhofflimmern , im EKG , QTc- und JTc-Dispersion , abnormale Time-domain-Analyse und spektrale Turbulenzanalyse des signalgemittelten EKG , ventrikulaere Arrhythmien und Herzfrequenzvariabilitaet im 24-Stunden-Langzeit-EKG, Baroreflexsensitivitaet und Mikrovolt-T-Wellen-Alternans unter Belastung . Instructions: please typing these entity words according to sentence: Verlaufsbeobachtung, Arrhythmiepraediktoren, Patienten, Kardiomyopathie, Klassifikation, New York, Vorhofflimmern, EKG, Turbulenzanalyse, EKG, Arrhythmien, Belastung Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Die Marburger Kardiomyopathie-Studie ( MACAS ) wurde als prospektive Verlaufsbeobachtung konzipiert , um die Wertigkeit der folgenden potentiellen nichtinvasiven Arrhythmiepraediktoren bei ueber 200 Patienten mit dilatativer Kardiomyopathie ( DCM ) im Verlauf von fuenf Jahren zu untersuchen : Stadium der Herzinsuffizienz nach der Klassifikation der New York Heart Association linksventrikulaerer enddiastolischer Diameter und Ejektionsfraktion , Linksschenkelblock und Vorhofflimmern , im EKG , QTc- und JTc-Dispersion , abnormale Time-domain-Analyse und spektrale Turbulenzanalyse des signalgemittelten EKG , ventrikulaere Arrhythmien und Herzfrequenzvariabilitaet im 24-Stunden-Langzeit-EKG, Baroreflexsensitivitaet und Mikrovolt-T-Wellen-Alternans unter Belastung .

[ "Die", "Marburger", "Kardiomyopathie", "-", "Studie", "(", "MACAS", ")", "wurde", "als", "prospektive", "Verlaufsbeobachtung", "konzipiert", ",", "um", "die", "Wertigkeit", "der", "folgenden", "potentiellen", "nichtinvasiven", "Arrhythmiepraediktoren", "bei", "ueber", "200", "Patienten", "mit", "dilatativer", "Kardiomyopathie", "(", "DCM", ")", "im", "Verlauf", "von", "fuenf", "Jahren", "zu", "untersuchen", ":", "Stadium", "der", "Herzinsuffizienz", "nach", "der", "Klassifikation", "der", "New", "York", "Heart", "Association", "linksventrikulaerer", "enddiastolischer", "Diameter", "und", "Ejektionsfraktion", ",", "Linksschenkelblock", "und", "Vorhofflimmern", ",", "im", "EKG", ",", "QTc-", "und", "JTc", "-", "Dispersion", ",", "abnormale", "Time", "-", "domain", "-", "Analyse", "und", "spektrale", "Turbulenzanalyse", "des", "signalgemittelten", "EKG", ",", "ventrikulaere", "Arrhythmien", "und", "Herzfrequenzvariabilitaet", "im", "24-Stunden", "-", "Langzeit", "-", "EKG", ",", "Baroreflexsensitivitaet", "und", "Mikrovolt", "-", "T", "-", "Wellen", "-", "Alternans", "unter", "Belastung", "." ]

[ "umlsterm" ]

Verlaufsbeobachtung, Arrhythmiepraediktoren, Patienten, Kardiomyopathie, Klassifikation, New York, Vorhofflimmern, EKG, Turbulenzanalyse, EKG, Arrhythmien, Belastung

Herz.00250189.ger.abstr_task2

Sentence: Die Marburger Kardiomyopathie-Studie ( MACAS ) wurde als prospektive Verlaufsbeobachtung konzipiert , um die Wertigkeit der folgenden potentiellen nichtinvasiven Arrhythmiepraediktoren bei ueber 200 Patienten mit dilatativer Kardiomyopathie ( DCM ) im Verlauf von fuenf Jahren zu untersuchen : Stadium der Herzinsuffizienz nach der Klassifikation der New York Heart Association linksventrikulaerer enddiastolischer Diameter und Ejektionsfraktion , Linksschenkelblock und Vorhofflimmern , im EKG , QTc- und JTc-Dispersion , abnormale Time-domain-Analyse und spektrale Turbulenzanalyse des signalgemittelten EKG , ventrikulaere Arrhythmien und Herzfrequenzvariabilitaet im 24-Stunden-Langzeit-EKG, Baroreflexsensitivitaet und Mikrovolt-T-Wellen-Alternans unter Belastung . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Die Marburger Kardiomyopathie-Studie ( MACAS ) wurde als prospektive Verlaufsbeobachtung konzipiert , um die Wertigkeit der folgenden potentiellen nichtinvasiven Arrhythmiepraediktoren bei ueber 200 Patienten mit dilatativer Kardiomyopathie ( DCM ) im Verlauf von fuenf Jahren zu untersuchen : Stadium der Herzinsuffizienz nach der Klassifikation der New York Heart Association linksventrikulaerer enddiastolischer Diameter und Ejektionsfraktion , Linksschenkelblock und Vorhofflimmern , im EKG , QTc- und JTc-Dispersion , abnormale Time-domain-Analyse und spektrale Turbulenzanalyse des signalgemittelten EKG , ventrikulaere Arrhythmien und Herzfrequenzvariabilitaet im 24-Stunden-Langzeit-EKG, Baroreflexsensitivitaet und Mikrovolt-T-Wellen-Alternans unter Belastung .

[ "Die", "Marburger", "Kardiomyopathie", "-", "Studie", "(", "MACAS", ")", "wurde", "als", "prospektive", "Verlaufsbeobachtung", "konzipiert", ",", "um", "die", "Wertigkeit", "der", "folgenden", "potentiellen", "nichtinvasiven", "Arrhythmiepraediktoren", "bei", "ueber", "200", "Patienten", "mit", "dilatativer", "Kardiomyopathie", "(", "DCM", ")", "im", "Verlauf", "von", "fuenf", "Jahren", "zu", "untersuchen", ":", "Stadium", "der", "Herzinsuffizienz", "nach", "der", "Klassifikation", "der", "New", "York", "Heart", "Association", "linksventrikulaerer", "enddiastolischer", "Diameter", "und", "Ejektionsfraktion", ",", "Linksschenkelblock", "und", "Vorhofflimmern", ",", "im", "EKG", ",", "QTc-", "und", "JTc", "-", "Dispersion", ",", "abnormale", "Time", "-", "domain", "-", "Analyse", "und", "spektrale", "Turbulenzanalyse", "des", "signalgemittelten", "EKG", ",", "ventrikulaere", "Arrhythmien", "und", "Herzfrequenzvariabilitaet", "im", "24-Stunden", "-", "Langzeit", "-", "EKG", ",", "Baroreflexsensitivitaet", "und", "Mikrovolt", "-", "T", "-", "Wellen", "-", "Alternans", "unter", "Belastung", "." ]

[ "umlsterm" ]

perforin is a Protein, granzyme B is a Protein, IFN - gamma is a Protein, T - bet is a Protein, Eomes is a Protein, IFN - gamma is a Protein, T - bet is a Protein, CD8 is a Protein, IFN - gamma is a Protein, Prf1 is a Protein, GzmB is a Protein, T - bet is a Protein, CD8 is a Protein, Eomes - VP16 is a Protein, Eo - VP16 is a Protein, GFP is a Protein, Granzyme B is a Protein, IFN - gamma is a Protein, IFN - gamma is a Protein, Eo - VP16 is a Protein, GFP is a Protein

134_task0

Sentence: Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments.

[ "Regulation", "of", "perforin", ",", "granzyme", "B", ",", "and", "IFN", "-", "gamma", "expression", "by", "T", "-", "bet", "and", "Eomes", "in", "differentiating", "CTLs", ".", "(", "A", ")", "IFN", "-", "gamma", "expression", "by", "WT", "(", "Tbx21+/+", ")", "and", "T", "-", "bet", "-", "deficient", "(", "Tbx21-/-", ")", "T", "cells", ".", "Naive", "CD8", "+", "T", "cells", ",", "or", "cells", "activated", "and", "cultured", "for", "4", "or", "6", "d", ",", "were", "restimulated", "with", "PMA", "and", "ionomycin", "for", "6", "h", ",", "and", "IFN", "-", "gamma", "expression", "was", "assessed", "by", "intracellular", "staining", ".", "Numbers", "show", "the", "percentage", "of", "IFN", "-", "gamma+", "cells", ".", "(", "B", ")", "Northern", "blot", "analysis", "of", "Prf1", "and", "GzmB", "mRNA", "expression", "in", "WT", "or", "T", "-", "bet", "-", "deficient", "CD8", "+", "T", "cells", "activated", "and", "either", "left", "uninfected", "(", "uninf", ")", "or", "transduced", "with", "retroviruses", "expressing", "Eomes", "-", "VP16", "(", "Eo", "-", "VP16", ")", "or", "an", "empty", "IRES", "-", "GFP", "cassette", "(", "GFP", ")", ".", "Total", "cellular", "RNA", "was", "analyzed", "on", "day", "6", "of", "culture", ".", "The", "frequency", "of", "transduced", "cells", "in", "the", "cultures", "was", "equivalent", "for", "both", "constructs", "(", "~65", "-", "70", "%", "GFP+", "cells", ";", "not", "depicted", ")", ".", "(", "C", ")", "Granzyme", "B", "and", "IFN", "-", "gamma", "expression", "by", "Tbx21+/+", "and", "Tbx21-/-", "T", "cells", "analyzed", "in", "restimulated", "cells", "that", "had", "been", "cultured", "for", "5", "d.", "(", "D", ")", "IFN", "-", "gamma", "production", "by", "cells", "transduced", "with", "Eo", "-", "VP16", "or", "control", "(", "GFP", ")", "retroviruses", "(", "RV", ")", "measured", "on", "day", "4", "after", "6", "h", "of", "restimulation", "with", "PMA", "and", "ionomycin", ".", "Numbers", "show", "the", "percentage", "of", "GFP+", "IFN", "-", "gamma+", "cells", ".", "Results", "are", "representative", "of", "three", "(", "A", "and", "C", ")", "or", "two", "(", "B", "and", "D", ")", "independent", "experiments", "." ]

[ "Protein" ]

perforin is a Protein, granzyme B is a Protein, IFN - gamma is a Protein, T - bet is a Protein, Eomes is a Protein, IFN - gamma is a Protein, T - bet is a Protein, CD8 is a Protein, IFN - gamma is a Protein, Prf1 is a Protein, GzmB is a Protein, T - bet is a Protein, CD8 is a Protein, Eomes - VP16 is a Protein, Eo - VP16 is a Protein, GFP is a Protein, Granzyme B is a Protein, IFN - gamma is a Protein, IFN - gamma is a Protein, Eo - VP16 is a Protein, GFP is a Protein

134_task1

Sentence: Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments. Instructions: please typing these entity words according to sentence: perforin, granzyme B, IFN - gamma, T - bet, Eomes, IFN - gamma, T - bet, CD8, IFN - gamma, Prf1, GzmB, T - bet, CD8, Eomes - VP16, Eo - VP16, GFP, Granzyme B, IFN - gamma, IFN - gamma, Eo - VP16, GFP Options: Protein

[ "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments.

[ "Regulation", "of", "perforin", ",", "granzyme", "B", ",", "and", "IFN", "-", "gamma", "expression", "by", "T", "-", "bet", "and", "Eomes", "in", "differentiating", "CTLs", ".", "(", "A", ")", "IFN", "-", "gamma", "expression", "by", "WT", "(", "Tbx21+/+", ")", "and", "T", "-", "bet", "-", "deficient", "(", "Tbx21-/-", ")", "T", "cells", ".", "Naive", "CD8", "+", "T", "cells", ",", "or", "cells", "activated", "and", "cultured", "for", "4", "or", "6", "d", ",", "were", "restimulated", "with", "PMA", "and", "ionomycin", "for", "6", "h", ",", "and", "IFN", "-", "gamma", "expression", "was", "assessed", "by", "intracellular", "staining", ".", "Numbers", "show", "the", "percentage", "of", "IFN", "-", "gamma+", "cells", ".", "(", "B", ")", "Northern", "blot", "analysis", "of", "Prf1", "and", "GzmB", "mRNA", "expression", "in", "WT", "or", "T", "-", "bet", "-", "deficient", "CD8", "+", "T", "cells", "activated", "and", "either", "left", "uninfected", "(", "uninf", ")", "or", "transduced", "with", "retroviruses", "expressing", "Eomes", "-", "VP16", "(", "Eo", "-", "VP16", ")", "or", "an", "empty", "IRES", "-", "GFP", "cassette", "(", "GFP", ")", ".", "Total", "cellular", "RNA", "was", "analyzed", "on", "day", "6", "of", "culture", ".", "The", "frequency", "of", "transduced", "cells", "in", "the", "cultures", "was", "equivalent", "for", "both", "constructs", "(", "~65", "-", "70", "%", "GFP+", "cells", ";", "not", "depicted", ")", ".", "(", "C", ")", "Granzyme", "B", "and", "IFN", "-", "gamma", "expression", "by", "Tbx21+/+", "and", "Tbx21-/-", "T", "cells", "analyzed", "in", "restimulated", "cells", "that", "had", "been", "cultured", "for", "5", "d.", "(", "D", ")", "IFN", "-", "gamma", "production", "by", "cells", "transduced", "with", "Eo", "-", "VP16", "or", "control", "(", "GFP", ")", "retroviruses", "(", "RV", ")", "measured", "on", "day", "4", "after", "6", "h", "of", "restimulation", "with", "PMA", "and", "ionomycin", ".", "Numbers", "show", "the", "percentage", "of", "GFP+", "IFN", "-", "gamma+", "cells", ".", "Results", "are", "representative", "of", "three", "(", "A", "and", "C", ")", "or", "two", "(", "B", "and", "D", ")", "independent", "experiments", "." ]

[ "Protein" ]

perforin, granzyme B, IFN - gamma, T - bet, Eomes, IFN - gamma, T - bet, CD8, IFN - gamma, Prf1, GzmB, T - bet, CD8, Eomes - VP16, Eo - VP16, GFP, Granzyme B, IFN - gamma, IFN - gamma, Eo - VP16, GFP

134_task2

Sentence: Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Regulation of perforin, granzyme B, and IFN-gamma expression by T-bet and Eomes in differentiating CTLs. (A) IFN-gamma expression by WT (Tbx21+/+) and T-bet-deficient (Tbx21-/-) T cells. Naive CD8+ T cells, or cells activated and cultured for 4 or 6 d, were restimulated with PMA and ionomycin for 6 h, and IFN-gamma expression was assessed by intracellular staining. Numbers show the percentage of IFN-gamma+ cells. (B) Northern blot analysis of Prf1 and GzmB mRNA expression in WT or T-bet-deficient CD8+ T cells activated and either left uninfected (uninf) or transduced with retroviruses expressing Eomes-VP16 (Eo-VP16) or an empty IRES-GFP cassette (GFP). Total cellular RNA was analyzed on day 6 of culture. The frequency of transduced cells in the cultures was equivalent for both constructs (~65-70% GFP+ cells; not depicted). (C) Granzyme B and IFN-gamma expression by Tbx21+/+ and Tbx21-/- T cells analyzed in restimulated cells that had been cultured for 5 d. (D) IFN-gamma production by cells transduced with Eo-VP16 or control (GFP) retroviruses (RV) measured on day 4 after 6 h of restimulation with PMA and ionomycin. Numbers show the percentage of GFP+ IFN-gamma+ cells. Results are representative of three (A and C) or two (B and D) independent experiments.

[ "Regulation", "of", "perforin", ",", "granzyme", "B", ",", "and", "IFN", "-", "gamma", "expression", "by", "T", "-", "bet", "and", "Eomes", "in", "differentiating", "CTLs", ".", "(", "A", ")", "IFN", "-", "gamma", "expression", "by", "WT", "(", "Tbx21+/+", ")", "and", "T", "-", "bet", "-", "deficient", "(", "Tbx21-/-", ")", "T", "cells", ".", "Naive", "CD8", "+", "T", "cells", ",", "or", "cells", "activated", "and", "cultured", "for", "4", "or", "6", "d", ",", "were", "restimulated", "with", "PMA", "and", "ionomycin", "for", "6", "h", ",", "and", "IFN", "-", "gamma", "expression", "was", "assessed", "by", "intracellular", "staining", ".", "Numbers", "show", "the", "percentage", "of", "IFN", "-", "gamma+", "cells", ".", "(", "B", ")", "Northern", "blot", "analysis", "of", "Prf1", "and", "GzmB", "mRNA", "expression", "in", "WT", "or", "T", "-", "bet", "-", "deficient", "CD8", "+", "T", "cells", "activated", "and", "either", "left", "uninfected", "(", "uninf", ")", "or", "transduced", "with", "retroviruses", "expressing", "Eomes", "-", "VP16", "(", "Eo", "-", "VP16", ")", "or", "an", "empty", "IRES", "-", "GFP", "cassette", "(", "GFP", ")", ".", "Total", "cellular", "RNA", "was", "analyzed", "on", "day", "6", "of", "culture", ".", "The", "frequency", "of", "transduced", "cells", "in", "the", "cultures", "was", "equivalent", "for", "both", "constructs", "(", "~65", "-", "70", "%", "GFP+", "cells", ";", "not", "depicted", ")", ".", "(", "C", ")", "Granzyme", "B", "and", "IFN", "-", "gamma", "expression", "by", "Tbx21+/+", "and", "Tbx21-/-", "T", "cells", "analyzed", "in", "restimulated", "cells", "that", "had", "been", "cultured", "for", "5", "d.", "(", "D", ")", "IFN", "-", "gamma", "production", "by", "cells", "transduced", "with", "Eo", "-", "VP16", "or", "control", "(", "GFP", ")", "retroviruses", "(", "RV", ")", "measured", "on", "day", "4", "after", "6", "h", "of", "restimulation", "with", "PMA", "and", "ionomycin", ".", "Numbers", "show", "the", "percentage", "of", "GFP+", "IFN", "-", "gamma+", "cells", ".", "Results", "are", "representative", "of", "three", "(", "A", "and", "C", ")", "or", "two", "(", "B", "and", "D", ")", "independent", "experiments", "." ]

[ "Protein" ]

care is an umlsterm, patients is an umlsterm, patients is an umlsterm, need is an umlsterm, care is an umlsterm, care is an umlsterm, psychiatric hospitals is an umlsterm, inpatient care is an umlsterm, care is an umlsterm, patients is an umlsterm, psychiatric nursing is an umlsterm, population is an umlsterm, patients is an umlsterm, homeless is an umlsterm, needs is an umlsterm, needs is an umlsterm, patients is an umlsterm, therapeutic is an umlsterm

DerNervenarzt.00710915.eng.abstr_task0

Sentence: Psychiatric care for chronic schizophrenic patients has improved in recent years , but for severely ill patients , often with multiple comorbid psychiatric conditions and in great need of care , the situation remains unsatisfactory . Community-based psychiatric care is limited and psychiatric hospitals are now cutting back on inpatient care . The quality of care that chronically mentally ill patients receive at independant psychiatric nursing homes removed from population centers is undetermined , and many patients end up in asylums or homeless shelters unable to provide for their psychiatric needs . Neither a reliable way to assess the needs of these complicated patients nor a scientific basis for therapeutic intervention exists yet . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Psychiatric care for chronic schizophrenic patients has improved in recent years , but for severely ill patients , often with multiple comorbid psychiatric conditions and in great need of care , the situation remains unsatisfactory . Community-based psychiatric care is limited and psychiatric hospitals are now cutting back on inpatient care . The quality of care that chronically mentally ill patients receive at independant psychiatric nursing homes removed from population centers is undetermined , and many patients end up in asylums or homeless shelters unable to provide for their psychiatric needs . Neither a reliable way to assess the needs of these complicated patients nor a scientific basis for therapeutic intervention exists yet .

[ "Psychiatric", "care", "for", "chronic", "schizophrenic", "patients", "has", "improved", "in", "recent", "years", ",", "but", "for", "severely", "ill", "patients", ",", "often", "with", "multiple", "comorbid", "psychiatric", "conditions", "and", "in", "great", "need", "of", "care", ",", "the", "situation", "remains", "unsatisfactory", ".", "Community", "-", "based", "psychiatric", "care", "is", "limited", "and", "psychiatric", "hospitals", "are", "now", "cutting", "back", "on", "inpatient", "care", ".", "The", "quality", "of", "care", "that", "chronically", "mentally", "ill", "patients", "receive", "at", "independant", "psychiatric", "nursing", "homes", "removed", "from", "population", "centers", "is", "undetermined", ",", "and", "many", "patients", "end", "up", "in", "asylums", "or", "homeless", "shelters", "unable", "to", "provide", "for", "their", "psychiatric", "needs", ".", "Neither", "a", "reliable", "way", "to", "assess", "the", "needs", "of", "these", "complicated", "patients", "nor", "a", "scientific", "basis", "for", "therapeutic", "intervention", "exists", "yet", "." ]

[ "umlsterm" ]

care is an umlsterm, patients is an umlsterm, patients is an umlsterm, need is an umlsterm, care is an umlsterm, care is an umlsterm, psychiatric hospitals is an umlsterm, inpatient care is an umlsterm, care is an umlsterm, patients is an umlsterm, psychiatric nursing is an umlsterm, population is an umlsterm, patients is an umlsterm, homeless is an umlsterm, needs is an umlsterm, needs is an umlsterm, patients is an umlsterm, therapeutic is an umlsterm

DerNervenarzt.00710915.eng.abstr_task1

Sentence: Psychiatric care for chronic schizophrenic patients has improved in recent years , but for severely ill patients , often with multiple comorbid psychiatric conditions and in great need of care , the situation remains unsatisfactory . Community-based psychiatric care is limited and psychiatric hospitals are now cutting back on inpatient care . The quality of care that chronically mentally ill patients receive at independant psychiatric nursing homes removed from population centers is undetermined , and many patients end up in asylums or homeless shelters unable to provide for their psychiatric needs . Neither a reliable way to assess the needs of these complicated patients nor a scientific basis for therapeutic intervention exists yet . Instructions: please typing these entity words according to sentence: care, patients, patients, need, care, care, psychiatric hospitals, inpatient care, care, patients, psychiatric nursing, population, patients, homeless, needs, needs, patients, therapeutic Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Psychiatric care for chronic schizophrenic patients has improved in recent years , but for severely ill patients , often with multiple comorbid psychiatric conditions and in great need of care , the situation remains unsatisfactory . Community-based psychiatric care is limited and psychiatric hospitals are now cutting back on inpatient care . The quality of care that chronically mentally ill patients receive at independant psychiatric nursing homes removed from population centers is undetermined , and many patients end up in asylums or homeless shelters unable to provide for their psychiatric needs . Neither a reliable way to assess the needs of these complicated patients nor a scientific basis for therapeutic intervention exists yet .

[ "Psychiatric", "care", "for", "chronic", "schizophrenic", "patients", "has", "improved", "in", "recent", "years", ",", "but", "for", "severely", "ill", "patients", ",", "often", "with", "multiple", "comorbid", "psychiatric", "conditions", "and", "in", "great", "need", "of", "care", ",", "the", "situation", "remains", "unsatisfactory", ".", "Community", "-", "based", "psychiatric", "care", "is", "limited", "and", "psychiatric", "hospitals", "are", "now", "cutting", "back", "on", "inpatient", "care", ".", "The", "quality", "of", "care", "that", "chronically", "mentally", "ill", "patients", "receive", "at", "independant", "psychiatric", "nursing", "homes", "removed", "from", "population", "centers", "is", "undetermined", ",", "and", "many", "patients", "end", "up", "in", "asylums", "or", "homeless", "shelters", "unable", "to", "provide", "for", "their", "psychiatric", "needs", ".", "Neither", "a", "reliable", "way", "to", "assess", "the", "needs", "of", "these", "complicated", "patients", "nor", "a", "scientific", "basis", "for", "therapeutic", "intervention", "exists", "yet", "." ]

[ "umlsterm" ]

care, patients, patients, need, care, care, psychiatric hospitals, inpatient care, care, patients, psychiatric nursing, population, patients, homeless, needs, needs, patients, therapeutic

DerNervenarzt.00710915.eng.abstr_task2

Sentence: Psychiatric care for chronic schizophrenic patients has improved in recent years , but for severely ill patients , often with multiple comorbid psychiatric conditions and in great need of care , the situation remains unsatisfactory . Community-based psychiatric care is limited and psychiatric hospitals are now cutting back on inpatient care . The quality of care that chronically mentally ill patients receive at independant psychiatric nursing homes removed from population centers is undetermined , and many patients end up in asylums or homeless shelters unable to provide for their psychiatric needs . Neither a reliable way to assess the needs of these complicated patients nor a scientific basis for therapeutic intervention exists yet . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Psychiatric care for chronic schizophrenic patients has improved in recent years , but for severely ill patients , often with multiple comorbid psychiatric conditions and in great need of care , the situation remains unsatisfactory . Community-based psychiatric care is limited and psychiatric hospitals are now cutting back on inpatient care . The quality of care that chronically mentally ill patients receive at independant psychiatric nursing homes removed from population centers is undetermined , and many patients end up in asylums or homeless shelters unable to provide for their psychiatric needs . Neither a reliable way to assess the needs of these complicated patients nor a scientific basis for therapeutic intervention exists yet .

[ "Psychiatric", "care", "for", "chronic", "schizophrenic", "patients", "has", "improved", "in", "recent", "years", ",", "but", "for", "severely", "ill", "patients", ",", "often", "with", "multiple", "comorbid", "psychiatric", "conditions", "and", "in", "great", "need", "of", "care", ",", "the", "situation", "remains", "unsatisfactory", ".", "Community", "-", "based", "psychiatric", "care", "is", "limited", "and", "psychiatric", "hospitals", "are", "now", "cutting", "back", "on", "inpatient", "care", ".", "The", "quality", "of", "care", "that", "chronically", "mentally", "ill", "patients", "receive", "at", "independant", "psychiatric", "nursing", "homes", "removed", "from", "population", "centers", "is", "undetermined", ",", "and", "many", "patients", "end", "up", "in", "asylums", "or", "homeless", "shelters", "unable", "to", "provide", "for", "their", "psychiatric", "needs", ".", "Neither", "a", "reliable", "way", "to", "assess", "the", "needs", "of", "these", "complicated", "patients", "nor", "a", "scientific", "basis", "for", "therapeutic", "intervention", "exists", "yet", "." ]

[ "umlsterm" ]

amphiphysin dimer is a protein-complex, clathrin is a protein-complex, α - adaptin is a protein, clathrin is a protein-complex, AP-2 is a protein-complex, dynamin 1 is a protein, synaptojanin 1 is a protein, clathrin is a protein-complex

1.0alpha7.train.449_task0

Sentence: The amphiphysin dimer also binds to clathrin (10, 11) and to the α-adaptin subunit of the plasma membrane clathrin adaptor AP-2 (9, 12) and thus may mediate recruitment of dynamin 1 and synaptojanin 1 to the site of clathrin-mediated endocytosis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-complex, protein

[ "O", "B-protein-complex", "I-protein-complex", "O", "O", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "B-protein-complex", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "I-protein", "O", "O", "O", "O", "B-protein-complex", "O", "O", "O", "O" ]

The amphiphysin dimer also binds to clathrin (10, 11) and to the α-adaptin subunit of the plasma membrane clathrin adaptor AP-2 (9, 12) and thus may mediate recruitment of dynamin 1 and synaptojanin 1 to the site of clathrin-mediated endocytosis.

[ "The", "amphiphysin", "dimer", "also", "binds", "to", "clathrin", "(", "10", ",", "11", ")", "and", "to", "the", "α", "-", "adaptin", "subunit", "of", "the", "plasma", "membrane", "clathrin", "adaptor", "AP-2", "(", "9", ",", "12", ")", "and", "thus", "may", "mediate", "recruitment", "of", "dynamin", "1", "and", "synaptojanin", "1", "to", "the", "site", "of", "clathrin", "-", "mediated", "endocytosis", "." ]

[ "protein-complex", "protein", "protein-family" ]

amphiphysin dimer is a protein-complex, clathrin is a protein-complex, α - adaptin is a protein, clathrin is a protein-complex, AP-2 is a protein-complex, dynamin 1 is a protein, synaptojanin 1 is a protein, clathrin is a protein-complex

1.0alpha7.train.449_task1

Sentence: The amphiphysin dimer also binds to clathrin (10, 11) and to the α-adaptin subunit of the plasma membrane clathrin adaptor AP-2 (9, 12) and thus may mediate recruitment of dynamin 1 and synaptojanin 1 to the site of clathrin-mediated endocytosis. Instructions: please typing these entity words according to sentence: amphiphysin dimer, clathrin, α - adaptin, clathrin, AP-2, dynamin 1, synaptojanin 1, clathrin Options: protein-complex, protein

[ "O", "B-protein-complex", "I-protein-complex", "O", "O", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "B-protein-complex", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "I-protein", "O", "O", "O", "O", "B-protein-complex", "O", "O", "O", "O" ]

The amphiphysin dimer also binds to clathrin (10, 11) and to the α-adaptin subunit of the plasma membrane clathrin adaptor AP-2 (9, 12) and thus may mediate recruitment of dynamin 1 and synaptojanin 1 to the site of clathrin-mediated endocytosis.

[ "The", "amphiphysin", "dimer", "also", "binds", "to", "clathrin", "(", "10", ",", "11", ")", "and", "to", "the", "α", "-", "adaptin", "subunit", "of", "the", "plasma", "membrane", "clathrin", "adaptor", "AP-2", "(", "9", ",", "12", ")", "and", "thus", "may", "mediate", "recruitment", "of", "dynamin", "1", "and", "synaptojanin", "1", "to", "the", "site", "of", "clathrin", "-", "mediated", "endocytosis", "." ]

[ "protein-complex", "protein", "protein-family" ]

amphiphysin dimer, clathrin, α - adaptin, clathrin, AP-2, dynamin 1, synaptojanin 1, clathrin

1.0alpha7.train.449_task2

Sentence: The amphiphysin dimer also binds to clathrin (10, 11) and to the α-adaptin subunit of the plasma membrane clathrin adaptor AP-2 (9, 12) and thus may mediate recruitment of dynamin 1 and synaptojanin 1 to the site of clathrin-mediated endocytosis. Instructions: please extract entity words from the input sentence

[ "O", "B-protein-complex", "I-protein-complex", "O", "O", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "B-protein-complex", "O", "B-protein-complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "I-protein", "O", "O", "O", "O", "B-protein-complex", "O", "O", "O", "O" ]

The amphiphysin dimer also binds to clathrin (10, 11) and to the α-adaptin subunit of the plasma membrane clathrin adaptor AP-2 (9, 12) and thus may mediate recruitment of dynamin 1 and synaptojanin 1 to the site of clathrin-mediated endocytosis.

[ "The", "amphiphysin", "dimer", "also", "binds", "to", "clathrin", "(", "10", ",", "11", ")", "and", "to", "the", "α", "-", "adaptin", "subunit", "of", "the", "plasma", "membrane", "clathrin", "adaptor", "AP-2", "(", "9", ",", "12", ")", "and", "thus", "may", "mediate", "recruitment", "of", "dynamin", "1", "and", "synaptojanin", "1", "to", "the", "site", "of", "clathrin", "-", "mediated", "endocytosis", "." ]

[ "protein-complex", "protein", "protein-family" ]

Neuropeptide S is a GENE-Y, MK801 is a CHEMICAL, scopolamine is a CHEMICAL, Aβ1 - 42 is a GENE-Y

23454528_task0

Sentence: Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks.

[ "Neuropeptide", "S", "enhances", "memory", "and", "mitigates", "memory", "impairment", "induced", "by", "MK801", ",", "scopolamine", "or", "Aβ1", "-", "42", "in", "mice", "novel", "object", "and", "object", "location", "recognition", "tasks", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Neuropeptide S is a GENE-Y, MK801 is a CHEMICAL, scopolamine is a CHEMICAL, Aβ1 - 42 is a GENE-Y

23454528_task1

Sentence: Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks. Instructions: please typing these entity words according to sentence: Neuropeptide S, MK801, scopolamine, Aβ1 - 42 Options: GENE-Y, CHEMICAL

[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks.

[ "Neuropeptide", "S", "enhances", "memory", "and", "mitigates", "memory", "impairment", "induced", "by", "MK801", ",", "scopolamine", "or", "Aβ1", "-", "42", "in", "mice", "novel", "object", "and", "object", "location", "recognition", "tasks", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Neuropeptide S, MK801, scopolamine, Aβ1 - 42

23454528_task2

Sentence: Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks. Instructions: please extract entity words from the input sentence

[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Aβ1-42 in mice novel object and object location recognition tasks.

[ "Neuropeptide", "S", "enhances", "memory", "and", "mitigates", "memory", "impairment", "induced", "by", "MK801", ",", "scopolamine", "or", "Aβ1", "-", "42", "in", "mice", "novel", "object", "and", "object", "location", "recognition", "tasks", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Patienten is an umlsterm, malignem Melanom is an umlsterm, Diagnose is an umlsterm, Melanompatienten is an umlsterm, Behandlung is an umlsterm, Melanompatienten is an umlsterm, Patienten is an umlsterm, Tumordicke is an umlsterm, Lymphadenektomie is an umlsterm, Patienten is an umlsterm, Trends is an umlsterm, Tumoren is an umlsterm

DerHautarzt.50460762.ger.abstr_task0

Sentence: Mehr als 90% aller Patienten mit malignem Melanom kamen waehrend der letzten Dekade mit einem Primaertumor allein zur ersten Diagnose . Die operative Versorgung des Primaertumors war daher fuer Melanompatienten die entscheidende Behandlungsmassnahme . Die vorliegende Untersuchung hatte zum Ziel , die Anwendung verschiedener Vorgehensweisen im deutschen Sprachraum zu dokumentieren und ihre Entwicklung waehrend der Jahre 1983-1993 zu analysieren . Insgesamt wurde die Behandlung von 15054 Melanompatienten in den Stadien I und II ( Primaertumor allein ) untersucht . Im genannten Zeitraum nahm der Anteil zweizeitiger operativer Versorgungen von ca. 30% auf 60% zu . Eine Lokalanaesthesie wurde 1983 bei ca. 40% der Patienten durchgefuehrt , im Jahre 1993 war der Anteil der Erstversorgung in Lokalanaesthesie auf ca. 80% angestiegen . Gleichzeitig nahm der mittlere Sicherheitsabstand bei operativer Versorgung des Primaertumors 33 mm auf 21 mm ab , wobei auch die Tumordicke im Durchschnitt von 2,1 auf 1,5 mm abnahm . Die elektive Lymphadenektomie wurde 1983 bei etwa 5% aller Patienten , 1993 dagegen bei 9% aller Kranken durchgefuehrt . Insgesamt unterschied sich das therapeutische Vorgehen in den verschiedenen Zentren bei vergleichbaren Indikationsstellungen erheblich voneinander . Zusammenfassend hat im genannten Zeitraum ein Wandel des therapeutischen Vorgehens im deutschsprachigen Raum stattgefunden , mit staerkerer Bevorzugung eines zweizeitigen operativen Vorgehens mit Erstversorgung in Lokalanaesthesie und der Wahl kleinerer Sicherheitsabstaende . Gruende fuer diese Trends im therapeutischen Vorgehen sind sowohl in der deutlich verbesserten Frueherkennung der behandelten Tumoren , als auch in einer Aenderung konzeptioneller therapeutischen Vorstellungen zu suchen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mehr als 90% aller Patienten mit malignem Melanom kamen waehrend der letzten Dekade mit einem Primaertumor allein zur ersten Diagnose . Die operative Versorgung des Primaertumors war daher fuer Melanompatienten die entscheidende Behandlungsmassnahme . Die vorliegende Untersuchung hatte zum Ziel , die Anwendung verschiedener Vorgehensweisen im deutschen Sprachraum zu dokumentieren und ihre Entwicklung waehrend der Jahre 1983-1993 zu analysieren . Insgesamt wurde die Behandlung von 15054 Melanompatienten in den Stadien I und II ( Primaertumor allein ) untersucht . Im genannten Zeitraum nahm der Anteil zweizeitiger operativer Versorgungen von ca. 30% auf 60% zu . Eine Lokalanaesthesie wurde 1983 bei ca. 40% der Patienten durchgefuehrt , im Jahre 1993 war der Anteil der Erstversorgung in Lokalanaesthesie auf ca. 80% angestiegen . Gleichzeitig nahm der mittlere Sicherheitsabstand bei operativer Versorgung des Primaertumors 33 mm auf 21 mm ab , wobei auch die Tumordicke im Durchschnitt von 2,1 auf 1,5 mm abnahm . Die elektive Lymphadenektomie wurde 1983 bei etwa 5% aller Patienten , 1993 dagegen bei 9% aller Kranken durchgefuehrt . Insgesamt unterschied sich das therapeutische Vorgehen in den verschiedenen Zentren bei vergleichbaren Indikationsstellungen erheblich voneinander . Zusammenfassend hat im genannten Zeitraum ein Wandel des therapeutischen Vorgehens im deutschsprachigen Raum stattgefunden , mit staerkerer Bevorzugung eines zweizeitigen operativen Vorgehens mit Erstversorgung in Lokalanaesthesie und der Wahl kleinerer Sicherheitsabstaende . Gruende fuer diese Trends im therapeutischen Vorgehen sind sowohl in der deutlich verbesserten Frueherkennung der behandelten Tumoren , als auch in einer Aenderung konzeptioneller therapeutischen Vorstellungen zu suchen .

[ "Mehr", "als", "90", "%", "aller", "Patienten", "mit", "malignem", "Melanom", "kamen", "waehrend", "der", "letzten", "Dekade", "mit", "einem", "Primaertumor", "allein", "zur", "ersten", "Diagnose", ".", "Die", "operative", "Versorgung", "des", "Primaertumors", "war", "daher", "fuer", "Melanompatienten", "die", "entscheidende", "Behandlungsmassnahme", ".", "Die", "vorliegende", "Untersuchung", "hatte", "zum", "Ziel", ",", "die", "Anwendung", "verschiedener", "Vorgehensweisen", "im", "deutschen", "Sprachraum", "zu", "dokumentieren", "und", "ihre", "Entwicklung", "waehrend", "der", "Jahre", "1983", "-", "1993", "zu", "analysieren", ".", "Insgesamt", "wurde", "die", "Behandlung", "von", "15054", "Melanompatienten", "in", "den", "Stadien", "I", "und", "II", "(", "Primaertumor", "allein", ")", "untersucht", ".", "Im", "genannten", "Zeitraum", "nahm", "der", "Anteil", "zweizeitiger", "operativer", "Versorgungen", "von", "ca", ".", "30", "%", "auf", "60", "%", "zu", ".", "Eine", "Lokalanaesthesie", "wurde", "1983", "bei", "ca", ".", "40", "%", "der", "Patienten", "durchgefuehrt", ",", "im", "Jahre", "1993", "war", "der", "Anteil", "der", "Erstversorgung", "in", "Lokalanaesthesie", "auf", "ca", ".", "80", "%", "angestiegen", ".", "Gleichzeitig", "nahm", "der", "mittlere", "Sicherheitsabstand", "bei", "operativer", "Versorgung", "des", "Primaertumors", "33", "mm", "auf", "21", "mm", "ab", ",", "wobei", "auch", "die", "Tumordicke", "im", "Durchschnitt", "von", "2,1", "auf", "1,5", "mm", "abnahm", ".", "Die", "elektive", "Lymphadenektomie", "wurde", "1983", "bei", "etwa", "5", "%", "aller", "Patienten", ",", "1993", "dagegen", "bei", "9", "%", "aller", "Kranken", "durchgefuehrt", ".", "Insgesamt", "unterschied", "sich", "das", "therapeutische", "Vorgehen", "in", "den", "verschiedenen", "Zentren", "bei", "vergleichbaren", "Indikationsstellungen", "erheblich", "voneinander", ".", "Zusammenfassend", "hat", "im", "genannten", "Zeitraum", "ein", "Wandel", "des", "therapeutischen", "Vorgehens", "im", "deutschsprachigen", "Raum", "stattgefunden", ",", "mit", "staerkerer", "Bevorzugung", "eines", "zweizeitigen", "operativen", "Vorgehens", "mit", "Erstversorgung", "in", "Lokalanaesthesie", "und", "der", "Wahl", "kleinerer", "Sicherheitsabstaende", ".", "Gruende", "fuer", "diese", "Trends", "im", "therapeutischen", "Vorgehen", "sind", "sowohl", "in", "der", "deutlich", "verbesserten", "Frueherkennung", "der", "behandelten", "Tumoren", ",", "als", "auch", "in", "einer", "Aenderung", "konzeptioneller", "therapeutischen", "Vorstellungen", "zu", "suchen", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, malignem Melanom is an umlsterm, Diagnose is an umlsterm, Melanompatienten is an umlsterm, Behandlung is an umlsterm, Melanompatienten is an umlsterm, Patienten is an umlsterm, Tumordicke is an umlsterm, Lymphadenektomie is an umlsterm, Patienten is an umlsterm, Trends is an umlsterm, Tumoren is an umlsterm

DerHautarzt.50460762.ger.abstr_task1

Sentence: Mehr als 90% aller Patienten mit malignem Melanom kamen waehrend der letzten Dekade mit einem Primaertumor allein zur ersten Diagnose . Die operative Versorgung des Primaertumors war daher fuer Melanompatienten die entscheidende Behandlungsmassnahme . Die vorliegende Untersuchung hatte zum Ziel , die Anwendung verschiedener Vorgehensweisen im deutschen Sprachraum zu dokumentieren und ihre Entwicklung waehrend der Jahre 1983-1993 zu analysieren . Insgesamt wurde die Behandlung von 15054 Melanompatienten in den Stadien I und II ( Primaertumor allein ) untersucht . Im genannten Zeitraum nahm der Anteil zweizeitiger operativer Versorgungen von ca. 30% auf 60% zu . Eine Lokalanaesthesie wurde 1983 bei ca. 40% der Patienten durchgefuehrt , im Jahre 1993 war der Anteil der Erstversorgung in Lokalanaesthesie auf ca. 80% angestiegen . Gleichzeitig nahm der mittlere Sicherheitsabstand bei operativer Versorgung des Primaertumors 33 mm auf 21 mm ab , wobei auch die Tumordicke im Durchschnitt von 2,1 auf 1,5 mm abnahm . Die elektive Lymphadenektomie wurde 1983 bei etwa 5% aller Patienten , 1993 dagegen bei 9% aller Kranken durchgefuehrt . Insgesamt unterschied sich das therapeutische Vorgehen in den verschiedenen Zentren bei vergleichbaren Indikationsstellungen erheblich voneinander . Zusammenfassend hat im genannten Zeitraum ein Wandel des therapeutischen Vorgehens im deutschsprachigen Raum stattgefunden , mit staerkerer Bevorzugung eines zweizeitigen operativen Vorgehens mit Erstversorgung in Lokalanaesthesie und der Wahl kleinerer Sicherheitsabstaende . Gruende fuer diese Trends im therapeutischen Vorgehen sind sowohl in der deutlich verbesserten Frueherkennung der behandelten Tumoren , als auch in einer Aenderung konzeptioneller therapeutischen Vorstellungen zu suchen . Instructions: please typing these entity words according to sentence: Patienten, malignem Melanom, Diagnose, Melanompatienten, Behandlung, Melanompatienten, Patienten, Tumordicke, Lymphadenektomie, Patienten, Trends, Tumoren Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mehr als 90% aller Patienten mit malignem Melanom kamen waehrend der letzten Dekade mit einem Primaertumor allein zur ersten Diagnose . Die operative Versorgung des Primaertumors war daher fuer Melanompatienten die entscheidende Behandlungsmassnahme . Die vorliegende Untersuchung hatte zum Ziel , die Anwendung verschiedener Vorgehensweisen im deutschen Sprachraum zu dokumentieren und ihre Entwicklung waehrend der Jahre 1983-1993 zu analysieren . Insgesamt wurde die Behandlung von 15054 Melanompatienten in den Stadien I und II ( Primaertumor allein ) untersucht . Im genannten Zeitraum nahm der Anteil zweizeitiger operativer Versorgungen von ca. 30% auf 60% zu . Eine Lokalanaesthesie wurde 1983 bei ca. 40% der Patienten durchgefuehrt , im Jahre 1993 war der Anteil der Erstversorgung in Lokalanaesthesie auf ca. 80% angestiegen . Gleichzeitig nahm der mittlere Sicherheitsabstand bei operativer Versorgung des Primaertumors 33 mm auf 21 mm ab , wobei auch die Tumordicke im Durchschnitt von 2,1 auf 1,5 mm abnahm . Die elektive Lymphadenektomie wurde 1983 bei etwa 5% aller Patienten , 1993 dagegen bei 9% aller Kranken durchgefuehrt . Insgesamt unterschied sich das therapeutische Vorgehen in den verschiedenen Zentren bei vergleichbaren Indikationsstellungen erheblich voneinander . Zusammenfassend hat im genannten Zeitraum ein Wandel des therapeutischen Vorgehens im deutschsprachigen Raum stattgefunden , mit staerkerer Bevorzugung eines zweizeitigen operativen Vorgehens mit Erstversorgung in Lokalanaesthesie und der Wahl kleinerer Sicherheitsabstaende . Gruende fuer diese Trends im therapeutischen Vorgehen sind sowohl in der deutlich verbesserten Frueherkennung der behandelten Tumoren , als auch in einer Aenderung konzeptioneller therapeutischen Vorstellungen zu suchen .

[ "Mehr", "als", "90", "%", "aller", "Patienten", "mit", "malignem", "Melanom", "kamen", "waehrend", "der", "letzten", "Dekade", "mit", "einem", "Primaertumor", "allein", "zur", "ersten", "Diagnose", ".", "Die", "operative", "Versorgung", "des", "Primaertumors", "war", "daher", "fuer", "Melanompatienten", "die", "entscheidende", "Behandlungsmassnahme", ".", "Die", "vorliegende", "Untersuchung", "hatte", "zum", "Ziel", ",", "die", "Anwendung", "verschiedener", "Vorgehensweisen", "im", "deutschen", "Sprachraum", "zu", "dokumentieren", "und", "ihre", "Entwicklung", "waehrend", "der", "Jahre", "1983", "-", "1993", "zu", "analysieren", ".", "Insgesamt", "wurde", "die", "Behandlung", "von", "15054", "Melanompatienten", "in", "den", "Stadien", "I", "und", "II", "(", "Primaertumor", "allein", ")", "untersucht", ".", "Im", "genannten", "Zeitraum", "nahm", "der", "Anteil", "zweizeitiger", "operativer", "Versorgungen", "von", "ca", ".", "30", "%", "auf", "60", "%", "zu", ".", "Eine", "Lokalanaesthesie", "wurde", "1983", "bei", "ca", ".", "40", "%", "der", "Patienten", "durchgefuehrt", ",", "im", "Jahre", "1993", "war", "der", "Anteil", "der", "Erstversorgung", "in", "Lokalanaesthesie", "auf", "ca", ".", "80", "%", "angestiegen", ".", "Gleichzeitig", "nahm", "der", "mittlere", "Sicherheitsabstand", "bei", "operativer", "Versorgung", "des", "Primaertumors", "33", "mm", "auf", "21", "mm", "ab", ",", "wobei", "auch", "die", "Tumordicke", "im", "Durchschnitt", "von", "2,1", "auf", "1,5", "mm", "abnahm", ".", "Die", "elektive", "Lymphadenektomie", "wurde", "1983", "bei", "etwa", "5", "%", "aller", "Patienten", ",", "1993", "dagegen", "bei", "9", "%", "aller", "Kranken", "durchgefuehrt", ".", "Insgesamt", "unterschied", "sich", "das", "therapeutische", "Vorgehen", "in", "den", "verschiedenen", "Zentren", "bei", "vergleichbaren", "Indikationsstellungen", "erheblich", "voneinander", ".", "Zusammenfassend", "hat", "im", "genannten", "Zeitraum", "ein", "Wandel", "des", "therapeutischen", "Vorgehens", "im", "deutschsprachigen", "Raum", "stattgefunden", ",", "mit", "staerkerer", "Bevorzugung", "eines", "zweizeitigen", "operativen", "Vorgehens", "mit", "Erstversorgung", "in", "Lokalanaesthesie", "und", "der", "Wahl", "kleinerer", "Sicherheitsabstaende", ".", "Gruende", "fuer", "diese", "Trends", "im", "therapeutischen", "Vorgehen", "sind", "sowohl", "in", "der", "deutlich", "verbesserten", "Frueherkennung", "der", "behandelten", "Tumoren", ",", "als", "auch", "in", "einer", "Aenderung", "konzeptioneller", "therapeutischen", "Vorstellungen", "zu", "suchen", "." ]

[ "umlsterm" ]

Patienten, malignem Melanom, Diagnose, Melanompatienten, Behandlung, Melanompatienten, Patienten, Tumordicke, Lymphadenektomie, Patienten, Trends, Tumoren

DerHautarzt.50460762.ger.abstr_task2

Sentence: Mehr als 90% aller Patienten mit malignem Melanom kamen waehrend der letzten Dekade mit einem Primaertumor allein zur ersten Diagnose . Die operative Versorgung des Primaertumors war daher fuer Melanompatienten die entscheidende Behandlungsmassnahme . Die vorliegende Untersuchung hatte zum Ziel , die Anwendung verschiedener Vorgehensweisen im deutschen Sprachraum zu dokumentieren und ihre Entwicklung waehrend der Jahre 1983-1993 zu analysieren . Insgesamt wurde die Behandlung von 15054 Melanompatienten in den Stadien I und II ( Primaertumor allein ) untersucht . Im genannten Zeitraum nahm der Anteil zweizeitiger operativer Versorgungen von ca. 30% auf 60% zu . Eine Lokalanaesthesie wurde 1983 bei ca. 40% der Patienten durchgefuehrt , im Jahre 1993 war der Anteil der Erstversorgung in Lokalanaesthesie auf ca. 80% angestiegen . Gleichzeitig nahm der mittlere Sicherheitsabstand bei operativer Versorgung des Primaertumors 33 mm auf 21 mm ab , wobei auch die Tumordicke im Durchschnitt von 2,1 auf 1,5 mm abnahm . Die elektive Lymphadenektomie wurde 1983 bei etwa 5% aller Patienten , 1993 dagegen bei 9% aller Kranken durchgefuehrt . Insgesamt unterschied sich das therapeutische Vorgehen in den verschiedenen Zentren bei vergleichbaren Indikationsstellungen erheblich voneinander . Zusammenfassend hat im genannten Zeitraum ein Wandel des therapeutischen Vorgehens im deutschsprachigen Raum stattgefunden , mit staerkerer Bevorzugung eines zweizeitigen operativen Vorgehens mit Erstversorgung in Lokalanaesthesie und der Wahl kleinerer Sicherheitsabstaende . Gruende fuer diese Trends im therapeutischen Vorgehen sind sowohl in der deutlich verbesserten Frueherkennung der behandelten Tumoren , als auch in einer Aenderung konzeptioneller therapeutischen Vorstellungen zu suchen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Mehr als 90% aller Patienten mit malignem Melanom kamen waehrend der letzten Dekade mit einem Primaertumor allein zur ersten Diagnose . Die operative Versorgung des Primaertumors war daher fuer Melanompatienten die entscheidende Behandlungsmassnahme . Die vorliegende Untersuchung hatte zum Ziel , die Anwendung verschiedener Vorgehensweisen im deutschen Sprachraum zu dokumentieren und ihre Entwicklung waehrend der Jahre 1983-1993 zu analysieren . Insgesamt wurde die Behandlung von 15054 Melanompatienten in den Stadien I und II ( Primaertumor allein ) untersucht . Im genannten Zeitraum nahm der Anteil zweizeitiger operativer Versorgungen von ca. 30% auf 60% zu . Eine Lokalanaesthesie wurde 1983 bei ca. 40% der Patienten durchgefuehrt , im Jahre 1993 war der Anteil der Erstversorgung in Lokalanaesthesie auf ca. 80% angestiegen . Gleichzeitig nahm der mittlere Sicherheitsabstand bei operativer Versorgung des Primaertumors 33 mm auf 21 mm ab , wobei auch die Tumordicke im Durchschnitt von 2,1 auf 1,5 mm abnahm . Die elektive Lymphadenektomie wurde 1983 bei etwa 5% aller Patienten , 1993 dagegen bei 9% aller Kranken durchgefuehrt . Insgesamt unterschied sich das therapeutische Vorgehen in den verschiedenen Zentren bei vergleichbaren Indikationsstellungen erheblich voneinander . Zusammenfassend hat im genannten Zeitraum ein Wandel des therapeutischen Vorgehens im deutschsprachigen Raum stattgefunden , mit staerkerer Bevorzugung eines zweizeitigen operativen Vorgehens mit Erstversorgung in Lokalanaesthesie und der Wahl kleinerer Sicherheitsabstaende . Gruende fuer diese Trends im therapeutischen Vorgehen sind sowohl in der deutlich verbesserten Frueherkennung der behandelten Tumoren , als auch in einer Aenderung konzeptioneller therapeutischen Vorstellungen zu suchen .

[ "Mehr", "als", "90", "%", "aller", "Patienten", "mit", "malignem", "Melanom", "kamen", "waehrend", "der", "letzten", "Dekade", "mit", "einem", "Primaertumor", "allein", "zur", "ersten", "Diagnose", ".", "Die", "operative", "Versorgung", "des", "Primaertumors", "war", "daher", "fuer", "Melanompatienten", "die", "entscheidende", "Behandlungsmassnahme", ".", "Die", "vorliegende", "Untersuchung", "hatte", "zum", "Ziel", ",", "die", "Anwendung", "verschiedener", "Vorgehensweisen", "im", "deutschen", "Sprachraum", "zu", "dokumentieren", "und", "ihre", "Entwicklung", "waehrend", "der", "Jahre", "1983", "-", "1993", "zu", "analysieren", ".", "Insgesamt", "wurde", "die", "Behandlung", "von", "15054", "Melanompatienten", "in", "den", "Stadien", "I", "und", "II", "(", "Primaertumor", "allein", ")", "untersucht", ".", "Im", "genannten", "Zeitraum", "nahm", "der", "Anteil", "zweizeitiger", "operativer", "Versorgungen", "von", "ca", ".", "30", "%", "auf", "60", "%", "zu", ".", "Eine", "Lokalanaesthesie", "wurde", "1983", "bei", "ca", ".", "40", "%", "der", "Patienten", "durchgefuehrt", ",", "im", "Jahre", "1993", "war", "der", "Anteil", "der", "Erstversorgung", "in", "Lokalanaesthesie", "auf", "ca", ".", "80", "%", "angestiegen", ".", "Gleichzeitig", "nahm", "der", "mittlere", "Sicherheitsabstand", "bei", "operativer", "Versorgung", "des", "Primaertumors", "33", "mm", "auf", "21", "mm", "ab", ",", "wobei", "auch", "die", "Tumordicke", "im", "Durchschnitt", "von", "2,1", "auf", "1,5", "mm", "abnahm", ".", "Die", "elektive", "Lymphadenektomie", "wurde", "1983", "bei", "etwa", "5", "%", "aller", "Patienten", ",", "1993", "dagegen", "bei", "9", "%", "aller", "Kranken", "durchgefuehrt", ".", "Insgesamt", "unterschied", "sich", "das", "therapeutische", "Vorgehen", "in", "den", "verschiedenen", "Zentren", "bei", "vergleichbaren", "Indikationsstellungen", "erheblich", "voneinander", ".", "Zusammenfassend", "hat", "im", "genannten", "Zeitraum", "ein", "Wandel", "des", "therapeutischen", "Vorgehens", "im", "deutschsprachigen", "Raum", "stattgefunden", ",", "mit", "staerkerer", "Bevorzugung", "eines", "zweizeitigen", "operativen", "Vorgehens", "mit", "Erstversorgung", "in", "Lokalanaesthesie", "und", "der", "Wahl", "kleinerer", "Sicherheitsabstaende", ".", "Gruende", "fuer", "diese", "Trends", "im", "therapeutischen", "Vorgehen", "sind", "sowohl", "in", "der", "deutlich", "verbesserten", "Frueherkennung", "der", "behandelten", "Tumoren", ",", "als", "auch", "in", "einer", "Aenderung", "konzeptioneller", "therapeutischen", "Vorstellungen", "zu", "suchen", "." ]

[ "umlsterm" ]

care is an umlsterm, patients is an umlsterm, multiple injuries is an umlsterm, identification is an umlsterm, baseline is an umlsterm, treatment is an umlsterm, documentation is an umlsterm, treatment is an umlsterm, emergency is an umlsterm, set is an umlsterm, baseline is an umlsterm, treatment is an umlsterm, patients is an umlsterm, algorithm is an umlsterm, criteria is an umlsterm, judgement is an umlsterm, care is an umlsterm, algorithm is an umlsterm, single is an umlsterm, criterion is an umlsterm, procedure is an umlsterm, patient is an umlsterm, judgement is an umlsterm, criteria is an umlsterm, assessment is an umlsterm, baseline is an umlsterm, times is an umlsterm, trauma is an umlsterm, trauma is an umlsterm, time is an umlsterm, patients is an umlsterm, blood is an umlsterm, computerised tomography is an umlsterm, injuries is an umlsterm, trauma is an umlsterm, period is an umlsterm, patients is an umlsterm, intubation is an umlsterm, chest tube is an umlsterm, blood transfusion is an umlsterm, shock is an umlsterm, blood is an umlsterm, emergency is an umlsterm, operations is an umlsterm, shock is an umlsterm, operations is an umlsterm, craniotomy is an umlsterm, surgery is an umlsterm, intensive care unit is an umlsterm, patients is an umlsterm, care is an umlsterm, patients is an umlsterm, indicators is an umlsterm, emergency is an umlsterm, baseline is an umlsterm, measures is an umlsterm, data collection is an umlsterm, exact is an umlsterm, analysis is an umlsterm

DerUnfallchirurg.71000811.eng.abstr_task0

Sentence: Quality management in early clinical care of patients with multiple injuries ( description of actual process , identification of problems , implementation of quality improvement ) is not possible without sufficient baseline data about the present situation of medical treatment . This study investigates whether the current documentation of treatment in the emergency room is appropriate to judge upon the quality of the process and to detect problems . In addition , a set of baseline data is presented . The performance in the treatment of 126 multiple injured patients was prospectively recorded from 1988 to 1993 and compared with an idealized process based upon an algorithm . The quality of present data recording was analysed , and criteria for judgement of quality of care were assessed . The algorithm was devided into 117 possible steps ( one step consisting of a single decision criterion , the decision and the corresponding procedure ) . Per patient , only 61 % +/- 12 % of these steps were sufficiently documented to allow judgement . Using several criteria for assessment , the following baseline data could be observed ( times shown refer to admission to the trauma room ) : ( 1 ) trauma room time of 129 +/- 55 min ; ( 2 ) completition of basic radiological and sonographic diagnostics in 91 % of patients ; ( 3 ) first blood collection after 17 +/- 11 min ; ( 4 ) cranial computerised tomography after 55 +/- 20 min ; ( 5 ) missed injuries during the trauma room period in 32 % of patients ; ( 6 ) intubation after 20 +/- 19 min ; ( 7 ) insertion of a chest tube after 30 +/- 17 min ; ( 8 ) first blood transfusion in shock after 32 +/- 17 min ; ( 9 ) transfused blood within the first hour of 4.2 +/- 2.8 units and within the second hour of 8.5 +/- 4.7 units ; ( 10 ) emergency operations in shock after 98 +/- 55 min ; ( 11 ) early operations after 156 +/- 69 min ; ( 12 ) craniotomy after 124 +/- 37 min ; ( 13 ) unplanned surgery within 24 hours after admission to the intensive care unit in 11 % of patients . The study presented here supplies information on timing and other process data of the acute clinical care of seriously injured patients . In particular , the data represent indicators for the quality of emergency room management , which may be used as a baseline to compose improvement measures of structure and process . The quality of data collection has to be improved for carrying out an exact analysis of the process . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O" ]

Quality management in early clinical care of patients with multiple injuries ( description of actual process , identification of problems , implementation of quality improvement ) is not possible without sufficient baseline data about the present situation of medical treatment . This study investigates whether the current documentation of treatment in the emergency room is appropriate to judge upon the quality of the process and to detect problems . In addition , a set of baseline data is presented . The performance in the treatment of 126 multiple injured patients was prospectively recorded from 1988 to 1993 and compared with an idealized process based upon an algorithm . The quality of present data recording was analysed , and criteria for judgement of quality of care were assessed . The algorithm was devided into 117 possible steps ( one step consisting of a single decision criterion , the decision and the corresponding procedure ) . Per patient , only 61 % +/- 12 % of these steps were sufficiently documented to allow judgement . Using several criteria for assessment , the following baseline data could be observed ( times shown refer to admission to the trauma room ) : ( 1 ) trauma room time of 129 +/- 55 min ; ( 2 ) completition of basic radiological and sonographic diagnostics in 91 % of patients ; ( 3 ) first blood collection after 17 +/- 11 min ; ( 4 ) cranial computerised tomography after 55 +/- 20 min ; ( 5 ) missed injuries during the trauma room period in 32 % of patients ; ( 6 ) intubation after 20 +/- 19 min ; ( 7 ) insertion of a chest tube after 30 +/- 17 min ; ( 8 ) first blood transfusion in shock after 32 +/- 17 min ; ( 9 ) transfused blood within the first hour of 4.2 +/- 2.8 units and within the second hour of 8.5 +/- 4.7 units ; ( 10 ) emergency operations in shock after 98 +/- 55 min ; ( 11 ) early operations after 156 +/- 69 min ; ( 12 ) craniotomy after 124 +/- 37 min ; ( 13 ) unplanned surgery within 24 hours after admission to the intensive care unit in 11 % of patients . The study presented here supplies information on timing and other process data of the acute clinical care of seriously injured patients . In particular , the data represent indicators for the quality of emergency room management , which may be used as a baseline to compose improvement measures of structure and process . The quality of data collection has to be improved for carrying out an exact analysis of the process .

[ "Quality", "management", "in", "early", "clinical", "care", "of", "patients", "with", "multiple", "injuries", "(", "description", "of", "actual", "process", ",", "identification", "of", "problems", ",", "implementation", "of", "quality", "improvement", ")", "is", "not", "possible", "without", "sufficient", "baseline", "data", "about", "the", "present", "situation", "of", "medical", "treatment", ".", "This", "study", "investigates", "whether", "the", "current", "documentation", "of", "treatment", "in", "the", "emergency", "room", "is", "appropriate", "to", "judge", "upon", "the", "quality", "of", "the", "process", "and", "to", "detect", "problems", ".", "In", "addition", ",", "a", "set", "of", "baseline", "data", "is", "presented", ".", "The", "performance", "in", "the", "treatment", "of", "126", "multiple", "injured", "patients", "was", "prospectively", "recorded", "from", "1988", "to", "1993", "and", "compared", "with", "an", "idealized", "process", "based", "upon", "an", "algorithm", ".", "The", "quality", "of", "present", "data", "recording", "was", "analysed", ",", "and", "criteria", "for", "judgement", "of", "quality", "of", "care", "were", "assessed", ".", "The", "algorithm", "was", "devided", "into", "117", "possible", "steps", "(", "one", "step", "consisting", "of", "a", "single", "decision", "criterion", ",", "the", "decision", "and", "the", "corresponding", "procedure", ")", ".", "Per", "patient", ",", "only", "61", "%", "+", "/-", "12", "%", "of", "these", "steps", "were", "sufficiently", "documented", "to", "allow", "judgement", ".", "Using", "several", "criteria", "for", "assessment", ",", "the", "following", "baseline", "data", "could", "be", "observed", "(", "times", "shown", "refer", "to", "admission", "to", "the", "trauma", "room", ")", ":", "(", "1", ")", "trauma", "room", "time", "of", "129", "+", "/-", "55", "min", ";", "(", "2", ")", "completition", "of", "basic", "radiological", "and", "sonographic", "diagnostics", "in", "91", "%", "of", "patients", ";", "(", "3", ")", "first", "blood", "collection", "after", "17", "+", "/-", "11", "min", ";", "(", "4", ")", "cranial", "computerised", "tomography", "after", "55", "+", "/-", "20", "min", ";", "(", "5", ")", "missed", "injuries", "during", "the", "trauma", "room", "period", "in", "32", "%", "of", "patients", ";", "(", "6", ")", "intubation", "after", "20", "+", "/-", "19", "min", ";", "(", "7", ")", "insertion", "of", "a", "chest", "tube", "after", "30", "+", "/-", "17", "min", ";", "(", "8", ")", "first", "blood", "transfusion", "in", "shock", "after", "32", "+", "/-", "17", "min", ";", "(", "9", ")", "transfused", "blood", "within", "the", "first", "hour", "of", "4.2", "+", "/-", "2.8", "units", "and", "within", "the", "second", "hour", "of", "8.5", "+", "/-", "4.7", "units", ";", "(", "10", ")", "emergency", "operations", "in", "shock", "after", "98", "+", "/-", "55", "min", ";", "(", "11", ")", "early", "operations", "after", "156", "+", "/-", "69", "min", ";", "(", "12", ")", "craniotomy", "after", "124", "+", "/-", "37", "min", ";", "(", "13", ")", "unplanned", "surgery", "within", "24", "hours", "after", "admission", "to", "the", "intensive", "care", "unit", "in", "11", "%", "of", "patients", ".", "The", "study", "presented", "here", "supplies", "information", "on", "timing", "and", "other", "process", "data", "of", "the", "acute", "clinical", "care", "of", "seriously", "injured", "patients", ".", "In", "particular", ",", "the", "data", "represent", "indicators", "for", "the", "quality", "of", "emergency", "room", "management", ",", "which", "may", "be", "used", "as", "a", "baseline", "to", "compose", "improvement", "measures", "of", "structure", "and", "process", ".", "The", "quality", "of", "data", "collection", "has", "to", "be", "improved", "for", "carrying", "out", "an", "exact", "analysis", "of", "the", "process", "." ]

[ "umlsterm" ]

care is an umlsterm, patients is an umlsterm, multiple injuries is an umlsterm, identification is an umlsterm, baseline is an umlsterm, treatment is an umlsterm, documentation is an umlsterm, treatment is an umlsterm, emergency is an umlsterm, set is an umlsterm, baseline is an umlsterm, treatment is an umlsterm, patients is an umlsterm, algorithm is an umlsterm, criteria is an umlsterm, judgement is an umlsterm, care is an umlsterm, algorithm is an umlsterm, single is an umlsterm, criterion is an umlsterm, procedure is an umlsterm, patient is an umlsterm, judgement is an umlsterm, criteria is an umlsterm, assessment is an umlsterm, baseline is an umlsterm, times is an umlsterm, trauma is an umlsterm, trauma is an umlsterm, time is an umlsterm, patients is an umlsterm, blood is an umlsterm, computerised tomography is an umlsterm, injuries is an umlsterm, trauma is an umlsterm, period is an umlsterm, patients is an umlsterm, intubation is an umlsterm, chest tube is an umlsterm, blood transfusion is an umlsterm, shock is an umlsterm, blood is an umlsterm, emergency is an umlsterm, operations is an umlsterm, shock is an umlsterm, operations is an umlsterm, craniotomy is an umlsterm, surgery is an umlsterm, intensive care unit is an umlsterm, patients is an umlsterm, care is an umlsterm, patients is an umlsterm, indicators is an umlsterm, emergency is an umlsterm, baseline is an umlsterm, measures is an umlsterm, data collection is an umlsterm, exact is an umlsterm, analysis is an umlsterm

DerUnfallchirurg.71000811.eng.abstr_task1

Sentence: Quality management in early clinical care of patients with multiple injuries ( description of actual process , identification of problems , implementation of quality improvement ) is not possible without sufficient baseline data about the present situation of medical treatment . This study investigates whether the current documentation of treatment in the emergency room is appropriate to judge upon the quality of the process and to detect problems . In addition , a set of baseline data is presented . The performance in the treatment of 126 multiple injured patients was prospectively recorded from 1988 to 1993 and compared with an idealized process based upon an algorithm . The quality of present data recording was analysed , and criteria for judgement of quality of care were assessed . The algorithm was devided into 117 possible steps ( one step consisting of a single decision criterion , the decision and the corresponding procedure ) . Per patient , only 61 % +/- 12 % of these steps were sufficiently documented to allow judgement . Using several criteria for assessment , the following baseline data could be observed ( times shown refer to admission to the trauma room ) : ( 1 ) trauma room time of 129 +/- 55 min ; ( 2 ) completition of basic radiological and sonographic diagnostics in 91 % of patients ; ( 3 ) first blood collection after 17 +/- 11 min ; ( 4 ) cranial computerised tomography after 55 +/- 20 min ; ( 5 ) missed injuries during the trauma room period in 32 % of patients ; ( 6 ) intubation after 20 +/- 19 min ; ( 7 ) insertion of a chest tube after 30 +/- 17 min ; ( 8 ) first blood transfusion in shock after 32 +/- 17 min ; ( 9 ) transfused blood within the first hour of 4.2 +/- 2.8 units and within the second hour of 8.5 +/- 4.7 units ; ( 10 ) emergency operations in shock after 98 +/- 55 min ; ( 11 ) early operations after 156 +/- 69 min ; ( 12 ) craniotomy after 124 +/- 37 min ; ( 13 ) unplanned surgery within 24 hours after admission to the intensive care unit in 11 % of patients . The study presented here supplies information on timing and other process data of the acute clinical care of seriously injured patients . In particular , the data represent indicators for the quality of emergency room management , which may be used as a baseline to compose improvement measures of structure and process . The quality of data collection has to be improved for carrying out an exact analysis of the process . Instructions: please typing these entity words according to sentence: care, patients, multiple injuries, identification, baseline, treatment, documentation, treatment, emergency, set, baseline, treatment, patients, algorithm, criteria, judgement, care, algorithm, single, criterion, procedure, patient, judgement, criteria, assessment, baseline, times, trauma, trauma, time, patients, blood, computerised tomography, injuries, trauma, period, patients, intubation, chest tube, blood transfusion, shock, blood, emergency, operations, shock, operations, craniotomy, surgery, intensive care unit, patients, care, patients, indicators, emergency, baseline, measures, data collection, exact, analysis Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O" ]

Quality management in early clinical care of patients with multiple injuries ( description of actual process , identification of problems , implementation of quality improvement ) is not possible without sufficient baseline data about the present situation of medical treatment . This study investigates whether the current documentation of treatment in the emergency room is appropriate to judge upon the quality of the process and to detect problems . In addition , a set of baseline data is presented . The performance in the treatment of 126 multiple injured patients was prospectively recorded from 1988 to 1993 and compared with an idealized process based upon an algorithm . The quality of present data recording was analysed , and criteria for judgement of quality of care were assessed . The algorithm was devided into 117 possible steps ( one step consisting of a single decision criterion , the decision and the corresponding procedure ) . Per patient , only 61 % +/- 12 % of these steps were sufficiently documented to allow judgement . Using several criteria for assessment , the following baseline data could be observed ( times shown refer to admission to the trauma room ) : ( 1 ) trauma room time of 129 +/- 55 min ; ( 2 ) completition of basic radiological and sonographic diagnostics in 91 % of patients ; ( 3 ) first blood collection after 17 +/- 11 min ; ( 4 ) cranial computerised tomography after 55 +/- 20 min ; ( 5 ) missed injuries during the trauma room period in 32 % of patients ; ( 6 ) intubation after 20 +/- 19 min ; ( 7 ) insertion of a chest tube after 30 +/- 17 min ; ( 8 ) first blood transfusion in shock after 32 +/- 17 min ; ( 9 ) transfused blood within the first hour of 4.2 +/- 2.8 units and within the second hour of 8.5 +/- 4.7 units ; ( 10 ) emergency operations in shock after 98 +/- 55 min ; ( 11 ) early operations after 156 +/- 69 min ; ( 12 ) craniotomy after 124 +/- 37 min ; ( 13 ) unplanned surgery within 24 hours after admission to the intensive care unit in 11 % of patients . The study presented here supplies information on timing and other process data of the acute clinical care of seriously injured patients . In particular , the data represent indicators for the quality of emergency room management , which may be used as a baseline to compose improvement measures of structure and process . The quality of data collection has to be improved for carrying out an exact analysis of the process .

[ "Quality", "management", "in", "early", "clinical", "care", "of", "patients", "with", "multiple", "injuries", "(", "description", "of", "actual", "process", ",", "identification", "of", "problems", ",", "implementation", "of", "quality", "improvement", ")", "is", "not", "possible", "without", "sufficient", "baseline", "data", "about", "the", "present", "situation", "of", "medical", "treatment", ".", "This", "study", "investigates", "whether", "the", "current", "documentation", "of", "treatment", "in", "the", "emergency", "room", "is", "appropriate", "to", "judge", "upon", "the", "quality", "of", "the", "process", "and", "to", "detect", "problems", ".", "In", "addition", ",", "a", "set", "of", "baseline", "data", "is", "presented", ".", "The", "performance", "in", "the", "treatment", "of", "126", "multiple", "injured", "patients", "was", "prospectively", "recorded", "from", "1988", "to", "1993", "and", "compared", "with", "an", "idealized", "process", "based", "upon", "an", "algorithm", ".", "The", "quality", "of", "present", "data", "recording", "was", "analysed", ",", "and", "criteria", "for", "judgement", "of", "quality", "of", "care", "were", "assessed", ".", "The", "algorithm", "was", "devided", "into", "117", "possible", "steps", "(", "one", "step", "consisting", "of", "a", "single", "decision", "criterion", ",", "the", "decision", "and", "the", "corresponding", "procedure", ")", ".", "Per", "patient", ",", "only", "61", "%", "+", "/-", "12", "%", "of", "these", "steps", "were", "sufficiently", "documented", "to", "allow", "judgement", ".", "Using", "several", "criteria", "for", "assessment", ",", "the", "following", "baseline", "data", "could", "be", "observed", "(", "times", "shown", "refer", "to", "admission", "to", "the", "trauma", "room", ")", ":", "(", "1", ")", "trauma", "room", "time", "of", "129", "+", "/-", "55", "min", ";", "(", "2", ")", "completition", "of", "basic", "radiological", "and", "sonographic", "diagnostics", "in", "91", "%", "of", "patients", ";", "(", "3", ")", "first", "blood", "collection", "after", "17", "+", "/-", "11", "min", ";", "(", "4", ")", "cranial", "computerised", "tomography", "after", "55", "+", "/-", "20", "min", ";", "(", "5", ")", "missed", "injuries", "during", "the", "trauma", "room", "period", "in", "32", "%", "of", "patients", ";", "(", "6", ")", "intubation", "after", "20", "+", "/-", "19", "min", ";", "(", "7", ")", "insertion", "of", "a", "chest", "tube", "after", "30", "+", "/-", "17", "min", ";", "(", "8", ")", "first", "blood", "transfusion", "in", "shock", "after", "32", "+", "/-", "17", "min", ";", "(", "9", ")", "transfused", "blood", "within", "the", "first", "hour", "of", "4.2", "+", "/-", "2.8", "units", "and", "within", "the", "second", "hour", "of", "8.5", "+", "/-", "4.7", "units", ";", "(", "10", ")", "emergency", "operations", "in", "shock", "after", "98", "+", "/-", "55", "min", ";", "(", "11", ")", "early", "operations", "after", "156", "+", "/-", "69", "min", ";", "(", "12", ")", "craniotomy", "after", "124", "+", "/-", "37", "min", ";", "(", "13", ")", "unplanned", "surgery", "within", "24", "hours", "after", "admission", "to", "the", "intensive", "care", "unit", "in", "11", "%", "of", "patients", ".", "The", "study", "presented", "here", "supplies", "information", "on", "timing", "and", "other", "process", "data", "of", "the", "acute", "clinical", "care", "of", "seriously", "injured", "patients", ".", "In", "particular", ",", "the", "data", "represent", "indicators", "for", "the", "quality", "of", "emergency", "room", "management", ",", "which", "may", "be", "used", "as", "a", "baseline", "to", "compose", "improvement", "measures", "of", "structure", "and", "process", ".", "The", "quality", "of", "data", "collection", "has", "to", "be", "improved", "for", "carrying", "out", "an", "exact", "analysis", "of", "the", "process", "." ]

[ "umlsterm" ]

care, patients, multiple injuries, identification, baseline, treatment, documentation, treatment, emergency, set, baseline, treatment, patients, algorithm, criteria, judgement, care, algorithm, single, criterion, procedure, patient, judgement, criteria, assessment, baseline, times, trauma, trauma, time, patients, blood, computerised tomography, injuries, trauma, period, patients, intubation, chest tube, blood transfusion, shock, blood, emergency, operations, shock, operations, craniotomy, surgery, intensive care unit, patients, care, patients, indicators, emergency, baseline, measures, data collection, exact, analysis

DerUnfallchirurg.71000811.eng.abstr_task2

Sentence: Quality management in early clinical care of patients with multiple injuries ( description of actual process , identification of problems , implementation of quality improvement ) is not possible without sufficient baseline data about the present situation of medical treatment . This study investigates whether the current documentation of treatment in the emergency room is appropriate to judge upon the quality of the process and to detect problems . In addition , a set of baseline data is presented . The performance in the treatment of 126 multiple injured patients was prospectively recorded from 1988 to 1993 and compared with an idealized process based upon an algorithm . The quality of present data recording was analysed , and criteria for judgement of quality of care were assessed . The algorithm was devided into 117 possible steps ( one step consisting of a single decision criterion , the decision and the corresponding procedure ) . Per patient , only 61 % +/- 12 % of these steps were sufficiently documented to allow judgement . Using several criteria for assessment , the following baseline data could be observed ( times shown refer to admission to the trauma room ) : ( 1 ) trauma room time of 129 +/- 55 min ; ( 2 ) completition of basic radiological and sonographic diagnostics in 91 % of patients ; ( 3 ) first blood collection after 17 +/- 11 min ; ( 4 ) cranial computerised tomography after 55 +/- 20 min ; ( 5 ) missed injuries during the trauma room period in 32 % of patients ; ( 6 ) intubation after 20 +/- 19 min ; ( 7 ) insertion of a chest tube after 30 +/- 17 min ; ( 8 ) first blood transfusion in shock after 32 +/- 17 min ; ( 9 ) transfused blood within the first hour of 4.2 +/- 2.8 units and within the second hour of 8.5 +/- 4.7 units ; ( 10 ) emergency operations in shock after 98 +/- 55 min ; ( 11 ) early operations after 156 +/- 69 min ; ( 12 ) craniotomy after 124 +/- 37 min ; ( 13 ) unplanned surgery within 24 hours after admission to the intensive care unit in 11 % of patients . The study presented here supplies information on timing and other process data of the acute clinical care of seriously injured patients . In particular , the data represent indicators for the quality of emergency room management , which may be used as a baseline to compose improvement measures of structure and process . The quality of data collection has to be improved for carrying out an exact analysis of the process . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O" ]

Quality management in early clinical care of patients with multiple injuries ( description of actual process , identification of problems , implementation of quality improvement ) is not possible without sufficient baseline data about the present situation of medical treatment . This study investigates whether the current documentation of treatment in the emergency room is appropriate to judge upon the quality of the process and to detect problems . In addition , a set of baseline data is presented . The performance in the treatment of 126 multiple injured patients was prospectively recorded from 1988 to 1993 and compared with an idealized process based upon an algorithm . The quality of present data recording was analysed , and criteria for judgement of quality of care were assessed . The algorithm was devided into 117 possible steps ( one step consisting of a single decision criterion , the decision and the corresponding procedure ) . Per patient , only 61 % +/- 12 % of these steps were sufficiently documented to allow judgement . Using several criteria for assessment , the following baseline data could be observed ( times shown refer to admission to the trauma room ) : ( 1 ) trauma room time of 129 +/- 55 min ; ( 2 ) completition of basic radiological and sonographic diagnostics in 91 % of patients ; ( 3 ) first blood collection after 17 +/- 11 min ; ( 4 ) cranial computerised tomography after 55 +/- 20 min ; ( 5 ) missed injuries during the trauma room period in 32 % of patients ; ( 6 ) intubation after 20 +/- 19 min ; ( 7 ) insertion of a chest tube after 30 +/- 17 min ; ( 8 ) first blood transfusion in shock after 32 +/- 17 min ; ( 9 ) transfused blood within the first hour of 4.2 +/- 2.8 units and within the second hour of 8.5 +/- 4.7 units ; ( 10 ) emergency operations in shock after 98 +/- 55 min ; ( 11 ) early operations after 156 +/- 69 min ; ( 12 ) craniotomy after 124 +/- 37 min ; ( 13 ) unplanned surgery within 24 hours after admission to the intensive care unit in 11 % of patients . The study presented here supplies information on timing and other process data of the acute clinical care of seriously injured patients . In particular , the data represent indicators for the quality of emergency room management , which may be used as a baseline to compose improvement measures of structure and process . The quality of data collection has to be improved for carrying out an exact analysis of the process .

[ "Quality", "management", "in", "early", "clinical", "care", "of", "patients", "with", "multiple", "injuries", "(", "description", "of", "actual", "process", ",", "identification", "of", "problems", ",", "implementation", "of", "quality", "improvement", ")", "is", "not", "possible", "without", "sufficient", "baseline", "data", "about", "the", "present", "situation", "of", "medical", "treatment", ".", "This", "study", "investigates", "whether", "the", "current", "documentation", "of", "treatment", "in", "the", "emergency", "room", "is", "appropriate", "to", "judge", "upon", "the", "quality", "of", "the", "process", "and", "to", "detect", "problems", ".", "In", "addition", ",", "a", "set", "of", "baseline", "data", "is", "presented", ".", "The", "performance", "in", "the", "treatment", "of", "126", "multiple", "injured", "patients", "was", "prospectively", "recorded", "from", "1988", "to", "1993", "and", "compared", "with", "an", "idealized", "process", "based", "upon", "an", "algorithm", ".", "The", "quality", "of", "present", "data", "recording", "was", "analysed", ",", "and", "criteria", "for", "judgement", "of", "quality", "of", "care", "were", "assessed", ".", "The", "algorithm", "was", "devided", "into", "117", "possible", "steps", "(", "one", "step", "consisting", "of", "a", "single", "decision", "criterion", ",", "the", "decision", "and", "the", "corresponding", "procedure", ")", ".", "Per", "patient", ",", "only", "61", "%", "+", "/-", "12", "%", "of", "these", "steps", "were", "sufficiently", "documented", "to", "allow", "judgement", ".", "Using", "several", "criteria", "for", "assessment", ",", "the", "following", "baseline", "data", "could", "be", "observed", "(", "times", "shown", "refer", "to", "admission", "to", "the", "trauma", "room", ")", ":", "(", "1", ")", "trauma", "room", "time", "of", "129", "+", "/-", "55", "min", ";", "(", "2", ")", "completition", "of", "basic", "radiological", "and", "sonographic", "diagnostics", "in", "91", "%", "of", "patients", ";", "(", "3", ")", "first", "blood", "collection", "after", "17", "+", "/-", "11", "min", ";", "(", "4", ")", "cranial", "computerised", "tomography", "after", "55", "+", "/-", "20", "min", ";", "(", "5", ")", "missed", "injuries", "during", "the", "trauma", "room", "period", "in", "32", "%", "of", "patients", ";", "(", "6", ")", "intubation", "after", "20", "+", "/-", "19", "min", ";", "(", "7", ")", "insertion", "of", "a", "chest", "tube", "after", "30", "+", "/-", "17", "min", ";", "(", "8", ")", "first", "blood", "transfusion", "in", "shock", "after", "32", "+", "/-", "17", "min", ";", "(", "9", ")", "transfused", "blood", "within", "the", "first", "hour", "of", "4.2", "+", "/-", "2.8", "units", "and", "within", "the", "second", "hour", "of", "8.5", "+", "/-", "4.7", "units", ";", "(", "10", ")", "emergency", "operations", "in", "shock", "after", "98", "+", "/-", "55", "min", ";", "(", "11", ")", "early", "operations", "after", "156", "+", "/-", "69", "min", ";", "(", "12", ")", "craniotomy", "after", "124", "+", "/-", "37", "min", ";", "(", "13", ")", "unplanned", "surgery", "within", "24", "hours", "after", "admission", "to", "the", "intensive", "care", "unit", "in", "11", "%", "of", "patients", ".", "The", "study", "presented", "here", "supplies", "information", "on", "timing", "and", "other", "process", "data", "of", "the", "acute", "clinical", "care", "of", "seriously", "injured", "patients", ".", "In", "particular", ",", "the", "data", "represent", "indicators", "for", "the", "quality", "of", "emergency", "room", "management", ",", "which", "may", "be", "used", "as", "a", "baseline", "to", "compose", "improvement", "measures", "of", "structure", "and", "process", ".", "The", "quality", "of", "data", "collection", "has", "to", "be", "improved", "for", "carrying", "out", "an", "exact", "analysis", "of", "the", "process", "." ]

[ "umlsterm" ]

cinacalcet is a compound, parathormone is a protein

DS.d389_task0

Sentence: Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma.

[ "Therefore", ",", "cinacalcet", ",", "which", "inhibit", "the", "production", "of", "parathormone", "by", "negative", "feedback", ",", "was", "considered", "a", "treatment", "option", "to", "control", "the", "evolution", "of", "calciphylaxis", "in", "a", "dialysed", "patient", "suffering", "from", "cholangiocarcinoma", "." ]

[ "protein", "compound" ]

cinacalcet is a compound, parathormone is a protein

DS.d389_task1

Sentence: Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma. Instructions: please typing these entity words according to sentence: cinacalcet, parathormone Options: compound, protein

[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma.

[ "Therefore", ",", "cinacalcet", ",", "which", "inhibit", "the", "production", "of", "parathormone", "by", "negative", "feedback", ",", "was", "considered", "a", "treatment", "option", "to", "control", "the", "evolution", "of", "calciphylaxis", "in", "a", "dialysed", "patient", "suffering", "from", "cholangiocarcinoma", "." ]

[ "protein", "compound" ]

cinacalcet, parathormone

DS.d389_task2

Sentence: Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Therefore, cinacalcet, which inhibit the production of parathormone by negative feedback, was considered a treatment option to control the evolution of calciphylaxis in a dialysed patient suffering from cholangiocarcinoma.

[ "Therefore", ",", "cinacalcet", ",", "which", "inhibit", "the", "production", "of", "parathormone", "by", "negative", "feedback", ",", "was", "considered", "a", "treatment", "option", "to", "control", "the", "evolution", "of", "calciphylaxis", "in", "a", "dialysed", "patient", "suffering", "from", "cholangiocarcinoma", "." ]

[ "protein", "compound" ]

gp120 is a Protein

583_task0

Sentence: Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans.

[ "Alteration", "of", "glycosylation", "renders", "HIV", "sensitive", "to", "inactivation", "by", "normal", "human", "serum", ".", "\n", "Retroviruses", "from", "various", "mammalian", "species", ",", "excluding", "humans", ",", "are", "effectively", "inactivated", "in", "normal", "human", "serum", "(", "NHS", ")", ".", "Recent", "studies", "have", "shown", "that", "NHS", "inactivation", "of", "retroviruses", "occurs", "through", "natural", "Ab", "recognition", "of", "a", "terminal", "glycosidic", "moiety", "on", "the", "viral", "envelope", "that", "is", "acquired", "during", "replication", "in", "the", "host", "cell", ".", "This", "carbohydrate", "structure", "(", "the", "alpha", "-", "galactosyl", "epitope", ")", "is", "expressed", "on", "the", "cells", "of", "most", "mammals", ",", "with", "the", "exception", "of", "humans", "and", "other", "Old", "World", "primates", ".", "In", "this", "study", ",", "NHS", "sensitivity", "of", "HIV", "was", "assessed", "following", "viral", "propagation", "in", "human", "cells", "that", "were", "manipulated", "to", "express", "the", "alpha", "-", "galactosyl", "epitope", ".", "HUT-78", "cells", "were", "transduced", "with", "an", "exogenous", "alpha1", "-", "3-galactosyl", "transferase", "gene", ",", "which", "codes", "for", "the", "terminal", "glycosyl", "transferase", "responsible", "for", "generation", "of", "the", "alpha", "-", "galactosyl", "epitope", ".", "The", "transduced", "HUT-78", "cells", "expressed", "high", "levels", "of", "the", "alpha", "-", "galactosyl", "epitope", "on", "their", "membrane", "surface", ",", "rendering", "them", "sensitive", "to", "killing", "in", "NHS", ".", "Similarly", ",", "HIV", "passaged", "through", "these", "cells", "acquired", "the", "alpha", "-", "galactosyl", "epitope", "in", "association", "with", "the", "envelope", "glycoprotein", "gp120", "and", "was", "also", "effectively", "inactivated", "in", "NHS", ".", "Viral", "inactivation", "was", "abolished", "by", "the", "addition", "of", "a", "synthetic", "disaccharide", "that", "contains", "the", "alpha", "-", "galactosyl", "epitope", ",", "indicating", "that", "virolysis", "is", "mediated", "by", "anti", "-", "alpha", "-", "galactosyl", "natural", "Ab", ".", "These", "results", "demonstrate", "that", ",", "like", "other", "retroviruses", "bearing", "the", "alpha", "-", "galactosyl", "epitope", ",", "HIV", "modified", "to", "express", "this", "epitope", "is", "inactivated", "in", "NHS", ".", "Furthermore", ",", "these", "data", "suggest", "that", "expression", "of", "the", "alpha", "-", "galactosyl", "epitope", "on", "the", "surface", "of", "viruses", "may", "have", "implications", "in", "the", "interspecies", "transmission", "of", "such", "viruses", "to", "humans", ".", "\n" ]

[ "Protein" ]

gp120 is a Protein

583_task1

Sentence: Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans. Instructions: please typing these entity words according to sentence: gp120 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans.

[ "Alteration", "of", "glycosylation", "renders", "HIV", "sensitive", "to", "inactivation", "by", "normal", "human", "serum", ".", "\n", "Retroviruses", "from", "various", "mammalian", "species", ",", "excluding", "humans", ",", "are", "effectively", "inactivated", "in", "normal", "human", "serum", "(", "NHS", ")", ".", "Recent", "studies", "have", "shown", "that", "NHS", "inactivation", "of", "retroviruses", "occurs", "through", "natural", "Ab", "recognition", "of", "a", "terminal", "glycosidic", "moiety", "on", "the", "viral", "envelope", "that", "is", "acquired", "during", "replication", "in", "the", "host", "cell", ".", "This", "carbohydrate", "structure", "(", "the", "alpha", "-", "galactosyl", "epitope", ")", "is", "expressed", "on", "the", "cells", "of", "most", "mammals", ",", "with", "the", "exception", "of", "humans", "and", "other", "Old", "World", "primates", ".", "In", "this", "study", ",", "NHS", "sensitivity", "of", "HIV", "was", "assessed", "following", "viral", "propagation", "in", "human", "cells", "that", "were", "manipulated", "to", "express", "the", "alpha", "-", "galactosyl", "epitope", ".", "HUT-78", "cells", "were", "transduced", "with", "an", "exogenous", "alpha1", "-", "3-galactosyl", "transferase", "gene", ",", "which", "codes", "for", "the", "terminal", "glycosyl", "transferase", "responsible", "for", "generation", "of", "the", "alpha", "-", "galactosyl", "epitope", ".", "The", "transduced", "HUT-78", "cells", "expressed", "high", "levels", "of", "the", "alpha", "-", "galactosyl", "epitope", "on", "their", "membrane", "surface", ",", "rendering", "them", "sensitive", "to", "killing", "in", "NHS", ".", "Similarly", ",", "HIV", "passaged", "through", "these", "cells", "acquired", "the", "alpha", "-", "galactosyl", "epitope", "in", "association", "with", "the", "envelope", "glycoprotein", "gp120", "and", "was", "also", "effectively", "inactivated", "in", "NHS", ".", "Viral", "inactivation", "was", "abolished", "by", "the", "addition", "of", "a", "synthetic", "disaccharide", "that", "contains", "the", "alpha", "-", "galactosyl", "epitope", ",", "indicating", "that", "virolysis", "is", "mediated", "by", "anti", "-", "alpha", "-", "galactosyl", "natural", "Ab", ".", "These", "results", "demonstrate", "that", ",", "like", "other", "retroviruses", "bearing", "the", "alpha", "-", "galactosyl", "epitope", ",", "HIV", "modified", "to", "express", "this", "epitope", "is", "inactivated", "in", "NHS", ".", "Furthermore", ",", "these", "data", "suggest", "that", "expression", "of", "the", "alpha", "-", "galactosyl", "epitope", "on", "the", "surface", "of", "viruses", "may", "have", "implications", "in", "the", "interspecies", "transmission", "of", "such", "viruses", "to", "humans", ".", "\n" ]

[ "Protein" ]

gp120

583_task2

Sentence: Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum. Retroviruses from various mammalian species, excluding humans, are effectively inactivated in normal human serum (NHS). Recent studies have shown that NHS inactivation of retroviruses occurs through natural Ab recognition of a terminal glycosidic moiety on the viral envelope that is acquired during replication in the host cell. This carbohydrate structure (the alpha-galactosyl epitope) is expressed on the cells of most mammals, with the exception of humans and other Old World primates. In this study, NHS sensitivity of HIV was assessed following viral propagation in human cells that were manipulated to express the alpha-galactosyl epitope. HUT-78 cells were transduced with an exogenous alpha1-3-galactosyl transferase gene, which codes for the terminal glycosyl transferase responsible for generation of the alpha-galactosyl epitope. The transduced HUT-78 cells expressed high levels of the alpha-galactosyl epitope on their membrane surface, rendering them sensitive to killing in NHS. Similarly, HIV passaged through these cells acquired the alpha-galactosyl epitope in association with the envelope glycoprotein gp120 and was also effectively inactivated in NHS. Viral inactivation was abolished by the addition of a synthetic disaccharide that contains the alpha-galactosyl epitope, indicating that virolysis is mediated by anti-alpha-galactosyl natural Ab. These results demonstrate that, like other retroviruses bearing the alpha-galactosyl epitope, HIV modified to express this epitope is inactivated in NHS. Furthermore, these data suggest that expression of the alpha-galactosyl epitope on the surface of viruses may have implications in the interspecies transmission of such viruses to humans.

[ "Alteration", "of", "glycosylation", "renders", "HIV", "sensitive", "to", "inactivation", "by", "normal", "human", "serum", ".", "\n", "Retroviruses", "from", "various", "mammalian", "species", ",", "excluding", "humans", ",", "are", "effectively", "inactivated", "in", "normal", "human", "serum", "(", "NHS", ")", ".", "Recent", "studies", "have", "shown", "that", "NHS", "inactivation", "of", "retroviruses", "occurs", "through", "natural", "Ab", "recognition", "of", "a", "terminal", "glycosidic", "moiety", "on", "the", "viral", "envelope", "that", "is", "acquired", "during", "replication", "in", "the", "host", "cell", ".", "This", "carbohydrate", "structure", "(", "the", "alpha", "-", "galactosyl", "epitope", ")", "is", "expressed", "on", "the", "cells", "of", "most", "mammals", ",", "with", "the", "exception", "of", "humans", "and", "other", "Old", "World", "primates", ".", "In", "this", "study", ",", "NHS", "sensitivity", "of", "HIV", "was", "assessed", "following", "viral", "propagation", "in", "human", "cells", "that", "were", "manipulated", "to", "express", "the", "alpha", "-", "galactosyl", "epitope", ".", "HUT-78", "cells", "were", "transduced", "with", "an", "exogenous", "alpha1", "-", "3-galactosyl", "transferase", "gene", ",", "which", "codes", "for", "the", "terminal", "glycosyl", "transferase", "responsible", "for", "generation", "of", "the", "alpha", "-", "galactosyl", "epitope", ".", "The", "transduced", "HUT-78", "cells", "expressed", "high", "levels", "of", "the", "alpha", "-", "galactosyl", "epitope", "on", "their", "membrane", "surface", ",", "rendering", "them", "sensitive", "to", "killing", "in", "NHS", ".", "Similarly", ",", "HIV", "passaged", "through", "these", "cells", "acquired", "the", "alpha", "-", "galactosyl", "epitope", "in", "association", "with", "the", "envelope", "glycoprotein", "gp120", "and", "was", "also", "effectively", "inactivated", "in", "NHS", ".", "Viral", "inactivation", "was", "abolished", "by", "the", "addition", "of", "a", "synthetic", "disaccharide", "that", "contains", "the", "alpha", "-", "galactosyl", "epitope", ",", "indicating", "that", "virolysis", "is", "mediated", "by", "anti", "-", "alpha", "-", "galactosyl", "natural", "Ab", ".", "These", "results", "demonstrate", "that", ",", "like", "other", "retroviruses", "bearing", "the", "alpha", "-", "galactosyl", "epitope", ",", "HIV", "modified", "to", "express", "this", "epitope", "is", "inactivated", "in", "NHS", ".", "Furthermore", ",", "these", "data", "suggest", "that", "expression", "of", "the", "alpha", "-", "galactosyl", "epitope", "on", "the", "surface", "of", "viruses", "may", "have", "implications", "in", "the", "interspecies", "transmission", "of", "such", "viruses", "to", "humans", ".", "\n" ]

[ "Protein" ]

beta - catenin is a Gene/protein/RNA, alpha - catenin is a Gene/protein/RNA

690_task0

Sentence: The concentration of beta-catenin was constant during the follicular phase, whereas the content of alpha-catenin decreased in granulosa cells after treatment with diethylstilboestrol or hCG. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA

[ "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The concentration of beta-catenin was constant during the follicular phase, whereas the content of alpha-catenin decreased in granulosa cells after treatment with diethylstilboestrol or hCG.

[ "The", "concentration", "of", "beta", "-", "catenin", "was", "constant", "during", "the", "follicular", "phase", ",", "whereas", "the", "content", "of", "alpha", "-", "catenin", "decreased", "in", "granulosa", "cells", "after", "treatment", "with", "diethylstilboestrol", "or", "hCG", "." ]

[ "Gene/protein/RNA" ]

beta - catenin is a Gene/protein/RNA, alpha - catenin is a Gene/protein/RNA

690_task1

Sentence: The concentration of beta-catenin was constant during the follicular phase, whereas the content of alpha-catenin decreased in granulosa cells after treatment with diethylstilboestrol or hCG. Instructions: please typing these entity words according to sentence: beta - catenin, alpha - catenin Options: Gene/protein/RNA

[ "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The concentration of beta-catenin was constant during the follicular phase, whereas the content of alpha-catenin decreased in granulosa cells after treatment with diethylstilboestrol or hCG.

[ "The", "concentration", "of", "beta", "-", "catenin", "was", "constant", "during", "the", "follicular", "phase", ",", "whereas", "the", "content", "of", "alpha", "-", "catenin", "decreased", "in", "granulosa", "cells", "after", "treatment", "with", "diethylstilboestrol", "or", "hCG", "." ]

[ "Gene/protein/RNA" ]

beta - catenin, alpha - catenin

690_task2

Sentence: The concentration of beta-catenin was constant during the follicular phase, whereas the content of alpha-catenin decreased in granulosa cells after treatment with diethylstilboestrol or hCG. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The concentration of beta-catenin was constant during the follicular phase, whereas the content of alpha-catenin decreased in granulosa cells after treatment with diethylstilboestrol or hCG.

[ "The", "concentration", "of", "beta", "-", "catenin", "was", "constant", "during", "the", "follicular", "phase", ",", "whereas", "the", "content", "of", "alpha", "-", "catenin", "decreased", "in", "granulosa", "cells", "after", "treatment", "with", "diethylstilboestrol", "or", "hCG", "." ]

[ "Gene/protein/RNA" ]

iron is a CHEMICAL, deferasirox is a CHEMICAL

23074173_task0

Sentence: The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.

[ "The", "iron", "chelator", ",", "deferasirox", ",", "as", "a", "novel", "strategy", "for", "cancer", "treatment", ":", "oral", "activity", "against", "human", "lung", "tumor", "xenografts", "and", "molecular", "mechanism", "of", "action", "." ]

[ "GENE-Y", "CHEMICAL" ]

iron is a CHEMICAL, deferasirox is a CHEMICAL

23074173_task1

Sentence: The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Instructions: please typing these entity words according to sentence: iron, deferasirox Options: CHEMICAL

[ "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.

[ "The", "iron", "chelator", ",", "deferasirox", ",", "as", "a", "novel", "strategy", "for", "cancer", "treatment", ":", "oral", "activity", "against", "human", "lung", "tumor", "xenografts", "and", "molecular", "mechanism", "of", "action", "." ]

[ "GENE-Y", "CHEMICAL" ]

iron, deferasirox

23074173_task2

Sentence: The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Instructions: please extract entity words from the input sentence

[ "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.

[ "The", "iron", "chelator", ",", "deferasirox", ",", "as", "a", "novel", "strategy", "for", "cancer", "treatment", ":", "oral", "activity", "against", "human", "lung", "tumor", "xenografts", "and", "molecular", "mechanism", "of", "action", "." ]

[ "GENE-Y", "CHEMICAL" ]

Patienten is an umlsterm, Angina pectoris is an umlsterm, Herzerkrankung is an umlsterm, Ballondilatation is an umlsterm, koerperliche Belastbarkeit is an umlsterm, Herzen is an umlsterm, Epikard is an umlsterm, Myokard is an umlsterm, Laserkanaele is an umlsterm, Myokard is an umlsterm

ZfuerKardiologie.0089vii31.ger.abstr_task0

Sentence: Bei Patienten mit schwerer Angina pectoris aufgrund einer koronaren Herzerkrankung , bei denen aufgrund der Koronarmorphologie oder vorausgegangener Interventionen keine Moeglichkeit einer Ballondilatation oder einer Bypassoperation mehr besteht , kann die klinische Symptomatik und die koerperliche Belastbarkeit haeufig durch eine transmyokardiale Laserrevaskularisation ( TMR ) gebessert werden . Ein Nachteil der TMR ist die Notwendigkeit eines chirurgischen Zugangs zum Herzen , um die Kannaele vom Epikard aus in das Myokard einzubringen . Daher wurde ein Kathetersystem entwickelt , mit dem die Laserkanaele vom linksventrikulaeren Kavum aus in das Myokard eingebracht werden koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Bei Patienten mit schwerer Angina pectoris aufgrund einer koronaren Herzerkrankung , bei denen aufgrund der Koronarmorphologie oder vorausgegangener Interventionen keine Moeglichkeit einer Ballondilatation oder einer Bypassoperation mehr besteht , kann die klinische Symptomatik und die koerperliche Belastbarkeit haeufig durch eine transmyokardiale Laserrevaskularisation ( TMR ) gebessert werden . Ein Nachteil der TMR ist die Notwendigkeit eines chirurgischen Zugangs zum Herzen , um die Kannaele vom Epikard aus in das Myokard einzubringen . Daher wurde ein Kathetersystem entwickelt , mit dem die Laserkanaele vom linksventrikulaeren Kavum aus in das Myokard eingebracht werden koennen .

[ "Bei", "Patienten", "mit", "schwerer", "Angina", "pectoris", "aufgrund", "einer", "koronaren", "Herzerkrankung", ",", "bei", "denen", "aufgrund", "der", "Koronarmorphologie", "oder", "vorausgegangener", "Interventionen", "keine", "Moeglichkeit", "einer", "Ballondilatation", "oder", "einer", "Bypassoperation", "mehr", "besteht", ",", "kann", "die", "klinische", "Symptomatik", "und", "die", "koerperliche", "Belastbarkeit", "haeufig", "durch", "eine", "transmyokardiale", "Laserrevaskularisation", "(", "TMR", ")", "gebessert", "werden", ".", "Ein", "Nachteil", "der", "TMR", "ist", "die", "Notwendigkeit", "eines", "chirurgischen", "Zugangs", "zum", "Herzen", ",", "um", "die", "Kannaele", "vom", "Epikard", "aus", "in", "das", "Myokard", "einzubringen", ".", "Daher", "wurde", "ein", "Kathetersystem", "entwickelt", ",", "mit", "dem", "die", "Laserkanaele", "vom", "linksventrikulaeren", "Kavum", "aus", "in", "das", "Myokard", "eingebracht", "werden", "koennen", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Angina pectoris is an umlsterm, Herzerkrankung is an umlsterm, Ballondilatation is an umlsterm, koerperliche Belastbarkeit is an umlsterm, Herzen is an umlsterm, Epikard is an umlsterm, Myokard is an umlsterm, Laserkanaele is an umlsterm, Myokard is an umlsterm

ZfuerKardiologie.0089vii31.ger.abstr_task1

Sentence: Bei Patienten mit schwerer Angina pectoris aufgrund einer koronaren Herzerkrankung , bei denen aufgrund der Koronarmorphologie oder vorausgegangener Interventionen keine Moeglichkeit einer Ballondilatation oder einer Bypassoperation mehr besteht , kann die klinische Symptomatik und die koerperliche Belastbarkeit haeufig durch eine transmyokardiale Laserrevaskularisation ( TMR ) gebessert werden . Ein Nachteil der TMR ist die Notwendigkeit eines chirurgischen Zugangs zum Herzen , um die Kannaele vom Epikard aus in das Myokard einzubringen . Daher wurde ein Kathetersystem entwickelt , mit dem die Laserkanaele vom linksventrikulaeren Kavum aus in das Myokard eingebracht werden koennen . Instructions: please typing these entity words according to sentence: Patienten, Angina pectoris, Herzerkrankung, Ballondilatation, koerperliche Belastbarkeit, Herzen, Epikard, Myokard, Laserkanaele, Myokard Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Bei Patienten mit schwerer Angina pectoris aufgrund einer koronaren Herzerkrankung , bei denen aufgrund der Koronarmorphologie oder vorausgegangener Interventionen keine Moeglichkeit einer Ballondilatation oder einer Bypassoperation mehr besteht , kann die klinische Symptomatik und die koerperliche Belastbarkeit haeufig durch eine transmyokardiale Laserrevaskularisation ( TMR ) gebessert werden . Ein Nachteil der TMR ist die Notwendigkeit eines chirurgischen Zugangs zum Herzen , um die Kannaele vom Epikard aus in das Myokard einzubringen . Daher wurde ein Kathetersystem entwickelt , mit dem die Laserkanaele vom linksventrikulaeren Kavum aus in das Myokard eingebracht werden koennen .

[ "Bei", "Patienten", "mit", "schwerer", "Angina", "pectoris", "aufgrund", "einer", "koronaren", "Herzerkrankung", ",", "bei", "denen", "aufgrund", "der", "Koronarmorphologie", "oder", "vorausgegangener", "Interventionen", "keine", "Moeglichkeit", "einer", "Ballondilatation", "oder", "einer", "Bypassoperation", "mehr", "besteht", ",", "kann", "die", "klinische", "Symptomatik", "und", "die", "koerperliche", "Belastbarkeit", "haeufig", "durch", "eine", "transmyokardiale", "Laserrevaskularisation", "(", "TMR", ")", "gebessert", "werden", ".", "Ein", "Nachteil", "der", "TMR", "ist", "die", "Notwendigkeit", "eines", "chirurgischen", "Zugangs", "zum", "Herzen", ",", "um", "die", "Kannaele", "vom", "Epikard", "aus", "in", "das", "Myokard", "einzubringen", ".", "Daher", "wurde", "ein", "Kathetersystem", "entwickelt", ",", "mit", "dem", "die", "Laserkanaele", "vom", "linksventrikulaeren", "Kavum", "aus", "in", "das", "Myokard", "eingebracht", "werden", "koennen", "." ]

[ "umlsterm" ]

Patienten, Angina pectoris, Herzerkrankung, Ballondilatation, koerperliche Belastbarkeit, Herzen, Epikard, Myokard, Laserkanaele, Myokard

ZfuerKardiologie.0089vii31.ger.abstr_task2

Sentence: Bei Patienten mit schwerer Angina pectoris aufgrund einer koronaren Herzerkrankung , bei denen aufgrund der Koronarmorphologie oder vorausgegangener Interventionen keine Moeglichkeit einer Ballondilatation oder einer Bypassoperation mehr besteht , kann die klinische Symptomatik und die koerperliche Belastbarkeit haeufig durch eine transmyokardiale Laserrevaskularisation ( TMR ) gebessert werden . Ein Nachteil der TMR ist die Notwendigkeit eines chirurgischen Zugangs zum Herzen , um die Kannaele vom Epikard aus in das Myokard einzubringen . Daher wurde ein Kathetersystem entwickelt , mit dem die Laserkanaele vom linksventrikulaeren Kavum aus in das Myokard eingebracht werden koennen . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Bei Patienten mit schwerer Angina pectoris aufgrund einer koronaren Herzerkrankung , bei denen aufgrund der Koronarmorphologie oder vorausgegangener Interventionen keine Moeglichkeit einer Ballondilatation oder einer Bypassoperation mehr besteht , kann die klinische Symptomatik und die koerperliche Belastbarkeit haeufig durch eine transmyokardiale Laserrevaskularisation ( TMR ) gebessert werden . Ein Nachteil der TMR ist die Notwendigkeit eines chirurgischen Zugangs zum Herzen , um die Kannaele vom Epikard aus in das Myokard einzubringen . Daher wurde ein Kathetersystem entwickelt , mit dem die Laserkanaele vom linksventrikulaeren Kavum aus in das Myokard eingebracht werden koennen .

[ "Bei", "Patienten", "mit", "schwerer", "Angina", "pectoris", "aufgrund", "einer", "koronaren", "Herzerkrankung", ",", "bei", "denen", "aufgrund", "der", "Koronarmorphologie", "oder", "vorausgegangener", "Interventionen", "keine", "Moeglichkeit", "einer", "Ballondilatation", "oder", "einer", "Bypassoperation", "mehr", "besteht", ",", "kann", "die", "klinische", "Symptomatik", "und", "die", "koerperliche", "Belastbarkeit", "haeufig", "durch", "eine", "transmyokardiale", "Laserrevaskularisation", "(", "TMR", ")", "gebessert", "werden", ".", "Ein", "Nachteil", "der", "TMR", "ist", "die", "Notwendigkeit", "eines", "chirurgischen", "Zugangs", "zum", "Herzen", ",", "um", "die", "Kannaele", "vom", "Epikard", "aus", "in", "das", "Myokard", "einzubringen", ".", "Daher", "wurde", "ein", "Kathetersystem", "entwickelt", ",", "mit", "dem", "die", "Laserkanaele", "vom", "linksventrikulaeren", "Kavum", "aus", "in", "das", "Myokard", "eingebracht", "werden", "koennen", "." ]

[ "umlsterm" ]

Lebensqualitaet is an umlsterm, Lebensqualitaet is an umlsterm, kranker is an umlsterm, Kinder is an umlsterm, Arbeit is an umlsterm, Literatur is an umlsterm, Arbeiten is an umlsterm, Lebensqualitaet is an umlsterm, Kindern is an umlsterm, Methoden is an umlsterm, Forschung is an umlsterm, Arbeiten is an umlsterm, Lebensqualitaet is an umlsterm, Kindern is an umlsterm, Lebensqualitaet is an umlsterm, Kindern is an umlsterm, Therapieevaluation is an umlsterm, Rehabilitation is an umlsterm

Bundesgesundheitsblatt.00430198.ger.abstr_task0

Sentence: Waehrend die gesundheitsbezogene Lebensqualitaet Erwachsener zunehmend erforscht ist , wird die Lebensqualitaet gesunder und chronisch kranker Kinder und Jugendlicher erst juengst thematisiert . In der vorliegenden Arbeit werden in der Literatur publizierte Arbeiten zum Thema gesundheitsbezogene Lebensqualitaet von Kindern ausgewertet hinsichtlich Schwerpunkten und Methoden der Forschung . Der Ueberblick zeigt , dass empirische Arbeiten bisher rar sind , die vorhandenen Messinstrumente zur Lebensqualitaet von Kindern werden beschrieben . Verstaerkte Forschungsaktivitaeten sind notwendig , um die Erfassung der Lebensqualitaet von Kindern in der Praevention , den Gesundheitswissenschaften , in Therapieevaluation und Rehabilitation einsetzen zu koennen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

Waehrend die gesundheitsbezogene Lebensqualitaet Erwachsener zunehmend erforscht ist , wird die Lebensqualitaet gesunder und chronisch kranker Kinder und Jugendlicher erst juengst thematisiert . In der vorliegenden Arbeit werden in der Literatur publizierte Arbeiten zum Thema gesundheitsbezogene Lebensqualitaet von Kindern ausgewertet hinsichtlich Schwerpunkten und Methoden der Forschung . Der Ueberblick zeigt , dass empirische Arbeiten bisher rar sind , die vorhandenen Messinstrumente zur Lebensqualitaet von Kindern werden beschrieben . Verstaerkte Forschungsaktivitaeten sind notwendig , um die Erfassung der Lebensqualitaet von Kindern in der Praevention , den Gesundheitswissenschaften , in Therapieevaluation und Rehabilitation einsetzen zu koennen .

[ "Waehrend", "die", "gesundheitsbezogene", "Lebensqualitaet", "Erwachsener", "zunehmend", "erforscht", "ist", ",", "wird", "die", "Lebensqualitaet", "gesunder", "und", "chronisch", "kranker", "Kinder", "und", "Jugendlicher", "erst", "juengst", "thematisiert", ".", "In", "der", "vorliegenden", "Arbeit", "werden", "in", "der", "Literatur", "publizierte", "Arbeiten", "zum", "Thema", "gesundheitsbezogene", "Lebensqualitaet", "von", "Kindern", "ausgewertet", "hinsichtlich", "Schwerpunkten", "und", "Methoden", "der", "Forschung", ".", "Der", "Ueberblick", "zeigt", ",", "dass", "empirische", "Arbeiten", "bisher", "rar", "sind", ",", "die", "vorhandenen", "Messinstrumente", "zur", "Lebensqualitaet", "von", "Kindern", "werden", "beschrieben", ".", "Verstaerkte", "Forschungsaktivitaeten", "sind", "notwendig", ",", "um", "die", "Erfassung", "der", "Lebensqualitaet", "von", "Kindern", "in", "der", "Praevention", ",", "den", "Gesundheitswissenschaften", ",", "in", "Therapieevaluation", "und", "Rehabilitation", "einsetzen", "zu", "koennen", "." ]

[ "umlsterm" ]

Lebensqualitaet is an umlsterm, Lebensqualitaet is an umlsterm, kranker is an umlsterm, Kinder is an umlsterm, Arbeit is an umlsterm, Literatur is an umlsterm, Arbeiten is an umlsterm, Lebensqualitaet is an umlsterm, Kindern is an umlsterm, Methoden is an umlsterm, Forschung is an umlsterm, Arbeiten is an umlsterm, Lebensqualitaet is an umlsterm, Kindern is an umlsterm, Lebensqualitaet is an umlsterm, Kindern is an umlsterm, Therapieevaluation is an umlsterm, Rehabilitation is an umlsterm

Bundesgesundheitsblatt.00430198.ger.abstr_task1

Sentence: Waehrend die gesundheitsbezogene Lebensqualitaet Erwachsener zunehmend erforscht ist , wird die Lebensqualitaet gesunder und chronisch kranker Kinder und Jugendlicher erst juengst thematisiert . In der vorliegenden Arbeit werden in der Literatur publizierte Arbeiten zum Thema gesundheitsbezogene Lebensqualitaet von Kindern ausgewertet hinsichtlich Schwerpunkten und Methoden der Forschung . Der Ueberblick zeigt , dass empirische Arbeiten bisher rar sind , die vorhandenen Messinstrumente zur Lebensqualitaet von Kindern werden beschrieben . Verstaerkte Forschungsaktivitaeten sind notwendig , um die Erfassung der Lebensqualitaet von Kindern in der Praevention , den Gesundheitswissenschaften , in Therapieevaluation und Rehabilitation einsetzen zu koennen . Instructions: please typing these entity words according to sentence: Lebensqualitaet, Lebensqualitaet, kranker, Kinder, Arbeit, Literatur, Arbeiten, Lebensqualitaet, Kindern, Methoden, Forschung, Arbeiten, Lebensqualitaet, Kindern, Lebensqualitaet, Kindern, Therapieevaluation, Rehabilitation Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

Waehrend die gesundheitsbezogene Lebensqualitaet Erwachsener zunehmend erforscht ist , wird die Lebensqualitaet gesunder und chronisch kranker Kinder und Jugendlicher erst juengst thematisiert . In der vorliegenden Arbeit werden in der Literatur publizierte Arbeiten zum Thema gesundheitsbezogene Lebensqualitaet von Kindern ausgewertet hinsichtlich Schwerpunkten und Methoden der Forschung . Der Ueberblick zeigt , dass empirische Arbeiten bisher rar sind , die vorhandenen Messinstrumente zur Lebensqualitaet von Kindern werden beschrieben . Verstaerkte Forschungsaktivitaeten sind notwendig , um die Erfassung der Lebensqualitaet von Kindern in der Praevention , den Gesundheitswissenschaften , in Therapieevaluation und Rehabilitation einsetzen zu koennen .

[ "Waehrend", "die", "gesundheitsbezogene", "Lebensqualitaet", "Erwachsener", "zunehmend", "erforscht", "ist", ",", "wird", "die", "Lebensqualitaet", "gesunder", "und", "chronisch", "kranker", "Kinder", "und", "Jugendlicher", "erst", "juengst", "thematisiert", ".", "In", "der", "vorliegenden", "Arbeit", "werden", "in", "der", "Literatur", "publizierte", "Arbeiten", "zum", "Thema", "gesundheitsbezogene", "Lebensqualitaet", "von", "Kindern", "ausgewertet", "hinsichtlich", "Schwerpunkten", "und", "Methoden", "der", "Forschung", ".", "Der", "Ueberblick", "zeigt", ",", "dass", "empirische", "Arbeiten", "bisher", "rar", "sind", ",", "die", "vorhandenen", "Messinstrumente", "zur", "Lebensqualitaet", "von", "Kindern", "werden", "beschrieben", ".", "Verstaerkte", "Forschungsaktivitaeten", "sind", "notwendig", ",", "um", "die", "Erfassung", "der", "Lebensqualitaet", "von", "Kindern", "in", "der", "Praevention", ",", "den", "Gesundheitswissenschaften", ",", "in", "Therapieevaluation", "und", "Rehabilitation", "einsetzen", "zu", "koennen", "." ]

[ "umlsterm" ]

Lebensqualitaet, Lebensqualitaet, kranker, Kinder, Arbeit, Literatur, Arbeiten, Lebensqualitaet, Kindern, Methoden, Forschung, Arbeiten, Lebensqualitaet, Kindern, Lebensqualitaet, Kindern, Therapieevaluation, Rehabilitation

Bundesgesundheitsblatt.00430198.ger.abstr_task2

Sentence: Waehrend die gesundheitsbezogene Lebensqualitaet Erwachsener zunehmend erforscht ist , wird die Lebensqualitaet gesunder und chronisch kranker Kinder und Jugendlicher erst juengst thematisiert . In der vorliegenden Arbeit werden in der Literatur publizierte Arbeiten zum Thema gesundheitsbezogene Lebensqualitaet von Kindern ausgewertet hinsichtlich Schwerpunkten und Methoden der Forschung . Der Ueberblick zeigt , dass empirische Arbeiten bisher rar sind , die vorhandenen Messinstrumente zur Lebensqualitaet von Kindern werden beschrieben . Verstaerkte Forschungsaktivitaeten sind notwendig , um die Erfassung der Lebensqualitaet von Kindern in der Praevention , den Gesundheitswissenschaften , in Therapieevaluation und Rehabilitation einsetzen zu koennen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

Waehrend die gesundheitsbezogene Lebensqualitaet Erwachsener zunehmend erforscht ist , wird die Lebensqualitaet gesunder und chronisch kranker Kinder und Jugendlicher erst juengst thematisiert . In der vorliegenden Arbeit werden in der Literatur publizierte Arbeiten zum Thema gesundheitsbezogene Lebensqualitaet von Kindern ausgewertet hinsichtlich Schwerpunkten und Methoden der Forschung . Der Ueberblick zeigt , dass empirische Arbeiten bisher rar sind , die vorhandenen Messinstrumente zur Lebensqualitaet von Kindern werden beschrieben . Verstaerkte Forschungsaktivitaeten sind notwendig , um die Erfassung der Lebensqualitaet von Kindern in der Praevention , den Gesundheitswissenschaften , in Therapieevaluation und Rehabilitation einsetzen zu koennen .

[ "Waehrend", "die", "gesundheitsbezogene", "Lebensqualitaet", "Erwachsener", "zunehmend", "erforscht", "ist", ",", "wird", "die", "Lebensqualitaet", "gesunder", "und", "chronisch", "kranker", "Kinder", "und", "Jugendlicher", "erst", "juengst", "thematisiert", ".", "In", "der", "vorliegenden", "Arbeit", "werden", "in", "der", "Literatur", "publizierte", "Arbeiten", "zum", "Thema", "gesundheitsbezogene", "Lebensqualitaet", "von", "Kindern", "ausgewertet", "hinsichtlich", "Schwerpunkten", "und", "Methoden", "der", "Forschung", ".", "Der", "Ueberblick", "zeigt", ",", "dass", "empirische", "Arbeiten", "bisher", "rar", "sind", ",", "die", "vorhandenen", "Messinstrumente", "zur", "Lebensqualitaet", "von", "Kindern", "werden", "beschrieben", ".", "Verstaerkte", "Forschungsaktivitaeten", "sind", "notwendig", ",", "um", "die", "Erfassung", "der", "Lebensqualitaet", "von", "Kindern", "in", "der", "Praevention", ",", "den", "Gesundheitswissenschaften", ",", "in", "Therapieevaluation", "und", "Rehabilitation", "einsetzen", "zu", "koennen", "." ]

[ "umlsterm" ]

intravenous synthetic human secretin is a Intervention_Pharmacological, autism is a Participant_Condition, intravenous infusion of synthetic human secretin is a Intervention_Pharmacological, language is a Outcome_Mental, behavioral symptoms is a Outcome_Mental, children is a Participant_Age, Forty - two is a Participant_Sample-size, 2 IU / kg of intravenous synthetic human secretin is a Intervention_Pharmacological, intravenous saline placebo is a Intervention_Control, assessments of language , behavior , and autism symptomatology is a Outcome_Mental, mean scores on any measure of language , behavior , or autism symptom severity is a Outcome_Mental

11757_task0

Sentence: Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Participant_Age, Participant_Sample-size, Outcome_Mental

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Age", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism .

[ "Lack", "of", "benefit", "of", "intravenous", "synthetic", "human", "secretin", "in", "the", "treatment", "of", "autism", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "if", "an", "intravenous", "infusion", "of", "synthetic", "human", "secretin", "improves", "language", "and", "behavioral", "symptoms", "in", "children", "with", "autism", ".", "Forty", "-", "two", "children", "with", "the", "diagnosis", "of", "autism", "were", "randomized", "to", "one", "of", "two", "groups", "in", "this", "double", "-", "blind", "cross", "-", "over", "trial", ".", "One", "group", "received", "2", "IU", "/", "kg", "of", "intravenous", "synthetic", "human", "secretin", "at", "the", "first", "visit", ",", "followed", "by", "an", "equal", "volume", "of", "intravenous", "saline", "placebo", "at", "week", "6", ".", "The", "other", "group", "received", "treatments", "in", "the", "reverse", "order", ".", "All", "children", "were", "evaluated", "at", "weeks", "1", ",", "3", ",", "6", ",", "9", ",", "and", "12", "with", "standardized", "assessments", "of", "language", ",", "behavior", ",", "and", "autism", "symptomatology", ".", "There", "were", "no", "significant", "differences", "in", "the", "mean", "scores", "on", "any", "measure", "of", "language", ",", "behavior", ",", "or", "autism", "symptom", "severity", "after", "treatment", "with", "secretin", "compared", "to", "treatment", "with", "placebo", ".", "The", "results", "of", "this", "study", "do", "not", "support", "secretin", "as", "a", "treatment", "for", "autism", "." ]

[ "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size", "Participant_Age", "Participant_Condition" ]

intravenous synthetic human secretin is a Intervention_Pharmacological, autism is a Participant_Condition, intravenous infusion of synthetic human secretin is a Intervention_Pharmacological, language is a Outcome_Mental, behavioral symptoms is a Outcome_Mental, children is a Participant_Age, Forty - two is a Participant_Sample-size, 2 IU / kg of intravenous synthetic human secretin is a Intervention_Pharmacological, intravenous saline placebo is a Intervention_Control, assessments of language , behavior , and autism symptomatology is a Outcome_Mental, mean scores on any measure of language , behavior , or autism symptom severity is a Outcome_Mental

11757_task1

Sentence: Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism . Instructions: please typing these entity words according to sentence: intravenous synthetic human secretin, autism, intravenous infusion of synthetic human secretin, language, behavioral symptoms, children, Forty - two, 2 IU / kg of intravenous synthetic human secretin, intravenous saline placebo, assessments of language , behavior , and autism symptomatology, mean scores on any measure of language , behavior , or autism symptom severity Options: Intervention_Pharmacological, Participant_Condition, Intervention_Control, Participant_Age, Participant_Sample-size, Outcome_Mental

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Age", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism .

[ "Lack", "of", "benefit", "of", "intravenous", "synthetic", "human", "secretin", "in", "the", "treatment", "of", "autism", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "if", "an", "intravenous", "infusion", "of", "synthetic", "human", "secretin", "improves", "language", "and", "behavioral", "symptoms", "in", "children", "with", "autism", ".", "Forty", "-", "two", "children", "with", "the", "diagnosis", "of", "autism", "were", "randomized", "to", "one", "of", "two", "groups", "in", "this", "double", "-", "blind", "cross", "-", "over", "trial", ".", "One", "group", "received", "2", "IU", "/", "kg", "of", "intravenous", "synthetic", "human", "secretin", "at", "the", "first", "visit", ",", "followed", "by", "an", "equal", "volume", "of", "intravenous", "saline", "placebo", "at", "week", "6", ".", "The", "other", "group", "received", "treatments", "in", "the", "reverse", "order", ".", "All", "children", "were", "evaluated", "at", "weeks", "1", ",", "3", ",", "6", ",", "9", ",", "and", "12", "with", "standardized", "assessments", "of", "language", ",", "behavior", ",", "and", "autism", "symptomatology", ".", "There", "were", "no", "significant", "differences", "in", "the", "mean", "scores", "on", "any", "measure", "of", "language", ",", "behavior", ",", "or", "autism", "symptom", "severity", "after", "treatment", "with", "secretin", "compared", "to", "treatment", "with", "placebo", ".", "The", "results", "of", "this", "study", "do", "not", "support", "secretin", "as", "a", "treatment", "for", "autism", "." ]

[ "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size", "Participant_Age", "Participant_Condition" ]

intravenous synthetic human secretin, autism, intravenous infusion of synthetic human secretin, language, behavioral symptoms, children, Forty - two, 2 IU / kg of intravenous synthetic human secretin, intravenous saline placebo, assessments of language , behavior , and autism symptomatology, mean scores on any measure of language , behavior , or autism symptom severity

11757_task2

Sentence: Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Participant_Age", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Lack of benefit of intravenous synthetic human secretin in the treatment of autism . The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism . Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial . One group received 2 IU/kg of intravenous synthetic human secretin at the first visit , followed by an equal volume of intravenous saline placebo at week 6 . The other group received treatments in the reverse order . All children were evaluated at weeks 1 , 3 , 6 , 9 , and 12 with standardized assessments of language , behavior , and autism symptomatology . There were no significant differences in the mean scores on any measure of language , behavior , or autism symptom severity after treatment with secretin compared to treatment with placebo . The results of this study do not support secretin as a treatment for autism .

[ "Lack", "of", "benefit", "of", "intravenous", "synthetic", "human", "secretin", "in", "the", "treatment", "of", "autism", ".", "The", "objective", "of", "this", "study", "was", "to", "determine", "if", "an", "intravenous", "infusion", "of", "synthetic", "human", "secretin", "improves", "language", "and", "behavioral", "symptoms", "in", "children", "with", "autism", ".", "Forty", "-", "two", "children", "with", "the", "diagnosis", "of", "autism", "were", "randomized", "to", "one", "of", "two", "groups", "in", "this", "double", "-", "blind", "cross", "-", "over", "trial", ".", "One", "group", "received", "2", "IU", "/", "kg", "of", "intravenous", "synthetic", "human", "secretin", "at", "the", "first", "visit", ",", "followed", "by", "an", "equal", "volume", "of", "intravenous", "saline", "placebo", "at", "week", "6", ".", "The", "other", "group", "received", "treatments", "in", "the", "reverse", "order", ".", "All", "children", "were", "evaluated", "at", "weeks", "1", ",", "3", ",", "6", ",", "9", ",", "and", "12", "with", "standardized", "assessments", "of", "language", ",", "behavior", ",", "and", "autism", "symptomatology", ".", "There", "were", "no", "significant", "differences", "in", "the", "mean", "scores", "on", "any", "measure", "of", "language", ",", "behavior", ",", "or", "autism", "symptom", "severity", "after", "treatment", "with", "secretin", "compared", "to", "treatment", "with", "placebo", ".", "The", "results", "of", "this", "study", "do", "not", "support", "secretin", "as", "a", "treatment", "for", "autism", "." ]

[ "Outcome_Mental", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size", "Participant_Age", "Participant_Condition" ]

quinidine is a CHEMICAL, HERG is a GENE-Y

15673388_task0

Sentence: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O" ]

Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.

[ "Further", "insights", "into", "the", "effect", "of", "quinidine", "in", "short", "QT", "syndrome", "caused", "by", "a", "mutation", "in", "HERG", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

quinidine is a CHEMICAL, HERG is a GENE-Y

15673388_task1

Sentence: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. Instructions: please typing these entity words according to sentence: quinidine, HERG Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O" ]

Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.

[ "Further", "insights", "into", "the", "effect", "of", "quinidine", "in", "short", "QT", "syndrome", "caused", "by", "a", "mutation", "in", "HERG", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

quinidine, HERG

15673388_task2

Sentence: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O" ]

Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.

[ "Further", "insights", "into", "the", "effect", "of", "quinidine", "in", "short", "QT", "syndrome", "caused", "by", "a", "mutation", "in", "HERG", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

Lef-1 is a protein, siamois promoter is a DNA, DNase I footprinting is an assay, Lef-1 is a protein, HMG is a protein-domain, S1234 restriction fragment is an experiment-tag

1.0alpha7.train.695_task0

Sentence: To further show the specificity of Lef-1 binding to the siamois promoter we performed DNase I footprinting assays by use of Lef-1 HMG domain and the S1234 restriction fragment used in the band shift assays described above. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA, assay, protein-domain, experiment-tag, protein

[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "B-assay", "I-assay", "I-assay", "O", "O", "O", "O", "O", "B-protein", "B-protein-domain", "O", "O", "O", "B-experiment-tag", "I-experiment-tag", "I-experiment-tag", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

To further show the specificity of Lef-1 binding to the siamois promoter we performed DNase I footprinting assays by use of Lef-1 HMG domain and the S1234 restriction fragment used in the band shift assays described above.

[ "To", "further", "show", "the", "specificity", "of", " ", "Lef-1", "binding", "to", "the", " ", "siamois", "promoter", "we", "performed", " ", "DNase", "I", "footprinting", "assays", "by", "use", "of", " ", "Lef-1", "HMG", "domain", "and", "the", "S1234", "restriction", "fragment", "used", "in", "the", "band", "shift", "assays", "described", "above", "." ]

[ "experiment-tag", "assay", "DNA", "protein", "protein-domain" ]

Lef-1 is a protein, siamois promoter is a DNA, DNase I footprinting is an assay, Lef-1 is a protein, HMG is a protein-domain, S1234 restriction fragment is an experiment-tag

1.0alpha7.train.695_task1

Sentence: To further show the specificity of Lef-1 binding to the siamois promoter we performed DNase I footprinting assays by use of Lef-1 HMG domain and the S1234 restriction fragment used in the band shift assays described above. Instructions: please typing these entity words according to sentence: Lef-1, siamois promoter, DNase I footprinting, Lef-1, HMG, S1234 restriction fragment Options: DNA, assay, protein-domain, experiment-tag, protein

[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "B-assay", "I-assay", "I-assay", "O", "O", "O", "O", "O", "B-protein", "B-protein-domain", "O", "O", "O", "B-experiment-tag", "I-experiment-tag", "I-experiment-tag", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

To further show the specificity of Lef-1 binding to the siamois promoter we performed DNase I footprinting assays by use of Lef-1 HMG domain and the S1234 restriction fragment used in the band shift assays described above.

[ "To", "further", "show", "the", "specificity", "of", " ", "Lef-1", "binding", "to", "the", " ", "siamois", "promoter", "we", "performed", " ", "DNase", "I", "footprinting", "assays", "by", "use", "of", " ", "Lef-1", "HMG", "domain", "and", "the", "S1234", "restriction", "fragment", "used", "in", "the", "band", "shift", "assays", "described", "above", "." ]

[ "experiment-tag", "assay", "DNA", "protein", "protein-domain" ]

Lef-1, siamois promoter, DNase I footprinting, Lef-1, HMG, S1234 restriction fragment

1.0alpha7.train.695_task2

Sentence: To further show the specificity of Lef-1 binding to the siamois promoter we performed DNase I footprinting assays by use of Lef-1 HMG domain and the S1234 restriction fragment used in the band shift assays described above. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "B-DNA", "I-DNA", "O", "O", "O", "B-assay", "I-assay", "I-assay", "O", "O", "O", "O", "O", "B-protein", "B-protein-domain", "O", "O", "O", "B-experiment-tag", "I-experiment-tag", "I-experiment-tag", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

To further show the specificity of Lef-1 binding to the siamois promoter we performed DNase I footprinting assays by use of Lef-1 HMG domain and the S1234 restriction fragment used in the band shift assays described above.

[ "To", "further", "show", "the", "specificity", "of", " ", "Lef-1", "binding", "to", "the", " ", "siamois", "promoter", "we", "performed", " ", "DNase", "I", "footprinting", "assays", "by", "use", "of", " ", "Lef-1", "HMG", "domain", "and", "the", "S1234", "restriction", "fragment", "used", "in", "the", "band", "shift", "assays", "described", "above", "." ]

[ "experiment-tag", "assay", "DNA", "protein", "protein-domain" ]

Perfusion is an umlsterm, Peptids is an umlsterm, Endothelin-1 is an umlsterm, ANP is an umlsterm, Haemodynamik is an umlsterm, Patienten is an umlsterm, angeborenen is an umlsterm, pulmonaler Hypertension is an umlsterm, Stickstoffmonoxid is an umlsterm, NO - Synthase is an umlsterm, ANP is an umlsterm, Guanosinmonophosphat is an umlsterm, Sauerstoff is an umlsterm, Patienten is an umlsterm, pulmonaler Hypertension is an umlsterm, Patienten is an umlsterm, pulmonaler Hypertension is an umlsterm, Feedback - Mechanismus is an umlsterm, ANP is an umlsterm, ET-1 is an umlsterm, ANP is an umlsterm, Vasodilatation is an umlsterm, Sauerstoff is an umlsterm

ZfuerKardiologie.00890100.ger.abstr_task0

Sentence: Die pulmonale Perfusion wird von vasokonstriktorischen und vasodilatatorischen Faktoren reguliert . Ziel der Studie war es , den Einfluss des vasokonstriktorischen Peptids Endothelin-1 ( ET-1) und des vasodilatatorischen atrialen natriuretischen Peptis ( ANP ) auf die pulmonale Haemodynamik bei Patienten mit angeborenen Shuntvitien und konsekutiver pulmonaler Hypertension zu untersuchen . Sowohl Stickstoffmonoxid ( NO ) , das von einer konstitutiven endothelialen NO-Synthase ( eNOS ) gebildet wird , als auch ANP entfalten ihre vasodilatatorische Wirkung durch den intrazellulaeren Botenstoff ( second messenger zyklisches Guanosinmonophosphat ( ) cGMP ) . Sauerstoff ist ein Kofaktor der eNOS und ein bedeutsamer pulmonaler Vasodilatator bei Patienten mit pulmonaler Hypertension . Es wurde ueberprueft , ob bei Patienten mit pulmonaler Hypertension ein Feedback-Mechanismus zwischen ANP und ET-1 besteht und inwieweit die cGMP-Produktion von der Stimulation durch ANP abhaengt . Darueber hinaus sollte untersucht werden , ob das Phaenomen einer pulmonalen Vasodilatation durch Sauerstoff mit Aenderungen der ET-1- oder cGMP-Plasmaspiegel einhergeht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die pulmonale Perfusion wird von vasokonstriktorischen und vasodilatatorischen Faktoren reguliert . Ziel der Studie war es , den Einfluss des vasokonstriktorischen Peptids Endothelin-1 ( ET-1) und des vasodilatatorischen atrialen natriuretischen Peptis ( ANP ) auf die pulmonale Haemodynamik bei Patienten mit angeborenen Shuntvitien und konsekutiver pulmonaler Hypertension zu untersuchen . Sowohl Stickstoffmonoxid ( NO ) , das von einer konstitutiven endothelialen NO-Synthase ( eNOS ) gebildet wird , als auch ANP entfalten ihre vasodilatatorische Wirkung durch den intrazellulaeren Botenstoff ( second messenger zyklisches Guanosinmonophosphat ( ) cGMP ) . Sauerstoff ist ein Kofaktor der eNOS und ein bedeutsamer pulmonaler Vasodilatator bei Patienten mit pulmonaler Hypertension . Es wurde ueberprueft , ob bei Patienten mit pulmonaler Hypertension ein Feedback-Mechanismus zwischen ANP und ET-1 besteht und inwieweit die cGMP-Produktion von der Stimulation durch ANP abhaengt . Darueber hinaus sollte untersucht werden , ob das Phaenomen einer pulmonalen Vasodilatation durch Sauerstoff mit Aenderungen der ET-1- oder cGMP-Plasmaspiegel einhergeht .

[ "Die", "pulmonale", "Perfusion", "wird", "von", "vasokonstriktorischen", "und", "vasodilatatorischen", "Faktoren", "reguliert", ".", "Ziel", "der", "Studie", "war", "es", ",", "den", "Einfluss", "des", "vasokonstriktorischen", "Peptids", "Endothelin-1", "(", "ET-1", ")", "und", "des", "vasodilatatorischen", "atrialen", "natriuretischen", "Peptis", "(", "ANP", ")", "auf", "die", "pulmonale", "Haemodynamik", "bei", "Patienten", "mit", "angeborenen", "Shuntvitien", "und", "konsekutiver", "pulmonaler", "Hypertension", "zu", "untersuchen", ".", "Sowohl", "Stickstoffmonoxid", "(", "NO", ")", ",", "das", "von", "einer", "konstitutiven", "endothelialen", "NO", "-", "Synthase", "(", "eNOS", ")", "gebildet", "wird", ",", "als", "auch", "ANP", "entfalten", "ihre", "vasodilatatorische", "Wirkung", "durch", "den", "intrazellulaeren", "Botenstoff", "(", "second", "messenger", "zyklisches", "Guanosinmonophosphat", "(", ")", "cGMP", ")", ".", "Sauerstoff", "ist", "ein", "Kofaktor", "der", "eNOS", "und", "ein", "bedeutsamer", "pulmonaler", "Vasodilatator", "bei", "Patienten", "mit", "pulmonaler", "Hypertension", ".", "Es", "wurde", "ueberprueft", ",", "ob", "bei", "Patienten", "mit", "pulmonaler", "Hypertension", "ein", "Feedback", "-", "Mechanismus", "zwischen", "ANP", "und", "ET-1", "besteht", "und", "inwieweit", "die", "cGMP", "-", "Produktion", "von", "der", "Stimulation", "durch", "ANP", "abhaengt", ".", "Darueber", "hinaus", "sollte", "untersucht", "werden", ",", "ob", "das", "Phaenomen", "einer", "pulmonalen", "Vasodilatation", "durch", "Sauerstoff", "mit", "Aenderungen", "der", "ET-1-", "oder", "cGMP", "-", "Plasmaspiegel", "einhergeht", "." ]

[ "umlsterm" ]